WO2019143874A1 - Substituted aminopyrimidine compounds and methods of use - Google Patents

Substituted aminopyrimidine compounds and methods of use Download PDF

Info

Publication number
WO2019143874A1
WO2019143874A1 PCT/US2019/014101 US2019014101W WO2019143874A1 WO 2019143874 A1 WO2019143874 A1 WO 2019143874A1 US 2019014101 W US2019014101 W US 2019014101W WO 2019143874 A1 WO2019143874 A1 WO 2019143874A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkylene
cycloalkyl
alkyl
membered heterocyclyl
optionally substituted
Prior art date
Application number
PCT/US2019/014101
Other languages
French (fr)
Inventor
Ning Xi
Liang Wang
Xuejin Feng
Min Liao
Original Assignee
Sunshine Lake Pharma Co., Ltd.
Calitor Sciences, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co., Ltd., Calitor Sciences, Llc filed Critical Sunshine Lake Pharma Co., Ltd.
Priority to AU2019209960A priority Critical patent/AU2019209960B2/en
Priority to KR1020207023828A priority patent/KR20200112900A/en
Priority to EP19741784.3A priority patent/EP3740468A4/en
Priority to JP2020538684A priority patent/JP7450541B2/en
Priority to CA3083040A priority patent/CA3083040A1/en
Publication of WO2019143874A1 publication Critical patent/WO2019143874A1/en
Priority to JP2023176720A priority patent/JP2023184559A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention is directed to certain novel compounds which are inhibitors of kinase activity, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various disorders. More specifically, the compounds disclosed herein are inhibitors of the activity or function of the phosphatidylinositol 3 -kinase kinase family (hereinafter PI3 -kinases, PI3Ks), for example RBKd, RI3Ka, RI3Kb and/or RI3Kg.
  • PI3 -kinases phosphatidylinositol 3 -kinase kinase family
  • the compounds disclosed herein are therefore potentially useful in the treatment of a wide range of disorders, particularly disorders including but not limited to autoimmune disorders, inflammatory diseases, allergic diseases, disease or infection associated immunopathologies, airway diseases, such as asthma and COPD, transplant rejection, cancers such as hematopoietic origin or solid tumors.
  • the compounds disclosed herein are inhibitors of the activity or function of PI3- kinases that may be useful in the treatment of disorders of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity; respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-vir
  • PI3 kinases a family of lipid kinases
  • RTKs receptor tyrosine kinases
  • GPCRs G protein-coupled receptors
  • PI3Ks transduce signals from various growth factors and cytokines into intracellular massages by generating phospholipids, which activate the serine-threonine protein kinase ART (also known as protein kinase B (PKB)) and other downstream effector pathways.
  • PLB protein kinase B
  • the tumor suppressor or PTEN (phosphatase and tensin homologue) is the most important negative regulator of the PI3K signaling pathway (“Small- molecule inhibitors of the PI3K signaling network.” Future Med Chem ., 2011, 3, 5, 549-565).
  • PI3Ks have been identified, divided into three main classes (I, II and III) on the basis of their genetic sequence, structure, adapter molecules, expression, mode of activation, and preferred substrate. Among them, Class I PI3Ks are further divided based on signaling pathways and regulatory proteins into class IA and class IB.
  • the class IA PI3Ks comprise three closely related kinases, RI3Ka, RI3Kb, and PI3K5, which exist as heterodimers composed of a catalytic subunit (r ⁇ ⁇ qa, r ⁇ ⁇ qb, and pl 105 respectively) and a p85 regulatory adapter subunits (i.e., r85a, r85b, r55d, p55a and p50a).
  • the catalytic pl lO subunit uses ATP to phosphorylate phosphatidylinositol (PI, Ptdlns), PI4P and PI (4,5) P2. These respond to signaling generally through receptor tyrosine kinases (RTKs).
  • the class IB RI3Kg signals through G-protein-coupled receptors (GPCRs) and is composed of a r ⁇ ⁇ qg catalytic domain that can associate with regulatory subunits distinct from the class IA isoforms.
  • class I PI3-kinases (e.g. RBKd, PBKdelta) generate second messengers from the membrane phospholipid pools.
  • Class I PI3Ks convert the membrane phospholipid PI(4,5) P2 into PI(3,4,5)P3, which functions as a second messenger.
  • PI and PI(4)P are also substrates of PI3K and can be phosphorylated and converted into PI3P and PI(3,4)P2, respectively.
  • these phosphoinositides can be converted into other phosphoinositides by 5'-specific and 3'- specific phophatases.
  • PI3K enzymatic activity results either directly or indirectly in the generation of two 3 '-phosphoinositide subtypes which function as second messengers in intracellular signal transduction pathways (. Nature Reviews Molecular Cell Biology , 2010, 11, 329).
  • PI3Ks In B and T cells, PI3Ks have an important role through activation of the Tec family of protein tyrosine kinases which include Bruton's tyrosine kinase (BTK) in B cells and lnterleukin- 2-inducible T-cell kinase (ITK) in T cells.
  • BTK Bruton's tyrosine kinase
  • ITK lnterleukin- 2-inducible T-cell kinase
  • PLOyl phospholipase C-gamma
  • DAG diacylglycerol
  • PI3K5 kinase dead knock-in mice are viable and their phenotype is restricted to defects in immune signaling (Okkenhaug et ah, Science , 2002, 297, p. 1031-4). These transgenic mice have offered insight into the function of PI3K5 in B-cell and T-cell signaling. In particular, PI3K5 is required for PI(3,4,5)P3 formation downstream of CD28 and/or T cell Receptor (TCR) signaling. A key effect of PI3K signaling downstream of TCR is the activation of Akt, which phosphorylates anti-apoptotic factors as well as various transcription factors for cytokine production.
  • TCR T cell Receptor
  • T cells with inactive PI3K5 have defects in proliferation and TM and Th2 cytokine secretion.
  • Activation of T cells through CD28 lowers the threshold for TCR activation by antigen and increases the magnitude and duration of the proliferative response.
  • PI3K inhibitors are anticipated to provide therapeutic benefit via its role in modulating T-cell mediated inflammatory responses associated to respiratory diseases such as asthma, COPD and cystic fibrosis.
  • T-cell directed therapies may provide corticosteroid sparing properties ⁇ Lancet, 1992, 339, p. 324-88) suggesting that it may provide a useful therapy either as a standalone or in combination with inhaled or oral glucocorticosteroids in respiratory diseases.
  • a PI3K inhibitor might also be used alongside other conventional therapies such as long acting beta-agonists (LABA) in asthma.
  • PI3K5 is expressed by endothelial cells and participates in neutrophil trafficking by modulating the proadhesive state of these cells in response to TNF alpha ⁇ Blood , 2004, 103, 9, p. 3448).
  • a role for PI3K5 in TNF alpha-induced signaling of endothelial cells is demonstrated by the pharmacological inhibition of Akt phosphorylation and PDK1 activity.
  • PI3K5 is implicated in vascular permeability and airway tissue edema through the VEGF pathway ⁇ Allergy Clin. Immunol., 2006, 118, 2, p. 403).
  • PI3K5 inhibition in asthma by the combined reduction of leukocyte extravasation and vascular permeability associated with asthma.
  • PI3K5 activity is required for mast cell function both in vitro and in vivo ⁇ Nature , 2004, 431, p. 1007; J. Immunol., 2008, 180, 4, p. 2538) further suggesting that PI3K inhibition should be of therapeutic benefit for allergic indications such asthma, allergic rhinitis and atopic dermatitis.
  • PI3K5 The role of PI3K5 in B cell proliferation, antibody secretion, B-cell antigen and IL-4 receptor signaling, B-cell antigen presenting function is also well established ⁇ J. Immunol., 2007, 178, 4, p. 2328-35; Blood , 2006, 107, 2, p. 642-50) and indicates a role in autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus. Therefore PI3K inhibitors may also be of benefit for these indications.
  • PI3K5 inhibits fMLP-dependent neutrophil chemotaxis on an ICAM coated agarose matrix integrin-dependent biased system ⁇ J. Immunol., 2003, 170, 5, p. 2647-54). Inhibition of PI3K5 regulates neutrophil activation, adhesion and migration without affecting neutrophil mediated phagocytosis and bactericidal activity over Staphylococcus aureus ⁇ Biochem. Biophys. Res. Commun, 2003, 308, 4, p. 764-9). Overall, the data suggest that PI3K5 inhibition should not globally inhibit neutrophil functions required for innate immune defense. PI3K5's role in neutrophils offers further scope for treating inflammatory diseases involving tissue remodeling such as COPD or rheumatoid arthritis.
  • PI3K5 The phosphoinositide 3 -kinase d subunit (PI3K5) isoform is mainly expressed in immune cells and is absent from most solid tumors.
  • Gene targeting in mice has established essential functions for PI3K5 in mature B cells and in other immune cell types.
  • a key downstream effector of PI3K5 in B cells is Bruton’s tyrosine kinase (BTK), which is a member of the TEC family of non-receptor tyrosine kinases.
  • BTK tyrosine kinase
  • PI3K5 and BTK are activated by signals from the B cell receptor (BCR), chemokines and cytokines to drive survival, proliferation and adhesion to supportive stromal cells.
  • PI3K5 inhibitors have shown acceptable safety profiles.
  • idelalisib chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL).
  • FDA US Food and Drug Administration
  • RI3Kg has been identified as a mediator of G beta-gamma-dependent regulation of JNK activity, and G beta-gamma are subunits of heterotrimeric G proteins (./. Biol. Chem ., 1998, 273, 5, p. 2505-8). It has been described that RI3Kg relays inflammatory signals through various G(i)-coupled receptors and is central to mast cell function, stimuli in the context of leukocytes, and immunology including cytokines, chemokines, adenosines, antibodies, integrins, aggregation factors, growth factors, viruses or hormones for example ( Immunity , 2002, 16, 3, p. 441-51; J. Cell Sci., 2001, 114 (Pt 16), p. 2903-10 and Curr. Opinion Cell Biol., 2002, 14, 2, p. 203-13).
  • PI3K enzymes contribute to turn ouri genesis in a wide variety of human cancers, either directly or indirectly ( Nature Reviews Cancer, 2002, 2, 7, p. 489-501).
  • inhibition of PI3K5 may have a therapeutic role for the treatment of malignant haematological disorders such as acute myeloid leukaemia ( Oncogene , 2006, 25, 50, p. 6648-59).
  • activating mutations within pl lOa PIK3CA gene
  • have been associated with various other tumors such as those of the colon and of the breast and lung (Science, 2004, 304, 5670, p. 554; Nature Reviews Cancer, 2009, 9, 551).
  • PI3K inhibitors may have anti-viral properties in addition to more established oncolytic and anti-inflammatory indications. These antiviral effects raise interesting prospects in viral induced inflammatory exacerbations.
  • HRV common cold human rhinovirus
  • COPD chronic obstruction pulmonary disease
  • Rhinoviral infection of epithelial cells leads to a PI3K dependent cytokine and chemokine secretion (J. Biol. Chem., 2005, 280, 44, p. 36952). This inflammatory response correlates with worsening of respiratory symptoms during infection. Therefore PI3K inhibitors may dampen an exaggerated immune response to an otherwise benign virus.
  • the majority of HRV strains infect bronchial epithelial cells by initially binding to the ICAM-l receptor.
  • the HRV-ICAM-l complex is then further internalised by endocytosis and it has been shown that this event requires PI3K activity (J. Immunol ., 2008, 180, 2, p. 870-880). Therefore, PI3K inhibitors may also block viral infections by inhibiting viral entry into host cells.
  • PI3K inhibitors may be useful in reducing other types of respiratory infections including the fungal infection aspergillosis (Mucosal Immunol ., 2010, 3, 2, p. 193-205).
  • PI3K5 deficient mice are more resistant towards infections by the protozoan parasite Leishmania major (J. Immunol . , 2009, 183, 3, p. 1921-1933).
  • J. Immunol . , 2009, 183, 3, p. 1921-1933 Taken with effects on viral infections, these reports suggest that PI3K inhibitors may be useful for the treatment of a wide variety of infections.
  • PI3K inhibition has also been shown to promote regulatory T cell differentiation ( Proc . Natl. Acad. Sci. USA, 2008, 105, 22, p. 7797-7802) suggesting that PI3K inhibitors may serve therapeutic purposes in auto-immune or allergic indications by inducing immuno-tolerance towards self-antigen or allergen.
  • PI3K5 isoform has also been linked to smoke induced glucocorticoid insensitivity (Am. J. Respir. Crit. Care Med., 2009, 179, 7, p. 542-548). This observation suggests that COPD patients, which otherwise respond poorly to corticosteroids, may benefit from the combination of a PI3K inhibitor with a corticosteroid.
  • PI3K has also been involved in other respiratory conditions such as idiopathic pulmonary fibrosis (IPF).
  • IPF idiopathic pulmonary fibrosis
  • IPF is a fibrotic disease with progressive decline of lung function and increased mortality due to respiratory failure.
  • circulating fibrocytes are directed to the lung via the chemokine receptor CXCR4.
  • PI3K is required for both signaling and expression of CXCR4 (Int. J. Biochem. and Cell Biol., 2009, 41, p.1708-1718). Therefore, by reducing CXCR4 expression and blocking its effector function, a PI3K inhibitor should inhibit the recruitment of fibrocytes to the lung and consequently slow down the fibrotic process underlying IPF, a disease with high unmet need.
  • PI3Ka and RI3Kb play an essential role in maintaining homeostasis and pharmacological inhibition of these molecular targets has been associated with cancer therapy (Maira et ak, Expert Opin. Ther. Targets, 2008, 12, 223).
  • PI3Ka is involved in insulin signaling and cellular growth pathways (Nature, 2006, 441, 366). PI3K5 isoform-selective inhibition is expected to avoid potential side effects such as hyperglycemia, and metabolic or growth deregulation. [025] Selective compounds to modulate RI3Kg are being developed by several groups as immunosuppressive agents for autoimmune disease (Nature Reviews , 2006, 5, 903-918).
  • AS 605240 a selective PBKgamma inhibitor, has been shown to be efficacious in a mouse model of rheumatoid arthritis (Nature Medicine, 2005, 11, 936-943) and to delay onset of disease in a model of systemic lupus erythematosis (Nature Medicine, 2005, 11, 933-935).
  • PI3K inhibitors that are good drug candidates.
  • compounds disclosed herein should bind potently to PI3K whilst showing little affinity for other receptors and show functional activity as inhibitors. They should be well absorbed from the gastrointestinal tract, be metabolically stable and possess favorable pharmacokinetic properties. When targeted against receptors in the central nervous system they should cross the blood brain barrier freely and when targeted selectively against receptors in the peripheral nervous system they should not cross the blood brain barrier. They should be non toxic and demonstrate few side-effects.
  • the ideal drug candidate will exist in a physical form that is stable, non-hygroscopic and easily formulated.
  • the compounds disclosed herein show a certain level of selectivity against the different paralogs PI3K a, b, g and d. In particular, show a certain level of selectivity for the isoform PI3K5.
  • the compounds disclosed herein are therefore potentially useful in the treatment of a wide range of disorders, particularly disorders including but not limited to autoimmune disorders, inflammatory diseases, allergic diseases, disease or infection associated immunopathologies, airway diseases, transplant rejection, cancers of hematopoietic origin or solid tumors.
  • the invention also relates to the treatment, either alone or in combination, with one or more other pharmacologically active compounds, includes methods of treating conditions, diseases or disorders in respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-viral respiratory infections including aspergillosis and leishmaniasis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis (Future Med.
  • respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF)
  • viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD
  • non-viral respiratory infections including asper
  • hematologic malignancies such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD), Chronic Myeloid Leukemia (CML), T-cell acute lymphoblastic leukaemia (T- ALL), B-cell chronic lymphocytic leukemia (B-CLL), B-cell Acute Lymphoblastic leukaemia
  • the present inventors have discovered novel compounds which are inhibitors of kinase activity, in particular PI3-kinase activity.
  • Compounds which are PI3-kinase inhibitors may be useful in the treatment of disorders associated with inappropriate kinase activity, in particular inappropriate PI3-kinase activity, for example in the treatment and prevention of disorders mediated by PI3-kinase mechanisms.
  • Such disorders include respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-viral respiratory infections including aspergillosis and leishmaniasis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigemin
  • compounds disclosed herein may show selectivity for PI3-kinases over other kinases.
  • compounds disclosed herein may be potent inhibitors of PI3K5.
  • compounds disclosed herein may show selectivity for PI3K5 over other PI3 -kinases.
  • X is 3-8 membered heterocyclyl, (C 6 -Cio)aryl or 5-10 membered heteroaryl, wherein X is optionally substituted by 1, 2, 3, 4 or 5 R 3 groups; m is 1, 2 or 3;
  • W is N or CR 5 ;
  • A is H, D, (Ci-C 6 )alkyl, (Ci-C 6 )haloalkyl, (Ci-C 6 )hydroxyalkyl, (Ci-C 6 )aminoalkyl, (C 3 - C 8 )cycloalkyl or 3-8 membered heterocyclyl, wherein each (Ci-C 6 )alkyl, ( (Ci-C 6 )haloalkyl, (Ci- C 6 )hydroxyalkyl, (Ci-C 6 )aminoalkyl, (C 3 -C 8 )cycloalkyl and 3-8 membered heterocyclyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH 2 , CN, N0 2 , (Ci-C 6 )alkyl and (Ci-C 6 )alkoxy;
  • o)aryl, 5-10 membered heteroaryl and -(Ci-C 4 )alkylene-(5-l0 membered heteroaryl) is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, N0 2 , N 3 , OH, NH 2 , (Ci-C 6 )alkyl, (Ci-C 6 )haloalkyl, (Ci-C 6 )alkoxy and (C C 6 )alkylamino; or R a and R b , together with the nitrogen atom they are attached to, form an optionally substituted 3-8 membered heterocyclic ring.
  • X is 3-6 membered heterocyclyl or 5-6 membered heteroaryl, wherein X is optionally substituted by 1, 2, 3 or 4 R 3 groups.
  • A is H, D, (Ci-C 4 )alkyl, (Ci-C 4 )haloalkyl, (Ci- C )hydroxyalkyl, (Ci-C )aminoalkyl, (C 3 -C 6 )cycloalkyl or 3-6 membered heterocyclyl, wherein each (Ci-C )alkyl, (Ci-C )haloalkyl, (Ci-C )hydroxyalkyl, (Ci-C )aminoalkyl, (C 3 -C 6 )cycloalkyl and 3-6 membered heterocyclyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH 2 , CN, N0 2 , (Ci-C 4 )alkyl and (Ci- C 4 )
  • A is H, D, methyl, ethyl, «-propyl, isopropyl, /er/-butyl, trifluorom ethyl, difluorom ethyl, l,2-difluoroethyl, 2,2-difluoroethyl, hydroxymethyl, 2- hydroxyethyl, 1 -hydroxy ethyl, 2-hydroxyprop-2-yl, aminomethyl, 2-aminoethyl, l-aminoethyl, 2-aminoprop-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiofen, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl, wherein each methyl, ethyl, «-propyl, iso
  • B is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl,
  • each R 1 and R 2 is independently H, D, F, CN, methyl, ethyl, n- propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl, wherein each of methyl, ethyl, «-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl and thiomorpholinyl is optionally substituted with 1, 2,
  • R a , R b and R c is independently H, (Ci-C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C )alkynyl, (C 3 -C 6 )cycloalkyl, -(Ci-C 2 )alkylene-(C3-C 6 )cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C 2 )alkylene-(3-6 membered heterocyclyl) or 5-6 membered heteroaryl, wherein each of the (Ci-C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C3-C 6 )cycloalkyl, -(Ci- C 2 )alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C 2 )alkyl,
  • each R a , R b and R c is independently H, methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of the methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl
  • the compound disclosed herein, or the pharmaceutically acceptable salt disclosed herein is provided for use as a medicament.
  • a pharmaceutical composition which comprises a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof, and a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the composition comprising one or more therapeutic agents.
  • the composition is a liquid, solid, semi-solid, gel, or an aerosol form.
  • Another aspect of the invention provides a method of modulating the activity of the PI3K enzymes, preferably of the PI3K5 isoform, in a subject, which comprises administering to the subject a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
  • Another aspect of the invention provides a method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a safe and effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
  • Another aspect of the invention provides a method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a pharmaceutical disclosed herein, to a patient in need thereof.
  • the disorder mediated by inappropriate PI3-kinase activity is a respiratory disease, a viral infection, a non-viral respiratory infection, an allergic disease, an autoimmune disease, an inflammatory disorder, a cardiovascular disease, a hematologic malignancy, a neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, or pain.
  • the disorder mediated by inappropriate PI3-kinase activity is asthma, chronic obstructive pulmonary disease (COPD), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or central pain.
  • COPD chronic obstructive pulmonary disease
  • Another aspect of the invention provides use of the compound disclosed herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of a disorder or a disease selected from asthma, chronic obstructive pulmonary disease (COPD), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, spermmotility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neural
  • a method of inhibiting a phosphatidyl inositol-3 kinase comprising: contacting the PI3 kinase with an effective amount of a compound disclosed herein.
  • the step of contacting comprises contacting a cell that contains said PI3 kinase.
  • the inhibition takes place in a subject suffering from a disorder associated with malfunctioning of one or more types of PI3 kinase.
  • Some exemplary diseases involving malfunctioning of one or more types of PI3 kinases are selected from the group consisting of autoimmune diseases, rheumatoid arthritis, respiratory disease, allergic reactions, and various types of cancers.
  • the method comprises administering a second therapeutic agent to the subject.
  • the PI3K-mediated condition or disorder is selected from rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, and autoimmune diseases.
  • the PI3K-mediated condition or disorder is selected from cardiovascular diseases, atherosclerosis, hypertension, deep venous thrombosis, stroke, myocardial infarction, unstable angina, thromboembolism, pulmonary embolism, thrombolytic diseases, acute arterial ischemia, peripheral thrombotic occlusions, and coronary artery disease.
  • the PI3K-mediated condition or disorder is selected from cancer, colon cancer, glioblastoma, endometrial carcinoma, hepatocellular cancer, lung cancer, melanoma, renal cell carcinoma, thyroid carcinoma, cell lymphoma, lymphoproliferative disorders, small cell lung cancer, squamous cell lung carcinoma, glioma, breast cancer, prostate cancer, ovarian cancer, cervical cancer, and leukemia.
  • the PBK-mediated condition or disorder is selected from type II diabetes.
  • the PBK-mediated condition or disorder is selected from respiratory diseases, bronchitis, asthma, and chronic obstructive pulmonary disease.
  • the subject is a human.
  • Another aspect of the invention relates to the treatment of PBK-mediated condition or disorder in a patient comprising the step of administering a compound according to any of the above embodiments.
  • Another aspect of the invention relates to the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases or autoimmune diseases in a patient comprising the step of administering a compound according to any of the above embodiments.
  • Another aspect of the invention relates to the treatment of respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) in a patient comprising the step of administering a compound according to any of the above embodiments.
  • respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF)
  • COPD chronic obstructive pulmonary disease
  • IPF idiopathic pulmonary fibrosis
  • Another aspect of the invention relates to the treatment of inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, skin complaints with inflammatory components, chronic inflammatory conditions, systemic lupus erythematosis (SLE), myestenia gravis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions and hypersensitivity in a patient, comprising the step of administering a compound according to any of the above or below embodiments.
  • SLE systemic lupus erythematosis
  • myestenia gravis acute disseminated encephalomyelitis
  • idiopathic thrombocytopenic purpura idiopathic thrombocytopenic purpura
  • multiples sclerosis multiples sclerosis
  • Sjoegren's syndrome and autoimmune hemolytic anemia allergic conditions and hypersensitivity in a patient
  • Another aspect of the invention relates to the treatment of cancers in a patient that are mediated, dependent on or associated with PI3K activity, particularly PBKdelta activity, comprising the step of administering a compound according to any of the above or below embodiments.
  • Another aspect of the invention relates to the treatment of cancers are selected from acute myeloid leukaemia, myelo-dysplastic syndrome, myeloproliferative diseases, chronic myeloid leukaemia, T-cell acute lymphoblastic leukaemia, B-cell acute lymphoblastic leukaemia, non-hodgkins lymphoma, B-cell lymphoma, solid tumors and breast cancer, comprising the step of administering a compound according to any of the above or below embodiments.
  • Another aspect of the invention relates to the use of a compound according to any of the above embodiments as a medicament.
  • Another aspect of the invention relates to the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of PBK-mediated condition or disorder in a patient.
  • Another aspect of the invention relates to the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), autoimmune diseases, and cancers.
  • COPD chronic obstructive pulmonary disease
  • IPF idiopathic pulmonary fibrosis
  • the salt is a pharmaceutically acceptable salt.
  • pharmaceutically acceptable indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
  • the compounds disclosed herein also include salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula (I) and/or for separating enantiomers of compounds of Formula (I).
  • the compounds disclosed herein, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
  • the compounds disclosed herein may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
  • Compounds disclosed herein can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof.
  • This invention is intended to encompass mixtures of isomers, rotamers, atropisomers, tautomers, partially mixed isomers, rotamers, atropisomers, or tautomers, and separated isomers, rotamers, atropisomers, tautomers.
  • the compounds disclosed herein include isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H, 14 C and 18 F, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
  • the term "a,” “an,” “the” and similar terms used in the context of the present invention are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
  • the term “subject” refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
  • patient refers to a human (including adults and children) or other animal. In one embodiment, “patient” refers to a human.
  • the present invention also includes isotopically-labelled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 3 ⁇ 4 3 ⁇ 4 13 C, 14 C, 15 N, 16 0, 17 0, 18 0, 31 P, 32 P, 36 S, 18 F, and 37 Cl.
  • isotopically-labeled compounds of the present invention for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-l4, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detection. Further, substitution with heavier isotopes such as deuterium, i.e., 2 H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
  • a specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture.
  • a 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
  • the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms.
  • Optically active ( R )- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or /ra//.s-configurati on .
  • the compounds disclosed herein may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds disclosed herein, including but not limited to, diastereomers, enantiomers, atropisomers, and geometric (or conformational) isomers as well as mixtures thereof such as racemic mixtures, form part of the present invention.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, atropisomeric and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers.
  • isomeric e.g., enantiomeric, diastereomeric, atropisomeric and geometric (or conformational)
  • tautomer or "tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier. Where tautomerization is possible (e.g. in solution), a chemical equilibrium of tautomers can be reached.
  • proton tautomers also known as prototropic tautomers
  • Valence tautomers include interconversions by reorganization of some of the bonding electrons.
  • keto- enol tautomerization is the interconversion of pentane-2, 4-dione and 4-hydroxypent-3-en-2-one tautomers.
  • Another example of tautomerization is phenol-keto tautomerization.
  • a specific example of phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4( 1 H)- one tautomers. Unless otherwise stated, all tautomeric forms of the compounds disclosed herein are within the scope of the invention.
  • any asymmetric atom (e.g., carbon or the like) of the compound(s) disclosed herein can be present in racemic or enantiomerically enriched, for example the ( R )-, (S)- or (Re configuration.
  • each asymmetric atom has at least 50 % enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the ( R )- or (S)- configuration.
  • Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- (Z)- or trans- (E)-form.
  • Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
  • Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by methods known to those skilled in the art, e.g., by separation of the diastereomeric salts thereof. Racemic products can also be resolved by chiral chromatography, e.g., high performance liquid chromatography (HPLC) using a chiral adsorbent. Preferred enantiomers can also be prepared by asymmetric syntheses. See, for example, Jacques, et ah, “Enantiomers, Racemates and Resolutions,” Wiley Interscience, New York, 1981; Gawley et ah, “Principles of Asymmetric Synthesis,” 2 nd Ed.
  • compounds disclosed herein may optionally be substituted with one or more substituents, such as are illustrated generally below, or as exemplified by particular classes, subclasses, and species of the invention.
  • substituents such as are illustrated generally below, or as exemplified by particular classes, subclasses, and species of the invention.
  • the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted”.
  • substituted refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent.
  • optionally or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
  • an optionally substituted group may have a substituent at each substitutable position of the group. When more than one position in a given structure can be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at each position.
  • alkyl or "alkyl group” refers to a saturated linear or branched-chain monovalent hydrocarbon radical of 1 to 20 carbon atoms, wherein the alkyl radical may be optionally substituted independently with one or more substituents described below. Unless otherwise specified, the alkyl group contains 1-20 carbon atoms. In some embodiments, the alkyl group contains 1-12 carbon atoms. In other embodiments, the alkyl group contains 1-10 carbon atoms. In other embodiments, the alkyl group contains 1-8 carbon atoms. In other embodiments, the alkyl group contains 1-6 carbon atoms. In still other embodiments, the alkyl group contains
  • the alkyl group contains 1-3 carbon atoms.
  • alkyl group examples include methyl (Me, -CH 3 ), ethyl (Et, - CH 2 CH 3 ), 1 -propyl ( «- Pr, «-propyl, -CH 2 CH 2 CH 3 ), 2-propyl (/-Pr, /-propyl, -CH(CH 3 ) 2 ), 1 -butyl (//-Bu, «-butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl-l-propyl (/-Bu, /-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (.s- Bu, 5-butyl, -CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (/-Bu, /-butyl, -C(CH 3 ) 3 ), 1 -pentyl ( «-pentyl, -CH 2 CH 2 CH 2 CH 3 ), 2-pentyl («-pentyl, -
  • alk- is inclusive of both straight chain and branched saturated carbon chain.
  • alkyl ene refers to a saturated divalent hydrocarbon group derived from a straight or branched chain saturated hydrocarbon by the removal of two hydrogen atoms. Unless otherwise specified, the alkyl ene group contains 1-6 carbon atoms. In some embodiments, the alkyl ene group contains 1-4 carbon atoms. In other embodiments, the alkyl ene group contains 1- 2 carbon atoms. Examples of the alkylene group include, but are not limited to, methylene (- CEE-), ethylidene (-CH 2 CH 2 -), isopropylidene (-CH(CH3)CH 2 -), and the like.
  • alkenyl refers to linear or branched-chain monovalent hydrocarbon radical of 2 to 12 carbon atoms with at least one site of unsaturation, i.e., a carbon-carbon, sp 2 double bond, wherein the alkenyl radical may be optionally substituted independently with one or more substituents described herein, and includes radicals having " cis " and “trans” orientations, or alternatively, "E” and “Z” orientations.
  • the alkenyl group contains 2 to 8 carbon atoms, more preferably, 2 to 6 carbon atoms, and most preferably 2 to 4 carbon atoms.
  • alkynyl refers to a linear or branched monovalent hydrocarbon radical of 2 to 12 carbon atoms with at least one site of unsaturation, i.e., a carbon-carbon, sp triple bond, wherein the alkynyl radical may be optionally substituted independently with one or more substituents described herein.
  • the alkynyl group contains 2 to 8 carbon atoms, more preferably 2 to 6 carbon atoms, and most preferably 2 to 4 carbon atoms.
  • Some non-limiting examples of the alkynyl group include ethynyl (-CoCH), propynyl (propargyl, -CH 2 CoCH), - CoC-CH 3 , and the like.
  • alkoxy refers to an alkyl group, as previously defined, attached to the principal carbon atom through an oxygen atom. Unless otherwise specified, the alkoxy group contains 1-20 carbon atoms. In some embodiments, the alkoxy group contains 1-10 carbon atoms. In other embodiments, the alkoxy group contains 1-8 carbon atoms. In still other embodiments, the alkoxy group contains 1-6 carbon atoms, and in yet other embodiments, the alkoxy group contains 1-4 carbon atoms. In further embodiments, the alkoxy group contains 1-3 carbon atoms.
  • alkoxy group examples include methoxy (MeO, -OCH 3 ), ethoxy (EtO, -OCH 2 CH 3 ), l-propoxy (//-PrO, n- propoxy, -OCH 2 CH 2 CH 3 ), 2-propoxy (7-PrO, /- propoxy, -OCH(CH 3 ) 2 ), l-butoxy (//-BuO, //-butoxy, -OCH 2 CH 2 CH 2 CH 3 ), 2-methyl -l-propoxy (7-BuO, /-butoxy, -OCH 2 CH(CH 3 ) 2 ), 2-butoxy (v-BuO, .v-butoxy, -OCH(CH 3 )CH 2 CH 3 ), 2- methyl-2-propoxy (/-BuO, /-butoxy, -OC(CH 3 ) 3 ), l-pentoxy (//-pentoxy, OCH 2 CH 2 CH 2 CH 2 CH 3 ), l-pentoxy (
  • haloalkyl refers to alkyl, alkenyl, or alkoxy, as the case may be, substituted with one or more halogen atoms.
  • the term "carbocycle”, “carbocyclyl”, or “carbocyclic ring” refers to a monovalent or multivalent non-aromatic, saturated or partially unsaturated ring having 3 to 12 carbon atoms as a monocyclic, bicyclic, or tricyclic ring system.
  • the carbobicyclyl system includes a spiro carbobicyclyl or a fused carbobicyclyl.
  • the carbocyclic ring group contains 3 to 8 carbon atoms.
  • Some non-limiting examples of the carbocyclyl group include cycloalkyl, cycloalkenyl, and cycloalkynyl.
  • carbocyclyl group examples include cyclopropyl, cyclobutyl, cyclopentyl, l-cyclopent-l-enyl, l-cyclopent-2-enyl, 1- cyclopent-3-enyl, cyclohexyl, l-cyclohex-l-enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, cyclohexadienyl, and the like.
  • cycloalkyl refers to a monovalent or multivalent saturated ring having 3 to 12 carbon atoms as a monocyclic, bicyclic, or tricyclic ring system.
  • a bicyclic ring system includes a spiro bicyclyl or a fused bicyclyl.
  • the cycloalkyl group contains 3 to 10 carbon atoms. In other embodiments, the cycloalkyl group contains 3 to 8 carbon atoms. In still other embodiments, the cycloalkyl group contains 3 to 6 carbon atoms, and in yet other embodiments, the cycloalkyl group contains 5 to 6 carbon atoms.
  • the cycloalkyl group is optionally substituted independently with one or more substituents described herein.
  • fused bicyclic refers to saturated bridged ring system, which refers to a bicyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon).
  • spirocyclyl refers to a ring originating from a particular annular carbon of another ring.
  • a saturated bridged ring system (ring B and B’) is termed as "fused bicyclic", whereas ring A and ring B share an atom between the two saturated ring system, which terms as a "spirocyclyl” or "spiro bicyclyl”.
  • spirocyclyl or spiro bicyclyl.
  • Each cyclic ring in a fused bicyclyl or a spiro bicyclyl can be either a carbocyclyl or a heterocyclyl.
  • heterocycle refers to a monocyclic, bicyclic, or tricyclic ring system in which one or more ring members are independently selected from heteroatoms and that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has one or more points of attachment to the rest of the molecule.
  • a bicyclic ring system includes a spiro bicyclyl or a fused bicyclyl, and one of the rings can be either a monocarbocycle or a monohetercycle.
  • One or more ring atoms are optionally substituted independently with one or more substituents described herein.
  • the heterocyclyl may be a carbon radical or heteroatom radical.
  • Some non-limiting examples of the heterocyclyl group include pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, homo-piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 4,5- dihydrooxazoly, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 277-pyranyl, 477-pyranyl, dioxany
  • heteroatom refers to one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon, including any oxidized form of nitrogen, sulfur, or phosphorus; the quatemized form of any basic nitrogen; or a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4- di hydro-2//-pyrrol yl ), NH (as in pyrrolidinyl) or NR (as in N- substituted pyrrolidinyl).
  • halogen refers to Fluoro (F), Chloro (Cl), Bromo (Br), or Iodo (I).
  • azido or "N 3 " refers to an azide moiety. This radical may be attached, for example, to a methyl group to form azidomethane (methyl azide, MeN 3 ); or attached to a phenyl group to form phenyl azide (PhN 3 ).
  • aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy” or “aryloxyalkyl” refers to monocyclic, bicyclic, and tricyclic carbocyclic ring systems having a total of 6 to 14 ring members, preferably, 6 to 12 ring members, and more preferably 6 to 10 ring members, wherein at least one ring in the system is aromatic, wherein each ring in the system contains 3 to 7 ring members and that has one or more points of attachment to the rest of the molecule.
  • aryl may be used interchangeably with the term “aryl ring” or "aromatic.” Some non-limiting examples of the aryl ring would include phenyl, naphthyl, and anthracenyl.
  • the aryl radical is optionally substituted independently with one or more substituents described herein.
  • heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy” refers to monocyclic, bicyclic, and tricyclic ring systems having a total of 5 to 14 ring members, preferably, 5 to 12 ring members, and more preferably 5 to 10 ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, wherein each ring in the system contains 5 to 7 ring members and that has one or more points of attachment to the rest of the molecule.
  • heteroaryl may be a 5-10 membered heteroaryl comprises 1, 2, 3 or 4 heteroatoms independently selected from O, S and N.
  • heteroaryl may be a 5-6 membered heteroaryl comprises 1, 2, 3 or 4 heteroatoms independently selected from O, S and N.
  • heteroaryl may be a 5-membered heteroaryl comprises 1, 2, 3 or 4 heteroatoms independently selected from O, S and N.
  • heteroaryl may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.
  • the heteroaryl radicals are optionally substituted independently with one or more substituents described herein.
  • heteroaryl ring examples include the following monocycles: 2-furanyl, 3-furanyl, A-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4- isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, /V-pyrrolyl, 2-pyrrolyl, 3- pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3- pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5//-tetrazolyl and 2 H- tetrazolyl ), triazolyl (e
  • carboxy or “carboxyl”, whether used alone or with other terms, such as “carboxyalkyl”, refers to -C0 2 H.
  • alkylamino embraces “/V-alkylamino” and "N, A'-di al kyl a i no" where amino groups are independently substituted with one alkyl radical or with two alkyl radicals, respectively.
  • alkylamino radicals are "lower alkylamino” radicals having one or two alkyl radicals of one to six carbon atoms, attached to a nitrogen atom.
  • Suitable alkylamino radicals may be mono or dialkylamino such as A'-rn ethyl ami no, A'-ethylamino, N, N- dimethylamino, N A'-di ethylamino and the like.
  • arylamino refers to amino groups, which have been substituted with one or two aryl radicals, such as A-phenylamino.
  • the arylamino radicals may be further substituted on the aryl ring portion of the radical.
  • aminoalkyl refers to linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more amino radicals. More preferred aminoalkyl radicals are "lower aminoalkyl” radicals having one to six carbon atoms and one or more amino radicals. Examples of such radicals include aminomethyl, aminoethyl, aminopropyl, aminobutyl and aminohexyl.
  • n membered where n is an integer typically describes the number of ring forming atoms in a moiety where the number of ring-forming atoms is n.
  • piperidinyl is an example of a 6 membered heterocycloalkyl
  • l,2,3,4-tetrahydro naphthalenyl is an example of a 10 membered carbocyclyl group.
  • a bond drawn from a substituent to the center of one ring within a ring system represents substitution of the substituent at any substitutable position on the ring to which it is attached.
  • Structure b represents possible substitutions in any of the positions on the D ring shown in Structure b-l, b-2, b-3, b-4, b-5, b-6, and b-7.
  • prodrug represents a compound that is transformed in vivo into a compound of formula (I). Such a transformation can be affected, for example, by hydrolysis in blood or enzymatic transformation of the prodrug form to the parent form in blood or tissue.
  • Prodrugs of the compounds disclosed herein may be, for example, esters. Esters that may be utilized as prodrugs in the present invention are phenyl esters, aliphatic (C 1 -C 24 ) esters, acyloxymethyl esters, carbonates, carbamates, and amino acid esters. For example, a compound disclosed herein that contains an OH group may be acylated at this position in its prodrug form.
  • prodrug forms include phosphates, such as, for example those phosphates resulting from the phosphonation of an OH group on the parent compound.
  • phosphates such as, for example those phosphates resulting from the phosphonation of an OH group on the parent compound.
  • a thorough discussion of prodrugs is provided in Higuchi et al., Pro-drugs as Novel Delivery Systems, Vol. 14, A.C.S. Symposium Series; Roche et al., Biorev ersible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987; Rautio et al., Prodrugs: Design and Clinical Applications, Nat. Rev. Drug Discovery , 2008, 7, 255-270, and Hecker et al., Prodrugs of Phosphates and Phosphonates, J. Med. Chem ., 2008, 51, 2328-2345, all of which are incorporated herein by reference.
  • a "metabolite” is a product produced through metabolism in the body of a specified compound or salt thereof.
  • the metabolite of a compound may be identified using routine techniques known in the art and their activities determined using tests such as those described herein. Such products may result for example from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound.
  • the invention includes metabolites of compounds disclosed herein, including compounds produced by a process comprising contacting a compound disclosed herein with a mammal for a period of time sufficient to yield a metabolic product thereof.
  • a "pharmaceutically acceptable salt” refers to organic or inorganic salts of a compound disclosed herein.
  • the pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharm. Sci., 1977, 66, 1-19, which is incorporated herein by reference.
  • the pharmaceutically acceptable salt include salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • compositions of the pharmaceutically acceptable salt include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemi sulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pa
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (Ci -4 alkyl) 4 salts.
  • This invention also envisions the quatemization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quatemization.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • compositions include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, Ci -8 sulfonate and aryl sulfonate.
  • a “solvate” refers to an association or complex of one or more solvent molecules and a compound disclosed herein.
  • solvents that form solvates include water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.
  • hydrate refers to the complex where the solvent molecule is water.
  • the term "pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, p. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • a therapeutically effective amount of a compound disclosed herein refers to an amount of the compound disclosed herein that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.
  • a therapeutically effective amount refers to the amount of the compound disclosed herein that, when administered to a subject, is effective to (1) at least partially alleviate, inhibit, prevent and/or ameliorate a condition, or a disorder or a disease (i) mediated by PI3K or (ii) associated with PI3K activity, or (iii) characterized by activity (normal or abnormal) of PI3K or (2) reduce or inhibit the activity of PI3K or (3) reduce or inhibit the expression of PI3K.
  • a therapeutically effective amount refers to the amount of the compound disclosed herein that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of PI3K; or at least partially reducing or inhibiting the expression of PI3K.
  • the meaning of the term "a therapeutically effective amount” as illustrated in the above embodiment for PI3K also applies by the same means to any other relevant proteins/peptides/enzymes.
  • the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • the term “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • the term “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
  • the term “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
  • protecting group refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound.
  • an "amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxy-carbonyl (BOC, Boc), benzyloxycarbonyl (CBZ, Cbz) and 9-fluorenylmethylenoxy-carbonyl (Fmoc).
  • a "hydroxy-protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality.
  • Suitable protecting groups include acetyl and silyl.
  • a "carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Common carboxy-protecting groups include -CH 2 CH 2 S02Ph, cyanoethyl, 2-(trimethylsilyl)ethyl, 2- (trimethylsilyl)ethoxy-methy-l, 2-(p-toluenesulfonyl) ethyl, 2-(p-nitrophenylsulfenyl)-ethyl, 2- (diphenylphosphino)-ethyl, nitroethyl and the like.
  • the present inventors have discovered novel compounds which are inhibitors of kinase activity, in particular PI3 -kinase activity.
  • Compounds which are PI3 -kinase inhibitors may be useful in the treatment of disorders associated with inappropriate kinase activity, in particular inappropriate PI3-kinase activity, for example in the treatment and prevention of disorders mediated by PI3-kinase mechanisms.
  • Such disorders include respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-viral respiratory infections including aspergillosis and leishmaniasis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigemin
  • compounds disclosed herein may show selectivity for PI3-kinases over other kinases.
  • compounds disclosed herein may be potent inhibitors of PI3K5.
  • compounds disclosed herein may show selectivity for PI3K5 over other PI3 -kinases.
  • X is 3-8 membered heterocyclyl, (C 6 -Ci 0 )aryl or 5-10 membered heteroaryl, wherein X is optionally substituted by 1, 2, 3, 4 or 5 R 3 groups; m is 1, 2 or 3;
  • W is N or CR 5 ;
  • A is H, D, (Ci-C 6 )alkyl, (Ci-C 6 )haloalkyl, (Ci-C 6 )hydroxyalkyl, (Ci-C 6 )aminoalkyl, (C 3 - C 8 )cycloalkyl or 3-8 membered heterocyclyl, wherein each (Ci-C 6 )alkyl, (Ci-C 6 )haloalkyl, (Ci- C 6 )hydroxyalkyl, (Ci-C 6 )aminoalkyl, (C 3 -C 8 )cycloalkyl and 3-8 membered heterocyclyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH 2 , CN, N0 2 , (Ci-C 6 )alkyl and (Ci-C 6 )alkoxy;
  • X is 3-6 membered heterocyclyl or 5-6 membered heteroaryl, wherein X is optionally substituted by 1, 2, 3 or 4 R 3 groups.
  • X is
  • A is H, D, (Ci-C 4 )alkyl, (Ci-C 4 )haloalkyl, (Ci- C )hydroxyalkyl, (Ci-C )aminoalkyl, (C 3 -C 6 )cycloalkyl or 3-6 membered heterocyclyl, wherein each (Ci-C 4 )alkyl, (Ci-C 4 )haloalkyl, (Ci-C 4 )hydroxyalkyl, (Ci-C 4 )aminoalkyl, (C 3 -C 6 )cycloalkyl and 3-6 membered heterocyclyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH 2 , CN, N0 2 , (Ci-C )alkyl and (Ci- C 4 )alkoxy.
  • A is H, D, methyl, ethyl, «-propyl, isopropyl, /er/-butyl, trifluorom ethyl, difluorom ethyl, l,2-difluoroethyl, 2,2-difluoroethyl, hydroxymethyl, 2- hydroxyethyl, 1 -hydroxy ethyl, 2-hydroxyprop-2-yl, aminomethyl, 2-aminoethyl, l-aminoethyl, 2-aminoprop-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiofen, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl, wherein each methyl, ethyl, «-propyl, iso
  • B is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl,
  • each R 1 and R 2 is independently H, D, F, CN, methyl, ethyl, n- propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl, wherein each of methyl, ethyl, «-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl and thiomorpholinyl is optionally substituted with 1, 2,
  • R a , R b and R c is independently H, (Ci-C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 2 -C 4 )alkynyl, (C3-C 6 )cycloalkyl, -(Ci-C 2 )alkylene-(C3-C 6 )cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C 2 )alkylene-(3-6 membered heterocyclyl) or 5-6 membered heteroaryl, wherein each of the (Ci-C )alkyl, (C 2 -C )alkenyl, (C 2 -C )alkynyl, (C3-C 6 )cycloalkyl, -(Ci- C 2 )alkylene-(C3-C 6 )cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C 2 )alkyl, 3-6
  • each R a , R b and R c is independently H, methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of the methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl
  • a pharmaceutical composition which comprises a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof, and a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the composition is a liquid, solid, semi-solid, gel, or an aerosol form.
  • a method of inhibiting a phosphatidyl inositol-3 kinase comprising: contacting the PI3 kinase with an effective amount of a compound disclosed herein.
  • the step of contacting comprises contacting a cell that contains said PI3 kinase.
  • the inhibition takes place in a subject suffering from a disorder associated with malfunctioning of one or more types of PI3 kinase.
  • Some exemplary diseases involving malfunctioning of one or more types of PI3 kinases are selected from the group consisting of autoimmune diseases, rheumatoid arthritis, respiratory disease, allergic reactions, and various types of cancers.
  • the method comprises administering a second therapeutic agent to the subject.
  • the PI3K-mediated condition or disorder is selected from rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, and autoimmune diseases.
  • the PI3K-mediated condition or disorder is selected from cardiovascular diseases, atherosclerosis, hypertension, deep venous thrombosis, stroke, myocardial infarction, unstable angina, thromboembolism, pulmonary embolism, thrombolytic diseases, acute arterial ischemia, peripheral thrombotic occlusions, and coronary artery disease.
  • the PBK-mediated condition or disorder is selected from cancer, colon cancer, glioblastoma, endometrial carcinoma, hepatocellular cancer, lung cancer, melanoma, renal cell carcinoma, thyroid carcinoma, cell lymphoma, lymphoproliferative disorders, small cell lung cancer, squamous cell lung carcinoma, glioma, breast cancer, prostate cancer, ovarian cancer, cervical cancer, and leukemia.
  • the PBK-mediated condition or disorder is selected from type II diabetes.
  • the PBK-mediated condition or disorder is selected from respiratory diseases, bronchitis, asthma, and chronic obstructive pulmonary disease.
  • the subject is a human.
  • Another aspect of the invention relates to the treatment of PBK-mediated condition or disorder in a patient comprising the step of administering a compound according to any of the above embodiments.
  • Another aspect of the invention relates to the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases or autoimmune diseases in a patient comprising the step of administering a compound according to any of the above embodiments.
  • Another aspect of the invention relates to the treatment of respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) in a patient comprising the step of administering a compound according to any of the above embodiments.
  • respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF)
  • COPD chronic obstructive pulmonary disease
  • IPF idiopathic pulmonary fibrosis
  • Another aspect of the invention relates to the treatment of inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, skin complaints with inflammatory components, chronic inflammatory conditions, systemic lupus erythematosis (SLE), myestenia gravis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions and hypersensitivity in a patient, comprising the step of administering a compound according to any of the above or below embodiments.
  • SLE systemic lupus erythematosis
  • myestenia gravis acute disseminated encephalomyelitis
  • idiopathic thrombocytopenic purpura idiopathic thrombocytopenic purpura
  • multiples sclerosis multiples sclerosis
  • Sjoegren's syndrome and autoimmune hemolytic anemia allergic conditions and hypersensitivity in a patient
  • Another aspect of the invention relates to the treatment of cancers in a patient that are mediated, dependent on or associated with PI3K activity, particularly PBKdelta activity, comprising the step of administering a compound according to any of the above or below embodiments.
  • Another aspect of the invention relates to the treatment of cancers are selected from acute myeloid leukaemia, myelo-dysplastic syndrome, myeloproliferative diseases, chronic myeloid leukaemia, T-cell acute lymphoblastic leukaemia, B-cell acute lymphoblastic leukaemia, non-hodgkins lymphoma, B-cell lymphoma, solid tumors and breast cancer, comprising the step of administering a compound according to any of the above or below embodiments.
  • Another aspect of the invention relates to the use of a compound according to any of the above embodiments as a medicament.
  • Another aspect of the invention relates to the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of PBK-mediated condition or disorder in a patient.
  • Another aspect of the invention relates to the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), autoimmune diseases, and cancers.
  • COPD chronic obstructive pulmonary disease
  • IPF idiopathic pulmonary fibrosis
  • the salt is a pharmaceutically acceptable salt.
  • pharmaceutically acceptable indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
  • the compounds disclosed herein also include salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula (I) and/or for separating enantiomers of compounds of Formula (I).
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandi sulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methyl sulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphat
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
  • compositions can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
  • the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
  • Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
  • the pharmaceutically acceptable salts disclosed herein can be synthesized from a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
  • the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
  • the compounds disclosed herein can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
  • the compounds disclosed herein may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
  • the compounds disclosed herein may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and diasteromers.
  • Compounds disclosed herein can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof.
  • This invention is intended to encompass mixtures of isomers, rotamers, atropisomers, tautomers, partially mixed isomers, rotamers, atropisomers, or tautomers, and separated isomers, rotamers, atropisomers, tautomers.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 ⁇ 4 U C, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 35 S, 36 Cl, and 125 I respectively.
  • the compounds disclosed herein include isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H, 14 C and 18 F, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
  • isotopically labelled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or labeled compound may be particularly desirable for PET or SPECT studies.
  • Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • substitution with heavier isotopes may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index.
  • deuterium in this context is regarded as a substituent of a compound of the formula (I).
  • concentration of such a heavier isotope, specifically deuterium may be defined by the isotopic enrichment factor.
  • isotopic enrichment factor as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
  • a substituent in a compound disclosed herein is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 0, acetone- ⁇ , or DMSO-i3 ⁇ 4.
  • compositions that include a compound of formula (I), or a compound listed in Table 1; and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • the amount of compound in the pharmaceutical compositions disclosed herein is such that is effective to detectably inhibit a protein kinase in a biological sample or in a patient.
  • compositions disclosed herein can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof.
  • pharmaceutically acceptable derivative include pharmaceutically acceptable prodrugs, salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
  • compositions or pharmaceutically acceptable compositions disclosed herein additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable carrier, adjuvant, or vehicle which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • compositions disclosed herein may be prepared and packaged in bulk form wherein a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof can be extracted and then given to the patient such as with powders or syrups.
  • the pharmaceutical compositions disclosed herein may be prepared and packaged in unit dosage form wherein each physically discrete unit contains a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical compositions disclosed herein typically may contain, for example, from 0.5 mg to 1 g, or from 1 mg to 700 mg, or from 5 mg to 100 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • compositions disclosed herein typically contain one compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • pharmaceutically acceptable excipient means a pharmaceutically acceptable material, composition or vehicle involved in giving form or consistency to the pharmaceutical composition.
  • Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of formula (I) or a pharmaceutically acceptable salt thereof when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically acceptable are avoided.
  • each excipient must of course be pharmaceutically-acceptable eg of sufficiently high purity.
  • the compound of formula (I) or a pharmaceutically acceptable salt thereof and the pharmaceutically acceptable excipient or excipients will typically be formulated into a dosage form adapted for administration to the patient by the desired route of administration.
  • dosage forms include those adapted for (1 ) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixers, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols, solutions, and dry powders; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
  • oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixers, suspensions, solutions, emulsions, sachets, and cachets
  • parenteral administration such as sterile solutions, suspensions, and powders for reconstitution
  • transdermal administration such as transdermal patches
  • rectal administration such as
  • Suitable pharmaceutically acceptable excipients will vary depending upon the particular dosage form chosen.
  • suitable pharmaceutically acceptable excipients may be chosen for a particular function that they may serve in the composition.
  • certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms.
  • Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms.
  • Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the carrying or transporting of the compound or compounds of formula (I) or pharmaceutically acceptable salts thereof once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body.
  • Certain pharmaceutically acceptable excipients may be chosen for their ability to enhance patient compliance.
  • Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweetners, flavoring agents, flavor masking agents, coloring agents, anticaking agents, hemectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
  • excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweetners, flavoring agents, flavor masking agents, coloring agents, anticaking agents, hemectants, chelating agents
  • Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically-acceptable excipients in appropriate amounts for use in the invention.
  • resources that are available to the skilled artisan which describe pharmaceutically acceptable excipients and may be useful in selecting suitable pharmaceutically acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
  • compositions disclosed herein are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
  • the invention is directed to process for the preparation of a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients which comprises mixing the ingredients.
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof may be prepared by, for example, admixture at ambient temperature and atmospheric pressure.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof will be formulated for oral administration. In another embodiment, the compounds of formula (I) or pharmaceutically acceptable salts thereof will be formulated for inhaled administration. In a further embodiment, the compounds of formula (I) or pharmaceutically acceptable salts thereof will be formulated for intranasal administration.
  • the invention is directed to a solid oral dosage form such as a tablet or capsule comprising a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a diluent or filler.
  • Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. com starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
  • the oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g.
  • the oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose.
  • the oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesuim stearate, calcium stearate, and talc.
  • dosage unit formulations for oral administration can be microencapsulated.
  • the composition can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may also be coupled with soluble polymers as targetable drug carriers.
  • soluble polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide -phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • biodegradable polymers useful in achieving controlled release of a drug
  • a drug for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • the invention is directed to a liquid oral dosage form.
  • Oral liquids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • Syrups can be prepared by dissolving the compound of formula (I) or a pharmaceutically acceptable salt thereof in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle.
  • Suspensions can be formulated by dispersing the compound of formula (I) or a pharmaceutically acceptable salt thereof in a non toxic vehicle.
  • Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
  • the invention is directed to a dosage form adapted for administration to a patient by inhalation, for example as a dry powder, an aerosol, a suspension, or a solution composition.
  • the invention is directed to a dosage form adapted for administration to a patient by inhalation as a dry powder.
  • the invention is directed to a dosage form adapted for administration to a patient by inhalation via a nebulizer.
  • Dry powder compositions for delivery to the lung by inhalation typically comprise a compound of formula (I) or a pharmaceutically acceptable salt thereof as a finely divided powder together with one or more pharmaceutically-acceptable excipients as finely divided powders.
  • compositions particularly suited for use in dry powders are known to those skilled in the art and include lactose, starch, mannitol, and mono-, di-, and polysaccharides.
  • the finely divided powder may be prepared by, for example, micronisation and milling.
  • the size-reduced (eg micronised) compound can be defined by a D 50 value of about 1 to about 10 microns (for example as measured using laser diffraction).
  • the dry powder may be administered to the patient via a reservoir dry powder inhaler (RDPI) having a reservoir suitable for storing multiple (un-metered doses) of medicament in dry powder form.
  • RDPIs typically include a means for metering each medicament dose from the reservoir to a delivery position.
  • the metering means may comprise a metering cup, which is movable from a first position where the cup may be filled with medicament from the reservoir to a second position where the metered medicament dose is made available to the patient for inhalation.
  • the dry powder may be presented in capsules (e.g. gelatin or plastic), cartridges, or blister packs for use in a multi-dose dry powder inhaler (MDPI).
  • MDPIs are inhalers wherein the medicament is comprised within a multi-dose pack containing (or otherwise carrying) multiple defined doses (or parts thereof) of medicament.
  • the dry powder is presented as a blister pack, it comprises multiple blisters for containment of the medicament in dry powder form.
  • the blisters are typically arranged in regular fashion for ease of release of the medicament therefrom.
  • the blisters may be arranged in a generally circular fashion on a disc-form blister pack, or the blisters may be elongate in form, for example comprising a strip or a tape.
  • Each capsule, cartridge, or blister may, for example, contain between 20 pg-lO mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • Aerosols may be formed by suspending or dissolving a compound of formula (I) or a pharmaceutically acceptable salt thereof in a liquified propellant.
  • Suitable propellants include halocarbons, hydrocarbons, and other liquified gases.
  • propellants include: trichlorofluoromethane (propellant 11), dichlorofluoromethane (propellant 12), dichlorotetrafluoroethane (propellant 114), tetrafluoroethane (HFA-l34a), l,l-difluoroethane (HFA-l52a), difluoromethane (HFA-32), pentafluoroethane (HFA-12), heptafluoropropane (HFA-227a), perfluoropropane, perfluorobutane, perfluoropentane, butane, isobutane, and pentane.
  • Aerosols comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof will typically be administered to a patient via a metered dose inhaler (MDI). Such devices are known to those skilled in the art.
  • the aerosol may contain additional pharmaceutically-acceptable excipients typically used with MDIs such as surfactants, lubricants, cosolvents and other excipients to improve the physical stability of the formulation, to improve valve performance, to improve solubility, or to improve taste.
  • additional pharmaceutically-acceptable excipients typically used with MDIs such as surfactants, lubricants, cosolvents and other excipients to improve the physical stability of the formulation, to improve valve performance, to improve solubility, or to improve taste.
  • a pharmaceutical aerosol formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon as propellant, optionally in combination with a surfactant and/or a cosolvent.
  • a pharmaceutical aerosol formulation wherein the propellant is selected from l,l,l,2-tetrafluoroethane, l,l,l,2,3,3,3-heptafluoro-n-propane and mixtures thereof.
  • formulations disclosed herein may be buffered by the addition of suitable buffering agents.
  • Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix for inhalation of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a suitable powder base such as lactose or starch.
  • a powder mix for inhalation of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a suitable powder base such as lactose or starch.
  • Each capsule or cartridge may generally contain from 20 pg to 10 mg of the compound of formula (I) or pharmaceutically acceptable salt thereof.
  • the compound of formula (I) or pharmaceutically acceptable salt thereof may be presented without excipients such as lactose.
  • the proportion of the active compound of formula (I) or pharmaceutically acceptable salt thereof in the local compositions according to the invention depends on the precise type of formulation to be prepared but will generally be within the range of from 0.001 to 10% by weight. Generally, for most types of preparations, the proportion used will be within the range of from 0.005 to 1 %, for example from 0.01 to 0.5%. However, in powders for inhalation or insufflation the proportion used will normally be within the range of from 0.1% to 5%.
  • Aerosol formulations are preferably arranged so that each metered dose or "puff 1 of aerosol contains from 20pg to lOmg, preferably from 20 pg to 2000 pg, more preferably from about 20 pg to 500 pg of a compound of formula (I). Administration may be once daily or several times daily, for example 2, 3, 4 or 8 times, giving for example 1, 2 or 3 doses each time.
  • the overall daily dose with an aerosol will be within the range from 100 pg to 10 mg, preferably from 200 pg to 2000 pg.
  • the overall daily dose and the metered dose delivered by capsules and cartridges in an inhaler or insufflator will generally be double that delivered with aerosol formulations.
  • the particle size of the particulate (e.g., micronised) drug should be such as to permit inhalation of substantially all the drug into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than 20 microns, and in particular in the range of from 1 to 10 microns, such as from 1 to 5 microns, more preferably from 2 to 3 microns.
  • formulations disclosed herein may be prepared by dispersal or dissolution of the medicament and a compound of formula (I) or a pharmaceutically acceptable salt thereof in the selected propellant in an appropriate container, for example, with the aid of sonication or a high- shear mixer.
  • the process is desirably carried out under controlled humidity conditions.
  • the chemical and physical stability and the pharmaceutical acceptability of the aerosol formulations according to the invention may be determined by techniques well known to those skilled in the art.
  • the chemical stability of the components may be determined by HPLC assay, for example, after prolonged storage of the product.
  • Physical stability data may be gained from other conventional analytical techniques such as, for example, by leak testing, by valve delivery assay (average shot weights per actuation), by dose reproducibility assay (active ingredient per actuation) and spray distribution analysis.
  • the stability of the suspension aerosol formulations according to the invention may be measured by conventional techniques, for example, by measuring flocculation size distribution using a back light scattering instrument or by measuring particle size distribution by cascade impaction or by the "twin impinger” analytical process.
  • twin impinger assay means "Determination of the deposition of the emitted dose in pressurised inhalations using apparatus A” as defined in British Pharmacopaeia 1988, pages A204-207, Appendix XVII C.
  • Such techniques enable the "respirable fraction" of the aerosol formulations to be calculated.
  • MDI tered dose inhaler
  • MDI system includes a suitable channelling device. Suitable channelling devices comprise for example, a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient such as a mouthpiece actuator.
  • MDI canisters generally comprise a container capable of withstanding the vapour pressure of the propellant used such as a plastic or plastic-coated glass bottle or preferably a metal can, for example, aluminium or an alloy thereof which may optionally be anodised, lacquer-coated and/or plastic-coated (for example incorporated herein by reference WO96/32099 wherein part or all of the internal surfaces are coated with one or more fluorocarbon polymers optionally in combination with one or more non-fluorocarbon polymers), which container is closed with a metering valve.
  • the cap may be secured onto the can via ultrasonic welding, screw fitting or crimping.
  • MDIs taught herein may be prepared by methods of the art (e.g. see Byron, above and WO96/32099).
  • the canister is fitted with a cap assembly, wherein a drug metering valve is situated in the cap, and said cap is crimped in place.
  • the metallic internal surface of the can is coated with a fluoropolymer, more preferably blended with a non-fluoropolymer.
  • the metallic internal surface of the can is coated with a polymer blend of polytetrafluoroethylene (PTFE) and polyethersulfone (PES).
  • the whole of the metallic internal surface of the can is coated with a polymer blend of polytetrafluoroethylene (PTFE) and polyethersulfone (PES).
  • the metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve.
  • the gasket may comprise any suitable elastomeric material such as, for example, low density polyethylene, chlorobutyl, bromobutyl, EPDM, black and white butadiene-acrylonitrile rubbers, butyl rubber and neoprene.
  • suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (e.g. DF10, DF30, DF60), Bespak pic, UK (e.g. BK300, BK357) and 3M- TM Neotechnic Ltd, UK (e.g. Spraymiser).
  • the MDIs may also be used in conjunction with other structures such as, without limitation, overwrap packages for storing and containing the MDIs, including those described in U.S. Patent Nos. 6,119,853; 6,179,118; 6,315,112; 6,352,152; 6,390,291; and 6,679,374, as well as dose counter units such as, but not limited to, those described in U.S. Patent Nos. 6,360,739 and 6,431,168.
  • overwrap packages for storing and containing the MDIs, including those described in U.S. Patent Nos. 6,119,853; 6,179,118; 6,315,112; 6,352,152; 6,390,291; and 6,679,374, as well as dose counter units such as, but not limited to, those described in U.S. Patent Nos. 6,360,739 and 6,431,168.
  • a metering valve is crimped onto an aluminium can to form an empty canister.
  • the liquefied propellant together with the optional excipients and the dissolved medicament is pressure filled through the charge vessel into a manufacturing vessel.
  • an aliquot of the liquefied formulation is added to an open canister under conditions which are sufficiently cold to ensure the formulation does not vaporise, and then a metering valve crimped onto the canister.
  • each filled canister is check- weighed, coded with a batch number and packed into a tray for storage before release testing.
  • Suspensions and solutions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof may also be administered to a patient via a nebulizer.
  • the solvent or suspension agent utilized for nebulization may be any pharmaceutically-acceptable liquid such as water, aqueous saline, alcohols or glycols, e.g., ethanol, isopropylalcohol, glycerol, propylene glycol, polyethylene glycol, etc. or mixtures thereof.
  • Saline solutions utilize salts which display little or no pharmacological activity after administration.
  • organic salts such as alkali metal or ammonium halogen salts, e.g., sodium chloride, potassium chloride or organic salts, such as potassium, sodium and ammonium salts or organic acids, e.g., ascorbic acid, citric acid, acetic acid, tartaric acid, etc. may be used for this purpose.
  • alkali metal or ammonium halogen salts e.g., sodium chloride, potassium chloride or organic salts, such as potassium, sodium and ammonium salts or organic acids, e.g., ascorbic acid, citric acid, acetic acid, tartaric acid, etc.
  • organic acids e.g., ascorbic acid, citric acid, acetic acid, tartaric acid, etc.
  • compositions may be added to the suspension or solution.
  • the compound of formula (I) or pharmaceutically acceptable salt thereof may be stabilized by the addition of an inorganic acid, e.g., hydrochloric acid, nitric acid, sulphuric acid and/or phosphoric acid; an organic acid, e.g., ascorbic acid, citric acid, acetic acid, and tartaric acid, etc., a complexing agent such as EDTA or citric acid and salts thereof; or an antioxidant such as antioxidant such as vitamin E or ascorbic acid.
  • an inorganic acid e.g., hydrochloric acid, nitric acid, sulphuric acid and/or phosphoric acid
  • organic acid e.g., ascorbic acid, citric acid, acetic acid, and tartaric acid, etc.
  • a complexing agent such as EDTA or citric acid and salts thereof
  • an antioxidant such as antioxidant such as vitamin E or ascorbic acid.
  • Preservatives may be added such as benzalkonium chloride or benzoic acid and salts thereof.
  • Surfactant may be added particularly to improve the physical stability of suspensions. These include lecithin, disodium di octyl sulphosuccinate, oleic acid and sorbitan esters.
  • the invention is directed to a dosage form adapted for intranasal administration.
  • Formulations for administration to the nose may include pressurised aerosol formulations and aqueous formulations administered to the nose by pressurised pump. Formulations which are non-pressurised and adapted to be administered topically to the nasal cavity are of particular interest. Suitable formulations contain water as the diluent or carrier for this purpose. Aqueous formulations for administration to the lung or nose may be provided with conventional excipients such as buffering agents, tonicity modifying agents and the like. Aqueous formulations may also be administered to the nose by nebulisation.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be formulated as a fluid formulation for delivery from a fluid dispenser, for example a fluid dispenser having a dispensing nozzle or dispensing orifice through which a metered dose of the fluid formulation is dispensed upon the application of a user-applied force to a pump mechanism of the fluid dispenser.
  • a fluid dispenser for example a fluid dispenser having a dispensing nozzle or dispensing orifice through which a metered dose of the fluid formulation is dispensed upon the application of a user-applied force to a pump mechanism of the fluid dispenser.
  • Such fluid dispensers are generally provided with a reservoir of multiple metered doses of the fluid formulation, the doses being dispensable upon sequential pump actuations.
  • the dispensing nozzle or orifice may be configured for insertion into the nostrils of the user for spray dispensing of the fluid formulation into the nasal cavity.
  • a fluid dispenser of the aforementioned type is described and illustrated in WO05/044354, the entire content of which is hereby incorporated herein by reference.
  • the dispenser has a housing which houses a fluid discharge device having a compression pump mounted on a container for containing a fluid formulation.
  • the housing has at least one finger-operable side lever which is movable inwardly with respect to the housing to cam the container upwardly in the housing to cause the pump to compress and pump a metered dose of the formulation out of a pump stem through a nasal nozzle of the housing.
  • the fluid dispenser is of the general type illustrated in Figures 30-40 of WO05/044354.
  • compositions adapted for intranasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • suitable compositions wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops include aqueous or oil solutions of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the patient for a prolonged period of time.
  • the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
  • compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • Ointments, creams and gels may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agent and/or solvents.
  • bases may thus, for example, include water and/or an oil such as liquid paraffin or a vegetable oil such as arachis oil or castor oil, or a solvent such as polyethylene glycol.
  • Thickening agents and gelling agents which may be used according to the nature of the base include soft paraffin, aluminium stearate, cetostearyl alcohol, polyethylene glycols, woolfat, beeswax, carboxypolymethylene and cellulose derivatives, and/or glyceryl monostearate and/or non-ionic emulsifying agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents or thickening agents.
  • Powders for external application may be formed with the aid of any suitable powder base, for example, talc, lactose or starch. Drops may be formulated with an aqueous or nonaqueous base also comprising one or more dispersing agents, solubilising agents, suspending agents or preservatives.
  • Topical preparations may be administered by one or more applications per day to the affected area; over skin areas occlusive dressings may advantageously be used. Continuous or prolonged delivery may be achieved by an adhesive reservoir system.
  • compositions may be applied as a topical ointment or cream.
  • the compound of formula (I) or a pharmaceutically acceptable salt thereof may be employed with either a paraffinic or a water-miscible ointment base.
  • the compound of formula (I) or pharmaceutically acceptable salt thereof may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti -oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • the compound and pharmaceutical formulations according to the invention may be used in combination with or include one or more other therapeutic agents, for example selected from anti-inflammatory agents, anticholinergic agents (particularly an M I /M 2 /M 3 receptor antagonist), p 2 -adrenoreceptor agonists, antiinfective agents, such as antibiotics or antivirals, or antihistamines.
  • other therapeutic agents for example selected from anti-inflammatory agents, anticholinergic agents (particularly an M I /M 2 /M 3 receptor antagonist), p 2 -adrenoreceptor agonists, antiinfective agents, such as antibiotics or antivirals, or antihistamines.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with one or more other therapeutically active agents, for example selected from an anti-inflammatory agent, such as a corticosteroid or an NSAID, an anticholinergic agent, a p 2 -adrenoreceptor agonist, an antiinfective agent, such as an antibiotic or an antiviral, or an antihistamine.
  • an anti-inflammatory agent such as a corticosteroid or an NSAID
  • an anticholinergic agent such as a corticosteroid or an NSAID
  • an anticholinergic agent such as a corticosteroid or an NSAID
  • an anticholinergic agent such as an antibiotic or an antiviral
  • an antiinfective agent such as an antibiotic or an antiviral
  • an antihistamine an antihistamine.
  • the invention encompasses a method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a safe and effective amount of a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with one or more therapeutically active agents.
  • Certain compounds disclosed herein may show selectivity for PI3K5 over other PI3- kinases.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof which is selective for PI3K5 together with a compound or pharmaceutically acceptable salt thereof which is selective for another PI3- kinase, for example RI3Kg.
  • One embodiment of the invention encompasses combinations comprising one or two other therapeutic agents.
  • the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl esters, or as solvates, for example hydrates to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient. It will be clear also that, where appropriate, the therapeutic ingredients may be used in optically pure form.
  • the invention provides a product comprising a compound of formula (I) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
  • the therapy is the treatment of a disease or condition mediated by the activity of the PI3K enzymes.
  • Products provided as a combined preparation include a composition comprising the compound of formula (I) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of formula (I) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • the invention provides a pharmaceutical composition comprising a compound of formula (I) and another therapeutic agent(s).
  • the pharmaceutical composition may comprise a pharmaceutically acceptable carrier, as described above.
  • the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I).
  • the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • a container, divided bottle, or divided foil packet An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
  • the kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit of the invention typically comprises directions for administration.
  • the compound disclosed herein and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound disclosed herein and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound disclosed herein and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound disclosed herein and the other therapeutic agent.
  • the invention provides the use of a compound of formula (I) for treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the medicament is prepared for administration with another therapeutic agent.
  • the invention also provides the use of another therapeutic agent for treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the medicament is administered with a compound of formula (I).
  • the invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the compound of formula (I) is prepared for administration with another therapeutic agent.
  • the invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the other therapeutic agent is prepared for administration with a compound of formula (I).
  • the invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by the activity of the PI3K enzymes wherein the compound of formula (I) is administered with another therapeutic agent.
  • the invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by the activity of the PI3K enzymes wherein the other therapeutic agent is administered with a compound of formula (I).
  • the invention also provides the use of a compound of formula (I) for treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the patient has previously (e.g. within 24 hours) been treated with another therapeutic agent.
  • the invention also provides the use of another therapeutic agent for treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the patient has previously (e.g. within 24 hours) been treated with a compound of formula (I).
  • the compounds of formula I may be administered as the sole active ingredient or in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g.
  • the compounds of formula I may be used in combination with a calcineurin inhibitor, e.g. cyclosporin A or FK 506; a mTOR inhibitor, e.g. rapamycin, 40-O-(2-hydroxyethyl)rapamycin, CCI779, ABT578, AP23573, TAFA-93, biolimus-7 or biolimus- 9; an ascomycin having immuno-suppressive properties, e.g.
  • a calcineurin inhibitor e.g. cyclosporin A or FK 506
  • a mTOR inhibitor e.g. rapamycin, 40-O-(2-hydroxyethyl)rapamycin, CCI779, ABT578, AP23573, TAFA-93, biolimus-7 or biolimus- 9
  • an ascomycin having immuno-suppressive properties e.g.
  • ABT-281, ASM981 , etc. corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic acid or salt; mycophenolate mofetil; l5-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof; a PKC inhibitor, e.g. as disclosed in WO 02/38561 or WO 03/82859, e.g. the compound of Example 56 or 70; a JAK3 kinase inhibitor, e.g.
  • mono- citrate also called CP-690,550
  • immunosuppressive monoclonal antibodies e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, CD52, CD58, CD80, CD86 or their ligands
  • other immunomodulatory compounds e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g.
  • CTLA4 an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4lg (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y; adhesion molecule inhibitors, e.g. LFA-l antagonists, ICAM-l or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; or antihistamines; or antitussives, or a bronchodilatory agent; or an angiotensin receptor blockers; or an anti-infectious agent.
  • CTLA4lg for ex. designated ATCC 68629
  • adhesion molecule inhibitors e.g. LFA-l antagonists, ICAM-l or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists
  • antihistamines or antitussives, or a bronchodilatory agent
  • an angiotensin receptor blockers or an anti-infect
  • the compounds of formula I are administered in conjunction with other immunosuppressive/immunomodulatory, anti-inflammatory, chemotherapeutic or anti- infectious therapy
  • dosages of the co-administered immunosuppressant, immunomodulatory, anti inflammatory, chemotherapeutic or anti-infectious compound will of course vary depending on the type of co-drug employed, e.g. whether it is a steroid or a calcineurin inhibitor, on the specific drug employed, on the condition being treated and so forth.
  • the invention encompasses a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a p 2 -adrenoreceptor agonist.
  • Examples of p 2 -adrenoreceptor agonists include salmeterol (which may be a racemate or a single enantiomer such as the //-enantiomer), salbutamol (which may be a racemate or a single enantiomer such as the //-enantiomer), formoterol (which may be a racemate or a single duastereomer such as the /.
  • salmefamol for example, compounds which provide effective bronchodilation for about 12 hrs or longer, are preferred.
  • the p 2 -adrenoreceptor agonist may be in the form of a salt formed with a pharmaceutically acceptable acid selected from sulphuric, hydrochloric, fumaric, hydroxynaphthoic (for example 1- or 3 -hydroxy -2-naphthoic), cinnamic, substituted cinnamic, triphenylacetic, sulphamic, sulphanilic, naphthaleneacrylic, benzoic, 4-methoxybenzoic, 2- or 4- hydroxybenzoic, 4-chlorobenzoic and 4-phenylbenzoic acid.
  • a pharmaceutically acceptable acid selected from sulphuric, hydrochloric, fumaric, hydroxynaphthoic (for example 1- or 3 -hydroxy -2-naphthoic), cinnamic, substituted cinnamic, triphenylacetic, sulphamic, sulphanilic, naphthaleneacryl
  • Suitable anti-inflammatory agents include corticosteroids.
  • Suitable corticosteroids which may be used in combination with the compounds of formula (I) or pharmaceutically acceptable salts thereof are those oral and inhaled corticosteroids and their pro-drugs which have anti-inflammatory activity.
  • Examples include methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6a,9a-difluoro- 11 b-hydroxy- 16a-m ethyl- 17a-[(4-methyl- 1 ,3 -thiazole-5- carbonyl)oxy]-3-oxo-androsta-l,4-diene-l7P-carbothioic acid S-fluoromethyl ester, 6a, 9a- difluoro- 17a-[(2-furanylcarbonyl)oxy]- l 1 b-hydroxy- 16a-methyl-3-oxo-androsta- 1 ,4-diene- 17b- carbothioic acid S-fluoromethyl ester (fluticasone furoate), 6a,9a-difluoro- 1 1 b-hydroxy- 16a- methyl-3-oxo-17a-propionyloxy-androsta-l,4-diene
  • Preferred corticosteroids include fluticasone propionate, 6a,9a-difluoro- 11 b-hydroxy- 16a-m ethyl- 17a-[(4-methyl- 1 ,3 -thiazole-5- carbonyl)oxy]-3-oxo-androsta-l,4-diene-17b-carbothioic acid S-fluoromethyl ester, 6a,9a- difluoro-17a-[(2-furanylcarbonyl)oxy]-llb-hydroxy-16a-methyl-3-oxo-androsta-l,4-diene-17b- carbothioic acid S-fluoromethyl ester, 6a,9a-difluoro- l 1 b-hydroxy- l 6a-methyl-3-oxo- 17 a- (2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-l,4-diene-17b-carbothioic acid S- cyan
  • the corticosteroid is 6a,9a-difluoro- l 7a-[(2-furanylcarbonyl)oxy]- l 1 b- hydroxy-16a-methyl-3-oxo-androsta-l,4-diene-17b-carbothioic acid S-fluoromethyl ester.
  • Non-steroidal compounds having glucocorticoid agonism that may possess selectivity for transrepression over transactivation and that may be useful in combination therapy include those covered in the following patents: WO03/082827, W098/54159, W004/005229, W004/009017, W004/018429, W003/104195, WO03/082787, W003/082280, WO03/059899, W003/101932, W002/02565, WO01/16128, WO00/66590, WO03/086294, WO04/026248, W003/061651 and W003/08277. Further non-steroidal compounds are covered in: W02006/000401, W02006/000398 and W02006/015870.
  • anti-inflammatory agents include non-steroidal anti-inflammatory drugs (NS AID's).
  • NSAID's include sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors (for example, theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors), leukotriene antagonists, inhibitors of leukotriene synthesis (for example montelukast), iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine receptor agonists or antagonists (e.g.
  • adenosine 2a agonists adenosine 2a agonists
  • cytokine antagonists for example chemokine antagonists, such as a CCR3 antagonist
  • inhibitors of cytokine synthesis or 5 -lipoxygenase inhibitors.
  • An iNOS (inducible nitric oxide synthase inhibitor) is preferably for oral administration.
  • iNOS inhibitors include those disclosed in WO93/13055, WO98/30537, W002/50021, W095/34534 and W099/62875.
  • CCR3 inhibitors include those disclosed in WO02/26722.
  • the invention provides the use of the compounds of formula (I) in combination with a phosphodiesterase 4 (PDE4) inhibitor, especially in the case of a formulation adapted for inhalation.
  • PDE4-specific inhibitor useful in this aspect of the invention may be any compound that is known to inhibit the PDE4 enzyme or which is discovered to act as a PDE4 inhibitor, and which are only PDE4 inhibitors, not compounds which inhibit other members of the PDE family, such as PDE3 and PDE5, as well as PDE4.
  • Compounds include cis- 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-l-carboxylic acid, 2-carbomethoxy- 4-cyano-4-(3-cyclopropylmethoxy-4- difluoromethoxyphenyl)cyclohexan-l-one and c/.s-[4- cyano-4-(3-cyclopropylmethoxy-4- difluoromethoxyphenyl)cyclohexan-l-ol].
  • anticholinergic agents are those compounds that act as antagonists at the muscarinic receptors, in particular those compounds which are antagonists of the Mi or M 3 receptors, dual antagonists of the M1/M3 or M 2 /M 3 , receptors or pan-antagonists of the M I /M 2 /M 3 receptors.
  • exemplary compounds for administration via inhalation include ipratropium (for example, as the bromide, CAS 22254-24-6, sold under the name Atrovent), oxitropium (for example, as the bromide, CAS 30286-75-0) and tiotropium (for example, as the bromide, CAS 136310-93-5, sold under the name Spiriva).
  • revatropate for example, as the hydrobromide, CAS 262586-79-8) and LAS- 34273 which is disclosed in W001/04118.
  • Exemplary compounds for oral administration include pirenzepine (CAS 28797- 61-7), darifenacin (CAS 133099-04-4, or CAS 133099- 07-7 for the hydrobromide sold under the name Enablex), oxybutynin (CAS 5633-20-5, sold under the name Ditropan), terodiline (CAS 15793-40-5), tolterodine (CAS 124937-51- 5, or CAS 124937-52-6 for the tartrate, sold under the name Detrol), otilonium (for example, as the bromide, CAS 26095-59-0, sold under the name Spasmomen), trospium chloride (CAS 10405-02-4) and solifenacin (CAS 242478-37- 1 , or CAS 242478-38-2 for the succinate also known as
  • the invention provides a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an Hl antagonist.
  • Hl antagonist include amelexanox, astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, levocetirizine, efletirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, mizolastine, mequitazine, mianserin, noberastine, meclizine, norastemizole, o
  • the invention provides a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an H3 antagonist (and/or inverse agonist).
  • H3 antagonists include, for example, those compounds disclosed in W02004/035556 and in W02006/045416.
  • Other histamine receptor antagonists which may be used in combination with the compounds disclosed herein include antagonists (and/or inverse agonists) of the H4 receptor, for example, the compounds disclosed in Jablonowski et ah, J Med. Chem., 2003, 46, 3957-3960.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a PDE4 inhibitor.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a b 2 - adrenoreceptor agonist.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a corticosteroid.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a non steroidal GR agonist.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an anticholinergic.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an antihistamine.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a PDE4 inhibitor and a p 2 -adrenoreceptor agonist.
  • the invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an anticholinergic and a PDE-4 inhibitor.
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention.
  • the individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • the individual compounds will be administered simultaneously in a combined pharmaceutical formulation.
  • Appropriate doses of known therapeutic agents will readily be appreciated by those skilled in the art.
  • the invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with another therapeutically active agent.
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a PDE4 inhibitor.
  • the invention thus provides, in a further aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a p 2 -adrenoreceptor agonist.
  • the invention thus provides, in a further aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a corticosteroid.
  • the invention thus provides, in a further aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a non-steroidal GR agonist.
  • the invention thus provides, in a further aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an anticholinergic.
  • the invention thus provides, in a further aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an antihistamine.
  • the invention thus provides, in a further aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a PDE4 inhibitor and a p 2 -adrenoreceptor agonist.
  • the invention thus provides, in a further aspect, a pharmaceutical composition
  • a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an anticholinergic and a PDE4 inhibitor.
  • a compound of the formula (I) may also be used to advantage in combination with each other or in combination with other therapeutic agents, especially other antiproliferative agents.
  • antiproliferative agents include, but are not limited to, aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active agents; alkylating agents; histone deacetylase inhibitors; compounds, which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase
  • aromatase inhibitor relates to a compound which inhibits the estrogen production, i.e., the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively.
  • the term includes, but is not limited to, steroids, especially atamestane, exemestane and formestane; and, in particular, nonsteroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketoconazole, vorozole, fadrozole, anastrozole and letrozole.
  • Exemestane can be administered, e.g., in the form as it is marketed, e.g., under the trademark AROMASIN.
  • Formestane can be administered, e.g., in the form as it is marketed, e.g., under the trademark LENTARON.
  • Fadrozole can be administered, e.g., in the form as it is marketed, e.g., under the trademark AFEMA.
  • Anastrozole can be administered, e.g., in the form as it is marketed, e.g., under the trademark ARIMTDEX.
  • Letrozole can be administered, e.g., in the form as it is marketed, e.g., under the trademark FEMARA or FEMAR.
  • Aminoglutethimide can be administered, e.g., in the form as it is marketed, e.g., under the trademark ORIMETEN.
  • a combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, e.g., breast tumors.
  • anti-estrogen relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level.
  • the term includes, but is not limited to, tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride.
  • Tamoxifen can be administered, e.g., in the form as it is marketed, e.g., under the trademark NOLVADEX.
  • Raloxifene hydrochloride can be administered, e.g., in the form as it is marketed, e.g., under the trademark EVISTA.
  • Fulvestrant can be formulated as disclosed in ET.S. Patent No.
  • 4,659,516 or it can be administered, e.g., in the form as it is marketed, e.g., under the trademark FASLODEX.
  • a combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, e.g., breast tumors.
  • anti -androgen relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX), which can be formulated, e.g., as disclosed in ET.S. Patent No. 4,636,505.
  • CASODEX bicalutamide
  • gonadorelin agonist includes, but is not limited to, abarelix, goserelin and goserelin acetate.
  • Goserelin is disclosed in U.S. Patent No. 4, 100,274 and can be administered, e.g., in the form as it is marketed, e.g., under the trademark ZOLADEX.
  • Abarelix can be formulated, e.g., as disclosed in U.S. Patent No. 5,843,901 .
  • topoisom erase I inhibitor includes, but is not limited to, topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound Al in WO 99/17804).
  • Irinotecan can be administered, e.g., in the form as it is marketed, e.g., under the trademark CAMPTOSAR.
  • Topotecan can be administered, e.g., in the form as it is marketed, e.g., under the trademark HYCAMTIN.
  • topoisom erase II inhibitor includes, but is not limited to, the anthracyclines, such as doxorubicin, including liposomal formulation, e.g., CAELYX; daunorubicin; epirubicin; idarubicin; nemorubicin; the anthraquinones mitoxantrone and losoxantrone; and the podophillotoxines etoposide and teniposide.
  • Etoposide can be administered, e.g., in the form as it is marketed, e.g., under the trademark ETOPOPHOS.
  • Teniposide can be administered, e.g., in the form as it is marketed, e.g., under the trademark VM 26-BRISTOL.
  • Doxorubicin can be administered, e.g., in the form as it is marketed, e.g., under the trademark ADRIBLASTIN or ADRIAMYCIN.
  • Epirubicin can be administered, e.g., in the form as it is marketed, e.g., under the trademark FARMORUBICIN.
  • Idarubicin can be administered, e.g., in the form as it is marketed, e.g., under the trademark ZAVEDOS.
  • Mitoxantrone can be administered, e.g., in the form as it is marketed, e.g., under the trademark NOVANTRON.
  • microtubule active agent relates to microtubule stabilizing, microtubule destabilizing agents and microtublin polymerization inhibitors including, but not limited to, taxanes, e.g., paclitaxel and docetaxel; vinca alkaloids, e.g., vinblastine, especially vinblastine sulfate; vincristine, especially vincristine sulfate and vinorelbine; discodermolides; cochicine; and epothilones and derivatives thereof, e.g., epothilone B or D or derivatives thereof.
  • taxanes e.g., paclitaxel and docetaxel
  • vinca alkaloids e.g., vinblastine, especially vinblastine sulfate
  • vincristine especially vincristine sulfate and vinorelbine
  • discodermolides e.g., cochicine
  • epothilones and derivatives thereof e.g.
  • Paclitaxel may be administered, e.g., in the form as it is marketed, e.g., TAXOL.
  • Docetaxel can be administered, e.g., in the form as it is marketed, e.g., under the trademark TAXOTERE.
  • Vinblastine sulfate can be administered, e.g., in the form as it is marketed, e.g., under the trademark VINBLASTIN R.P
  • Vincristine sulfate can be administered, e.g., in the form as it is marketed, e.g., under the trademark FARMISTIN.
  • Discodermolide can be obtained, e.g., as disclosed in U.S. Patent No. 5,010,099.
  • epothilone derivatives which are disclosed in WO 98/10121, U.S. Patent No. 6, 194,181, WO 98/25929, WO 98/08849, WO 99/43653, WO 98/22461 and WO 00/31247. Especially preferred are epothilone A and/or B.
  • alkylating agent includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel).
  • Cyclophosphamide can be administered, e.g., in the form as it is marketed, e.g., under the trademark CYCLOSTIN.
  • Ifosfamide can be administered, e.g., in the form as it is marketed, e.g., under the trademark HOLOXAN.
  • histone deacetylase inhibitors or "HDAC inhibitors” relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes compounds disclosed in WO 02/22577, especially /V-hydroxy-3-[4-[[(2- hydroxy ethyl) [2-( ⁇ H— indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, /V-hydroxy-3-[4-[[[2-(2-methyl-li7- indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide and pharmaceutically acceptable salts thereof. It further especially includes suberoylanilide hydroxamic acid (SAHA).
  • SAHA suberoylanilide hydroxamic acid
  • anti-plastic antimetabolite includes, but is not limited to, 5-fluorouracil or 5-FU; capecitabine; gemcitabine; DNA demethylating agents, such as 5-azacytidine and decitabine; methotrexate and edatrexate; and folic acid antagonists, such as pemetrexed.
  • Capecitabine can be administered, e.g., in the form as it is marketed, e.g., under the trademark XELODA.
  • Gemcitabine can be administered, e.g., in the form as it is marketed, e.g., under the trademark GEMZAR.
  • the monoclonal antibody trastuzumab which can be administered, e.g., in the form as it is marketed, e.g., under the trademark HERCEPTIN.
  • platinum compound includes, but is not limited to, carboplatin, c/.s-platin, cisplatinum and oxaliplatin.
  • Carboplatin can be administered, e.g., in the form as it is marketed, e.g., under the trademark CARBOPLAT.
  • Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g., under the trademark ELOXATIN.
  • the term "compounds targeting/decreasing a protein or lipid kinase activity; or a protein or lipid phosphatase activity; or further anti -angiogenic compounds”, as used herein, includes, but is not limited to, protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g., a) compounds targeting, decreasing or inhibiting the activity of the platelet- derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, e.g., a Y-phenyl -2-pyri m i di ne- amine derivative, e.g., imatinib, SU101 , SU6668 and GFB-lll;
  • PDGFR platelet- derived growth factor-receptors
  • FGFR fibroblast growth factor- receptors
  • IGF-IR insulin-like growth factor receptor I
  • compounds which target, decrease or inhibit the activity of IGF-IR especially compounds which inhibit the IGF-IR receptor, such as those compounds disclosed in WO 02/092599;
  • compounds targeting, decreasing or inhibiting the activity of members of the c-Abl family and their gene-fusion products e.g., BCR-Abl kinase, such as compounds which target decrease or inhibit the activity of c-Abl family members and their gene fusion products, e.g., a N -phenyl- 2-pyrimidine-amine derivative, e.g., imatinib, PD180970, AG957, NSC 680410 or PD173955 from ParkeDavis;
  • examples of further compounds include, e.g., UCN-01 ; safmgol; BAY 43-9006; Bryostatin 1 ; Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521 ; LY333531/LY379196; isochinoline compounds, such as those disclosed in WO 00/09495; FTIs; PD 184352; or QAN697 (a P13K inhibitor);
  • k) compounds targeting, decreasing or inhibiting the activity of protein-tyrosine kinase inhibitors include imatinib mesylate (GLEEVEC) or tyrphostin.
  • Atyrphostin is preferably a low molecular weight (Mr ⁇ 1500) compound, or a pharmaceutically acceptable salt thereof, especially a compound selected from the benzylidenemalonitrile class or the S- arylbenzenemalonirile or bisubstrate quinoline class of compounds, more especially any compound selected from the group consisting of Tyrphostin A23/RG-50810, AG 99, Tyrphostin AG 213, Tyrphostin AG 1748, Tyrphostin AG 490, Tyrphostin B44, Tyrphostin B44 (+) enantiomer, Tyrphostin AG 555, AG 494, Tyrphostin AG 556, AG957 and adaphostin (4- ⁇ [(2,5- dihydroxyphenyl)methyl]amino ⁇ -benzoic acid adamantyl ester, NSC 680410, adaphostin; and
  • compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, e.g., EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, and are in particular those compounds, proteins or monoclonal antibodies generically and specifically disclosed in WO 97/02266, e.g., the compound of Example 39, or in EP 0 564 409; WO 99/03854; EP 0520722; EP 0 566 226; EP 0 787 722; EP 0 837 063; U.S.
  • anti-angiogenic compounds include compounds having another mechanism for their activity, e.g., unrelated to protein or lipid kinase inhibition, e.g., thalidomide (THALOMID) and TNP-470.
  • Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are, e.g., inhibitors of phosphatase 1 , phosphatase 2A, PTEN or CDC25, e.g., okadaic acid or a derivative thereof.
  • Compounds which induce cell differentiation processes are e.g. retinoic acid, a- g- or d-tocopherol or a- g- or d-tocotrienol.
  • cyclooxygenase inhibitor includes, but is not limited to, e.g., Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, e.g., 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid or lumiracoxib.
  • Cox-2 inhibitors such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, e.g., 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid or lumiracoxib.
  • bisphosphonates includes, but is not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid.
  • Etridonic acid can be administered, e.g., in the form as it is marketed, e.g., under the trademark DIDRONEL.
  • Clodronic acid can be administered, e.g., in the form as it is marketed, e.g., under the trademark BONEFOS.
  • titaniumudronic acid can be administered, e.g., in the form as it is marketed, e.g., under the trademark SKELID.
  • “Pamidronic acid” can be administered, e.g., in the form as it is marketed, e.g., under the trademark AREDIATM.
  • “Alendronic acid” can be administered, e.g., in the form as it is marketed, e.g., under the trademark FOSAMAX.
  • “Ibandronic acid” can be administered, e.g., in the form as it is marketed, e.g., under the trademark BONDRANAT.
  • “Risedronic acid” can be administered, e.g., in the form as it is marketed, e.g., under the trademark ACTONEL.
  • "Zoledronic acid” can be administered, e.g., in the form as it is marketed, e.g., under the trademark ZOMETA.
  • mTOR inhibitors relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity, such as sirolimus (RAPAMUNE ® ), everolimus (CERTICANTM), CCI-779 and ABT578.
  • heparanase inhibitor refers to compounds which target, decrease or inhibit heparin sulphate degradation.
  • the term includes, but is not limited to, PI-88.
  • biological response modifier refers to a lymphokine or interferons, e.g., interferon g.
  • inhibitor of Ras oncogenic isoforms e.g., H-Ras, K-Ras or N-Ras, as used herein, refers to compounds which target, decrease or inhibit the oncogenic activity of Ras, e.g., a "famesyl transferase inhibitor”, e.g., L-744832, DK8G557 or Rl 15777 (Zarnestra).
  • telomerase inhibitor refers to compounds which target, decrease or inhibit the activity of telomerase.
  • Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, e.g., telomestatin.
  • methionine aminopeptidase inhibitor refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase.
  • Compounds which target, decrease or inhibit the activity of methionine aminopeptidase are, e.g., bengamide or a derivative thereof.
  • proteasome inhibitor refers to compounds which target, decrease or inhibit the activity of the proteasome.
  • Compounds which target, decrease or inhibit the activity of the proteasome include, e.g., PS-341 and MLN 341.
  • matrix metalloproteinase inhibitor or "MMP inhibitor”, as used herein, includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g., hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551 ) BMS-279251 , BAY 12-9566, TAA211 , MMI270B or AAJ996.
  • MMP inhibitor matrix metalloproteinase inhibitor
  • agents used in the treatment of hematologic malignancies includes, but is not limited to, FMS-like tyrosine kinase inhibitors, e.g., compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R); interferon, 1- b-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors, e.g., compounds which target, decrease or inhibit anaplastic lymphoma kinase.
  • FMS-like tyrosine kinase inhibitors e.g., compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R); interferon, 1- b-D-arabinofuransylcytosine (ara-c) and bisulfan
  • ALK inhibitors e.g., compounds which target, decrease or inhibit anaplastic lymphoma kina
  • FMS-like tyrosine kinase receptors are especially compounds, proteins or antibodies which inhibit members of the Flt-3R receptor kinase family, e.g., PKC412, midostaurin, a staurosporine derivative, SU1 1248 and MLN518.
  • HSP90 inhibitors includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteasome pathway.
  • Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90, e.g., l7-allylamino, l7-demethoxygeldanamycin (17AAG), a geldanamycin derivative, other geldanamycin related compounds, radicicol and HD AC inhibitors.
  • antiproliferative antibodies includes, but is not limited to, trastuzumab (HerceptinTM), Trastuzumab-DMl , erlotinib (TarcevaTM), bevacizumab (AvastinTM), rituximab (Rituxan ® ), PR064553 (anti-CD40) and 2C4 antibody.
  • trastuzumab HerceptinTM
  • Trastuzumab-DMl erlotinib
  • bevacizumab AvastinTM
  • rituximab Raritaan ®
  • PR064553 anti-CD40
  • compounds of formula (I) can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML.
  • compounds of formula (I) can be administered in combination with, e.g., famesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP- 16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
  • a compound of the formula (I) may also be used to advantage in combination with each other or in combination with other therapeutic agents, especially other anti-malarial agents.
  • anti-malarial agents include, but are not limited to proguanil, chlorproguanil, trimethoprim, chloroquine, mefloquine, lumefantrine, atovaquone, pyrimethamine-sulfadoxine, pyrimethamine-dapsone, halofantrine, quinine, quinidine, amodiaquine, amopyroquine, sulphonamides, artemisinin, arteflene, artemether, artesunate, primaquine, inhaled NO, L- arginine, Dipropylenetri-amine NONOate (NO donor), Rosiglitzone (PPARy agonist), activated charcoal, Erythropoietin, Levamisole, and pyronaridine.
  • anti-malarial agents include, but are not limited to proguan
  • a compound of the formula (I) may also be used to advantage in combination with each other or in combination with other therapeutic agents, such as used for the treatment of Leishmaniosis, Trypanosomiasis, Toxoplasmosis and Neurocysticercosis.
  • Such agents include, but are not limited to chloroquine sulfate, atovaquone-proguanil, artemether- lumefantrine, quinine-sulfate, artesunate, quinine, doxycycline, clindamycin, meglumine antimoniate, sodium stibogluconate, miltefosine, ketoconazole, pentamidine, amphotericin B (AmB), liposomal-AmB, paromomycine, eflomithine, nifurtimox, suramin, melarsoprol, prednisolone, benznidazole, sulfadiazine, pyrimethamine, clindamycin, trimetropim, sulfamethoxazole, azitromycin, atovaquone, dexamethasone, praziquantel, albendazole, beta-lactams, fluoroquinolones, macrol
  • a compound of the formula (I) may also be used to advantage in combination with known therapeutic processes, e.g., the administration of hormones or especially radiation.
  • a compound of formula (I) may in particular be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.
  • ком ⁇ онент there is meant either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula (I) and a combination partner may be administered independently at the same time or separately within time intervals that especially allow that the combination partners show a cooperative, e.g., synergistic, effect or any combination thereof.
  • coadministration or “combined administration” or the like as utilized herein are meant to encompass administration of the selected combination partner to a single subject in need thereof (e.g. a patient), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • pharmaceutical combination means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
  • fixed combination means that the active ingredients, e.g. a compound of formula I and a combination partner, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • non-fixed combination means that the active ingredients, e.g. a compound of formula (I) and a combination partner, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient.
  • cocktail therapy e.g. the administration of three or more active ingredients.
  • the compounds disclosed herein are inhibitors of kinase activity, in particular PI3- kinase activity.
  • Compounds which are PI3 -kinase inhibitors may be useful in the treatment of disorders wherein the underlying pathology is (at least in part) attributable to inappropriate PI3- kinase activity, such as asthma and chronic obstructive pulmonary disease (COPD).
  • inappropriate PI3-kinase activity refers to any PI3-kinase activity that deviates from the normal PI3 -kinase activity expected in a particular patient.
  • Inappropriate PI3 -kinase may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and or control of PI3-kinase activity. Such inappropriate activity may result then, for example, from overexpression or mutation of the protein kinase leading to inappropriate or uncontrolled activation. Accordingly, in another aspect the invention is directed to methods of treating such disorders.
  • Such disorders include, but not limited to, respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-viral respiratory infections including aspergillosis and leishmaniasis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic
  • such disorders include respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD); allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia and Central pain.
  • COPD chronic obstructive pulmonary disease
  • allergic diseases including allergic rhinitis and atopic dermatitis
  • autoimmune diseases including rheumatoid arthritis and multiple s
  • the methods of treatment of the invention comprise administering a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • Individual embodiments of the invention include methods of treating any one of the above-mentioned disorders by administering a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered by any suitable route of administration, including both systemic administration and topical administration.
  • Systemic administration includes oral administration, parenteral administration, transdermal administration and rectal administration.
  • Parenteral administration refers to routes of administration other than enteral or transdermal, and is typically by injection or infusion.
  • Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion.
  • Topical administration includes application to the skin as well as intraocular, otic, intravaginal, inhaled and intranasal administration. Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered orally. In another embodiment, the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered by inhalation. In a further embodiment, the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered intranasally.
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. In one embodiment, a dose is administered once per day. In a further embodiment, a dose is administered twice per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of formula (I) or a pharmaceutically acceptable salt thereof depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan.
  • suitable dosing regimens including the duration such regimens are administered, for a compound of formula (I) or a pharmaceutically acceptable salt thereof depend on the disorder being treated, the severity of the disorder being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
  • the compound disclosed herein may be administered either simultaneously with, or before or after, one or more other therapeutic agent.
  • the compound disclosed herein may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents.
  • the pharmaceutical composition or combination disclosed herein can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients.
  • the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
  • the above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
  • the compounds disclosed herein can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution.
  • a therapeutically effective amount in vivo may range depending on the route of administration, between about 0.01-500 mg/kg, or between about 1 -100 mg/kg.
  • the compounds of formula (I) may be administered as prodrugs.
  • a "prodrug" of a compound of formula (I) is a functional derivative of the compound which, upon administration to a patient, eventually liberates the compound of formula (I) in vivo.
  • Administration of a compound of formula (I) as a prodrug may enable the skilled artisan to do one or more of the following: (a) modify the onset of the activity of the compound in vivo; (b) modify the duration of action of the compound in vivo; (c) modify the transportation or distribution of the compound in vivo; (d) modify the solubility of the compound in vivo; and (e) overcome a side effect or other difficulty encountered with the compound.
  • Typical functional derivatives used to prepare prodrugs include modifications of the compound that are chemically or enzymatically cleavable in vivo. Such modifications, which include the preparation of phosphates, amides, esters, thioesters, carbonates, and carbamates, are well known to those skilled in the art.
  • the invention provides a method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • the conditions, diseases or disorders mediated by inappropriate PI3-kinase activity is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-viral respiratory infections including aspergillosis and leishmaniasis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post
  • Compounds disclosed herein may be useful in the treatment of conditions, diseases or disorders including disease or infection associated immunopathology in which one or more of the functions of B cells such as antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable including rheumatoid arthritis, pemphigus vulgaris and related diseases, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjogren's syndrome, autoimmune hemolytic anemia, ANCA- associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), goodpasture's syndrome, AMR (antibody-mediated transplant rejection), B cell-mediated hyperacute, acute and chronic transplant rejection and cancers of haematopoietic origin including but not limited
  • the invention includes methods of treating conditions, diseases or disorders in which one or more of the functions of neutrophils, such as superoxide release, stimulated exocytosis, or chemoatractic migration are abnormal or are undesirable including rheumatoid arthritis, sepsis, pulmonary or resporatory disorders such as asthma, inflammatory dermatoses such as psoriasis as well as in disease or infection associated immunopathology and others.
  • the invention includes methods of treating conditions, diseases or disorders in which one or more of the functions of basophil and mast cells such as chemoatractic migration or allergen-lgE-mediated degranulation are abnormal or are undesirable including allergic diseases (atopic dermatitis, contact dermatitis, allergic rhinitis) as well as other disorders such as COPD, asthma or emphysema.
  • the invention includes methods of treating conditions, diseases or disorders in which one or more of the functions of T cells such as cytokine production or cell-mediated cytotoxicity abnormal or are undesirable including rheumatoid arthritis, multiple sclerosis, acute or chronic rejection of cell tissue or organ grafts or cancers of haematopoietic origin as well as in disease or infection associated immunopathology.
  • T cells such as cytokine production or cell-mediated cytotoxicity abnormal or are undesirable including rheumatoid arthritis, multiple sclerosis, acute or chronic rejection of cell tissue or organ grafts or cancers of haematopoietic origin as well as in disease or infection associated immunopathology.
  • the invention includes methods of treating neurodegenerative diseases, cardiovascular diseases and platelet aggregation.
  • the invention includes methods of treating skin diseases such as porphyria cutanea tarda, polymorphous light eruption, dermatomyositis, solar urticaria, oral lichen planus, panniculitis, scleroderma, urticarial vasculitis.
  • skin diseases such as porphyria cutanea tarda, polymorphous light eruption, dermatomyositis, solar urticaria, oral lichen planus, panniculitis, scleroderma, urticarial vasculitis.
  • the invention includes methods of treating chronic inflammatory diseases such as sarcoidosis, granuloma annulare.
  • the condition or disorder is selected from the group consisting of: polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, asthma, COPD, ARDS, Loffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma, eosinophil-related disorders affecting the airways occasioned by drug-reaction, psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, ur
  • haemolytic anaemia haemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia
  • systemic lupus erythematosus polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven- Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g.
  • endocrine opthalmopathy Grave's disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis, cardiovascular diseases, atherosclerosis, hypertension, deep venous thrombosis, stroke, myocardial infarction, unstable angina, thromboembolism, pulmonary embolism, thrombolytic diseases, acute arterial ischemia, peripheral thrombotic occlusions, and coronary artery disease, reperfusion injuries, retinopathy, such as diabetic retinopathy or hyperbaric oxygen-induced retinopathy, and conditions characterized by elevated intraocular pressure or secretion of ocular aqueous humor, such as glaucoma.
  • Grave's disease sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis,
  • the disorder mediated by inappropriate PI3-kinase activity is pain.
  • the compounds disclosed herein are useful in the treatment of conditions or disorders selected from the group consisting of, primary cutaneous B-cell lymphoma, immunobullous disease, pemphigus vulgaris, pemphigus foliaceus, endemic form of Brazilian pemphigus (Fogo selvagem), paraneoplastic pemphigus, bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, chronic graft versus host disease, dermatomyositis, systemic lupus erythematosus, vasculitis, small vessel vasculitis, hypocomplementemic urticarial vasculitis, antineutrophil cytoplasmic antibody-vasculitis, cryoglobulinemia, Schnitzler syndrome, Waldenstrom's macroglobulinemia, angioedema, vitiligo, systemic lupus erythematosus, idiopathic
  • the compounds disclosed herein are useful in the treatment, prevention, or amelioration of autoimmune disease and of inflammatory conditions, in particular inflammatory conditions with an aetiology including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases, including inflammatory conditions and rheumatic diseases involving bone loss, inflammatory pain, spondyloarhropathies including ankolsing spondylitis, Reiter syndrome, reactive arthritis, psoriatic arthritis, and enterophathics arthritis, hypersensitivity (including both airways hypersensitivity and dermal hypersensitivity) and allergies.
  • arthritis for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans
  • rheumatic diseases including inflammatory conditions and rheumatic diseases involving bone loss, inflammatory pain, spondyloarhropathies including ankolsing spondylitis, Reiter syndrome, reactive arthritis, p
  • autoimmune haematological disorders including e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopa-thic thrombocytopenia), acquired hemophilia A, cold agglutinin disease, cryoglobulinemia, thrombotic thrombocytopenic purpura, Sjogren's syndrome, systemic lupus erythematosus, inflammatory muscle disorders, polychondritis, sclerodoma, anti-neutrophil cytoplasmic antibody-associated vasculitis, IgM mediated neuropathy, opsoclonus myoclonus syndrome, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven- Johnson syndrome, pemphigus vulgaris, pemphigus foliacius, idio pathic sprue,
  • autoimmune haematological disorders including e.g. hemolytic an
  • ulcerative colitis Crohn's disease and Irritable Bowel Syndrome
  • endocrine ophthalmopathy Graves' disease, sarcoidosis, multiple sclerosis, neuromyelitis optica, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior, intermediate and posterior as well as panuveitis), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephro-tic syndrome or minimal change nephropathy), tumors, inflammatory disease of skin and cornea, myositis, loosening of bone implants, metabolic disorders, such as atherosclerosis, diabetes, and dislipidemia.
  • nephrotic syndrome e.g. including idiopathic ne
  • the present invention provides the use of a compound of formula (I) in therapy.
  • the therapy is selected from a disease which may be treated by inhibition of PI3K.
  • the disease is selected from the afore mentioned list, suitably from autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and COPD, transplant rejection; antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable including rheumatoid arthritis, pemphigus vulgaris, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjogren's syndrome, autoimmune hemolytic anemia, ANCA-associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic r
  • the present invention provides the use of a compound of formula (I) for the manufacture of a medicament.
  • the medicament is for treatment of a disease which may be treated inhibition of PI3K.
  • the disease is selected from the afore-mentioned list, suitably from autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and COPD, transplant rejection; antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable including rheumatoid arthritis, pemphigus vulgaris, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjogren's syndrome, autoimmune hemolytic anemia, ANCA-associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic rheumatoid arthritis, pemphigus vulgaris,
  • the compounds disclosed herein may be prepared by methods described herein, wherein the substituents are as defined for formula (I), above, except where further noted.
  • the following non-limiting schemes and examples are presented to further exemplify the invention.
  • Persons skilled in the art will recognize that the chemical reactions described herein may be readily adapted to prepare a number of other compounds disclosed herein, and alternative methods for preparing the compounds disclosed herein are deemed to be within the scope of this invention.
  • the synthesis of non-exemplified compounds according to the invention may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, and/or by making routine modifications of reaction conditions.
  • other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds disclosed herein.
  • MS data were generally determined on an Agilent 6120 Quadrupole HPLC-MS (Zorbax SB-C18, 2.1 x 30 mm, 3.5 micron, 6 minutes run, 0.6 mL/min flow rate, 5% to 95% (0.1% formic acid in CH 3 CN) in (0.1% formic acid in H 2 0)) with UV detection at 210 nm/254 nm and electrospray ionization mode (ESI).
  • Agilent 6120 Quadrupole HPLC-MS Zorbax SB-C18, 2.1 x 30 mm, 3.5 micron, 6 minutes run, 0.6 mL/min flow rate, 5% to 95% (0.1% formic acid in CH 3 CN) in (0.1% formic acid in H 2 0)
  • UV detection at 210 nm/254 nm
  • ESI electrospray ionization mode
  • LiHMDS lithium bis(trimethylsilyl)-amide
  • LDA lithium diisopropylamide MBP myelin basic protein
  • L is halo
  • the intermediate (2a) disclosed herein can be prepared according to the synthetic route illustrated above. First, compound (2b) is coupled with compound (3a) in the presence of Pd catalyst to give compound (2c). Then protecting group is removed from compound (2c) to produce compound (2a).
  • Step 1) (S)-tert- butyl ( 1 -(5-(3-hydroxy-3-methylbut- l -yn- 1 -yl )-4-oxo-3-phenyl-3.4- dihvdroquinazolin-2-yl)ethyl)carbamate
  • Step 2) 0V)-2-( l -aminoethyl )-5-(3-hydroxy-3-methylbut- l -yn- 1 -yl )-3-phenylquinazolin-4(3//)- one
  • Step 3) 6y)-2-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vOpyrimidin-4-vOamino)ethvO-5-(3- hydroxy-3 -methylbut- 1 -vn- 1 -vO-3 -phenyl quinazolin-4 -one
  • Step 2) 2-((S) ⁇ 1 -aminoethyl)-5 -(3 -hydroxybut- 1 -vn- 1 -vO-3 -phenylquinazolin-4 -one
  • the reaction mixture was filtered, and washed with EtOAc (lOOmL). The filtrate was washed with water (100 mL c 3). The organic phase was concentrated in vacuo to give the crude product as a yellow solid.
  • Step 2 (S)-2-( ⁇ -(Y6-amino-5-(3-methyl- l .2.4-oxadiazol-5-yl )pyrimidin-4-yl ) amino)ethvD-3- phenyl-5-(prop-l-vn-l-vQquinazolin- -one
  • Step 2) (X)-2-(T-aminopropyO-3 -phenyl-5 -(prop- l-vn-l-vQquinazolin-
  • Step 3) 0y ) -2- ( T- ( Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vDpyrimidin-4-vDamino)propyD-3- phenyl-5-(prop-l-vn-l-vQquinazolin- -one
  • Step 1) 0V)-3-( l -aminoethyl )-2-phenyl-8-(prop- 1 -vn- 1 -yl )isoquinolin- l -one
  • Step 2) (A)-3-(l-((6-amino-5-(3-methyl-L2.4-oxadiazol-5-vOpyrimidin-4-vOamino)ethvO-2- phenyl -8 -(prop- 1 -yn- 1 -vDisoquinolin- 1 (2H)-one
  • Step 1) (S)-tert- butyl ( 1 -(3-cvclopropyl -4-oxo-5-(prop- l -vn- 1 -yl )-3.4- dihvdroquinazolin-2- vOethyQcarbamate
  • Step 2) (S)-2-( 1 -aminoethvD-3 -cvclopropyl-5-(prop- 1 -yn- 1 -yl )quinazolin-4 -one
  • Step 1 (A)-3-( ⁇ -aminoethyl )-2-cvclopropyl-8-(prop- l -vn- 1 -yl )isoquinolin- l -one
  • Step 1) (M-fer/-butyl ri -G-cvclopropyl -4-oxo-5-(prop- l -vn- 1 -yl )-3.4-dihydroquinazolin-2- yl ipropyl icarbamate
  • Step _ 1) _ (S)-tert- butyl _ ( 1 -(3 -cvclopropyl-5 -(3 -hydroxyprop- 1 -yn- 1 -yl )-4-oxo-3.4- dihvdroquinazolin-2-vDpropyDcarbamate
  • Step 3) 6y ) -2- ( T- ( Y6-amino-5-(5-methyl-L3.4-oxadiazol-2-vDpyrimidin-4-vDamino)propyD-3- cvclopropyl-5-(3-hvdroxyprop- l -yn- 1 -yl )quinazolin- -one
  • Step _ 1) _ (S)-tert- butyl _ ( 1 -(3 -cvclopropyl-5 -(3 -hydroxyprop- 1 -yn- 1 -yl )-4-oxo-3.4- dihydroquinazolin-2-vDethvDcarbamate
  • Step 2 (S)-2-( ⁇ -aminoethyl )-3-cvclopropyl-5-(3-hvdroxyprop- l -vn- 1 -yl )quinazolin- -one
  • Stepl) 0V)-3-( l -aminoethyl )-2-cvclopropyl-8-(3-hvdroxyprop- l -vn- 1 -yl )isoquinolin-U2//)-one
  • Step 2 (y)-3-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vD-pyrimidin-4-vPamino)ethvD-2- cvclopropyl-8-(3-hvdroxyprop- l -vn- 1 -yl )-isoquinolin-U2//)-one [0394]
  • Step 2 (S)-2-( 1 -aminoethyl)-5 -(3 -hydroxyprop- 1 -yn- 1 -vO-3 -phenyl quinazolin-4 one
  • Step 3 (M-2-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vDpyrimidin-4-vDamino)ethvD-5-(3- hydroxyprop- 1 -yn- 1 -vD-3 -phenyl quinazolin-4 -one
  • Step 2) (S)-2-( 1 -aminopropyD-5-(3 -hydroxyprop- 1 -yn- 1 -yl)-3 -phenyl quinazolin-4 -one
  • Step 2) fV)-3-( l -aminoethyl )-8-chloro-2-phenylisoquinolin- -one
  • Step 2) 6-ami no-24) romo-3-fluoro-A f -phenylbenzamide
  • Step 6) (S)-2-( ⁇ -aminoethyl )-6-f1uoro-5-(3-hvdroxyprop- l -yn- 1 -yl )-3-phenylquinazolin-4 - one
  • Step _ 1) (S)-tert- butyl (T-(3-cvclopropyl-5-ethvnyl-4-oxo-3.4-dihvdroquinazolin-2- vOethvOcarbamate
  • Step 2 (S)-2-( ⁇ -aminoethyl )-3-cvclopropyl-5-ethvnylquinazolin- -one

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.

Description

SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF
USE
CROSS-REFERENCE TO RELATED APPLICATIONS
[001] This application claims the benefits of U.S. Provisional Application No. 62/619,741 filed on January 20, 2018, which is hereby incorporated by reference in their entirety.
FIELD OF THE INVENTION
[002] The present invention is directed to certain novel compounds which are inhibitors of kinase activity, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various disorders. More specifically, the compounds disclosed herein are inhibitors of the activity or function of the phosphatidylinositol 3 -kinase kinase family (hereinafter PI3 -kinases, PI3Ks), for example RBKd, RI3Ka, RI3Kb and/or RI3Kg.
[003] The compounds disclosed herein are therefore potentially useful in the treatment of a wide range of disorders, particularly disorders including but not limited to autoimmune disorders, inflammatory diseases, allergic diseases, disease or infection associated immunopathologies, airway diseases, such as asthma and COPD, transplant rejection, cancers such as hematopoietic origin or solid tumors.
[004] The compounds disclosed herein are inhibitors of the activity or function of PI3- kinases that may be useful in the treatment of disorders of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity; respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-viral respiratory infections including aspergillosis and leishmaniasis; cardiovascular diseases including thrombosis and atherosclerosis; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia and Central pain; hematologic malignancies such as acute myeloid leukaemia (AML), myelo-dysplastic syndrome (MDS), myelo-proliferative diseases (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukaemia (T-ALL), B-cell acute lymphoblastic leukaemia (B-ALL), Non Hodgkins Lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.
BACKGROUND OF THE INVENTION
[005] The phosphoinositide 3-kinases (PI3 kinases or PI3Ks), a family of lipid kinases, have been found to have key regulatory roles in many cellular processes including cell survival, proliferation and differentiation. As major effectors downstream of receptor tyrosine kinases (RTKs) and G protein-coupled receptors (GPCRs), PI3Ks transduce signals from various growth factors and cytokines into intracellular massages by generating phospholipids, which activate the serine-threonine protein kinase ART (also known as protein kinase B (PKB)) and other downstream effector pathways. The tumor suppressor or PTEN (phosphatase and tensin homologue) is the most important negative regulator of the PI3K signaling pathway (“Small- molecule inhibitors of the PI3K signaling network.” Future Med Chem ., 2011, 3, 5, 549-565).
[006] To date, eight mammalian PI3Ks have been identified, divided into three main classes (I, II and III) on the basis of their genetic sequence, structure, adapter molecules, expression, mode of activation, and preferred substrate. Among them, Class I PI3Ks are further divided based on signaling pathways and regulatory proteins into class IA and class IB. The class IA PI3Ks comprise three closely related kinases, RI3Ka, RI3Kb, and PI3K5, which exist as heterodimers composed of a catalytic subunit (rΐ ΐqa, rΐ ΐqb, and pl 105 respectively) and a p85 regulatory adapter subunits (i.e., r85a, r85b, r55d, p55a and p50a). The catalytic pl lO subunit uses ATP to phosphorylate phosphatidylinositol (PI, Ptdlns), PI4P and PI (4,5) P2. These respond to signaling generally through receptor tyrosine kinases (RTKs). The class IB RI3Kg signals through G-protein-coupled receptors (GPCRs) and is composed of a rΐ ΐqg catalytic domain that can associate with regulatory subunits distinct from the class IA isoforms.
[007] In relation to function and regulation of effector enzymes in phospholipids signaling pathways, class I PI3-kinases (e.g. RBKd, PBKdelta) generate second messengers from the membrane phospholipid pools. Class I PI3Ks convert the membrane phospholipid PI(4,5) P2 into PI(3,4,5)P3, which functions as a second messenger. PI and PI(4)P are also substrates of PI3K and can be phosphorylated and converted into PI3P and PI(3,4)P2, respectively. In addition, these phosphoinositides can be converted into other phosphoinositides by 5'-specific and 3'- specific phophatases. Thus, PI3K enzymatic activity results either directly or indirectly in the generation of two 3 '-phosphoinositide subtypes which function as second messengers in intracellular signal transduction pathways (. Nature Reviews Molecular Cell Biology , 2010, 11, 329).
[008] Expression of the PI3Ka and RI3Kb isoforms is ubiquitous, while the expression pattern of PI3K5 and RI3Kg seems more restricted, with both isoforms found primarily in leukocytes. The relatively restricted expression pattern of PI3K5 and RI3Kg, in addition to data accumulated from studies in mice suggests that these two isoforms play a major role in the adaptive and innate immune systems (J. Med. Chem ., 2012, 55, 20, 8559-8581).
[009] In B and T cells, PI3Ks have an important role through activation of the Tec family of protein tyrosine kinases which include Bruton's tyrosine kinase (BTK) in B cells and lnterleukin- 2-inducible T-cell kinase (ITK) in T cells. Upon PI3K activation, BTK or ITK translocate to the plasma membrane where they are subsequently phosphorylated by Src kinases. One of the major targets of activated ITK is phospholipase C-gamma (PLOyl), which hydrolyses PI(4,5)P2 into PI(3,4,5)P3 and initiates an intracellular increase in calcium levels and diacylglycerol (DAG) which can activate Protein Kinases C in activated T cells.
[010] The PI3K5 kinase dead knock-in mice are viable and their phenotype is restricted to defects in immune signaling (Okkenhaug et ah, Science , 2002, 297, p. 1031-4). These transgenic mice have offered insight into the function of PI3K5 in B-cell and T-cell signaling. In particular, PI3K5 is required for PI(3,4,5)P3 formation downstream of CD28 and/or T cell Receptor (TCR) signaling. A key effect of PI3K signaling downstream of TCR is the activation of Akt, which phosphorylates anti-apoptotic factors as well as various transcription factors for cytokine production. As a consequence, T cells with inactive PI3K5 have defects in proliferation and TM and Th2 cytokine secretion. Activation of T cells through CD28 lowers the threshold for TCR activation by antigen and increases the magnitude and duration of the proliferative response. These effects are mediated by the RBKd-dependent increase in the transcription of a number of genes including IL2, an important T cell growth factor.
[011] Therefore, PI3K inhibitors are anticipated to provide therapeutic benefit via its role in modulating T-cell mediated inflammatory responses associated to respiratory diseases such as asthma, COPD and cystic fibrosis. In addition, there is indication that T-cell directed therapies may provide corticosteroid sparing properties {Lancet, 1992, 339, p. 324-8) suggesting that it may provide a useful therapy either as a standalone or in combination with inhaled or oral glucocorticosteroids in respiratory diseases. A PI3K inhibitor might also be used alongside other conventional therapies such as long acting beta-agonists (LABA) in asthma.
[012] In the vasculature, PI3K5 is expressed by endothelial cells and participates in neutrophil trafficking by modulating the proadhesive state of these cells in response to TNF alpha {Blood , 2004, 103, 9, p. 3448). A role for PI3K5 in TNF alpha-induced signaling of endothelial cells is demonstrated by the pharmacological inhibition of Akt phosphorylation and PDK1 activity. In addition, PI3K5 is implicated in vascular permeability and airway tissue edema through the VEGF pathway {Allergy Clin. Immunol., 2006, 118, 2, p. 403). These observations suggest additional benefits of PI3K5 inhibition in asthma by the combined reduction of leukocyte extravasation and vascular permeability associated with asthma. In addition, PI3K5 activity is required for mast cell function both in vitro and in vivo { Nature , 2004, 431, p. 1007; J. Immunol., 2008, 180, 4, p. 2538) further suggesting that PI3K inhibition should be of therapeutic benefit for allergic indications such asthma, allergic rhinitis and atopic dermatitis.
[013] The role of PI3K5 in B cell proliferation, antibody secretion, B-cell antigen and IL-4 receptor signaling, B-cell antigen presenting function is also well established {J. Immunol., 2007, 178, 4, p. 2328-35; Blood , 2006, 107, 2, p. 642-50) and indicates a role in autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus. Therefore PI3K inhibitors may also be of benefit for these indications.
[014] Pharmacological inhibition of PI3K5 inhibits fMLP-dependent neutrophil chemotaxis on an ICAM coated agarose matrix integrin-dependent biased system {J. Immunol., 2003, 170, 5, p. 2647-54). Inhibition of PI3K5 regulates neutrophil activation, adhesion and migration without affecting neutrophil mediated phagocytosis and bactericidal activity over Staphylococcus aureus {Biochem. Biophys. Res. Commun, 2003, 308, 4, p. 764-9). Overall, the data suggest that PI3K5 inhibition should not globally inhibit neutrophil functions required for innate immune defense. PI3K5's role in neutrophils offers further scope for treating inflammatory diseases involving tissue remodeling such as COPD or rheumatoid arthritis.
[015] The phosphoinositide 3 -kinase d subunit (PI3K5) isoform is mainly expressed in immune cells and is absent from most solid tumors. Gene targeting in mice has established essential functions for PI3K5 in mature B cells and in other immune cell types. A key downstream effector of PI3K5 in B cells is Bruton’s tyrosine kinase (BTK), which is a member of the TEC family of non-receptor tyrosine kinases. PI3K5 and BTK are activated by signals from the B cell receptor (BCR), chemokines and cytokines to drive survival, proliferation and adhesion to supportive stromal cells. However, activating mutations in PI3K5 is not present in B cell tumors, and inhibitors of these enzymes were initially developed for application in immune diseases. Unexpectedly, Phase I clinical trials of a PI3K5 inhibitor (CAL-101, renamed GS-1101) showed dramatic and durable responses in a subset of patients with indolent B cell malignancies. Even greater efficacy was achieved in combination studies with rituximab and/or bendamustine. PI3K5 inhibitors has shown acceptable safety profiles. The compound, now called idelalisib, was approved by US Food and Drug Administration (FDA) to treat chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL). (Nature Review Drug Discovery, 2014, 13, pl40-l56)
[016] RI3Kg has been identified as a mediator of G beta-gamma-dependent regulation of JNK activity, and G beta-gamma are subunits of heterotrimeric G proteins (./. Biol. Chem ., 1998, 273, 5, p. 2505-8). It has been described that RI3Kg relays inflammatory signals through various G(i)-coupled receptors and is central to mast cell function, stimuli in the context of leukocytes, and immunology including cytokines, chemokines, adenosines, antibodies, integrins, aggregation factors, growth factors, viruses or hormones for example ( Immunity , 2002, 16, 3, p. 441-51; J. Cell Sci., 2001, 114 (Pt 16), p. 2903-10 and Curr. Opinion Cell Biol., 2002, 14, 2, p. 203-13).
[017] It is now well understood that deregulation of oncogenes and tumor suppressor genes contributes to the formation of malignant tumors, for example by way of increased cell growth and proliferation or increased cell survival. It is also now known that signaling pathways mediated by the PI3K family have a central role in a number of cell processes including proliferation and survival, and deregulation of these pathways is a causative factor a wide spectrum of human cancers and other diseases ( Annual Rev. Cell Dev. Biol., 2001, 17, p. 615- 675 and J. Cell Science, 2003, 116, 15, p. 3037-3040).
[018] There is good evidence that class I PI3K enzymes contribute to turn ouri genesis in a wide variety of human cancers, either directly or indirectly ( Nature Reviews Cancer, 2002, 2, 7, p. 489-501). For example, inhibition of PI3K5 may have a therapeutic role for the treatment of malignant haematological disorders such as acute myeloid leukaemia ( Oncogene , 2006, 25, 50, p. 6648-59). Moreover, activating mutations within pl lOa (PIK3CA gene) have been associated with various other tumors such as those of the colon and of the breast and lung (Science, 2004, 304, 5670, p. 554; Nature Reviews Cancer, 2009, 9, 551).
[019] A wide variety of retroviruses and DNA based viruses activate the PI3K pathway as a way of preventing host cell death during viral infection and ultimately exploiting the host cell synthesis machinery for its replication (Virology, 2006, 344, 1, p. 131-8 and Nat. Rev. Microbiol., 2008, 6, 4, p. 265-75). Therefore PI3K inhibitors may have anti-viral properties in addition to more established oncolytic and anti-inflammatory indications. These antiviral effects raise interesting prospects in viral induced inflammatory exacerbations. For example, the common cold human rhinovirus (HRV) is responsible for more than 50% of respiratory tract infections but complications of these infections can be significant in certain populations. This is particularly the case in respiratory diseases such as asthma or chronic obstruction pulmonary disease (COPD). Rhinoviral infection of epithelial cells leads to a PI3K dependent cytokine and chemokine secretion (J. Biol. Chem., 2005, 280, 44, p. 36952). This inflammatory response correlates with worsening of respiratory symptoms during infection. Therefore PI3K inhibitors may dampen an exaggerated immune response to an otherwise benign virus. The majority of HRV strains infect bronchial epithelial cells by initially binding to the ICAM-l receptor. The HRV-ICAM-l complex is then further internalised by endocytosis and it has been shown that this event requires PI3K activity (J. Immunol ., 2008, 180, 2, p. 870-880). Therefore, PI3K inhibitors may also block viral infections by inhibiting viral entry into host cells.
[020] PI3K inhibitors may be useful in reducing other types of respiratory infections including the fungal infection aspergillosis (Mucosal Immunol ., 2010, 3, 2, p. 193-205). In addition, PI3K5 deficient mice are more resistant towards infections by the protozoan parasite Leishmania major (J. Immunol . , 2009, 183, 3, p. 1921-1933). Taken with effects on viral infections, these reports suggest that PI3K inhibitors may be useful for the treatment of a wide variety of infections.
[021] PI3K inhibition has also been shown to promote regulatory T cell differentiation ( Proc . Natl. Acad. Sci. USA, 2008, 105, 22, p. 7797-7802) suggesting that PI3K inhibitors may serve therapeutic purposes in auto-immune or allergic indications by inducing immuno-tolerance towards self-antigen or allergen. Recently the PI3K5 isoform has also been linked to smoke induced glucocorticoid insensitivity (Am. J. Respir. Crit. Care Med., 2009, 179, 7, p. 542-548). This observation suggests that COPD patients, which otherwise respond poorly to corticosteroids, may benefit from the combination of a PI3K inhibitor with a corticosteroid.
[022] PI3K has also been involved in other respiratory conditions such as idiopathic pulmonary fibrosis (IPF). IPF is a fibrotic disease with progressive decline of lung function and increased mortality due to respiratory failure. In IPF, circulating fibrocytes are directed to the lung via the chemokine receptor CXCR4. PI3K is required for both signaling and expression of CXCR4 (Int. J. Biochem. and Cell Biol., 2009, 41, p.1708-1718). Therefore, by reducing CXCR4 expression and blocking its effector function, a PI3K inhibitor should inhibit the recruitment of fibrocytes to the lung and consequently slow down the fibrotic process underlying IPF, a disease with high unmet need.
[023] PI3Ka and RI3Kb play an essential role in maintaining homeostasis and pharmacological inhibition of these molecular targets has been associated with cancer therapy (Maira et ak, Expert Opin. Ther. Targets, 2008, 12, 223).
[024] PI3Ka is involved in insulin signaling and cellular growth pathways (Nature, 2006, 441, 366). PI3K5 isoform-selective inhibition is expected to avoid potential side effects such as hyperglycemia, and metabolic or growth deregulation. [025] Selective compounds to modulate RI3Kg are being developed by several groups as immunosuppressive agents for autoimmune disease (Nature Reviews , 2006, 5, 903-918). Of note, AS 605240, a selective PBKgamma inhibitor, has been shown to be efficacious in a mouse model of rheumatoid arthritis (Nature Medicine, 2005, 11, 936-943) and to delay onset of disease in a model of systemic lupus erythematosis (Nature Medicine, 2005, 11, 933-935).
[026] There is a need to provide new PI3K inhibitors that are good drug candidates. In particular, compounds disclosed herein should bind potently to PI3K whilst showing little affinity for other receptors and show functional activity as inhibitors. They should be well absorbed from the gastrointestinal tract, be metabolically stable and possess favorable pharmacokinetic properties. When targeted against receptors in the central nervous system they should cross the blood brain barrier freely and when targeted selectively against receptors in the peripheral nervous system they should not cross the blood brain barrier. They should be non toxic and demonstrate few side-effects. Furthermore, the ideal drug candidate will exist in a physical form that is stable, non-hygroscopic and easily formulated. The compounds disclosed herein show a certain level of selectivity against the different paralogs PI3K a, b, g and d. In particular, show a certain level of selectivity for the isoform PI3K5.
[027] The compounds disclosed herein are therefore potentially useful in the treatment of a wide range of disorders, particularly disorders including but not limited to autoimmune disorders, inflammatory diseases, allergic diseases, disease or infection associated immunopathologies, airway diseases, transplant rejection, cancers of hematopoietic origin or solid tumors.
[028] The invention also relates to the treatment, either alone or in combination, with one or more other pharmacologically active compounds, includes methods of treating conditions, diseases or disorders in respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-viral respiratory infections including aspergillosis and leishmaniasis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis (Future Med. Chem., 2013, 5, 4, 479-492; Biochemical Society Transactions, 2004, 32, 378); hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia and Central pain; hematologic malignancies such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD), Chronic Myeloid Leukemia (CML), T-cell acute lymphoblastic leukaemia (T- ALL), B-cell chronic lymphocytic leukemia (B-CLL), B-cell Acute Lymphoblastic leukaemia (B-ALL), follicular B-cell non-Hodgkin lymphoma (FL), relapsed small lymphocytic lymphoma (SLL), Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer and lung cancer.
SUMMARY OF THE INVENTION
[029] The present inventors have discovered novel compounds which are inhibitors of kinase activity, in particular PI3-kinase activity. Compounds which are PI3-kinase inhibitors may be useful in the treatment of disorders associated with inappropriate kinase activity, in particular inappropriate PI3-kinase activity, for example in the treatment and prevention of disorders mediated by PI3-kinase mechanisms. Such disorders include respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-viral respiratory infections including aspergillosis and leishmaniasis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia and central pain.
[030] In one embodiment, compounds disclosed herein may show selectivity for PI3-kinases over other kinases.
[031] In another embodiment, compounds disclosed herein may be potent inhibitors of PI3K5.
[032] In a further embodiment, compounds disclosed herein may show selectivity for PI3K5 over other PI3 -kinases.
[033] In one aspect, provided herein is a compound having Formula (I):
Figure imgf000010_0001
or a stereoisomer, a geometric isomer, a tautomer, an /V-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each of X, W, A, B, m, Ra, Rb, R1, R2 and R4 is as defined herein.
[034] In certain embodiments, each R1 and R2 is independently H, D, F, CN, N02, -C(=0)Ra, -C(=0)0Ra, -C(=0)NRaRb, -(Ci-C4)alkylene-C(=0)NRaRb, -(Ci-C4)alkylene-N(Rc)C(=0)NRaRb, -(C ! -C4)alkyl ene-N (Rc)C (=0)0Ra, -(Ci-C4)alkylene-OC(=0)NRaRb, -(Ci-C4)alkylene-
S(=0)2NRaRb, -(Ci-C4)alkylene-N(Rc)S(=0)2Rb, -(Ci-C4)alkylene-ORa, -(Ci-C4)alkylene-NRaRb, (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, -(Ci-C )alkylene-(C3- C8)cycloalkyl, 3-8 membered heterocyclyl, -(Ci-C )alkylene-(3-8 membered heterocyclyl), (C6- C!o)aryl, -(Ci-C4)alkylene-(C6-Cio)aryl, 5-10 membered heteroaryl, or -(Ci-C4)alkylene-(5-l0 membered heteroaryl), wherein each of the (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3- C8)cycloalkyl, -(Ci-C )alkylene-(C3-C8)cycloalkyl, 3-8 membered heterocyclyl, -(Ci- C )alkylene-(3-8 membered heterocyclyl), (C6-Ci0)aryl, -(Ci-C )alkylene-(C6-Cio)aryl, 5-10 membered heteroaryl and -(Ci-C4)alkylene-(5-l0 membered heteroaryl) is optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, Br, oxo (=0), CN, Ra, ORa, NRaRb, (Ci-C6)alkyl, -(Ci-C )alkylene-ORa and -(Ci-C )alkylene-NRaRb; or R1 and R2, together with the carbon atom they are attached to, form an optionally substituted 3-8 membered carbocyclic or heterocyclic ring;
X is 3-8 membered heterocyclyl, (C6-Cio)aryl or 5-10 membered heteroaryl, wherein X is optionally substituted by 1, 2, 3, 4 or 5 R3 groups; m is 1, 2 or 3;
W is N or CR5;
A is H, D, (Ci-C6)alkyl, (Ci-C6)haloalkyl, (Ci-C6)hydroxyalkyl, (Ci-C6)aminoalkyl, (C3- C8)cycloalkyl or 3-8 membered heterocyclyl, wherein each (Ci-C6)alkyl, ( (Ci-C6)haloalkyl, (Ci- C6)hydroxyalkyl, (Ci-C6)aminoalkyl, (C3-C8)cycloalkyl and 3-8 membered heterocyclyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH2, CN, N02, (Ci-C6)alkyl and (Ci-C6)alkoxy;
B is (C3-C8)cycloalkyl, 3-8 membered heterocyclyl, (C6-Ci0)aryl or 5-10 membered heteroaryl, wherein each of the (C3-C8)cycloalkyl, 3-8 membered heterocyclyl, (C6-Cio)aryl and 5-10 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo (=0), F, Cl, Br, CN, Ra, ORa, NRaRb, (Ci-C6)alkyl, -(Ci-C4)alkylene-ORa and -(Ci-C4)alkylene-NRaRb; each R3, R4 and R5 is independently H, D, F, Cl, Br, CN, N02, oxo (=0), -C(=0)Ra, - C(=0)0Ra, -C(=0)NRaRb, -0C(=0)NRaRb, -0C(=0)0Ra, -N(Rc)C(=0)NRaRb, -
N(Rc)C(=0)0Ra, -N(Rc)C(=0)Ra, -S(=0)2NRaRb, -S(=0)2Ra, -N(Rc)S(=0)2Ra, -N(Rc)-(Ci- C4)alkyl ene- S (=0)2Ra, -(Ci-C4)alkylene-C(=0)NRaRb, -(Ci-C4)alkylene-N(Rc)C(=0)NRaRb, - (Ci-C4)alkylene-N(Rc)C(=0)ORa, -(Ci-C4)alkylene-OC(=0)NRaRb, -(Ci-C4)alkylene- S(=0)2NRaRb, -(Ci-C4)alkylene-N(Rc)S(=0)2Ra, ORa, NRaRb, -(Ci-C4)alkylene-ORa, -(Ci- C )alkylene-NRaRb, (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, -(Ci- C )alkylene-(C3-C8)cycloalkyl, 3-8 membered heterocyclyl, -(Ci-C )alkylene-(3-8 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C4)alkylene-(C6-Cio)aryl, 5-10 membered heteroaryl, or -(Ci- C4)alkylene-(5-l0 membered heteroaryl), wherein each of the (Ci-C6)alkyl, (C2-C6)alkenyl, (C2- C6)alkynyl, (C3-C8)cycloalkyl, -(Ci-C )alkylene-(C3-C8)cycloalkyl, 3-8 membered heterocyclyl, -(Ci-C )alkylene-(3-8 membered heterocyclyl), (C6-Ci0)aryl, -(Ci-C )alkylene-(C6-Ci0)aryl, 5-10 membered heteroaryl and -(Ci-C4)alkylene-(5-l0 membered heteroaryl) is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, oxo (=0), Ra, ORa, NRaRb, (Ci-C6)alkyl, -(Ci-C4)alkylene-ORa and -(Ci-C4)alkylene-NRaRb; and each Ra, Rb and Rc is independently H, (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3- C6)cycloalkyl, -(Ci-C4)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci- C4)alkylene-(3-6 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C4)alkylene-(C6-Cio)aryl, 5-10 membered heteroaryl, or -(Ci-C )alkylene-(5-l0 membered heteroaryl), wherein each of the (Ci- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl, -(Ci-C )alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C4)alkylene-(3-6 membered heterocyclyl), (C6-Cio)aryl, -(Ci- C4)alkylene-(C6-C!o)aryl, 5-10 membered heteroaryl and -(Ci-C4)alkylene-(5-l0 membered heteroaryl) is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, N02, N3, OH, NH2, (Ci-C6)alkyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy and (C C6)alkylamino; or Ra and Rb, together with the nitrogen atom they are attached to, form an optionally substituted 3-8 membered heterocyclic ring.
[035] In another embodiment, a compound having Formula (II):
Figure imgf000012_0001
[036] In another embodiment, X is 3-6 membered heterocyclyl or 5-6 membered heteroaryl, wherein X is optionally substituted by 1, 2, 3 or 4 R3 groups.
[037] In another embodiment, X is
Figure imgf000012_0002
optionally substituted by 1, 2, or 3 R3 groups.
Figure imgf000012_0003
3
Figure imgf000012_0004
; and wherein X is optionally substituted by 1, 2, or 3 R groups. [039] In another embodiment, A is H, D, (Ci-C4)alkyl, (Ci-C4)haloalkyl, (Ci- C )hydroxyalkyl, (Ci-C )aminoalkyl, (C3-C6)cycloalkyl or 3-6 membered heterocyclyl, wherein each (Ci-C )alkyl, (Ci-C )haloalkyl, (Ci-C )hydroxyalkyl, (Ci-C )aminoalkyl, (C3-C6)cycloalkyl and 3-6 membered heterocyclyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH2, CN, N02, (Ci-C4)alkyl and (Ci- C4)alkoxy.
[040] In another embodiment, A is H, D, methyl, ethyl, «-propyl, isopropyl, /er/-butyl, trifluorom ethyl, difluorom ethyl, l,2-difluoroethyl, 2,2-difluoroethyl, hydroxymethyl, 2- hydroxyethyl, 1 -hydroxy ethyl, 2-hydroxyprop-2-yl, aminomethyl, 2-aminoethyl, l-aminoethyl, 2-aminoprop-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiofen, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl, wherein each methyl, ethyl, «-propyl, isopropyl, /er/-butyl, trifluorom ethyl, difluoromethyl, 1,2- difluoroethyl, 2,2-difluoroethyl, hydroxymethyl, 2-hydroxy ethyl, 1 -hydroxy ethyl, 2- hydroxyprop-2-yl, aminomethyl, 2-aminoethyl, l-aminoethyl, 2-aminoprop-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiofen, piperidyl, piperazinyl, morpholinyl and thiomorpholinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH2, CN, N02, methyl, ethyl, «-propyl, isopropyl, /er/-butyl, methoxyl and ethoxyl.
[041] In another embodiment, B is (C3-C6)cycloalkyl, 3-6 membered heterocyclyl, (C6- C!o)aryl or 5-6 membered heteroaryl, wherein each of the (C3-C6)cycloalkyl, 3-6 membered heterocyclyl, (C6-Cio)aryl and 5-6 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo (=0), F, Cl, Br, CN, Ra, ORa, NRaRb, (Ci- C4)alkyl, -(Ci-C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb.
[042] In another embodiment, B is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo (=0), F, Cl, Br, CN, Ra, ORa, NRaRb, methyl, ethyl, «-propyl, isopropyl, /er/-butyl, -(Ci- C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb. [043] In another embodiment, each R1 and R2 is independently H, D, F, CN, N02, - C(=0)NRaRb, -(Ci-C2)alkylene-C(=0)NRaRb, -(Ci-C2)alkylene-N(Rc)C(=0)NRaRb, -(Ci- C2)alkyl ene-N (Rc)C (=0)0Ra, -(Ci-C2)alkylene-OC(=0)NRaRb, -(Ci-C2)alkylene-S(=0)2NRaRb, -(Ci-C2)alkylene-N(Rc)S(=0)2Rb, -(Ci-C2)alkylene-ORa, -(Ci-C2)alkylene-NRaRb, (Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl), (C6-Ci0)aryl, -(Ci- C2)alkylene-(C6-Cl0)aryl, 5-6 membered heteroaryl, or -(Ci-C )alkylene-(5-6 membered heteroaryl), wherein each of the (Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl), phenyl, -(Ci-C2)alkylene-phenyl, 5-6 membered heteroaryl and -(Ci- C2)alkylene-(5-6 membered heteroaryl) is optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, Br, oxo (=0), CN, Ra, ORa, NRaRb, (Ci-C4)alkyl, -(Ci- C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb; or R1 and R2, together with the carbon atom they are attached to, form an optionally substituted 3-6 membered carbocyclic or heterocyclic ring.
[044] In another embodiment, each R1 and R2 is independently H, D, F, CN, methyl, ethyl, n- propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl, wherein each of methyl, ethyl, «-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl and thiomorpholinyl is optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, Br, oxo (=0), CN, Ra, ORa, NRaRb, (Ci- C )alkyl, -(Ci-C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb; or R1 and R2, together with the carbon atom they are attached to, form an optionally substituted 3-6 membered carbocyclic or heterocyclic ring.
[045] In another embodiment, each R3, R4 and R5 is independently H, D, F, Cl, Br, CN, N02, oxo (=0), -C(=0)NRaRb, -N(Rc)C(=0)NRaRb, -N(Rc)C(=0)0Ra, -N(Rc)C(=0)Ra, -S(=0)2NRaRb, -N(Rc)S(=0)2Ra, -N (Rc)-(C i -C2)alkyl ene- S (=0)2Ra, -(Ci-C2)alkylene-C(=0)NRaRb, -(Ci- C2)alkylene-N(Rc)C(=0)NRaRb, -(Ci-C2)alkylene-S(=0)2NRaRb, -(Ci-C2)alkylene- N(Rc)S(=0)2Ra, ORa, NRaRb, -(Ci-C2)alkylene-ORa, -(Ci-C2)alkylene-NRaRb, (Ci-C4)alkyl, (C2- C )alkenyl, (C2-C )alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl), (C6-Ci0)aryl, -(Ci- C2)alkylene-(C6-C!o)aryl, 5-6 membered heteroaryl, or -(Ci-C2)alkylene-(5-6 membered heteroaryl), wherein each of the (Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C2)alkylene-(C6-Cio)aryl, 5-6 membered heteroaryl and -(Ci-C2)alkylene-(5-6 membered heteroaryl) is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, oxo (=0), Ra, ORa, NRaRb, (Ci- C4)alkyl, -(Ci-C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb.
[046] In another embodiment, each R3, R4 and R5 is independently H, D, F, Cl, Br, CN, N02, oxo (=0), -C(=0)NRaRb, -N(Rc)C(=0)NRaRb, -N(Rc)C(=0)0Ra, -N(Rc)C(=0)Ra, -S(=0)2NRaRb, -N(Rc)S(=0)2Ra, ORa, NRaRb, methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, oxo (=0), Ra, ORa, NRaRb, methyl, ethyl, «-propyl or isopropyl.
[047] In another embodiment, Ra, Rb and Rc is independently H, (Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C )alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl) or 5-6 membered heteroaryl, wherein each of the (Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C6)cycloalkyl, -(Ci- C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl) and 5-6 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, CN, N02, N3, OH, NH2, (Ci-C )alkyl, (Ci- C4)haloalkyl, (Ci-C4)alkoxy and (Ci-C4)alkylamino.
[048] In another embodiment, each Ra, Rb and Rc is independently H, methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of the methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, CN, N02, N3, OH, NH2, methyl, ethyl, «-propyl, isopropyl, trifluoromethyl, difluoromethyl, methoxyl, ethoxyl, methylamino and dimethylamino.
[049] In one aspect of the invention, the compound disclosed herein, or the pharmaceutically acceptable salt disclosed herein is provided for use as a medicament.
[050] In another of the invention, a pharmaceutical composition is provided which comprises a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof, and a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the composition comprising one or more therapeutic agents. In another embodiment, the composition is a liquid, solid, semi-solid, gel, or an aerosol form.
[051] Another aspect of the invention provides a method of modulating the activity of the PI3K enzymes, preferably of the PI3K5 isoform, in a subject, which comprises administering to the subject a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof.
[052] Another aspect of the invention provides a method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a safe and effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
[053] Another aspect of the invention provides a method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a pharmaceutical disclosed herein, to a patient in need thereof.
[054] In some embodiments, the disorder mediated by inappropriate PI3-kinase activity is a respiratory disease, a viral infection, a non-viral respiratory infection, an allergic disease, an autoimmune disease, an inflammatory disorder, a cardiovascular disease, a hematologic malignancy, a neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, or pain.
[055] In another embodiments, the disorder mediated by inappropriate PI3-kinase activity is asthma, chronic obstructive pulmonary disease (COPD), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or central pain.
[056] Another aspect of the invention provides use of the compound disclosed herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of a disorder or a disease selected from asthma, chronic obstructive pulmonary disease (COPD), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, spermmotility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or central pain.
[057] In another aspect of the invention, a method of inhibiting a phosphatidyl inositol-3 kinase (PI3 kinase), is provided comprising: contacting the PI3 kinase with an effective amount of a compound disclosed herein. In some embodiments, the step of contacting comprises contacting a cell that contains said PI3 kinase. In some embodiments of the method, the inhibition takes place in a subject suffering from a disorder associated with malfunctioning of one or more types of PI3 kinase. Some exemplary diseases involving malfunctioning of one or more types of PI3 kinases are selected from the group consisting of autoimmune diseases, rheumatoid arthritis, respiratory disease, allergic reactions, and various types of cancers.
[058] In some embodiments, the method comprises administering a second therapeutic agent to the subject.
[059] In certain embodiments, the PI3K-mediated condition or disorder is selected from rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, and autoimmune diseases. In other embodiments, the PI3K-mediated condition or disorder is selected from cardiovascular diseases, atherosclerosis, hypertension, deep venous thrombosis, stroke, myocardial infarction, unstable angina, thromboembolism, pulmonary embolism, thrombolytic diseases, acute arterial ischemia, peripheral thrombotic occlusions, and coronary artery disease. In still other embodiments, the PI3K-mediated condition or disorder is selected from cancer, colon cancer, glioblastoma, endometrial carcinoma, hepatocellular cancer, lung cancer, melanoma, renal cell carcinoma, thyroid carcinoma, cell lymphoma, lymphoproliferative disorders, small cell lung cancer, squamous cell lung carcinoma, glioma, breast cancer, prostate cancer, ovarian cancer, cervical cancer, and leukemia. In yet another embodiment, the PBK-mediated condition or disorder is selected from type II diabetes. In still other embodiments, the PBK-mediated condition or disorder is selected from respiratory diseases, bronchitis, asthma, and chronic obstructive pulmonary disease. In certain embodiments, the subject is a human.
[060] Another aspect of the invention relates to the treatment of PBK-mediated condition or disorder in a patient comprising the step of administering a compound according to any of the above embodiments.
[061] Another aspect of the invention relates to the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases or autoimmune diseases in a patient comprising the step of administering a compound according to any of the above embodiments.
[062] Another aspect of the invention relates to the treatment of respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) in a patient comprising the step of administering a compound according to any of the above embodiments.
[063] Another aspect of the invention relates to the treatment of inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, skin complaints with inflammatory components, chronic inflammatory conditions, systemic lupus erythematosis (SLE), myestenia gravis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions and hypersensitivity in a patient, comprising the step of administering a compound according to any of the above or below embodiments.
[064] Another aspect of the invention relates to the treatment of cancers in a patient that are mediated, dependent on or associated with PI3K activity, particularly PBKdelta activity, comprising the step of administering a compound according to any of the above or below embodiments.
[065] Another aspect of the invention relates to the treatment of cancers are selected from acute myeloid leukaemia, myelo-dysplastic syndrome, myeloproliferative diseases, chronic myeloid leukaemia, T-cell acute lymphoblastic leukaemia, B-cell acute lymphoblastic leukaemia, non-hodgkins lymphoma, B-cell lymphoma, solid tumors and breast cancer, comprising the step of administering a compound according to any of the above or below embodiments.
[066] Another aspect of the invention relates to the use of a compound according to any of the above embodiments as a medicament. [067] Another aspect of the invention relates to the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of PBK-mediated condition or disorder in a patient.
[068] Another aspect of the invention relates to the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), autoimmune diseases, and cancers.
[069] Unless otherwise stated, all stereoisomers, geometric isomers, tautomers, solvates, hydrates, metabolites, salts, and pharmaceutically acceptable prodrugs of the compounds disclosed herein are within the scope of the invention.
[070] In certain embodiments, the salt is a pharmaceutically acceptable salt. The phrase "pharmaceutically acceptable" indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
[071] The compounds disclosed herein also include salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula (I) and/or for separating enantiomers of compounds of Formula (I).
[072] The compounds disclosed herein, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. The compounds disclosed herein may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
[073] In another aspect, provided herein are methods of preparing, methods of separating, and methods of purifying compounds of Formula (I). The compounds disclosed herein may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and diasteromers.
[074] Compounds disclosed herein can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof. This invention is intended to encompass mixtures of isomers, rotamers, atropisomers, tautomers, partially mixed isomers, rotamers, atropisomers, or tautomers, and separated isomers, rotamers, atropisomers, tautomers. [075] In another aspect, the compounds disclosed herein include isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3H, 14C and 18F, or those into which non-radioactive isotopes, such as 2H and 13C are present.
[076] In another aspect, provided herein are methods of preparing, methods of separating, and methods of purifying compounds of Formula (I).
[077] The foregoing merely summarizes certain aspects of the invention and is not intended to be limiting in nature. These aspects and other aspects and embodiments are described more fully below.
DETAILED DESCRIPTION OF THE INVENTION
DEFINITIONS AND GENERAL TERMINOLOGY
[078] Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated in the accompanying structures and formulas. The invention is intended to cover all alternatives, modifications, and equivalents which may be included within the scope of the present invention as defined by the claims. One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described herein. In the event that one or more of the incorporated literature, patents, and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.
[079] ETnless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference.
[080] As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, and the Handbook of Chemistry and Physics, 75th Ed. 1994. Additionally, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, ETniversity Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry,” by Michael B. Smith and Jerry March, John Wiley & Sons, New York: 2007, all of which are incorporated by reference in their entireties..
[081] As used in the specification and claims, the term "a," "an," "the" and similar terms used in the context of the present invention are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. [082] As used herein, the term "subject" refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
[083] As used herein, "patient" refers to a human (including adults and children) or other animal. In one embodiment, "patient" refers to a human.
[084] The present invention also includes isotopically-labelled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as ¾ ¾ 13C, 14C, 15N, 160, 170, 180, 31P, 32P, 36S, 18F, and 37Cl.
[085] Compounds disclosed herein that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-l4, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detection. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
[086] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994.
[087] Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and 1 or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or / meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
[088] Depending on the choice of the starting materials and procedures, the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms. Optically active ( R )- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or /ra//.s-configurati on .
[089] The compounds disclosed herein may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds disclosed herein, including but not limited to, diastereomers, enantiomers, atropisomers, and geometric (or conformational) isomers as well as mixtures thereof such as racemic mixtures, form part of the present invention.
[090] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, atropisomeric and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers.
[091] The term "tautomer" or "tautomeric form" refers to structural isomers of different energies which are interconvertible via a low energy barrier. Where tautomerization is possible (e.g. in solution), a chemical equilibrium of tautomers can be reached. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions by reorganization of some of the bonding electrons. A specific example of keto- enol tautomerization is the interconversion of pentane-2, 4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. A specific example of phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4( 1 H)- one tautomers. Unless otherwise stated, all tautomeric forms of the compounds disclosed herein are within the scope of the invention.
[092] Any asymmetric atom (e.g., carbon or the like) of the compound(s) disclosed herein can be present in racemic or enantiomerically enriched, for example the ( R )-, (S)- or (Re configuration. In certain embodiments, each asymmetric atom has at least 50 % enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the ( R )- or (S)- configuration. Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- (Z)- or trans- (E)-form.
[093] Accordingly, as used herein a compound disclosed herein can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric ( cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
[094] Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
[095] Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by methods known to those skilled in the art, e.g., by separation of the diastereomeric salts thereof. Racemic products can also be resolved by chiral chromatography, e.g., high performance liquid chromatography (HPLC) using a chiral adsorbent. Preferred enantiomers can also be prepared by asymmetric syntheses. See, for example, Jacques, et ah, “Enantiomers, Racemates and Resolutions,” Wiley Interscience, New York, 1981; Gawley et ah, “Principles of Asymmetric Synthesis,” 2nd Ed. Elsevier, Oxford, UK, 2012; Eliel et ah, Stereochemistry of Carbon Compounds, McGraw-Hill, NY, 1962; Wilen et ah, “Tables of Resolving Agents and Optical Resolutions,” p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972) and Subramanian et ah,“Chiral Separation Techniques: A Practical Approach,” Ed., Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2007.
[096] As described herein, compounds disclosed herein may optionally be substituted with one or more substituents, such as are illustrated generally below, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted". In general, the term "substituted" refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent. The term "optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group. When more than one position in a given structure can be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at each position. [097] The term "alkyl" or "alkyl group" refers to a saturated linear or branched-chain monovalent hydrocarbon radical of 1 to 20 carbon atoms, wherein the alkyl radical may be optionally substituted independently with one or more substituents described below. Unless otherwise specified, the alkyl group contains 1-20 carbon atoms. In some embodiments, the alkyl group contains 1-12 carbon atoms. In other embodiments, the alkyl group contains 1-10 carbon atoms. In other embodiments, the alkyl group contains 1-8 carbon atoms. In other embodiments, the alkyl group contains 1-6 carbon atoms. In still other embodiments, the alkyl group contains
1-4 carbon atoms, and in yet other embodiments, the alkyl group contains 1-3 carbon atoms.
[098] Some non-limiting examples of the alkyl group include methyl (Me, -CH3), ethyl (Et, - CH2CH3), 1 -propyl («- Pr, «-propyl, -CH2CH2CH3), 2-propyl (/-Pr, /-propyl, -CH(CH3)2), 1 -butyl (//-Bu, «-butyl, -CH2CH2CH2CH3), 2-methyl-l-propyl (/-Bu, /-butyl, -CH2CH(CH3)2), 2-butyl (.s- Bu, 5-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (/-Bu, /-butyl, -C(CH3)3), 1 -pentyl («-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3 -pentyl (-CH(CH2CH3)2), 2-methyl-
2-butyl (-C(CH3)2CH2CH3), 3 -methyl -2 -butyl (-CH(CH3)CH(CH3)2), 3-methyl-l-butyl (-
CH2CH2CH(CH3)2), 2-methyl-l -butyl (-CH2CH(CH3)CH2CH3), 1 -hexyl (-
CH2CH2CH2CH2CH2CH3), 2-hexyl (-CEhCEyCEECEECEECEE), 3 -hexyl (-
CH(CH2CH3)(CH2CH2CH3)), 2 -methyl -2 -pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (- CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3 -methyl-3 -pentyl (- C(CH3)(CH2CH3)2), 2-methyl-3 -pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (- C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3, l-heptyl, l-octyl, and the like.
[099] The prefix "alk-" is inclusive of both straight chain and branched saturated carbon chain.
[0100] The term "alkyl ene" refers to a saturated divalent hydrocarbon group derived from a straight or branched chain saturated hydrocarbon by the removal of two hydrogen atoms. Unless otherwise specified, the alkyl ene group contains 1-6 carbon atoms. In some embodiments, the alkyl ene group contains 1-4 carbon atoms. In other embodiments, the alkyl ene group contains 1- 2 carbon atoms. Examples of the alkylene group include, but are not limited to, methylene (- CEE-), ethylidene (-CH2CH2-), isopropylidene (-CH(CH3)CH2-), and the like.
[0101] The term "alkenyl" refers to linear or branched-chain monovalent hydrocarbon radical of 2 to 12 carbon atoms with at least one site of unsaturation, i.e., a carbon-carbon, sp2 double bond, wherein the alkenyl radical may be optionally substituted independently with one or more substituents described herein, and includes radicals having " cis " and "trans" orientations, or alternatively, "E" and "Z" orientations. Preferably the alkenyl group contains 2 to 8 carbon atoms, more preferably, 2 to 6 carbon atoms, and most preferably 2 to 4 carbon atoms. Some non- limiting examples of the alkenyl group include ethylenyl or vinyl (-CH=CH2), allyl (- CH2CH=CH2), and the like.
[0102] The term "alkynyl" refers to a linear or branched monovalent hydrocarbon radical of 2 to 12 carbon atoms with at least one site of unsaturation, i.e., a carbon-carbon, sp triple bond, wherein the alkynyl radical may be optionally substituted independently with one or more substituents described herein. Preferably the alkynyl group contains 2 to 8 carbon atoms, more preferably 2 to 6 carbon atoms, and most preferably 2 to 4 carbon atoms. Some non-limiting examples of the alkynyl group include ethynyl (-CºCH), propynyl (propargyl, -CH2CºCH), - CºC-CH3, and the like.
[0103] The term "alkoxy" refers to an alkyl group, as previously defined, attached to the principal carbon atom through an oxygen atom. Unless otherwise specified, the alkoxy group contains 1-20 carbon atoms. In some embodiments, the alkoxy group contains 1-10 carbon atoms. In other embodiments, the alkoxy group contains 1-8 carbon atoms. In still other embodiments, the alkoxy group contains 1-6 carbon atoms, and in yet other embodiments, the alkoxy group contains 1-4 carbon atoms. In further embodiments, the alkoxy group contains 1-3 carbon atoms.
[0104] Some non-limiting examples of the alkoxy group include methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), l-propoxy (//-PrO, n- propoxy, -OCH2CH2CH3), 2-propoxy (7-PrO, /- propoxy, -OCH(CH3)2), l-butoxy (//-BuO, //-butoxy, -OCH2CH2CH2CH3), 2-methyl -l-propoxy (7-BuO, /-butoxy, -OCH2CH(CH3)2), 2-butoxy (v-BuO, .v-butoxy, -OCH(CH3)CH2CH3), 2- methyl-2-propoxy (/-BuO, /-butoxy, -OC(CH3)3), l-pentoxy (//-pentoxy, OCH2CH2CH2CH2CH3), 2-pentoxy (-OCH(CH3)CH2CH2CH3), 3 -pentoxy (-OCH(CH2CH3)2), 2- methyl-2-butoxy (-OC(CH3)2CH2CH3), 3 -methyl -2-butoxy (-OCH(CH3)CH(CH3)2), 3-methyl-l- butoxy (-OCH2CH2CH(CH3)2), 2-methyl-l-butoxy (-OCH2CH(CH3)CH2CH3), and the like.
[0105] The term "haloalkyl", "haloalkenyl" or "haloalkoxy" refers to alkyl, alkenyl, or alkoxy, as the case may be, substituted with one or more halogen atoms.
[0106] The term "carbocycle", "carbocyclyl", or "carbocyclic ring" refers to a monovalent or multivalent non-aromatic, saturated or partially unsaturated ring having 3 to 12 carbon atoms as a monocyclic, bicyclic, or tricyclic ring system. The carbobicyclyl system includes a spiro carbobicyclyl or a fused carbobicyclyl. In some embodiments, the carbocyclic ring group contains 3 to 8 carbon atoms. Some non-limiting examples of the carbocyclyl group include cycloalkyl, cycloalkenyl, and cycloalkynyl. Further non-limiting examples of the carbocyclyl group include cyclopropyl, cyclobutyl, cyclopentyl, l-cyclopent-l-enyl, l-cyclopent-2-enyl, 1- cyclopent-3-enyl, cyclohexyl, l-cyclohex-l-enyl, l-cyclohex-2-enyl, l-cyclohex-3-enyl, cyclohexadienyl, and the like. [0107] The term "cycloalkyl" refers to a monovalent or multivalent saturated ring having 3 to 12 carbon atoms as a monocyclic, bicyclic, or tricyclic ring system. A bicyclic ring system includes a spiro bicyclyl or a fused bicyclyl. In some embodiments, the cycloalkyl group contains 3 to 10 carbon atoms. In other embodiments, the cycloalkyl group contains 3 to 8 carbon atoms. In still other embodiments, the cycloalkyl group contains 3 to 6 carbon atoms, and in yet other embodiments, the cycloalkyl group contains 5 to 6 carbon atoms. The cycloalkyl group is optionally substituted independently with one or more substituents described herein.
[0108] The terms "fused bicyclic", "fused cyclic", "fused bicyclyl" and "fused cyclyl" are used interchangeably refer to saturated bridged ring system, which refers to a bicyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). The terms "spirocyclyl", "spirocyclic", "spiro bicyclyl" or "spiro bicyclic" are used interchangeably and refer to a ring originating from a particular annular carbon of another ring. For example, as depicted below in Structure a, a saturated bridged ring system (ring B and B’) is termed as "fused bicyclic", whereas ring A and ring B share an atom between the two saturated ring system, which terms as a "spirocyclyl" or "spiro bicyclyl". Each cyclic ring in a fused bicyclyl or a spiro bicyclyl can be either a carbocyclyl or a heterocyclyl.
Figure imgf000026_0001
Structu re a
[0109] The term "heterocycle", "heterocyclyl" or "heterocyclic ring" as used interchangeably herein refers to a monocyclic, bicyclic, or tricyclic ring system in which one or more ring members are independently selected from heteroatoms and that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has one or more points of attachment to the rest of the molecule. A bicyclic ring system includes a spiro bicyclyl or a fused bicyclyl, and one of the rings can be either a monocarbocycle or a monohetercycle. One or more ring atoms are optionally substituted independently with one or more substituents described herein. In some embodiments, the "heterocycle", "heterocyclyl", or "heterocyclic ring" group is a monocycle having 4 to 8 ring members (3 to 7 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S, wherein the S or P is optionally substituted with one or more oxo to provide the group S=0 or S02, PO or P02). In other embodiments, the "heterocycle", "heterocyclyl", or "heterocyclic ring" group is a monocycle having 4 to 7 ring members (3 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S, wherein the S or P is optionally substituted with one or more oxo to provide the group S=0 or S02, PO or P02). In other embodiments, the "heterocycle", "heterocyclyl", or "heterocyclic ring" group is a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S, wherein the S or P is optionally substituted with one or more oxo to provide the group S=0 or S02, PO or P02). In still other embodiments, the "heterocycle", "heterocyclyl", or "heterocyclic ring" group is a monocycle having 4 to 6 ring members (3 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S, wherein the S or P is optionally substituted with one or more oxo to provide the group S=0 or S02, PO or P02). In yet other embodiments, the "heterocycle", "heterocyclyl", or "heterocyclic ring" group is a monocycle having 3 to 6 ring members (2 to 5 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S, wherein the S or P is optionally substituted with one or more oxo to provide the group S=0 or S02, PO or P02), or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S, wherein the S or P is optionally substituted with one or more oxo to provide the group S=0 or S02, PO or P02).
[0110] The heterocyclyl may be a carbon radical or heteroatom radical. Some non-limiting examples of the heterocyclyl group include pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, homo-piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 4,5- dihydrooxazoly, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 277-pyranyl, 477-pyranyl, dioxanyl, 1,3- dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinylimidazolinyl, imidazolidinyl, l,2,3,4-tetrahydroisoquinolinyl. Examples of a heterocyclic group wherein 2 ring carbon atoms are substituted with oxo (=0) moieties are pyrimidindionyl and l,l-dioxo-thiomorpholinyl.
[0111] The term "heteroatom" refers to one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon, including any oxidized form of nitrogen, sulfur, or phosphorus; the quatemized form of any basic nitrogen; or a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4- di hydro-2//-pyrrol yl ), NH (as in pyrrolidinyl) or NR (as in N- substituted pyrrolidinyl).
[0112] The term "halogen" refers to Fluoro (F), Chloro (Cl), Bromo (Br), or Iodo (I).
[0113] The term "azido" or "N3" refers to an azide moiety. This radical may be attached, for example, to a methyl group to form azidomethane (methyl azide, MeN3); or attached to a phenyl group to form phenyl azide (PhN3).
[0114] The term "aryl" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy" or "aryloxyalkyl" refers to monocyclic, bicyclic, and tricyclic carbocyclic ring systems having a total of 6 to 14 ring members, preferably, 6 to 12 ring members, and more preferably 6 to 10 ring members, wherein at least one ring in the system is aromatic, wherein each ring in the system contains 3 to 7 ring members and that has one or more points of attachment to the rest of the molecule. The term "aryl" may be used interchangeably with the term "aryl ring" or "aromatic." Some non-limiting examples of the aryl ring would include phenyl, naphthyl, and anthracenyl. The aryl radical is optionally substituted independently with one or more substituents described herein.
[0115] The term "heteroaryl" used alone or as part of a larger moiety as in "heteroaralkyl" or "heteroarylalkoxy" refers to monocyclic, bicyclic, and tricyclic ring systems having a total of 5 to 14 ring members, preferably, 5 to 12 ring members, and more preferably 5 to 10 ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, wherein each ring in the system contains 5 to 7 ring members and that has one or more points of attachment to the rest of the molecule. In some embodiments, heteroaryl may be a 5-10 membered heteroaryl comprises 1, 2, 3 or 4 heteroatoms independently selected from O, S and N. In another embodiments, heteroaryl may be a 5-6 membered heteroaryl comprises 1, 2, 3 or 4 heteroatoms independently selected from O, S and N. In still another embodiments, heteroaryl may be a 5-membered heteroaryl comprises 1, 2, 3 or 4 heteroatoms independently selected from O, S and N. The term "heteroaryl" may be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic". The heteroaryl radicals are optionally substituted independently with one or more substituents described herein.
[0116] Some non-limiting examples of the heteroaryl ring include the following monocycles: 2-furanyl, 3-furanyl, A-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4- isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, /V-pyrrolyl, 2-pyrrolyl, 3- pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3- pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5//-tetrazolyl and 2 H- tetrazolyl ), triazolyl (e.g., 2-triazolyl, 5-triazolyl, 4//- 1 ,2,4-tri azolyf 1 //- 1 ,2,4-triazolyl, and
1.2.3-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (e.g., 2-pyrazolyl and 3-pyrazolyl), isothiazolyl,
1.2.3-oxadiazolyl, l,2,5-oxadiazolyl, l,2,4-oxadiazolyl, l,3,4-oxadiazolyl, 1,2, 3 -triazolyl, 1,2,4- triazolyl, l,2,3-thiadiazolyl, l,3,4-thiadiazolyl, l,2,5-thiadiazolyl, pyrazinyl, l,3,5-triazinyl, and the following bicycles: benzimidazolyl, benzofuryl, benzothiophenyl, indolyl (e.g., 2-indolyl), purinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), and isoquinolinyl (e.g., 1- isoquinolinyl, 3 -isoquinolinyl, or 4-isoquinolinyl).
[0117] The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", refers to -C02H. The term "carbonyl", whether used alone or with other terms, such as "aminocarbonyl", denotes -(C=0)-.
[0118] The term "alkylamino" embraces "/V-alkylamino" and "N, A'-di al kyl a i no" where amino groups are independently substituted with one alkyl radical or with two alkyl radicals, respectively. Some non-limiting examples of alkylamino radicals are "lower alkylamino" radicals having one or two alkyl radicals of one to six carbon atoms, attached to a nitrogen atom. Suitable alkylamino radicals may be mono or dialkylamino such as A'-rn ethyl ami no, A'-ethylamino, N, N- dimethylamino, N A'-di ethylamino and the like.
[0119] The term "arylamino" refers to amino groups, which have been substituted with one or two aryl radicals, such as A-phenylamino. The arylamino radicals may be further substituted on the aryl ring portion of the radical.
[0120] The term "aminoalkyl" refers to linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more amino radicals. More preferred aminoalkyl radicals are "lower aminoalkyl" radicals having one to six carbon atoms and one or more amino radicals. Examples of such radicals include aminomethyl, aminoethyl, aminopropyl, aminobutyl and aminohexyl.
[0121] The term "n membered" where n is an integer typically describes the number of ring forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6 membered heterocycloalkyl and l,2,3,4-tetrahydro naphthalenyl is an example of a 10 membered carbocyclyl group.
[0122] As described herein, a bond drawn from a substituent to the center of one ring within a ring system (as shown below) represents substitution of the substituent at any substitutable position on the ring to which it is attached. For example, Structure b represents possible substitutions in any of the positions on the D ring shown in Structure b-l, b-2, b-3, b-4, b-5, b-6, and b-7.
Figure imgf000029_0001
Structure b Structure b- 1 Structure b-2 Structure b-3
Figure imgf000029_0002
Structure b-4 Structure b-5 Structure b-6 Structure b-7 [0123] The term "unsaturated" refers to a moiety having one or more units of unsaturation.
[0124] The term "comprising" is meant to be open ended, including the indicated component but not excluding other elements.
[0125] The term "prodrug" as used herein, represents a compound that is transformed in vivo into a compound of formula (I). Such a transformation can be affected, for example, by hydrolysis in blood or enzymatic transformation of the prodrug form to the parent form in blood or tissue. Prodrugs of the compounds disclosed herein may be, for example, esters. Esters that may be utilized as prodrugs in the present invention are phenyl esters, aliphatic (C1-C24) esters, acyloxymethyl esters, carbonates, carbamates, and amino acid esters. For example, a compound disclosed herein that contains an OH group may be acylated at this position in its prodrug form. Other prodrug forms include phosphates, such as, for example those phosphates resulting from the phosphonation of an OH group on the parent compound. A thorough discussion of prodrugs is provided in Higuchi et al., Pro-drugs as Novel Delivery Systems, Vol. 14, A.C.S. Symposium Series; Roche et al., Biorev ersible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987; Rautio et al., Prodrugs: Design and Clinical Applications, Nat. Rev. Drug Discovery , 2008, 7, 255-270, and Hecker et al., Prodrugs of Phosphates and Phosphonates, J. Med. Chem ., 2008, 51, 2328-2345, all of which are incorporated herein by reference.
[0126] A "metabolite" is a product produced through metabolism in the body of a specified compound or salt thereof. The metabolite of a compound may be identified using routine techniques known in the art and their activities determined using tests such as those described herein. Such products may result for example from the oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound. Accordingly, the invention includes metabolites of compounds disclosed herein, including compounds produced by a process comprising contacting a compound disclosed herein with a mammal for a period of time sufficient to yield a metabolic product thereof.
[0127] A "pharmaceutically acceptable salt" refers to organic or inorganic salts of a compound disclosed herein. The pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharm. Sci., 1977, 66, 1-19, which is incorporated herein by reference. Some non-limiting examples of the pharmaceutically acceptable salt include salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
[0128] Other examples of the pharmaceutically acceptable salt include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemi sulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, / oluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Ci-4alkyl)4 salts. This invention also envisions the quatemization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quatemization. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further examples of the pharmaceutically acceptable salt include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, Ci-8 sulfonate and aryl sulfonate.
[0129] A "solvate" refers to an association or complex of one or more solvent molecules and a compound disclosed herein. Some non-limiting examples of solvents that form solvates include water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" refers to the complex where the solvent molecule is water.
[0130] As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, p. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
[0131] The term "a therapeutically effective amount" of a compound disclosed herein refers to an amount of the compound disclosed herein that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound disclosed herein that, when administered to a subject, is effective to (1) at least partially alleviate, inhibit, prevent and/or ameliorate a condition, or a disorder or a disease (i) mediated by PI3K or (ii) associated with PI3K activity, or (iii) characterized by activity (normal or abnormal) of PI3K or (2) reduce or inhibit the activity of PI3K or (3) reduce or inhibit the expression of PI3K. In another non-limiting embodiment, the term "a therapeutically effective amount" refers to the amount of the compound disclosed herein that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of PI3K; or at least partially reducing or inhibiting the expression of PI3K. The meaning of the term "a therapeutically effective amount" as illustrated in the above embodiment for PI3K also applies by the same means to any other relevant proteins/peptides/enzymes.
[0132] As used herein, the term "treat", "treating" or "treatment" of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment, the term "treat", "treating" or "treatment" refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, the term "treat", "treating" or "treatment" refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, the term "treat", "treating" or "treatment" refers to preventing or delaying the onset or development or progression of the disease or disorder.
[0133] The term "protecting group" or "PG" refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound. For example, an "amino-protecting group" is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxy-carbonyl (BOC, Boc), benzyloxycarbonyl (CBZ, Cbz) and 9-fluorenylmethylenoxy-carbonyl (Fmoc). Similarly, a "hydroxy-protecting group" refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include acetyl and silyl. A "carboxy-protecting group" refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Common carboxy-protecting groups include -CH2CH2S02Ph, cyanoethyl, 2-(trimethylsilyl)ethyl, 2- (trimethylsilyl)ethoxy-methy-l, 2-(p-toluenesulfonyl) ethyl, 2-(p-nitrophenylsulfenyl)-ethyl, 2- (diphenylphosphino)-ethyl, nitroethyl and the like. For a general description of protecting groups and their use, see Greene et ak, Protective Groups in Organic Synthesis , John Wiley & Sons, New York, 1991 and Kocienski et ak, Protecting Groups , Thieme, Stuttgart, 2005
DESCRIPTION OF THE COMPOUNDS DISCLOSED HEREIN
[0134] The present inventors have discovered novel compounds which are inhibitors of kinase activity, in particular PI3 -kinase activity. Compounds which are PI3 -kinase inhibitors may be useful in the treatment of disorders associated with inappropriate kinase activity, in particular inappropriate PI3-kinase activity, for example in the treatment and prevention of disorders mediated by PI3-kinase mechanisms. Such disorders include respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-viral respiratory infections including aspergillosis and leishmaniasis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia and central pain.
[0135] In one embodiment, compounds disclosed herein may show selectivity for PI3-kinases over other kinases.
[0136] In another embodiment, compounds disclosed herein may be potent inhibitors of PI3K5.
[0137] In a further embodiment, compounds disclosed herein may show selectivity for PI3K5 over other PI3 -kinases.
[0138] In one aspect, provided herein is a compound having Formula (I):
Figure imgf000033_0001
or a stereoisomer, a geometric isomer, a tautomer, an /V-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each of X, W, A, B, m, Ra, Rb, R1, R2 and R4 is as defined herein.
[0139] In certain embodiments, each R1 and R2 is independently H, D, F, CN, N02, -C(=0)Ra, -C(=0)0Ra, -C(=0)NRaRb, -(Ci-C4)alkylene-C(=0)NRaRb, -(Ci-C4)alkylene-N(Rc)C(=0)NRaRb, -(C i -C4)alkyl ene-N (Rc)C (=0)0Ra, -(Ci-C4)alkylene-OC(=0)NRaRb, -(Ci-C4)alkylene-
S(=0)2NRaRb, -(Ci-C4)alkylene-N(Rc)S(=0)2Rb, -(Ci-C4)alkylene-ORa, -(Ci-C4)alkylene-NRaRb, (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, -(Ci-C4)alkylene-(C3- C8)cycloalkyl, 3-8 membered heterocyclyl, -(Ci-C4)alkylene-(3-8 membered heterocyclyl), (C6- Cl0)aryl, -(Ci-C )alkylene-(C6-Cio)aryl, 5-10 membered heteroaryl, or -(Ci-C )alkylene-(5-l0 membered heteroaryl), wherein each of the (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3- C8)cycloalkyl, -(Ci-C4)alkylene-(C3-C8)cycloalkyl, 3-8 membered heterocyclyl, -(Ci- C4)alkylene-(3-8 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C4)alkylene-(C6-Cio)aryl, 5-10 membered heteroaryl and -(Ci-C )alkylene-(5-l0 membered heteroaryl) is optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, Br, oxo (=0), CN, Ra, ORa, NRaRb, (Ci-C6)alkyl, -(Ci-C4)alkylene-ORa and -(Ci-C4)alkylene-NRaRb; or R1 and R2, together with the carbon atom they are attached to, form an optionally substituted 3-8 membered carbocyclic or heterocyclic ring;
X is 3-8 membered heterocyclyl, (C6-Ci0)aryl or 5-10 membered heteroaryl, wherein X is optionally substituted by 1, 2, 3, 4 or 5 R3 groups; m is 1, 2 or 3;
W is N or CR5;
A is H, D, (Ci-C6)alkyl, (Ci-C6)haloalkyl, (Ci-C6)hydroxyalkyl, (Ci-C6)aminoalkyl, (C3- C8)cycloalkyl or 3-8 membered heterocyclyl, wherein each (Ci-C6)alkyl, (Ci-C6)haloalkyl, (Ci- C6)hydroxyalkyl, (Ci-C6)aminoalkyl, (C3-C8)cycloalkyl and 3-8 membered heterocyclyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH2, CN, N02, (Ci-C6)alkyl and (Ci-C6)alkoxy;
B is (C3-C8)cycloalkyl, 3-8 membered heterocyclyl, (C6-Cio)aryl or 5-10 membered heteroaryl, wherein each of the (C3-C8)cycloalkyl, 3-8 membered heterocyclyl, (C6-Cio)aryl and 5-10 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo (=0), F, Cl, Br, CN, Ra, ORa, NRaRb, (Ci-C6)alkyl, -(Ci-C4)alkylene-ORa and -(Ci-C4)alkylene-NRaRb; each R3, R4 and R5 is independently H, D, F, Cl, Br, CN, N02, oxo (=0), -C(=0)Ra, - C(=0)0Ra, -C(=0)NRaRb, -0C(=0)NRaRb, -0C(=0)0Ra, -N(Rc)C(=0)NRaRb, -
N(Rc)C(=0)0Ra, -N(Rc)C(=0)Ra, -S(=0)2NRaRb, -S(=0)2Ra, -N(Rc)S(=0)2Ra, -N(Rc)-(Ci- C4)alkyl ene- S (=0)2Ra, -(Ci-C4)alkylene-C(=0)NRaRb, -(Ci-C4)alkylene-N(Rc)C(=0)NRaRb, - (Ci-C4)alkylene-N(Rc)C(=0)0Ra, -(Ci-C4)alkylene-0C(=0)NRaRb, -(Ci-C4)alkylene- S(=0)2NRaRb, -(C i -C4)alkyl ene-N (Rc) S (=0)2Ra, 0Ra, NRaRb, -(Ci-C4)alkylene-ORa, -(Ci- C )alkylene-NRaRb, (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, -(Ci- C4)alkylene-(C3-C8)cycloalkyl, 3-8 membered heterocyclyl, -(Ci-C4)alkylene-(3-8 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C4)alkylene-(C6-Cio)aryl, 5-10 membered heteroaryl, or -(Ci- C )alkylene-(5-l0 membered heteroaryl), wherein each of the (Ci-C6)alkyl, (C2-C6)alkenyl, (C2- C6)alkynyl, (C3-C8)cycloalkyl, -(Ci-C )alkylene-(C3-C8)cycloalkyl, 3-8 membered heterocyclyl, -(Ci-C4)alkylene-(3-8 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C4)alkylene-(C6-Cio)aryl, 5-10 membered heteroaryl and -(Ci-C4)alkylene-(5-l0 membered heteroaryl) is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, oxo (=0), Ra, ORa, NRaRb, (Ci-C6)alkyl, -(Ci-C4)alkylene-ORa and -(Ci-C4)alkylene-NRaRb; and each Ra, Rb and Rc is independently H, (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3- C6)cycloalkyl, -(Ci-C4)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci- C )alkylene-(3-6 membered heterocyclyl), (C6-Ci0)aryl, -(Ci-C )alkylene-(C6-Ci0)aryl, 5-10 membered heteroaryl, or -(Ci-C )alkylene-(5-l0 membered heteroaryl), wherein each of the (Ci- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl, -(Ci-C4)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C4)alkylene-(3-6 membered heterocyclyl), (C6-Cio)aryl, -(Ci- C )alkylene-(C6-Cl0)aryl, 5-10 membered heteroaryl and -(Ci-C )alkylene-(5-l0 membered heteroaryl) is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, N02, N3, OH, NH2, (Ci-C6)alkyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy and (Ci- C6)alkylamino; or Ra and Rb, together with the nitrogen atom they are attached to, form an optionally substituted 3-8 membered heterocyclic ring.
[0140] In another embodiment, a compound having Formula (II):
Figure imgf000035_0001
[0141] In another embodiment, X is 3-6 membered heterocyclyl or 5-6 membered heteroaryl, wherein X is optionally substituted by 1, 2, 3 or 4 R3 groups. [0142] In another embodiment, X is
Figure imgf000036_0001
optionally substituted by 1, 2, or 3 R3 groups.
Figure imgf000036_0003
Figure imgf000036_0002
; and wherein X is optionally substituted by 1, 2, or 3 R3 groups.
[0144] In another embodiment, A is H, D, (Ci-C4)alkyl, (Ci-C4)haloalkyl, (Ci- C )hydroxyalkyl, (Ci-C )aminoalkyl, (C3-C6)cycloalkyl or 3-6 membered heterocyclyl, wherein each (Ci-C4)alkyl, (Ci-C4)haloalkyl, (Ci-C4)hydroxyalkyl, (Ci-C4)aminoalkyl, (C3-C6)cycloalkyl and 3-6 membered heterocyclyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH2, CN, N02, (Ci-C )alkyl and (Ci- C4)alkoxy. [0145] In another embodiment, A is H, D, methyl, ethyl, «-propyl, isopropyl, /er/-butyl, trifluorom ethyl, difluorom ethyl, l,2-difluoroethyl, 2,2-difluoroethyl, hydroxymethyl, 2- hydroxyethyl, 1 -hydroxy ethyl, 2-hydroxyprop-2-yl, aminomethyl, 2-aminoethyl, l-aminoethyl, 2-aminoprop-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiofen, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl, wherein each methyl, ethyl, «-propyl, isopropyl, /er/-butyl, trifluorom ethyl, difluoromethyl, 1,2- difluoroethyl, 2,2-difluoroethyl, hydroxymethyl, 2-hydroxy ethyl, 1 -hydroxy ethyl, 2- hydroxyprop-2-yl, aminomethyl, 2-aminoethyl, l-aminoethyl, 2-aminoprop-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiofen, piperidyl, piperazinyl, morpholinyl and thiomorpholinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH2, CN, N02, methyl, ethyl, «-propyl, isopropyl, /er/-butyl, methoxyl and ethoxyl.
[0146] In another embodiment, B is (C3-C6)cycloalkyl, 3-6 membered heterocyclyl, (C6- Cl0)aryl or 5-6 membered heteroaryl, wherein each of the (C3-C6)cycloalkyl, 3-6 membered heterocyclyl, (C6-Ci0)aryl and 5-6 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo (=0), F, Cl, Br, CN, Ra, ORa, NRaRb, (Ci- C4)alkyl, -(Ci-C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb.
[0147] In another embodiment, B is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo (=0), F, Cl, Br, CN, Ra, ORa, NRaRb, methyl, ethyl, «-propyl, isopropyl, /er/-butyl, -(Ci- C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb.
[0148] In another embodiment, each R1 and R2 is independently H, D, F, CN, N02, - C(=0)NRaRb, -(Ci-C2)alkylene-C(=0)NRaRb, -(Ci-C2)alkylene-N(Rc)C(=0)NRaRb, -(Ci- C2)alkyl ene-N (Rc)C (=0)ORa, -(Ci-C2)alkylene-OC(=0)NRaRb, -(Ci-C2)alkylene-S(=0)2NRaRb, -(Ci-C2)alkylene-N(Rc)S(=0)2Rb, -(Ci-C2)alkylene-ORa, -(Ci-C2)alkylene-NRaRb, (Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl), (C6-Ci0)aryl, -(Ci- C2)alkylene-(C6-Cio)aryl, 5-6 membered heteroaryl, or -(Ci-C4)alkylene-(5-6 membered heteroaryl), wherein each of the (Ci-C4)alkyl, (C2-C )alkenyl, (C2-C )alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl), phenyl, -(Ci-C2)alkylene-phenyl, 5-6 membered heteroaryl and -(Ci- C2)alkylene-(5-6 membered heteroaryl) is optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, Br, oxo (=0), CN, Ra, ORa, NRaRb, (Ci-C )alkyl, -(Ci- C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb; or R1 and R2, together with the carbon atom they are attached to, form an optionally substituted 3-6 membered carbocyclic or heterocyclic ring.
[0149] In another embodiment, each R1 and R2 is independently H, D, F, CN, methyl, ethyl, n- propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl, wherein each of methyl, ethyl, «-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl and thiomorpholinyl is optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, Br, oxo (=0), CN, Ra, ORa, NRaRb, (Ci- C4)alkyl, -(Ci-C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb; or R1 and R2, together with the carbon atom they are attached to, form an optionally substituted 3-6 membered carbocyclic or heterocyclic ring.
[0150] In another embodiment, each R3, R4 and R5 is independently H, D, F, Cl, Br, CN, N02, oxo (=0), -C(=0)NRaRb, -N(Rc)C(=0)NRaRb, -N(Rc)C(=0)0Ra, -N(Rc)C(=0)Ra, -S(=0)2NRaRb, -N(Rc)S(=0)2Ra, -N(Rc)-(Ci-C2)alkylene-S(=0)2Ra, -(Ci-C2)alkylene-C(=0)NRaRb, -(Ci- C2)alkylene-N(Rc)C(=0)NRaRb, -(Ci-C2)alkylene-S(=0)2NRaRb, -(Ci-C2)alkylene- N(Rc)S(=0)2Ra, ORa, NRaRb, -(Ci-C2)alkylene-ORa, -(Ci-C2)alkylene-NRaRb, (Ci-C4)alkyl, (C2- C4)alkenyl, (C2-C4)alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl), (C6-Cio)aryl, -(Ci- C2)alkylene-(C6-Clo)aryl, 5-6 membered heteroaryl, or -(Ci-C2)alkylene-(5-6 membered heteroaryl), wherein each of the (Ci-C )alkyl, (C2-C )alkenyl, (C2-C )alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C2)alkylene-(C6-Cio)aryl, 5-6 membered heteroaryl and -(Ci-C2)alkylene-(5-6 membered heteroaryl) is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, oxo (=0), Ra, ORa, NRaRb, (Ci- C4)alkyl, -(Ci-C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb.
[0151] In another embodiment, each R3, R4 and R5 is independently H, D, F, Cl, Br, CN, N02, oxo (=0), -C(=0)NRaRb, -N(Rc)C(=0)NRaRb, -N(Rc)C(=0)0Ra, -N(Rc)C(=0)Ra, -S(=0)2NRaRb, -N(Rc)S(=0)2Ra, ORa, NRaRb, methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, oxo (=0), Ra, ORa, NRaRb, methyl, ethyl, «-propyl or isopropyl.
[0152] In another embodiment, Ra, Rb and Rc is independently H, (Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl) or 5-6 membered heteroaryl, wherein each of the (Ci-C )alkyl, (C2-C )alkenyl, (C2-C )alkynyl, (C3-C6)cycloalkyl, -(Ci- C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl) and 5-6 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, CN, N02, N3, OH, NH2, (Ci-C4)alkyl, (Ci- C )haloalkyl, (Ci-C )alkoxy and (Ci-C )alkylamino.
[0153] In another embodiment, each Ra, Rb and Rc is independently H, methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of the methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, CN, N02, N3, OH, NH2, methyl, ethyl, «-propyl, isopropyl, trifluoromethyl, difluoromethyl, methoxyl, ethoxyl, methylamino and dimethylamino.
[0154] Some non-limiting examples of the compound disclosed herein are shown in the following:
Table 1
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
[0155] In one aspect of the invention, a pharmaceutical composition is provided which comprises a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof, and a compound of formula (I) or a pharmaceutically acceptable salt thereof. In some embodiments, the composition is a liquid, solid, semi-solid, gel, or an aerosol form.
[0156] In another aspect of the invention, a method of inhibiting a phosphatidyl inositol-3 kinase (PI3 kinase), is provided comprising: contacting the PI3 kinase with an effective amount of a compound disclosed herein. In some embodiments, the step of contacting comprises contacting a cell that contains said PI3 kinase. In some embodiments of the method, the inhibition takes place in a subject suffering from a disorder associated with malfunctioning of one or more types of PI3 kinase. Some exemplary diseases involving malfunctioning of one or more types of PI3 kinases are selected from the group consisting of autoimmune diseases, rheumatoid arthritis, respiratory disease, allergic reactions, and various types of cancers.
[0157] In some embodiments, the method comprises administering a second therapeutic agent to the subject.
[0158] In certain embodiments, the PI3K-mediated condition or disorder is selected from rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, and autoimmune diseases. In other embodiments, the PI3K-mediated condition or disorder is selected from cardiovascular diseases, atherosclerosis, hypertension, deep venous thrombosis, stroke, myocardial infarction, unstable angina, thromboembolism, pulmonary embolism, thrombolytic diseases, acute arterial ischemia, peripheral thrombotic occlusions, and coronary artery disease. In still other embodiments, the PBK-mediated condition or disorder is selected from cancer, colon cancer, glioblastoma, endometrial carcinoma, hepatocellular cancer, lung cancer, melanoma, renal cell carcinoma, thyroid carcinoma, cell lymphoma, lymphoproliferative disorders, small cell lung cancer, squamous cell lung carcinoma, glioma, breast cancer, prostate cancer, ovarian cancer, cervical cancer, and leukemia. In yet another embodiment, the PBK-mediated condition or disorder is selected from type II diabetes. In still other embodiments, the PBK-mediated condition or disorder is selected from respiratory diseases, bronchitis, asthma, and chronic obstructive pulmonary disease. In certain embodiments, the subject is a human.
[0159] Another aspect of the invention relates to the treatment of PBK-mediated condition or disorder in a patient comprising the step of administering a compound according to any of the above embodiments.
[0160] Another aspect of the invention relates to the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases or autoimmune diseases in a patient comprising the step of administering a compound according to any of the above embodiments.
[0161] Another aspect of the invention relates to the treatment of respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) in a patient comprising the step of administering a compound according to any of the above embodiments.
[0162] Another aspect of the invention relates to the treatment of inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, skin complaints with inflammatory components, chronic inflammatory conditions, systemic lupus erythematosis (SLE), myestenia gravis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions and hypersensitivity in a patient, comprising the step of administering a compound according to any of the above or below embodiments.
[0163] Another aspect of the invention relates to the treatment of cancers in a patient that are mediated, dependent on or associated with PI3K activity, particularly PBKdelta activity, comprising the step of administering a compound according to any of the above or below embodiments. [0164] Another aspect of the invention relates to the treatment of cancers are selected from acute myeloid leukaemia, myelo-dysplastic syndrome, myeloproliferative diseases, chronic myeloid leukaemia, T-cell acute lymphoblastic leukaemia, B-cell acute lymphoblastic leukaemia, non-hodgkins lymphoma, B-cell lymphoma, solid tumors and breast cancer, comprising the step of administering a compound according to any of the above or below embodiments.
[0165] Another aspect of the invention relates to the use of a compound according to any of the above embodiments as a medicament.
[0166] Another aspect of the invention relates to the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of PBK-mediated condition or disorder in a patient.
[0167] Another aspect of the invention relates to the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), autoimmune diseases, and cancers.
[0168] Unless otherwise stated, all stereoisomers, geometric isomers, tautomers, solvates, hydrates, metabolites, salts, and pharmaceutically acceptable prodrugs of the compounds disclosed herein are within the scope of the invention.
[0169] In certain embodiments, the salt is a pharmaceutically acceptable salt. The phrase "pharmaceutically acceptable" indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
[0170] The compounds disclosed herein also include salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula (I) and/or for separating enantiomers of compounds of Formula (I).
[0171] Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandi sulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methyl sulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, subsalicylate, tartrate, tosylate and trifluoroacetate salts.
[0172] Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
[0173] Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
[0174] Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
[0175] Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
[0176] Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
[0177] The pharmaceutically acceptable salts disclosed herein can be synthesized from a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in "Remington's Pharmaceutical Sciences," 20th ed., Mack Publishing Company, Easton, PA, 1985; and in "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth, Wiley-VCH, Weinheim, Germany, 2002
[0178] Furthermore, the compounds disclosed herein, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. The compounds disclosed herein may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
[0179] In another aspect, provided herein are methods of preparing, methods of separating, and methods of purifying compounds of Formula (I). The compounds disclosed herein may have in general several asymmetric centers and are typically depicted in the form of racemic mixtures. This invention is intended to encompass racemic mixtures, partially racemic mixtures and separate enantiomers and diasteromers.
[0180] Compounds disclosed herein can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof. This invention is intended to encompass mixtures of isomers, rotamers, atropisomers, tautomers, partially mixed isomers, rotamers, atropisomers, or tautomers, and separated isomers, rotamers, atropisomers, tautomers.
[0181] Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds disclosed herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, ¾ UC,13C, 14C, 15N, 18F, 31P, 32P, 35S, 36Cl, and 125I respectively.
[0182] In another aspect, the compounds disclosed herein include isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3H, 14C and 18F, or those into which non-radioactive isotopes, such as 2H and 13C are present. Such isotopically labelled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F or labeled compound may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
[0183] Further, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the formula (I). The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound disclosed herein is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D20, acetone-^, or DMSO-i¾.
COMPOSITION, FORMULATIONS AND ADMINISTRATION OF THE COMPOUNDS
DISCLOSED HEREIN
[0184] In one aspect, featured herein are pharmaceutical compositions that include a compound of formula (I), or a compound listed in Table 1; and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of compound in the pharmaceutical compositions disclosed herein is such that is effective to detectably inhibit a protein kinase in a biological sample or in a patient.
[0185] It will also be appreciated that certain of the compounds disclosed herein can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. Some non-limiting examples of pharmaceutically acceptable derivative include pharmaceutically acceptable prodrugs, salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
[0186] As described above, the pharmaceutical compositions or pharmaceutically acceptable compositions disclosed herein additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. In Remington: The Science and Practice of Pharmacy, 2lst edition, 2005, ed. D.B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York, the contents of each of which is incorporated by reference herein, are disclosed various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds disclosed herein, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
[0187] The pharmaceutical compositions disclosed herein may be prepared and packaged in bulk form wherein a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof can be extracted and then given to the patient such as with powders or syrups. Alternatively, the pharmaceutical compositions disclosed herein may be prepared and packaged in unit dosage form wherein each physically discrete unit contains a compound of formula (I) or a pharmaceutically acceptable salt thereof. When prepared in unit dosage form, the pharmaceutical compositions disclosed herein typically may contain, for example, from 0.5 mg to 1 g, or from 1 mg to 700 mg, or from 5 mg to 100 mg of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0188] The pharmaceutical compositions disclosed herein typically contain one compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0189] As used herein, "pharmaceutically acceptable excipient" means a pharmaceutically acceptable material, composition or vehicle involved in giving form or consistency to the pharmaceutical composition. Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of formula (I) or a pharmaceutically acceptable salt thereof when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically acceptable are avoided. In addition, each excipient must of course be pharmaceutically-acceptable eg of sufficiently high purity. The compound of formula (I) or a pharmaceutically acceptable salt thereof and the pharmaceutically acceptable excipient or excipients will typically be formulated into a dosage form adapted for administration to the patient by the desired route of administration. For example, dosage forms include those adapted for (1 ) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixers, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as aerosols, solutions, and dry powders; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
[0190] Suitable pharmaceutically acceptable excipients will vary depending upon the particular dosage form chosen. In addition, suitable pharmaceutically acceptable excipients may be chosen for a particular function that they may serve in the composition. For example, certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms. Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms. Certain pharmaceutically acceptable excipients may be chosen for their ability to facilitate the carrying or transporting of the compound or compounds of formula (I) or pharmaceutically acceptable salts thereof once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body. Certain pharmaceutically acceptable excipients may be chosen for their ability to enhance patient compliance.
[0191] Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweetners, flavoring agents, flavor masking agents, coloring agents, anticaking agents, hemectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents. The skilled artisan will appreciate that certain pharmaceutically acceptable excipients may serve more than one function and may serve alternative functions depending on how much of the excipient is present in the formulation and what other excipients are present in the formulation.
[0192] Skilled artisans possess the knowledge and skill in the art to enable them to select suitable pharmaceutically-acceptable excipients in appropriate amounts for use in the invention. In addition, there are a number of resources that are available to the skilled artisan which describe pharmaceutically acceptable excipients and may be useful in selecting suitable pharmaceutically acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
[0193] The pharmaceutical compositions disclosed herein are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
[0194] Accordingly, in another aspect the invention is directed to process for the preparation of a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients which comprises mixing the ingredients. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof may be prepared by, for example, admixture at ambient temperature and atmospheric pressure.
[0195] In one embodiment, the compounds of formula (I) or pharmaceutically acceptable salts thereof will be formulated for oral administration. In another embodiment, the compounds of formula (I) or pharmaceutically acceptable salts thereof will be formulated for inhaled administration. In a further embodiment, the compounds of formula (I) or pharmaceutically acceptable salts thereof will be formulated for intranasal administration.
[0196] In one aspect, the invention is directed to a solid oral dosage form such as a tablet or capsule comprising a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a diluent or filler. Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. com starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate. The oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g. com starch, potato starch, and pre-gelatinized starch), gelatin, acacia, sodium alginate, alginic acid, tragacanth, guar gum, povidone, and cellulose and its derivatives (e.g. microcrystalline cellulose). The oral solid dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose. The oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesuim stearate, calcium stearate, and talc.
[0197] Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The composition can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.
[0198] The compounds of formula (I) or pharmaceutically acceptable salts thereof may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide -phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of formula (I) or pharmaceutically acceptable salts thereof may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
[0199] In another aspect, the invention is directed to a liquid oral dosage form. Oral liquids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Syrups can be prepared by dissolving the compound of formula (I) or a pharmaceutically acceptable salt thereof in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound of formula (I) or a pharmaceutically acceptable salt thereof in a non toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
[0200] In another aspect, the invention is directed to a dosage form adapted for administration to a patient by inhalation, for example as a dry powder, an aerosol, a suspension, or a solution composition. In one embodiment, the invention is directed to a dosage form adapted for administration to a patient by inhalation as a dry powder. In a further embodiment, the invention is directed to a dosage form adapted for administration to a patient by inhalation via a nebulizer. Dry powder compositions for delivery to the lung by inhalation typically comprise a compound of formula (I) or a pharmaceutically acceptable salt thereof as a finely divided powder together with one or more pharmaceutically-acceptable excipients as finely divided powders. Pharmaceutically-acceptable excipients particularly suited for use in dry powders are known to those skilled in the art and include lactose, starch, mannitol, and mono-, di-, and polysaccharides. The finely divided powder may be prepared by, for example, micronisation and milling. Generally, the size-reduced (eg micronised) compound can be defined by a D50 value of about 1 to about 10 microns (for example as measured using laser diffraction).
[0201] The dry powder may be administered to the patient via a reservoir dry powder inhaler (RDPI) having a reservoir suitable for storing multiple (un-metered doses) of medicament in dry powder form. RDPIs typically include a means for metering each medicament dose from the reservoir to a delivery position. For example, the metering means may comprise a metering cup, which is movable from a first position where the cup may be filled with medicament from the reservoir to a second position where the metered medicament dose is made available to the patient for inhalation.
[0202] Alternatively, the dry powder may be presented in capsules (e.g. gelatin or plastic), cartridges, or blister packs for use in a multi-dose dry powder inhaler (MDPI). MDPIs are inhalers wherein the medicament is comprised within a multi-dose pack containing (or otherwise carrying) multiple defined doses (or parts thereof) of medicament. When the dry powder is presented as a blister pack, it comprises multiple blisters for containment of the medicament in dry powder form. The blisters are typically arranged in regular fashion for ease of release of the medicament therefrom. For example, the blisters may be arranged in a generally circular fashion on a disc-form blister pack, or the blisters may be elongate in form, for example comprising a strip or a tape. Each capsule, cartridge, or blister may, for example, contain between 20 pg-lO mg of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0203] Aerosols may be formed by suspending or dissolving a compound of formula (I) or a pharmaceutically acceptable salt thereof in a liquified propellant. Suitable propellants include halocarbons, hydrocarbons, and other liquified gases. Representative propellants include: trichlorofluoromethane (propellant 11), dichlorofluoromethane (propellant 12), dichlorotetrafluoroethane (propellant 114), tetrafluoroethane (HFA-l34a), l,l-difluoroethane (HFA-l52a), difluoromethane (HFA-32), pentafluoroethane (HFA-12), heptafluoropropane (HFA-227a), perfluoropropane, perfluorobutane, perfluoropentane, butane, isobutane, and pentane. Aerosols comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof will typically be administered to a patient via a metered dose inhaler (MDI). Such devices are known to those skilled in the art.
[0204] The aerosol may contain additional pharmaceutically-acceptable excipients typically used with MDIs such as surfactants, lubricants, cosolvents and other excipients to improve the physical stability of the formulation, to improve valve performance, to improve solubility, or to improve taste.
[0205] There is thus provided as a further aspect of the invention a pharmaceutical aerosol formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon as propellant, optionally in combination with a surfactant and/or a cosolvent.
[0206] According to another aspect of the invention, there is provided a pharmaceutical aerosol formulation wherein the propellant is selected from l,l,l,2-tetrafluoroethane, l,l,l,2,3,3,3-heptafluoro-n-propane and mixtures thereof.
[0207] The formulations disclosed herein may be buffered by the addition of suitable buffering agents.
[0208] Capsules and cartridges for use in an inhaler or insufflator, of for example gelatine, may be formulated containing a powder mix for inhalation of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a suitable powder base such as lactose or starch. Each capsule or cartridge may generally contain from 20 pg to 10 mg of the compound of formula (I) or pharmaceutically acceptable salt thereof. Alternatively, the compound of formula (I) or pharmaceutically acceptable salt thereof may be presented without excipients such as lactose.
[0209] The proportion of the active compound of formula (I) or pharmaceutically acceptable salt thereof in the local compositions according to the invention depends on the precise type of formulation to be prepared but will generally be within the range of from 0.001 to 10% by weight. Generally, for most types of preparations, the proportion used will be within the range of from 0.005 to 1 %, for example from 0.01 to 0.5%. However, in powders for inhalation or insufflation the proportion used will normally be within the range of from 0.1% to 5%.
[0210] Aerosol formulations are preferably arranged so that each metered dose or "puff1 of aerosol contains from 20pg to lOmg, preferably from 20 pg to 2000 pg, more preferably from about 20 pg to 500 pg of a compound of formula (I). Administration may be once daily or several times daily, for example 2, 3, 4 or 8 times, giving for example 1, 2 or 3 doses each time. The overall daily dose with an aerosol will be within the range from 100 pg to 10 mg, preferably from 200 pg to 2000 pg. The overall daily dose and the metered dose delivered by capsules and cartridges in an inhaler or insufflator will generally be double that delivered with aerosol formulations.
[0211] In the case of suspension aerosol formulations, the particle size of the particulate (e.g., micronised) drug should be such as to permit inhalation of substantially all the drug into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than 20 microns, and in particular in the range of from 1 to 10 microns, such as from 1 to 5 microns, more preferably from 2 to 3 microns.
[0212] The formulations disclosed herein may be prepared by dispersal or dissolution of the medicament and a compound of formula (I) or a pharmaceutically acceptable salt thereof in the selected propellant in an appropriate container, for example, with the aid of sonication or a high- shear mixer. The process is desirably carried out under controlled humidity conditions.
[0213] The chemical and physical stability and the pharmaceutical acceptability of the aerosol formulations according to the invention may be determined by techniques well known to those skilled in the art. Thus, for example, the chemical stability of the components may be determined by HPLC assay, for example, after prolonged storage of the product. Physical stability data may be gained from other conventional analytical techniques such as, for example, by leak testing, by valve delivery assay (average shot weights per actuation), by dose reproducibility assay (active ingredient per actuation) and spray distribution analysis.
[0214] The stability of the suspension aerosol formulations according to the invention may be measured by conventional techniques, for example, by measuring flocculation size distribution using a back light scattering instrument or by measuring particle size distribution by cascade impaction or by the "twin impinger" analytical process. As used herein reference to the "twin impinger" assay means "Determination of the deposition of the emitted dose in pressurised inhalations using apparatus A" as defined in British Pharmacopaeia 1988, pages A204-207, Appendix XVII C. Such techniques enable the "respirable fraction" of the aerosol formulations to be calculated. One method used to calculate the "respirable fraction" is by reference to "fine particle fraction" which is the amount of active ingredient collected in the lower impingement chamber per actuation expressed as a percentage of the total amount of active ingredient delivered per actuation using the twin impinger method described above.
[0215] The term "metered dose inhaler" or MDI means a unit comprising a can, a secured cap covering the can and a formulation metering valve situated in the cap. MDI system includes a suitable channelling device. Suitable channelling devices comprise for example, a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient such as a mouthpiece actuator.
[0216] MDI canisters generally comprise a container capable of withstanding the vapour pressure of the propellant used such as a plastic or plastic-coated glass bottle or preferably a metal can, for example, aluminium or an alloy thereof which may optionally be anodised, lacquer-coated and/or plastic-coated (for example incorporated herein by reference WO96/32099 wherein part or all of the internal surfaces are coated with one or more fluorocarbon polymers optionally in combination with one or more non-fluorocarbon polymers), which container is closed with a metering valve. The cap may be secured onto the can via ultrasonic welding, screw fitting or crimping. MDIs taught herein may be prepared by methods of the art (e.g. see Byron, above and WO96/32099). Preferably the canister is fitted with a cap assembly, wherein a drug metering valve is situated in the cap, and said cap is crimped in place.
[0217] In one embodiment of the invention the metallic internal surface of the can is coated with a fluoropolymer, more preferably blended with a non-fluoropolymer. In another embodiment of the invention the metallic internal surface of the can is coated with a polymer blend of polytetrafluoroethylene (PTFE) and polyethersulfone (PES). In a further embodiment of the invention the whole of the metallic internal surface of the can is coated with a polymer blend of polytetrafluoroethylene (PTFE) and polyethersulfone (PES). The metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve. The gasket may comprise any suitable elastomeric material such as, for example, low density polyethylene, chlorobutyl, bromobutyl, EPDM, black and white butadiene-acrylonitrile rubbers, butyl rubber and neoprene. Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (e.g. DF10, DF30, DF60), Bespak pic, UK (e.g. BK300, BK357) and 3M- TM Neotechnic Ltd, UK (e.g. Spraymiser).
[0218] In various embodiments, the MDIs may also be used in conjunction with other structures such as, without limitation, overwrap packages for storing and containing the MDIs, including those described in U.S. Patent Nos. 6,119,853; 6,179,118; 6,315,112; 6,352,152; 6,390,291; and 6,679,374, as well as dose counter units such as, but not limited to, those described in U.S. Patent Nos. 6,360,739 and 6,431,168.
[0219] Conventional bulk manufacturing methods and machinery well known to those skilled in the art of pharmaceutical aerosol manufacture may be employed for the preparation of large- scale batches for the commercial production of filled canisters. Thus, for example, in one bulk manufacturing method for preparing suspension aerosol formulations a metering valve is crimped onto an aluminium can to form an empty canister. The particulate medicament is added to a charge vessel and liquefied propellant together with the optional excipients is pressure filled through the charge vessel into a manufacturing vessel. The drug suspension is mixed before recirculation to a filling machine and an aliquot of the drug suspension is then filled through the metering valve into the canister. In one example bulk manufacturing method for preparing solution aerosol formulations a metering valve is crimped onto an aluminium can to form an empty canister. The liquefied propellant together with the optional excipients and the dissolved medicament is pressure filled through the charge vessel into a manufacturing vessel.
[0220] In an alternative process, an aliquot of the liquefied formulation is added to an open canister under conditions which are sufficiently cold to ensure the formulation does not vaporise, and then a metering valve crimped onto the canister.
[0221] Typically, in batches prepared for pharmaceutical use, each filled canister is check- weighed, coded with a batch number and packed into a tray for storage before release testing. Suspensions and solutions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof may also be administered to a patient via a nebulizer. The solvent or suspension agent utilized for nebulization may be any pharmaceutically-acceptable liquid such as water, aqueous saline, alcohols or glycols, e.g., ethanol, isopropylalcohol, glycerol, propylene glycol, polyethylene glycol, etc. or mixtures thereof. Saline solutions utilize salts which display little or no pharmacological activity after administration. Both organic salts, such as alkali metal or ammonium halogen salts, e.g., sodium chloride, potassium chloride or organic salts, such as potassium, sodium and ammonium salts or organic acids, e.g., ascorbic acid, citric acid, acetic acid, tartaric acid, etc. may be used for this purpose.
[0222] Other pharmaceutically-acceptable excipients may be added to the suspension or solution. The compound of formula (I) or pharmaceutically acceptable salt thereof may be stabilized by the addition of an inorganic acid, e.g., hydrochloric acid, nitric acid, sulphuric acid and/or phosphoric acid; an organic acid, e.g., ascorbic acid, citric acid, acetic acid, and tartaric acid, etc., a complexing agent such as EDTA or citric acid and salts thereof; or an antioxidant such as antioxidant such as vitamin E or ascorbic acid. These may be used alone or together to stabilize the compound of formula (I) or pharmaceutically acceptable salt thereof. Preservatives may be added such as benzalkonium chloride or benzoic acid and salts thereof. Surfactant may be added particularly to improve the physical stability of suspensions. These include lecithin, disodium di octyl sulphosuccinate, oleic acid and sorbitan esters.
[0223] In a further aspect, the invention is directed to a dosage form adapted for intranasal administration.
[0224] Formulations for administration to the nose may include pressurised aerosol formulations and aqueous formulations administered to the nose by pressurised pump. Formulations which are non-pressurised and adapted to be administered topically to the nasal cavity are of particular interest. Suitable formulations contain water as the diluent or carrier for this purpose. Aqueous formulations for administration to the lung or nose may be provided with conventional excipients such as buffering agents, tonicity modifying agents and the like. Aqueous formulations may also be administered to the nose by nebulisation. The compounds of formula (I) or pharmaceutically acceptable salts thereof may be formulated as a fluid formulation for delivery from a fluid dispenser, for example a fluid dispenser having a dispensing nozzle or dispensing orifice through which a metered dose of the fluid formulation is dispensed upon the application of a user-applied force to a pump mechanism of the fluid dispenser. Such fluid dispensers are generally provided with a reservoir of multiple metered doses of the fluid formulation, the doses being dispensable upon sequential pump actuations. The dispensing nozzle or orifice may be configured for insertion into the nostrils of the user for spray dispensing of the fluid formulation into the nasal cavity. A fluid dispenser of the aforementioned type is described and illustrated in WO05/044354, the entire content of which is hereby incorporated herein by reference. The dispenser has a housing which houses a fluid discharge device having a compression pump mounted on a container for containing a fluid formulation. The housing has at least one finger-operable side lever which is movable inwardly with respect to the housing to cam the container upwardly in the housing to cause the pump to compress and pump a metered dose of the formulation out of a pump stem through a nasal nozzle of the housing. In one embodiment, the fluid dispenser is of the general type illustrated in Figures 30-40 of WO05/044354.
[0225] Pharmaceutical compositions adapted for intranasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable compositions wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0226] Pharmaceutical compositions adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the patient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3(6), 318 (1986).
[0227] Pharmaceutical compositions adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. Ointments, creams and gels, may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agent and/or solvents. Such bases may thus, for example, include water and/or an oil such as liquid paraffin or a vegetable oil such as arachis oil or castor oil, or a solvent such as polyethylene glycol. Thickening agents and gelling agents which may be used according to the nature of the base include soft paraffin, aluminium stearate, cetostearyl alcohol, polyethylene glycols, woolfat, beeswax, carboxypolymethylene and cellulose derivatives, and/or glyceryl monostearate and/or non-ionic emulsifying agents.
[0228] Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents or thickening agents.
[0229] Powders for external application may be formed with the aid of any suitable powder base, for example, talc, lactose or starch. Drops may be formulated with an aqueous or nonaqueous base also comprising one or more dispersing agents, solubilising agents, suspending agents or preservatives.
[0230] Topical preparations may be administered by one or more applications per day to the affected area; over skin areas occlusive dressings may advantageously be used. Continuous or prolonged delivery may be achieved by an adhesive reservoir system.
[0231] For treatments of the eye or other external tissues, for example mouth and skin, the compositions may be applied as a topical ointment or cream. When formulated in an ointment, the compound of formula (I) or a pharmaceutically acceptable salt thereof may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the compound of formula (I) or pharmaceutically acceptable salt thereof may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.
[0232] Pharmaceutical compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti -oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
[0233] The compound and pharmaceutical formulations according to the invention may be used in combination with or include one or more other therapeutic agents, for example selected from anti-inflammatory agents, anticholinergic agents (particularly an MI/M2/M3 receptor antagonist), p2-adrenoreceptor agonists, antiinfective agents, such as antibiotics or antivirals, or antihistamines. The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with one or more other therapeutically active agents, for example selected from an anti-inflammatory agent, such as a corticosteroid or an NSAID, an anticholinergic agent, a p2-adrenoreceptor agonist, an antiinfective agent, such as an antibiotic or an antiviral, or an antihistamine. One embodiment of the invention encompasses combinations comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a p2-adrenoreceptor agonist, and/or an anticholinergic, and/or a PDE-4 inhibitor, and/or an antihistamine.
[0234] In one embodiment, the invention encompasses a method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a safe and effective amount of a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with one or more therapeutically active agents.
[0235] Certain compounds disclosed herein may show selectivity for PI3K5 over other PI3- kinases. The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof which is selective for PI3K5 together with a compound or pharmaceutically acceptable salt thereof which is selective for another PI3- kinase, for example RI3Kg. [0236] One embodiment of the invention encompasses combinations comprising one or two other therapeutic agents.
[0237] It will be clear to a person skilled in the art that, where appropriate, the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl esters, or as solvates, for example hydrates to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient. It will be clear also that, where appropriate, the therapeutic ingredients may be used in optically pure form.
[0238] In one embodiment, the invention provides a product comprising a compound of formula (I) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or condition mediated by the activity of the PI3K enzymes. Products provided as a combined preparation include a composition comprising the compound of formula (I) and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of formula (I) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
[0239] In one embodiment, the invention provides a pharmaceutical composition comprising a compound of formula (I) and another therapeutic agent(s). Optionally, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier, as described above.
[0240] In one embodiment, the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I). In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
[0241] The kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit of the invention typically comprises directions for administration.
[0242] In the combination therapies of the invention, the compound disclosed herein and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound disclosed herein and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound disclosed herein and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential administration of the compound disclosed herein and the other therapeutic agent.
[0243] Accordingly, the invention provides the use of a compound of formula (I) for treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the medicament is prepared for administration with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the medicament is administered with a compound of formula (I).
[0244] The invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the compound of formula (I) is prepared for administration with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the other therapeutic agent is prepared for administration with a compound of formula (I). The invention also provides a compound of formula (I) for use in a method of treating a disease or condition mediated by the activity of the PI3K enzymes wherein the compound of formula (I) is administered with another therapeutic agent. The invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by the activity of the PI3K enzymes wherein the other therapeutic agent is administered with a compound of formula (I).
[0245] The invention also provides the use of a compound of formula (I) for treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the patient has previously (e.g. within 24 hours) been treated with another therapeutic agent. The invention also provides the use of another therapeutic agent for treating a disease or condition mediated by the activity of the PI3K enzymes, wherein the patient has previously (e.g. within 24 hours) been treated with a compound of formula (I). The compounds of formula I may be administered as the sole active ingredient or in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of alio- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders, or a chemotherapeutic agent, e.g a malignant cell anti-proliferative agent. For example, the compounds of formula I may be used in combination with a calcineurin inhibitor, e.g. cyclosporin A or FK 506; a mTOR inhibitor, e.g. rapamycin, 40-O-(2-hydroxyethyl)rapamycin, CCI779, ABT578, AP23573, TAFA-93, biolimus-7 or biolimus- 9; an ascomycin having immuno-suppressive properties, e.g. ABT-281, ASM981 , etc.; corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic acid or salt; mycophenolate mofetil; l5-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof; a PKC inhibitor, e.g. as disclosed in WO 02/38561 or WO 03/82859, e.g. the compound of Example 56 or 70; a JAK3 kinase inhibitor, e.g. N- benzyl-3, 4- dihydroxy-benzylidene-cyanoacetamide-a-cyano-(3,4-dihydroxy)-/V-benzylcinnamamide (Tyrphostin AG 490), prodigiosin 25-C (PNEil 56804), [4-(4'-hydroxyphenyl)-amino-6,7- dimethoxyquinazoline] (WHI-P131), [4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7- dimethoxyquinazoline] (WHI-P154), [4-(3',5'-dibromo-4'-hydroxylphenyl)-amino-6,7- dimethoxyquinazoline] WHI-P97, KRX-21 l,3-{(3i?,4i?)-4-methyl-3-[methyl-(7/7-pyrrolo[2,3- d]pyrimidin-4-yl)-amino]-piperidin-l-yl}-3-oxo-propionitrile, in free form or in a pharmaceutically acceptable salt form, e.g. mono- citrate (also called CP-690,550), or a compound as disclosed in WO 04/052359 or WO 05/066156; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, CD52, CD58, CD80, CD86 or their ligands; other immunomodulatory compounds, e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4lg (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y; adhesion molecule inhibitors, e.g. LFA-l antagonists, ICAM-l or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists; or antihistamines; or antitussives, or a bronchodilatory agent; or an angiotensin receptor blockers; or an anti-infectious agent.
[0246] Where the compounds of formula I are administered in conjunction with other immunosuppressive/immunomodulatory, anti-inflammatory, chemotherapeutic or anti- infectious therapy, dosages of the co-administered immunosuppressant, immunomodulatory, anti inflammatory, chemotherapeutic or anti-infectious compound will of course vary depending on the type of co-drug employed, e.g. whether it is a steroid or a calcineurin inhibitor, on the specific drug employed, on the condition being treated and so forth.
[0247] In one embodiment, the invention encompasses a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a p2-adrenoreceptor agonist.
[0248] Examples of p2-adrenoreceptor agonists include salmeterol (which may be a racemate or a single enantiomer such as the //-enantiomer), salbutamol (which may be a racemate or a single enantiomer such as the //-enantiomer), formoterol (which may be a racemate or a single duastereomer such as the /. /-diastereomer), salmefamol, fenoterol, carmoterol, etanterol, naminterol, clenbuterol, pirbuterol, flerbuterol, reproterol, bambuterol, indacaterol, terbutaline and salts thereof, for example the xinafoate (l-hydroxy-2-naphthalenecarboxylate) salt of salmeterol, the sulphate salt or free base of salbutamol or the fumarate salt of formoterol. In one embodiment, long-acting p2-adrenoreceptor agonists, for example, compounds which provide effective bronchodilation for about 12 hrs or longer, are preferred.
[0249] The p2-adrenoreceptor agonist may be in the form of a salt formed with a pharmaceutically acceptable acid selected from sulphuric, hydrochloric, fumaric, hydroxynaphthoic (for example 1- or 3 -hydroxy -2-naphthoic), cinnamic, substituted cinnamic, triphenylacetic, sulphamic, sulphanilic, naphthaleneacrylic, benzoic, 4-methoxybenzoic, 2- or 4- hydroxybenzoic, 4-chlorobenzoic and 4-phenylbenzoic acid.
[0250] Suitable anti-inflammatory agents include corticosteroids. Suitable corticosteroids which may be used in combination with the compounds of formula (I) or pharmaceutically acceptable salts thereof are those oral and inhaled corticosteroids and their pro-drugs which have anti-inflammatory activity. Examples include methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6a,9a-difluoro- 11 b-hydroxy- 16a-m ethyl- 17a-[(4-methyl- 1 ,3 -thiazole-5- carbonyl)oxy]-3-oxo-androsta-l,4-diene-l7P-carbothioic acid S-fluoromethyl ester, 6a, 9a- difluoro- 17a-[(2-furanylcarbonyl)oxy]- l 1 b-hydroxy- 16a-methyl-3-oxo-androsta- 1 ,4-diene- 17b- carbothioic acid S-fluoromethyl ester (fluticasone furoate), 6a,9a-difluoro- 1 1 b-hydroxy- 16a- methyl-3-oxo-17a-propionyloxy-androsta-l,4-diene-17b-carbothioic acid S-(2-oxo-tetrahydro- furan-3 S-yl) ester, 6a,9a-difluoro- 11 b-hydroxy- 16a-methyl-3 -oxo- 17a-(2,2,3 ,3 - tetramethycyclopropylcarbonyl)oxy-androsta-l,4-diene-17b-carbothioic acid S-cyanomethyl ester and 6a,9a-difluoro-l ^-hydroxy-l6a-methyl-l7a-(l-ethycyclopropylcarbonyl)oxy-3-oxo- androsta-l,4-diene-17b-carbothioic acid S-fluoromethyl ester, beclomethasone esters (for example the 17-propionate ester or the 17,21 -dipropionate ester), budesonide, flunisolide, mometasone esters (for example mometasone furoate), triamcinolone acetonide, rofleponide, ciclesonide ( 16a, 17-[[(A>)-cyclohexyl methyl ene]bis(oxy)]- l ] b 21 -dihydroxy-pregna- 1 ,4-diene- 3,20-dione), butixocort propionate, RPR-106541, and ST-126. Preferred corticosteroids include fluticasone propionate, 6a,9a-difluoro- 11 b-hydroxy- 16a-m ethyl- 17a-[(4-methyl- 1 ,3 -thiazole-5- carbonyl)oxy]-3-oxo-androsta-l,4-diene-17b-carbothioic acid S-fluoromethyl ester, 6a,9a- difluoro-17a-[(2-furanylcarbonyl)oxy]-llb-hydroxy-16a-methyl-3-oxo-androsta-l,4-diene-17b- carbothioic acid S-fluoromethyl ester, 6a,9a-difluoro- l 1 b-hydroxy- l 6a-methyl-3-oxo- 17 a- (2,2,3,3-tetramethycyclopropylcarbonyl)oxy-androsta-l,4-diene-17b-carbothioic acid S- cyanomethyl ester and 6a,9a-difluoro- l 1 b-hydroxy- l 6a-methyl- l 7a-( l - methycyclopropylcarbonyl)oxy-3 -oxo-androsta- 1 ,4-diene- 17b^L>oώΐoΐo acid S-fluoromethyl ester. In one embodiment the corticosteroid is 6a,9a-difluoro- l 7a-[(2-furanylcarbonyl)oxy]- l 1 b- hydroxy-16a-methyl-3-oxo-androsta-l,4-diene-17b-carbothioic acid S-fluoromethyl ester. [0251] Non-steroidal compounds having glucocorticoid agonism that may possess selectivity for transrepression over transactivation and that may be useful in combination therapy include those covered in the following patents: WO03/082827, W098/54159, W004/005229, W004/009017, W004/018429, W003/104195, WO03/082787, W003/082280, WO03/059899, W003/101932, W002/02565, WO01/16128, WO00/66590, WO03/086294, WO04/026248, W003/061651 and W003/08277. Further non-steroidal compounds are covered in: W02006/000401, W02006/000398 and W02006/015870.
[0252] Examples of anti-inflammatory agents include non-steroidal anti-inflammatory drugs (NS AID's).
[0253] Examples of NSAID's include sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors (for example, theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors), leukotriene antagonists, inhibitors of leukotriene synthesis (for example montelukast), iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine receptor agonists or antagonists (e.g. adenosine 2a agonists), cytokine antagonists (for example chemokine antagonists, such as a CCR3 antagonist) or inhibitors of cytokine synthesis, or 5 -lipoxygenase inhibitors. An iNOS (inducible nitric oxide synthase inhibitor) is preferably for oral administration. Examples of iNOS inhibitors include those disclosed in WO93/13055, WO98/30537, W002/50021, W095/34534 and W099/62875. Examples of CCR3 inhibitors include those disclosed in WO02/26722.
[0254] In one embodiment, the invention provides the use of the compounds of formula (I) in combination with a phosphodiesterase 4 (PDE4) inhibitor, especially in the case of a formulation adapted for inhalation. The PDE4-specific inhibitor useful in this aspect of the invention may be any compound that is known to inhibit the PDE4 enzyme or which is discovered to act as a PDE4 inhibitor, and which are only PDE4 inhibitors, not compounds which inhibit other members of the PDE family, such as PDE3 and PDE5, as well as PDE4. Compounds include cis- 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-l-carboxylic acid, 2-carbomethoxy- 4-cyano-4-(3-cyclopropylmethoxy-4- difluoromethoxyphenyl)cyclohexan-l-one and c/.s-[4- cyano-4-(3-cyclopropylmethoxy-4- difluoromethoxyphenyl)cyclohexan-l-ol]. Also, cis- 4-cyano- 4-[3-(cyclopentyloxy)-4- methoxyphenyl]cyclohexane-l-carboxylic acid (also known as cilomilast) and its salts, esters, pro-drugs or physical forms, which is described in U.S. patent 5,552,438 issued 03 September, 1996; this patent and the compounds it discloses are incorporated herein in full by reference.
[0255] Examples of anticholinergic agents are those compounds that act as antagonists at the muscarinic receptors, in particular those compounds which are antagonists of the Mi or M3 receptors, dual antagonists of the M1/M3 or M2/M3, receptors or pan-antagonists of the MI/M2/M3 receptors. Exemplary compounds for administration via inhalation include ipratropium (for example, as the bromide, CAS 22254-24-6, sold under the name Atrovent), oxitropium (for example, as the bromide, CAS 30286-75-0) and tiotropium (for example, as the bromide, CAS 136310-93-5, sold under the name Spiriva). Also of interest are revatropate (for example, as the hydrobromide, CAS 262586-79-8) and LAS- 34273 which is disclosed in W001/04118. Exemplary compounds for oral administration include pirenzepine (CAS 28797- 61-7), darifenacin (CAS 133099-04-4, or CAS 133099- 07-7 for the hydrobromide sold under the name Enablex), oxybutynin (CAS 5633-20-5, sold under the name Ditropan), terodiline (CAS 15793-40-5), tolterodine (CAS 124937-51- 5, or CAS 124937-52-6 for the tartrate, sold under the name Detrol), otilonium (for example, as the bromide, CAS 26095-59-0, sold under the name Spasmomen), trospium chloride (CAS 10405-02-4) and solifenacin (CAS 242478-37- 1 , or CAS 242478-38-2 for the succinate also known as YM-905 and sold under the name Vesicare).
[0256] In one embodiment the invention provides a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an Hl antagonist. Some non-limiting examples of the Hl antagonist include amelexanox, astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, levocetirizine, efletirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, mizolastine, mequitazine, mianserin, noberastine, meclizine, norastemizole, olopatadine, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine and triprolidine, particularly cetirizine, levocetirizine, efletirizine and fexofenadine. In a further embodiment the invention provides a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an H3 antagonist (and/or inverse agonist). Examples of H3 antagonists include, for example, those compounds disclosed in W02004/035556 and in W02006/045416. Other histamine receptor antagonists which may be used in combination with the compounds disclosed herein include antagonists (and/or inverse agonists) of the H4 receptor, for example, the compounds disclosed in Jablonowski et ah, J Med. Chem., 2003, 46, 3957-3960.
[0257] The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a PDE4 inhibitor.
[0258] The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a b2- adrenoreceptor agonist.
[0259] The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a corticosteroid.
[0260] The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a non steroidal GR agonist.
[0261] The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an anticholinergic.
[0262] The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an antihistamine.
[0263] The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a PDE4 inhibitor and a p2-adrenoreceptor agonist.
[0264] The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an anticholinergic and a PDE-4 inhibitor.
[0265] The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical composition and thus pharmaceutical compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention.
[0266] The individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations. In one embodiment, the individual compounds will be administered simultaneously in a combined pharmaceutical formulation. Appropriate doses of known therapeutic agents will readily be appreciated by those skilled in the art.
[0267] The invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with another therapeutically active agent. [0268] The invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a PDE4 inhibitor.
[0269] The invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a p2-adrenoreceptor agonist.
[0270] The invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a corticosteroid.
[0271] The invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a non-steroidal GR agonist.
[0272] The invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an anticholinergic.
[0273] The invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an antihistamine.
[0274] The invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with a PDE4 inhibitor and a p2-adrenoreceptor agonist.
[0275] The invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof together with an anticholinergic and a PDE4 inhibitor.
[0276] A compound of the formula (I) may also be used to advantage in combination with each other or in combination with other therapeutic agents, especially other antiproliferative agents. Such antiproliferative agents include, but are not limited to, aromatase inhibitors; antiestrogens; topoisomerase I inhibitors; topoisomerase II inhibitors; microtubule active agents; alkylating agents; histone deacetylase inhibitors; compounds, which induce cell differentiation processes; cyclooxygenase inhibitors; MMP inhibitors; mTOR inhibitors; antineoplastic antimetabolites; platin compounds; compounds targeting/decreasing a protein or lipid kinase activity and further anti-angiogenic compounds; compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase; gonadorelin agonists; anti-androgens; methionine aminopeptidase inhibitors; bisphosphonates; biological response modifiers; antiproliferative antibodies; heparanase inhibitors; inhibitors of Ras oncogenic isoforms; telomerase inhibitors; proteasome inhibitors; agents used in the treatment of hematologic malignancies; compounds which target, decrease or inhibit the activity of Flt-3; Hsp90 inhibitors; temozolomide (TEMODAL®); and leucovorin.
[0277] The term "aromatase inhibitor", as used herein, relates to a compound which inhibits the estrogen production, i.e., the conversion of the substrates androstenedione and testosterone to estrone and estradiol, respectively. The term includes, but is not limited to, steroids, especially atamestane, exemestane and formestane; and, in particular, nonsteroids, especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone, ketoconazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane can be administered, e.g., in the form as it is marketed, e.g., under the trademark AROMASIN. Formestane can be administered, e.g., in the form as it is marketed, e.g., under the trademark LENTARON. Fadrozole can be administered, e.g., in the form as it is marketed, e.g., under the trademark AFEMA. Anastrozole can be administered, e.g., in the form as it is marketed, e.g., under the trademark ARIMTDEX. Letrozole can be administered, e.g., in the form as it is marketed, e.g., under the trademark FEMARA or FEMAR. Aminoglutethimide can be administered, e.g., in the form as it is marketed, e.g., under the trademark ORIMETEN. A combination of the invention comprising a chemotherapeutic agent which is an aromatase inhibitor is particularly useful for the treatment of hormone receptor positive tumors, e.g., breast tumors.
[0278] The term "anti-estrogen", as used herein, relates to a compound which antagonizes the effect of estrogens at the estrogen receptor level. The term includes, but is not limited to, tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen can be administered, e.g., in the form as it is marketed, e.g., under the trademark NOLVADEX. Raloxifene hydrochloride can be administered, e.g., in the form as it is marketed, e.g., under the trademark EVISTA. Fulvestrant can be formulated as disclosed in ET.S. Patent No. 4,659,516 or it can be administered, e.g., in the form as it is marketed, e.g., under the trademark FASLODEX. A combination of the invention comprising a chemotherapeutic agent which is an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors, e.g., breast tumors.
[0279] The term "anti -androgen", as used herein, relates to any substance which is capable of inhibiting the biological effects of androgenic hormones and includes, but is not limited to, bicalutamide (CASODEX), which can be formulated, e.g., as disclosed in ET.S. Patent No. 4,636,505.
[0280] The term "gonadorelin agonist", as used herein, includes, but is not limited to, abarelix, goserelin and goserelin acetate. Goserelin is disclosed in U.S. Patent No. 4, 100,274 and can be administered, e.g., in the form as it is marketed, e.g., under the trademark ZOLADEX. Abarelix can be formulated, e.g., as disclosed in U.S. Patent No. 5,843,901 . The term "topoisom erase I inhibitor", as used herein, includes, but is not limited to, topotecan, gimatecan, irinotecan, camptothecian and its analogues, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-166148 (compound Al in WO 99/17804). Irinotecan can be administered, e.g., in the form as it is marketed, e.g., under the trademark CAMPTOSAR. Topotecan can be administered, e.g., in the form as it is marketed, e.g., under the trademark HYCAMTIN.
[0281] The term "topoisom erase II inhibitor", as used herein, includes, but is not limited to, the anthracyclines, such as doxorubicin, including liposomal formulation, e.g., CAELYX; daunorubicin; epirubicin; idarubicin; nemorubicin; the anthraquinones mitoxantrone and losoxantrone; and the podophillotoxines etoposide and teniposide. Etoposide can be administered, e.g., in the form as it is marketed, e.g., under the trademark ETOPOPHOS. Teniposide can be administered, e.g., in the form as it is marketed, e.g., under the trademark VM 26-BRISTOL. Doxorubicin can be administered, e.g., in the form as it is marketed, e.g., under the trademark ADRIBLASTIN or ADRIAMYCIN.
[0282] Epirubicin can be administered, e.g., in the form as it is marketed, e.g., under the trademark FARMORUBICIN. Idarubicin can be administered, e.g., in the form as it is marketed, e.g., under the trademark ZAVEDOS. Mitoxantrone can be administered, e.g., in the form as it is marketed, e.g., under the trademark NOVANTRON.
[0283] The term "microtubule active agent" relates to microtubule stabilizing, microtubule destabilizing agents and microtublin polymerization inhibitors including, but not limited to, taxanes, e.g., paclitaxel and docetaxel; vinca alkaloids, e.g., vinblastine, especially vinblastine sulfate; vincristine, especially vincristine sulfate and vinorelbine; discodermolides; cochicine; and epothilones and derivatives thereof, e.g., epothilone B or D or derivatives thereof. Paclitaxel may be administered, e.g., in the form as it is marketed, e.g., TAXOL. Docetaxel can be administered, e.g., in the form as it is marketed, e.g., under the trademark TAXOTERE. Vinblastine sulfate can be administered, e.g., in the form as it is marketed, e.g., under the trademark VINBLASTIN R.P Vincristine sulfate can be administered, e.g., in the form as it is marketed, e.g., under the trademark FARMISTIN. Discodermolide can be obtained, e.g., as disclosed in U.S. Patent No. 5,010,099. Also included are epothilone derivatives which are disclosed in WO 98/10121, U.S. Patent No. 6, 194,181, WO 98/25929, WO 98/08849, WO 99/43653, WO 98/22461 and WO 00/31247. Especially preferred are epothilone A and/or B.
[0284] The term "alkylating agent", as used herein, includes, but is not limited to, cyclophosphamide, ifosfamide, melphalan or nitrosourea (BCNU or Gliadel). Cyclophosphamide can be administered, e.g., in the form as it is marketed, e.g., under the trademark CYCLOSTIN. Ifosfamide can be administered, e.g., in the form as it is marketed, e.g., under the trademark HOLOXAN.
[0285] The term "histone deacetylase inhibitors" or "HDAC inhibitors" relates to compounds which inhibit the histone deacetylase and which possess antiproliferative activity. This includes compounds disclosed in WO 02/22577, especially /V-hydroxy-3-[4-[[(2- hydroxy ethyl) [2-( \H— indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide, /V-hydroxy-3-[4-[[[2-(2-methyl-li7- indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide and pharmaceutically acceptable salts thereof. It further especially includes suberoylanilide hydroxamic acid (SAHA).
[0286] The term "antineoplastic antimetabolite" includes, but is not limited to, 5-fluorouracil or 5-FU; capecitabine; gemcitabine; DNA demethylating agents, such as 5-azacytidine and decitabine; methotrexate and edatrexate; and folic acid antagonists, such as pemetrexed. Capecitabine can be administered, e.g., in the form as it is marketed, e.g., under the trademark XELODA. Gemcitabine can be administered, e.g., in the form as it is marketed, e.g., under the trademark GEMZAR. Also included is the monoclonal antibody trastuzumab which can be administered, e.g., in the form as it is marketed, e.g., under the trademark HERCEPTIN.
[0287] The term "platin compound", as used herein, includes, but is not limited to, carboplatin, c/.s-platin, cisplatinum and oxaliplatin. Carboplatin can be administered, e.g., in the form as it is marketed, e.g., under the trademark CARBOPLAT. Oxaliplatin can be administered, e.g., in the form as it is marketed, e.g., under the trademark ELOXATIN. The term "compounds targeting/decreasing a protein or lipid kinase activity; or a protein or lipid phosphatase activity; or further anti -angiogenic compounds", as used herein, includes, but is not limited to, protein tyrosine kinase and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g., a) compounds targeting, decreasing or inhibiting the activity of the platelet- derived growth factor-receptors (PDGFR), such as compounds which target, decrease or inhibit the activity of PDGFR, especially compounds which inhibit the PDGF receptor, e.g., a Y-phenyl -2-pyri m i di ne- amine derivative, e.g., imatinib, SU101 , SU6668 and GFB-lll;
b) compounds targeting, decreasing or inhibiting the activity of the fibroblast growth factor- receptors (FGFR);
c) compounds targeting, decreasing or inhibiting the activity of the insulin-like growth factor receptor I (IGF-IR), such as compounds which target, decrease or inhibit the activity of IGF-IR, especially compounds which inhibit the IGF-IR receptor, such as those compounds disclosed in WO 02/092599;
d) compounds targeting, decreasing or inhibiting the activity of the Trk receptor tyrosine kinase family;
e) compounds targeting, decreasing or inhibiting the activity of the Axl receptor tyrosine kinase family;
f) compounds targeting, decreasing or inhibiting the activity of the c-Met receptor;
g) compounds targeting, decreasing or inhibiting the activity of the Kit/SCFR receptor tyrosine kinase;
h) compounds targeting, decreasing or inhibiting the activity of the C-kit receptor tyrosine kinases - (part of the PDGFR family), such as compounds which target, decrease or inhibit the activity of the c-Kit receptor tyrosine kinase family, especially compounds which inhibit the c- Kit receptor, e.g., imatinib;
i) compounds targeting, decreasing or inhibiting the activity of members of the c-Abl family and their gene-fusion products, e.g., BCR-Abl kinase, such as compounds which target decrease or inhibit the activity of c-Abl family members and their gene fusion products, e.g., a N -phenyl- 2-pyrimidine-amine derivative, e.g., imatinib, PD180970, AG957, NSC 680410 or PD173955 from ParkeDavis;
j) compounds targeting, decreasing or inhibiting the activity of members of the protein kinase C (PKC) and Raf family of serine/threonine kinases, members of the MEK, SRC, JAK, FAR, PDK and Ras/MAPK family members, or Pl(3) kinase family, or of the Pl(3 ^kinase- related kinase family, and/or members of the cyclin- dependent kinase family (CDK) and are especially those staurosporine derivatives disclosed in U.S. Patent No. 5,093,330, e.g., midostaurin; examples of further compounds include, e.g., UCN-01 ; safmgol; BAY 43-9006; Bryostatin 1 ; Perifosine; llmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521 ; LY333531/LY379196; isochinoline compounds, such as those disclosed in WO 00/09495; FTIs; PD 184352; or QAN697 (a P13K inhibitor);
k) compounds targeting, decreasing or inhibiting the activity of protein-tyrosine kinase inhibitors, such as compounds which target, decrease or inhibit the activity of protein-tyrosine kinase inhibitors include imatinib mesylate (GLEEVEC) or tyrphostin. Atyrphostin is preferably a low molecular weight (Mr < 1500) compound, or a pharmaceutically acceptable salt thereof, especially a compound selected from the benzylidenemalonitrile class or the S- arylbenzenemalonirile or bisubstrate quinoline class of compounds, more especially any compound selected from the group consisting of Tyrphostin A23/RG-50810, AG 99, Tyrphostin AG 213, Tyrphostin AG 1748, Tyrphostin AG 490, Tyrphostin B44, Tyrphostin B44 (+) enantiomer, Tyrphostin AG 555, AG 494, Tyrphostin AG 556, AG957 and adaphostin (4-{ [(2,5- dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester, NSC 680410, adaphostin; and
I) compounds targeting, decreasing or inhibiting the activity of the epidermal growth factor family of receptor tyrosine kinases (EGFR, ErbB2, ErbB3, ErbB4 as homo- or hetero-dimers), such as compounds which target, decrease or inhibit the activity of the epidermal growth factor receptor family are especially compounds, proteins or antibodies which inhibit members of the EGF receptor tyrosine kinase family, e.g., EGF receptor, ErbB2, ErbB3 and ErbB4 or bind to EGF or EGF related ligands, and are in particular those compounds, proteins or monoclonal antibodies generically and specifically disclosed in WO 97/02266, e.g., the compound of Example 39, or in EP 0 564 409; WO 99/03854; EP 0520722; EP 0 566 226; EP 0 787 722; EP 0 837 063; U.S. Patent No. 5,747,498; WO 98/10767; WO 97/30034; WO 97/49688; WO 97/38983 and, especially, WO 96/30347, e.g., compound known as CP 358774; WO 96/33980, e.g., compound ZD 1839; and WO 95/03283, e.g., compound ZM105180, e.g., trastuzumab (HERCEPTIN), cetuximab, Iressa, Tarceva, OSI-774, CI-1033, EKB-569, GW-2016, El.l , E2.4, E2.5, E6.2, E6.4, E2.1 1 , E6.3 or E7.6.3; and 7H-pyrrolo-[2,3-d]pyrimidine derivatives which are disclosed in WO 03/013541 . Further anti-angiogenic compounds include compounds having another mechanism for their activity, e.g., unrelated to protein or lipid kinase inhibition, e.g., thalidomide (THALOMID) and TNP-470. Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are, e.g., inhibitors of phosphatase 1 , phosphatase 2A, PTEN or CDC25, e.g., okadaic acid or a derivative thereof.
[0288] Compounds which induce cell differentiation processes are e.g. retinoic acid, a- g- or d-tocopherol or a- g- or d-tocotrienol.
[0289] The term cyclooxygenase inhibitor, as used herein, includes, but is not limited to, e.g., Cox-2 inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid and derivatives, such as celecoxib (CELEBREX), rofecoxib (VIOXX), etoricoxib, valdecoxib or a 5-alkyl-2- arylaminophenylacetic acid, e.g., 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenyl acetic acid or lumiracoxib.
[0290] The term "bisphosphonates", as used herein, includes, but is not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid. "Etridonic acid" can be administered, e.g., in the form as it is marketed, e.g., under the trademark DIDRONEL. "Clodronic acid" can be administered, e.g., in the form as it is marketed, e.g., under the trademark BONEFOS. "Tiludronic acid" can be administered, e.g., in the form as it is marketed, e.g., under the trademark SKELID. "Pamidronic acid" can be administered, e.g., in the form as it is marketed, e.g., under the trademark AREDIA™. "Alendronic acid" can be administered, e.g., in the form as it is marketed, e.g., under the trademark FOSAMAX. "Ibandronic acid" can be administered, e.g., in the form as it is marketed, e.g., under the trademark BONDRANAT. "Risedronic acid" can be administered, e.g., in the form as it is marketed, e.g., under the trademark ACTONEL. "Zoledronic acid" can be administered, e.g., in the form as it is marketed, e.g., under the trademark ZOMETA.
[0291] The term "mTOR inhibitors" relates to compounds which inhibit the mammalian target of rapamycin (mTOR) and which possess antiproliferative activity, such as sirolimus (RAPAMUNE®), everolimus (CERTICAN™), CCI-779 and ABT578.
[0292] The term "heparanase inhibitor", as used herein, refers to compounds which target, decrease or inhibit heparin sulphate degradation. The term includes, but is not limited to, PI-88.
[0293] The term "biological response modifier", as used herein, refers to a lymphokine or interferons, e.g., interferon g.
[0294] The term "inhibitor of Ras oncogenic isoforms", e.g., H-Ras, K-Ras or N-Ras, as used herein, refers to compounds which target, decrease or inhibit the oncogenic activity of Ras, e.g., a "famesyl transferase inhibitor", e.g., L-744832, DK8G557 or Rl 15777 (Zarnestra).
[0295] The term "telomerase inhibitor", as used herein, refers to compounds which target, decrease or inhibit the activity of telomerase. Compounds which target, decrease or inhibit the activity of telomerase are especially compounds which inhibit the telomerase receptor, e.g., telomestatin.
[0296] The term "methionine aminopeptidase inhibitor", as used herein, refers to compounds which target, decrease or inhibit the activity of methionine aminopeptidase. Compounds which target, decrease or inhibit the activity of methionine aminopeptidase are, e.g., bengamide or a derivative thereof.
[0297] The term "proteasome inhibitor", as used herein, refers to compounds which target, decrease or inhibit the activity of the proteasome. Compounds which target, decrease or inhibit the activity of the proteasome include, e.g., PS-341 and MLN 341.
[0298] The term "matrix metalloproteinase inhibitor" or "MMP inhibitor", as used herein, includes, but is not limited to, collagen peptidomimetic and nonpeptidomimetic inhibitors, tetracycline derivatives, e.g., hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat (BB-2516), prinomastat (AG3340), metastat (NSC 683551 ) BMS-279251 , BAY 12-9566, TAA211 , MMI270B or AAJ996. [0299] The term "agents used in the treatment of hematologic malignancies", as used herein, includes, but is not limited to, FMS-like tyrosine kinase inhibitors, e.g., compounds targeting, decreasing or inhibiting the activity of FMS-like tyrosine kinase receptors (Flt-3R); interferon, 1- b-D-arabinofuransylcytosine (ara-c) and bisulfan; and ALK inhibitors, e.g., compounds which target, decrease or inhibit anaplastic lymphoma kinase.
[0300] Compounds which target, decrease or inhibit the activity of FMS-like tyrosine kinase receptors (Flt-3R) are especially compounds, proteins or antibodies which inhibit members of the Flt-3R receptor kinase family, e.g., PKC412, midostaurin, a staurosporine derivative, SU1 1248 and MLN518.
[0301] The term "HSP90 inhibitors", as used herein, includes, but is not limited to, compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90; degrading, targeting, decreasing or inhibiting the HSP90 client proteins via the ubiquitin proteasome pathway. Compounds targeting, decreasing or inhibiting the intrinsic ATPase activity of HSP90 are especially compounds, proteins or antibodies which inhibit the ATPase activity of HSP90, e.g., l7-allylamino, l7-demethoxygeldanamycin (17AAG), a geldanamycin derivative, other geldanamycin related compounds, radicicol and HD AC inhibitors.
[0302] The term "antiproliferative antibodies", as used herein, includes, but is not limited to, trastuzumab (Herceptin™), Trastuzumab-DMl , erlotinib (Tarceva™), bevacizumab (Avastin™), rituximab (Rituxan®), PR064553 (anti-CD40) and 2C4 antibody. By antibodies is meant, e.g., intact monoclonal antibodies, polyclonal antibodies, multispecific antibodies formed from at least two intact antibodies, and antibodies fragments so long as they exhibit the desired biological activity. For the treatment of acute myeloid leukemia (AML), compounds of formula (I) can be used in combination with standard leukemia therapies, especially in combination with therapies used for the treatment of AML. In particular, compounds of formula (I) can be administered in combination with, e.g., famesyl transferase inhibitors and/or other drugs useful for the treatment of AML, such as Daunorubicin, Adriamycin, Ara-C, VP- 16, Teniposide, Mitoxantrone, Idarubicin, Carboplatinum and PKC412.
[0303] A compound of the formula (I) may also be used to advantage in combination with each other or in combination with other therapeutic agents, especially other anti-malarial agents. Such anti-malarial agents include, but are not limited to proguanil, chlorproguanil, trimethoprim, chloroquine, mefloquine, lumefantrine, atovaquone, pyrimethamine-sulfadoxine, pyrimethamine-dapsone, halofantrine, quinine, quinidine, amodiaquine, amopyroquine, sulphonamides, artemisinin, arteflene, artemether, artesunate, primaquine, inhaled NO, L- arginine, Dipropylenetri-amine NONOate (NO donor), Rosiglitzone (PPARy agonist), activated charcoal, Erythropoietin, Levamisole, and pyronaridine.
[0304] A compound of the formula (I) may also be used to advantage in combination with each other or in combination with other therapeutic agents, such as used for the treatment of Leishmaniosis, Trypanosomiasis, Toxoplasmosis and Neurocysticercosis. Such agents include, but are not limited to chloroquine sulfate, atovaquone-proguanil, artemether- lumefantrine, quinine-sulfate, artesunate, quinine, doxycycline, clindamycin, meglumine antimoniate, sodium stibogluconate, miltefosine, ketoconazole, pentamidine, amphotericin B (AmB), liposomal-AmB, paromomycine, eflomithine, nifurtimox, suramin, melarsoprol, prednisolone, benznidazole, sulfadiazine, pyrimethamine, clindamycin, trimetropim, sulfamethoxazole, azitromycin, atovaquone, dexamethasone, praziquantel, albendazole, beta-lactams, fluoroquinolones, macrolides, aminoglycosides, sulfadiazine and pyrimethamine.
[0305] The structure of the active agents identified by code nos., generic or trade names may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g., Patents International, e.g., IMS World Publications.
[0306] The above-mentioned compounds, which can be used in combination with a compound of the formula (I), can be prepared and administered as described in the art, such as in the documents cited above.
[0307] A compound of the formula (I) may also be used to advantage in combination with known therapeutic processes, e.g., the administration of hormones or especially radiation.
[0308] A compound of formula (I) may in particular be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.
[0309] By "combination", there is meant either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula (I) and a combination partner may be administered independently at the same time or separately within time intervals that especially allow that the combination partners show a cooperative, e.g., synergistic, effect or any combination thereof. The terms "coadministration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected combination partner to a single subject in need thereof (e.g. a patient), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time. The term "pharmaceutical combination" as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" means that the active ingredients, e.g. a compound of formula I and a combination partner, are both administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients, e.g. a compound of formula (I) and a combination partner, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients.
USES OF THE COMPOUNDS AND COMPOSITIONS DISCLOSED HEREIN
[0310] The compounds disclosed herein are inhibitors of kinase activity, in particular PI3- kinase activity. Compounds which are PI3 -kinase inhibitors may be useful in the treatment of disorders wherein the underlying pathology is (at least in part) attributable to inappropriate PI3- kinase activity, such as asthma and chronic obstructive pulmonary disease (COPD). "Inappropriate PI3-kinase activity" refers to any PI3-kinase activity that deviates from the normal PI3 -kinase activity expected in a particular patient. Inappropriate PI3 -kinase may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and or control of PI3-kinase activity. Such inappropriate activity may result then, for example, from overexpression or mutation of the protein kinase leading to inappropriate or uncontrolled activation. Accordingly, in another aspect the invention is directed to methods of treating such disorders.
[0311] Such disorders include, but not limited to, respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-viral respiratory infections including aspergillosis and leishmaniasis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia and Central pain.
[0312] In one embodiment, such disorders include respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD); allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia and Central pain.
[0313] The methods of treatment of the invention comprise administering a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof. Individual embodiments of the invention include methods of treating any one of the above-mentioned disorders by administering a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
[0314] The compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered by any suitable route of administration, including both systemic administration and topical administration. Systemic administration includes oral administration, parenteral administration, transdermal administration and rectal administration. Parenteral administration refers to routes of administration other than enteral or transdermal, and is typically by injection or infusion. Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion. Topical administration includes application to the skin as well as intraocular, otic, intravaginal, inhaled and intranasal administration. Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages. In one embodiment, the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered orally. In another embodiment, the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered by inhalation. In a further embodiment, the compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered intranasally.
[0315] The compounds of formula (I) or pharmaceutically acceptable salts thereof may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. In one embodiment, a dose is administered once per day. In a further embodiment, a dose is administered twice per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of formula (I) or a pharmaceutically acceptable salt thereof depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan. In addition, suitable dosing regimens, including the duration such regimens are administered, for a compound of formula (I) or a pharmaceutically acceptable salt thereof depend on the disorder being treated, the severity of the disorder being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
[0316] The compound disclosed herein may be administered either simultaneously with, or before or after, one or more other therapeutic agent. The compound disclosed herein may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents.
[0317] The pharmaceutical composition or combination disclosed herein can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients. The therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease. The above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds disclosed herein can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution. A therapeutically effective amount in vivo may range depending on the route of administration, between about 0.01-500 mg/kg, or between about 1 -100 mg/kg.
[0318] Additionally, the compounds of formula (I) may be administered as prodrugs. As used herein, a "prodrug" of a compound of formula (I) is a functional derivative of the compound which, upon administration to a patient, eventually liberates the compound of formula (I) in vivo. Administration of a compound of formula (I) as a prodrug may enable the skilled artisan to do one or more of the following: (a) modify the onset of the activity of the compound in vivo; (b) modify the duration of action of the compound in vivo; (c) modify the transportation or distribution of the compound in vivo; (d) modify the solubility of the compound in vivo; and (e) overcome a side effect or other difficulty encountered with the compound. Typical functional derivatives used to prepare prodrugs include modifications of the compound that are chemically or enzymatically cleavable in vivo. Such modifications, which include the preparation of phosphates, amides, esters, thioesters, carbonates, and carbamates, are well known to those skilled in the art.
[0319] In one aspect, the invention provides a method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
[0320] In one embodiment, the conditions, diseases or disorders mediated by inappropriate PI3-kinase activity is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); viral infections including viral respiratory tract infections and viral exacerbation of respiratory diseases such as asthma and COPD; non-viral respiratory infections including aspergillosis and leishmaniasis; allergic diseases including allergic rhinitis and atopic dermatitis; autoimmune diseases including rheumatoid arthritis and multiple sclerosis; inflammatory disorders including inflammatory bowel disease; cardiovascular diseases including thrombosis and atherosclerosis; hematologic malignancies; neurodegenerative diseases; pancreatitis; multiorgan failure; kidney diseases; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injuries; and pain including pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia and Central pain.
[0321] Compounds disclosed herein may be useful in the treatment of conditions, diseases or disorders including disease or infection associated immunopathology in which one or more of the functions of B cells such as antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable including rheumatoid arthritis, pemphigus vulgaris and related diseases, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjogren's syndrome, autoimmune hemolytic anemia, ANCA- associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), goodpasture's syndrome, AMR (antibody-mediated transplant rejection), B cell-mediated hyperacute, acute and chronic transplant rejection and cancers of haematopoietic origin including but not limited to multiple myeloma; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non- Hodgkin lymphoma; lymphomas; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Walden stroem disease.
[0322] The invention includes methods of treating conditions, diseases or disorders in which one or more of the functions of neutrophils, such as superoxide release, stimulated exocytosis, or chemoatractic migration are abnormal or are undesirable including rheumatoid arthritis, sepsis, pulmonary or resporatory disorders such as asthma, inflammatory dermatoses such as psoriasis as well as in disease or infection associated immunopathology and others.
[0323] The invention includes methods of treating conditions, diseases or disorders in which one or more of the functions of basophil and mast cells such as chemoatractic migration or allergen-lgE-mediated degranulation are abnormal or are undesirable including allergic diseases (atopic dermatitis, contact dermatitis, allergic rhinitis) as well as other disorders such as COPD, asthma or emphysema.
[0324] The invention includes methods of treating conditions, diseases or disorders in which one or more of the functions of T cells such as cytokine production or cell-mediated cytotoxicity abnormal or are undesirable including rheumatoid arthritis, multiple sclerosis, acute or chronic rejection of cell tissue or organ grafts or cancers of haematopoietic origin as well as in disease or infection associated immunopathology.
[0325] Further, the invention includes methods of treating neurodegenerative diseases, cardiovascular diseases and platelet aggregation.
[0326] Further, the invention includes methods of treating skin diseases such as porphyria cutanea tarda, polymorphous light eruption, dermatomyositis, solar urticaria, oral lichen planus, panniculitis, scleroderma, urticarial vasculitis.
[0327] Further, the invention includes methods of treating chronic inflammatory diseases such as sarcoidosis, granuloma annulare.
[0328] In other embodiments, the condition or disorder (e.g. PI3K-mediated) is selected from the group consisting of: polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, asthma, COPD, ARDS, Loffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma, eosinophil-related disorders affecting the airways occasioned by drug-reaction, psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphigus, epidermolysis bullosa acquisita, autoimmune haematogical disorders (e.g. haemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven- Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease), endocrine opthalmopathy, Grave's disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis, cardiovascular diseases, atherosclerosis, hypertension, deep venous thrombosis, stroke, myocardial infarction, unstable angina, thromboembolism, pulmonary embolism, thrombolytic diseases, acute arterial ischemia, peripheral thrombotic occlusions, and coronary artery disease, reperfusion injuries, retinopathy, such as diabetic retinopathy or hyperbaric oxygen-induced retinopathy, and conditions characterized by elevated intraocular pressure or secretion of ocular aqueous humor, such as glaucoma.
[0329] In one embodiment, the disorder mediated by inappropriate PI3-kinase activity is pain.
[0330] In another embodiment, the compounds disclosed herein are useful in the treatment of conditions or disorders selected from the group consisting of, primary cutaneous B-cell lymphoma, immunobullous disease, pemphigus vulgaris, pemphigus foliaceus, endemic form of Brazilian pemphigus (Fogo selvagem), paraneoplastic pemphigus, bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, chronic graft versus host disease, dermatomyositis, systemic lupus erythematosus, vasculitis, small vessel vasculitis, hypocomplementemic urticarial vasculitis, antineutrophil cytoplasmic antibody-vasculitis, cryoglobulinemia, Schnitzler syndrome, Waldenstrom's macroglobulinemia, angioedema, vitiligo, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, multiple sclerosis, cold agglutinin disease, autoimmune hemolytic anemia, antineutrophil cytoplasmic antibody- associated vasculitis, graft versus host disease, cryoglobulinemia and thrombotic thromb ocytop eni c .
[0331] In another embodiment, the compounds disclosed herein are useful in the treatment, prevention, or amelioration of autoimmune disease and of inflammatory conditions, in particular inflammatory conditions with an aetiology including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases, including inflammatory conditions and rheumatic diseases involving bone loss, inflammatory pain, spondyloarhropathies including ankolsing spondylitis, Reiter syndrome, reactive arthritis, psoriatic arthritis, and enterophathics arthritis, hypersensitivity (including both airways hypersensitivity and dermal hypersensitivity) and allergies. Specific auto-immune diseases for which antibodies of the invention may be employed include autoimmune haematological disorders (including e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopa-thic thrombocytopenia), acquired hemophilia A, cold agglutinin disease, cryoglobulinemia, thrombotic thrombocytopenic purpura, Sjogren's syndrome, systemic lupus erythematosus, inflammatory muscle disorders, polychondritis, sclerodoma, anti-neutrophil cytoplasmic antibody-associated vasculitis, IgM mediated neuropathy, opsoclonus myoclonus syndrome, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven- Johnson syndrome, pemphigus vulgaris, pemphigus foliacius, idio pathic sprue, autoimmune inflammatory bowel disease (including e.g. ulcerative colitis, Crohn's disease and Irritable Bowel Syndrome), endocrine ophthalmopathy, Graves' disease, sarcoidosis, multiple sclerosis, neuromyelitis optica, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior, intermediate and posterior as well as panuveitis), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephro-tic syndrome or minimal change nephropathy), tumors, inflammatory disease of skin and cornea, myositis, loosening of bone implants, metabolic disorders, such as atherosclerosis, diabetes, and dislipidemia.
[0332] In one embodiment, the present invention provides the use of a compound of formula (I) in therapy. In a further embodiment, the therapy is selected from a disease which may be treated by inhibition of PI3K. In another embodiment, the disease is selected from the afore mentioned list, suitably from autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and COPD, transplant rejection; antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable including rheumatoid arthritis, pemphigus vulgaris, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjogren's syndrome, autoimmune hemolytic anemia, ANCA-associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), goodpasture's syndrome, AMR (antibody-mediated transplant rejection), B cell-mediated hyperacute, acute and chronic transplant rejection and cancers of haematopoietic origin including but not limited to multiple myeloma; a leukaemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; lymphomas; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Walden stroem disease; more suitably from rheumatoid arthritis (RA), pemphigus vulgaris (PV), idiopathic thrombocytopenia purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune hemolytic anemia (AIHA), acquired hemophilia type A (AHA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), myasthenia gravis (MG), Sjogren's syndrome (SS), ANCA-associated vasculitides, cryoglobulinemia, chronic autoimmune urticaria (CAU), allergy (atopic dermatitis, contact dermatitis, allergic rhinitis) , goodpasture's syndrome, transplant rejection and cancers of haematopoietic origin as well as in disease or infection associated immunopathology, for example in severe and cerebral malaria, trypanosomiasis, leishmaniasis, toxoplasmosis and neurocy sti cercosi s .
[0333] Thus, as a further embodiment, the present invention provides the use of a compound of formula (I) for the manufacture of a medicament. In a further embodiment, the medicament is for treatment of a disease which may be treated inhibition of PI3K. In another embodiment, the disease is selected from the afore-mentioned list, suitably from autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and COPD, transplant rejection; antibody production, antigen presentation, cytokine production or lymphoid organogenesis are abnormal or are undesirable including rheumatoid arthritis, pemphigus vulgaris, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, Sjogren's syndrome, autoimmune hemolytic anemia, ANCA-associated vasculitides, cryoglobulinemia, thrombotic thrombocytopenic purpura, chronic autoimmune urticaria, allergy (atopic dermatitis, contact dermatitis, allergic rhinitis), goodpasture's syndrome, AMR (antibody-mediated transplant rejection), B cell-mediated hyperacute, acute and chronic transplant rejection and cancers of haematopoietic origin including but not limited to multiple myeloma; a leukaemia; acute myelogenous leukemia; chronic myelogenous leukemia; lymphocytic leukemia; myeloid leukemia; non-Hodgkin lymphoma; lymphomas; polycythemia vera; essential thrombocythemia; myelofibrosis with myeloid metaplasia; and Walden stroem disease; more suitably from rheumatoid arthritis (RA), pemphigus vulgaris (PV), idiopathic thrombocytopenia purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune hemolytic anemia (AIHA), acquired hemophilia type A (AHA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), myasthenia gravis (MG), Sjogren's syndrome (SS), ANCA- associated vasculitides, cryoglobulinemia, chronic autoimmune urticaria (CAU), allergy (atopic dermatitis, contact dermatitis, allergic rhinitis) , goodpasture's syndrome, transplant rejection and cancers of haematopoietic origin as well as in disease or infection associated immunopathology, for example in severe and cerebral malaria, trypanosomiasis, leishmaniasis, toxoplasmosis and neurocy sticercosi s .
GENERAL SYNTHETIC PROCEDURES [0334] In order to illustrate the invention, the following examples are included. However, it is to be understood that these examples do not limit the invention and are only meant to suggest a method of practicing the invention.
[0335] Generally, the compounds disclosed herein may be prepared by methods described herein, wherein the substituents are as defined for formula (I), above, except where further noted. The following non-limiting schemes and examples are presented to further exemplify the invention. Persons skilled in the art will recognize that the chemical reactions described herein may be readily adapted to prepare a number of other compounds disclosed herein, and alternative methods for preparing the compounds disclosed herein are deemed to be within the scope of this invention. For example, the synthesis of non-exemplified compounds according to the invention may be successfully performed by modifications apparent to those skilled in the art, e.g., by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, and/or by making routine modifications of reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds disclosed herein.
[0336] In the examples described below, unless otherwise indicated all temperatures are set forth in degrees Celsius. Reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Arco Chemical Company and Alfa Chemical Company, Shanghai Medpep. Co Ltd, Aladdin-Shanghai Jinchun Reagents, Ltd, and were used without further purification unless otherwise indicated. Common solvents were purchased from commercial suppliers such as Shantou XiLong Chemical Factory, Guangdong Guanghua Reagent Chemical Factory Co. Ltd., Guangzhou Reagent Chemical Factory, Tainjin YuYu Fine Chemical Ltd., Qingdao Tenglong Reagent Chemical Ltd., and Qingdao Ocean Chemical Factory.
[0337] Anhydrous THF, dioxane, toluene, and ether were obtained by refluxing the solvent with sodium. Anhydrous CH2CI2 and CHCI3 were obtained by refluxing the solvent with CaH2. EtOAc, PE, hexanes, DMA and DMF were treated with anhydrous Na2S04 prior use.
[0338] The reactions set forth below were done generally under a positive pressure of nitrogen or argon or with a drying tube (unless otherwise stated) in anhydrous solvents, and the reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried.
[0339] Column chromatography was conducted using a silica gel column. Silica gel (300-400 mesh) was purchased from Qingdao Ocean Chemical Factory. 1H NMR spectra were recorded with a Bruker 400 MHz spectrometer or a Bruker 600 MHz spectrometer at ambient temperature. 1H NMR spectra were obtained as CDC13, DMSO-i¾, CD3OD or acetone-i/6 solutions (reported in ppm), using TMS (0 ppm) or chloroform (7.26 ppm) as the reference standard. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets). Coupling constants (./), when given, are reported in Hertz (Hz).
[0340] Low-resolution mass spectral (MS) data were generally determined on an Agilent 6120 Quadrupole HPLC-MS (Zorbax SB-C18, 2.1 x 30 mm, 3.5 micron, 6 minutes run, 0.6 mL/min flow rate, 5% to 95% (0.1% formic acid in CH3CN) in (0.1% formic acid in H20)) with UV detection at 210 nm/254 nm and electrospray ionization mode (ESI).
[0341] Purities of compounds were assessed by Agilent 1260 Pre-HPLC or Calesep Pump 250 Pre-HPLC (Column NOVASEP 50/80 mm DAC) with UV detection at 210 nm/254 nm.
[0342] The following abbreviations are used throughout the specification:
ATP adenosine triphosphate
AcOH, HAc, HO Ac, CH3COOH acetic acid
AcOK, CH3COOK potassium acetate
BSA N,0-Bis(trimethylsilyl)acetamide
BOC, Boc butyloxycarbonyl
//-BuOH butyl alcohol
//-BuLi //-butylbthium
Cs2C03 cesium carbonate
CH2CI2, DCM methylene chloride
CHCI3 chloroform
CDCI3 chloroform deuterated
CH3CN acetonitrile
CH3CI methyl chloride
Cu copper
Cul cuprous iodide
D2 deuterium gas
DIEA, DIPEA, iPr2Net A/ A-Di i sopropyl ethyl a i ne
DMF dimethylformamide DMAC dimethylacetamide
DMAP 4-dimethylaminopyridine
DMSO dimethylsulfoxide
DTT DL-Dithiothreitol
Et3N, TEA triethylamine
EtOAc, EA, ethyl acetate
Et20 diethyl ether
EtOH ethanol
FBS fetal bovine serum
Fe iron
g gram
h hour
FtATU 2-(7-Aza- 1 //-benzotriazole- 1 -yl )- 1 , 1 ,3,3-tetra ethyluronium hexafluorophosphate
HBr hydrobromic acid
HC1 hydrochloric acid
H2 hydrogen
H20 water
H202 hydrogen peroxide
H3PO4 orthophosphoric acid
H7SO4 sulphuric acid
HNO3 nitric acid
HCOOK potassium formate
HCOONH4 ammonium formate
HMDS hexamethyldisilazane
HPLC high performance liquid chromatography or high pressure liquid chromatography I2 iodine
LiHMDS lithium bis(trimethylsilyl)-amide LDA lithium diisopropylamide MBP myelin basic protein
MCPBA meta-chloroperbenzoic acid
MeCN, CH3CN acetonitrile
MgS04 magnesium sulfate
MeOH, CH3OH methanol
Mel methyl iodide
mL, ml milliliter
min minute
N2 nitrogen
NMP A-m ethyl pyrrol i di n one
NaHCC sodium bicarbonate
NaBH4 sodium borohydride
NaBH3CN sodium cyanoborohydride
NaOtBu sodium ter /-but oxide
NaOMe, CH3ONa, NaOCH3 sodium methoxide
NaOH sodium hydroxide
NaCl02 sodium chlorite
NaClO sodium hypochlorite
NaCl sodium chloride
NaH2P04 sodium biphosphate
NaH sodium hydride
Nal sodium iodide
Na2S04 sodium sulfate
Na2S2C>3 sodium thiosulfate
NBS A-bromosuccinimide
NIS A-iodosuccinimide NCS /V-chlorosuccinimide
NEt3 triethylamine
NH3 ammonia
NH4CI ammonium chloride
NH2OH>HCl hydroxylamine hydrochloride
(NH4)2Ce(N03)6 ceric ammonium nitrate
Pd/C palladium on carbon
Pd2(dba)3 bis(dibenzylideneacetone) palladium
Pd(OAc)2 palladium acetate
Pd(OH)2 palladium hydroxide
Pd(PPh3)4 palladium tetrakis triphenylphosphine
Pd(PPh3)2Cl2 bis(triphenylphosphine)palladium(II) chloride
Pd(dppf)Cl2 l,l-bis(diphenylphosphino)ferrocene palladium chloride
PdCl2(PCy3)2 Bis(tricyclohexylphosphine)dichloropalladium
P(t-Bu)3 tri(/c77-butyl /phosphine
PE petroleum ether (60-90 °C)
PBS phosphate buffered saline
Ph phenyl
POCl3 phosphorous oxychloride
PhI(OAc)2 iodobenzene di acetate
K2C03 potassium carbonate
KOH potassium hydroxide
RT rt r.t. room temperature
Rt retention time
SOCl2 thionyl chloride
S02Cl2 sulfuryl chloride
/-BuOK Potassium ter /-butanol ate TBS tris buffered saline
THF tetrahydrofuran TFA trifluoroacetic acid TEAC bis(/e/ra-ethylammonium)carbonate Tris trihydroxymethyl aminomethane TsCl 4-toluene sulfonyl chloride pL microliter
X-Phos 5-Bromo-4-chloro-3-indolylphosphat p-Toluidine salt
[0343] Representative synthetic procedures for the preparation of compounds of the disclosure are outlined below in following schemes. Unless otherwise indicated, each X, W, A, B, m, Ra, Rb, R1, R2 and R4 carry the definitions set forth above in connection with formula (I). "PG" is a suitable protecting group.
Scheme 1
Figure imgf000090_0001
Wherein Q is halo;
The compounds disclosed herein can be prepared according to the synthetic route illustrated above. Compound (la) is reacted with compound (2a) to obtain compound £H) in the presence of a base.
Scheme 2
Figure imgf000090_0002
L is halo.
The intermediate (2a) disclosed herein can be prepared according to the synthetic route illustrated above. First, compound (2b) is coupled with compound (3a) in the presence of Pd catalyst to give compound (2c). Then protecting group is removed from compound (2c) to produce compound (2a).
EXAMPLE
Example 1 (A)-2-(l-((6-amino-5-(3-methyl-E2.4-oxadiazol-5-yl)pyrimidin-4-yl)amino)ethyl)-5- (3 -hydroxy-3 -methylbut- 1 -vn- 1 -yl)-3 -phenyl quinazolin-4 -one
Figure imgf000091_0001
Figure imgf000091_0002
Step 1) (S)-tert- butyl ( 1 -(5-(3-hydroxy-3-methylbut- l -yn- 1 -yl )-4-oxo-3-phenyl-3.4- dihvdroquinazolin-2-yl)ethyl)carbamate
[0344] To a suspension of {S)-tert- butyl (l-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin- 2-yl)ethyl)carbamate (1.01 g, 2.53 mmol) (See the synthetic method of steps 1-4 of example 64 in W02015042077), cuprous iodide (51 mg, 0.26 mmol), palladium acetate (61 mg, 0.27 mmol), X-phos (243 mg, 0.51 mmol) and DIPEA (1.7 mL, 9.7 mmol) in DMF (10 mL) was added 2- methylbut-3-yn-2-ol (1 mL, 10.3 mmol) under a N2 atmosphere. The reaction mixture was heated to 100 °C for 6.5 h, cooled to rt., diluted with EtOAc (100 mL), and then washed with water (100 mL x 4) and saturated brine (100 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc / PE (v/v) = 1/2) to give the title compound as a light-yellow solid (610 mg, 54%).
MS (ESI, Pos. Ion) m/z: 448.5 [M + H]+.
Step 2) 0V)-2-( l -aminoethyl )-5-(3-hydroxy-3-methylbut- l -yn- 1 -yl )-3-phenylquinazolin-4(3//)- one
[0345] To a solution of (S)-tert- butyl (l-(5-(3-hydroxy-3-methylbut-l-yn-l-yl)-4-oxo-3- phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (610 mg, 1.36 mmol) in EtOAc (10 mL) was added hydrogen chloride (gas) in EtOAc (3 M, 10 mL, 30 mmol). The reaction was stirred at room temperature for 2 h and then diluted with H20 (100 mL) and EtOAc (20 mL). The organic layer was separated and the aqueous phase was basified with NaHC03 powder to pH = 8.5, extracted with DCM (50 mL c 2). The combined organic phase was washed with saturated brine (50 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 1/20) to give the title compound as a light-yellow solid (246 mg, 52%).
MS (ESI, Pos. Ion) m/z: 348.4 [M + H]+;
1HNMR (400 MHz, DMSO-i¾) d (ppm): 7.75 (dd, J= 7.6, 8.0 Hz, 1H), 7.63 (d, J= 8.0 Hz, 1H), 7.60-7.45 (m, 6H), 5.35 (s, 1H), 3.40- 3.34 (m, 1H), 1.91 (br.s, 2H), 1.41 (s, 6H), 1.14 (d, J= 6.4 Hz, 3H).
Step 3) 6y)-2-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vOpyrimidin-4-vOamino)ethvO-5-(3- hydroxy-3 -methylbut- 1 -vn- 1 -vO-3 -phenyl quinazolin-4 -one
Figure imgf000092_0001
[0346] A mixture of (ri)-2-(l-aminoethyl)-5 -(3 -hydroxy-3 -methylbut- l-yn-l-yl)-3- phenylquinazolin-4(3//)-one (30.0 mg, 0.08 mmol), 6-chloro-5-(3 -methyl- 1,2, 4- oxadiazol-5- yl)pyrimidin-4-amine (25.2 mg, 0.12 mmol) (See the synthetic method of steps 1-4 of example 3 in W02015042077) and DIPEA (16.2 mg, 0.12 mmol) in propan-2-ol (1 mL) was heated to 85 °C for 5 h. The mixture was cooled down to room temperature, and then added water (1 mL) dropwise, stirred for 10 min and filtered. The filter cake was dried in vacuo to give the title compound as a light-yellow solid (25.8mg, 57%).
MS (ESI, Pos. Ion) m/z: 523.3 [M + H]+;
1HNMR (400 MHz, DMSO-i¾) d (ppm): 9.20 (d, j= 6.4 Hz, 1H), 7.98 (s, 1H), 7.80 (dd, j= 8.0, 8.0 Hz, 1H), 7.67-7.53 (m, 9H), 5.38 (s, 1H), 4.93-4.86 (m, 1H), 2.5 (s, 3H), 1.42 (s, 6H), 1.34 (d, J= 6.8 Hz, 3H).
Example 2 (y)-2-(T-(Y6-amino-5-(5-methyl-L3.4-oxadiazol-2-vOpyrimidin-4-vOamino)ethvO-5- (3 -hydroxy-3 -methylbut- 1 -vn- 1 -vO-3 -phenyl quinazolin-4 -one
Figure imgf000092_0002
Figure imgf000093_0001
[0347] A mixture of (ri)-2-(l-aminoethyl)-5 -(3 -hydroxy-3 -methylbut-l-yn- l-yl)-3- phenylquinazolin-4(3i )-one (29.8 mg, 0.08 mmol), 6-chloro-5-(5-methyl-l,3,4-oxadiazol-2- yl)pyrimidin-4-amine (23.3 mg, 0.11 mmol) (See the synthetic method of step 5-8 of example 2 in W02015042077) and DIPEA (14.1 mg, 0.11 mmol) in propan-2-ol (1 mL) was heated to 85 °C for 24 h. The mixture was cooled down to room temperature, concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 1/20) to give the crude compound which was purified once again by preparative TLC (MeOH / DCM (v/v) = 3/100) to give the title compound as an off-white solid (24 mg, 54 %).
MS (ESI, Pos. Ion) m/z: 523.3 [M + H]+;
1HNMR (400 MHz, CDCl3) d (ppm): 8.50 (d, J = 7.2Hz, 1H), 8.01 (s, 1H), 7.63-7.52 (m, 6H), 7.44-7.42 (m, 1H), 7.35-7.33 (m, 1H), 6.39 (br.s, 2H), 5.13-5.07 (m, 1H), 3.06 (br.s, 1H), 2.67 (s, 3H), 1.58 (s, 6H), 1.43 (d, j= 6.4 Hz, 3H).
Example 3 (y)-2-(T-(Y6-amino-5-(5-methyl-E2.4-oxadiazol-3-vOpyrimidin-4-vOamino)ethvO-5- (3 -hydroxy-3 -methylbut- 1 -vn- 1 -vO-3 -phenyl quinazolin-4 -one
Figure imgf000093_0002
Figure imgf000093_0003
[0348] A mixture of (ri)-2-(l-aminoethyl)-5 -(3 -hydroxy-3 -methylbut- l-yn-l-yl)-3- phenylquinazolin-4(3//)-one (29.9 mg, 0.08 mmol), 6-chloro-5-(5-methyl-l,2,4-oxadiazol-3- yl)pyrimidin-4-amine (20.9 mg, 0.10 mmol) (See the synthetic method of steps 1-5 of example 12 in W02015042077) and DIPEA (14.7 mg, 0.114 mmol) in propan-2-ol (1 mL) was heated to 85 °C for 24 h. The mixture was then cooled down to room temperature, concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 3/200) to give the title compound as a light-yellow solid (27 mg, 60%).
MS (ESI, Pos. Ion) m/z: 523.3 [M + H]+;
1HNMR (400 MHz, CDCl3) d (ppm): 8.76 (d, J = 6.8 Hz, 1H), 7.98 (s, 1H), 7.63-7.45 (m, 7H), 7.32 (d, j= 7.6 Hz, 1H), 5.11-5.05 (m 1H), 3.05 (br.s, 1H), 2.72 (s, 3H), 1.58 (s, 6H), 1.44 (d, J = 6.8 Hz, 3H).
Example 4 (y)-2-(T-(Y6-amino-5-(2 -methyl -2H-tetrazol-5-vDpyrimidin-4-vPamino)ethvD-5-(3- hydroxy-3 -methylbut- 1 -vn- 1 -vO-3 -phenyl quinazolin-4 -one
Figure imgf000094_0001
Figure imgf000094_0002
[0349] A mixture of (ri)-2-(l-aminoethyl)-5 -(3 -hydroxy-3 -methylbut- l-yn-l-yl)-3- phenylquinazolin-4(3//)-one (41.1 mg, 0.118 mmol), 6-chloro-5-(2 -methyl -2H-tetrazol-5- yl)pyrimidin-4-amine (28.7 mg, 0.136 mmol) (See the synthetic method of steps 1-6 of example 12 in WO2015042078) and DIPEA (21.1 mg, 0.163 mmol) in «-butanol (1 mL) was heated to 120 °C for 18 h. The mixture was then cooled down to room temperature, and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 1/50) to give crude product which was further purified by preparative TLC (MeOH / DCM (v/v) = 1/30) to give the title compound as a light-yellow solid (24 mg, 39%).
MS (ESI, Pos. Ion) m/z: 523.6 [M + H]+;
1H NMR (600 MHz, CDCl3) d (ppm): 8.86 (d, J= 7.2 Hz, 1H), 8.00 (s, 1H), 7.62-7.50 (m, 6H), 7.48-7.46 (m, 1H), 7.35 (d, J= 7.8 Hz, 1H), 5.55 (br.s, 2H), 5.13-5.09 (m, 1H), 4.49 (s, 3H), 3.13 (br.s, 1H), l .57(s, 6H), 1.47 (d, j= 6.6 Hz, 3H).
13C NMR (151 MHz, CDCl3) d (ppm): 162.6, 161.2, 160.6, 159.1, 158.5, 157.8, 148.6, 136.4, 133.3, 132.9, 129.9, 129.6, 129.6, 129.1, 128.9, 127.7, 123.0, 121.2, 100.4, 83.2, 81.8, 65.6, 48.8, 39.8, 31.2, 31.2, 20.3. Example 5 2-(YA)-l-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vOpyrimidin-4-vOamino)ethvO-5- (3 -hydroxybut- 1 -vn- 1 -vD-3 -phenyl quinazolin- -one
Figure imgf000095_0001
Step 1) fer/-butyl (Tf V)- l -(5-(3-chlorobut- l -vn- 1 -yl )-4-oxo-3 -phenyl -3.4-dihydroqui nazolin-2- vOethvOcarbamate
[0350] To a solution of {S)-tert- butyl (l-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2- yl)ethyl)carbamate (3.0 g, 7.5 mmol) in DMAC (17 mL) was added potassium carbonate (1.6 g, 11 mmol), X-Phos (0.36 g, 0.74 mmol) and 10 % Pd/C (0.8 g). The reaction was degassed with nitrogen. After being stirred at 110 °C overnight, the reaction mixture was diluted with CH2CI2 (100 mL) and filtered. The filtrate was washed with H20 (30 mL c 6) and saturated brine (30 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc/PE (v/v) = 1/6) to give the title compound as a yellow solid (2.6 g, 80 %).
MS (ESI, pos. ion) m/z: 434.3 [M + H]+;
1H NMR (400 MHz, CDCI3) d (ppm): 7.68 (d, J= 4.4 Hz, 2H), 7.58 (m, 4H), 7.40 (d, J= 7.0 Hz, 1H), 7.30 (d, J= 7.4 Hz, 1H), 5.64 (d, J= 8.3 Hz, 1H), 4.77 (q, J= 6.3 Hz, 1H), 4.56 - 4.43 (m, 1H), 2.77 (s, 1H), 1.53 (d, J = 6.6 Hz, 3H), 1.43 (s, 9H), 1.27 (d, j= 6.7 Hz, 3H).
Step 2) 2-((S)~ 1 -aminoethyl)-5 -(3 -hydroxybut- 1 -vn- 1 -vO-3 -phenylquinazolin-4 -one
Figure imgf000095_0002
[0351] To a solution of /er/-butyl ((lri)-l-(5-(3-chlorobut-l-yn-l-yl)-4-oxo-3-phenyl-3,4- dihydroquinazolin-2-yl)ethyl)carbamate (1.0 g, 2.3 mmol) in dioxane (10 mL) was added con. HC1 (1 mL). After being stirred at 30 °C for 2h, the reaction mixture was concentrated in vacuo. The residue was diluted with CH2CI2 (30 mL) and neutralized with 5 M NaOH to rH=10. The organic layer was separated and the aqueous phase was extracted with CH2Cl2 (30 mL c 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo to give the title compound as a yellow solid (0.84 g, 110 %).
MS (ESI, pos. ion) m/z: 334.1 [M + H]+; 1H NMR (400 MHz, CDCl3) d (ppm): 7.68 (d, J= 4.3 Hz, 2H), 7.62 - 7.49 (m, 4H), 7.30 (s, 2H),
4.78 (q, J = 6.6 Hz, 1H), 3.72 (s, 1H), 3.68 (q, J = 6.5 Hz, 1H), 2.00 (s, 2H), 1.54 (d, J = 6.6 Hz, 3H), 1.28 (d, J= 6.5 Hz, 3H).
Step 3) 2-(YA)-l-(Y6-amino-5-(3-methyl-E2.4-oxadiazol-5-vOpyrimidin-4-vOamino)ethvO-5-(3- hydroxybut- 1 -vn- 1 -vO-3 -phenyl quinazolin- -one
Figure imgf000096_0001
[0352] To a solution of 2-((A)-l-aminoethyl)-5 -(3 -hydroxybut-l-yn- l-yl)-3 -phenyl quinazolin- 4(3i )-one (61 mg, 0.18 mmol) in «-butanol (1 mL) was added 6-chloro-5-(3-methyl-l,2,4- oxadiazol-5-yl)pyrimidin-4-amine (39 mg, 0.18 mmol) and DIPEA (0.1 mL, 0.6 mmol). After being stirred at 110 °C for 6 h, the reaction mixture was concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH/DCM (v/v) = 1/20) to give the title compound as a yellow solid (69 mg, 74 %).
MS (ESI, pos. ion) m/z: 509.1 [M + H]+;
1H NMR (400 MHz, CDCI3) d (ppm): 8.85 (d, J= 7.0 Hz, 1H), 8.05 (s, 1H), 7.76 - 7.64 (m, 2H), 7.64 - 7.52 (m, 3H), 7.45 (d, J= 7.0 Hz, 1H), 7.38 (dd, J= 7.4, 1.8 Hz, 1H), 5.20 - 5.08 (m, 1H),
4.79 (dd, j = 14.0, 7.3 Hz, 1H), 2.55 (s,3H), 2.51 (s, 1H), 1.54 (d, j = 6.6 Hz, 3H), 1.47 (d, j = 6.7 Hz, 3H).
Example 6 2-('(y)-l-(Y6-amino-5-(5-methyl-E2.4-oxadiazol-3-vDpyrimidin-4-vPamino)ethvD-5- (3-hy droxybut- 1 -yn- 1 -yl )-3-phenylquinazolin-4 -one
Figure imgf000096_0002
Figure imgf000096_0003
[0353] To a solution of 2-((A)-l-aminoethyl)-5 -(3 -hy droxybut- l-yn-l-yl)-3 -phenyl quinazolin- 4(3i )-one (61 mg, 0.18 mmol) in «-butanol (1 mL) was added 6-chloro-5-(5-methyl-l,2,4- oxadiazol-3-yl)pyrimidin-4-amine (39 mg, 0.18 mmol) and DIPEA (0.1 mL, 0.6 mmol). After being stirred at 110 °C for 6 h, the reaction mixture was concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH/CH2Cl2 (v/v) = 1/20) to give the title compound as a yellow solid (66 mg, 71 %).
MS (ESI, pos. ion) m/z: 509.5 [M + H]+; 1H NMR (400 MHz, CDCl3) d (ppm): 8.79 (d, J= 6.6 Hz, 1H), 8.00 (s, 1H), 7.71 - 7.64 (m, 2H), 7.62 - 7.52 (m, 3H), 7.49 (d, J = 7.2 Hz, 1H), 7.35 (d, J = 6.6 Hz, 1H), 5.17 - 5.06 (m, 1H), 4.79 (dd, j= 13.0, 6.5 Hz, 1H), 2.74 (s, 3H), 2.44 (s, 1H), 1.54 (d, j= 6.6 Hz, 3H), 1.48 (d, j= 6.7 Hz, 3H). (6-amino-5-(5-methyl-l.3.4-oxadiazol-2-vDpyrimidin-4- ethvD-5-
Figure imgf000097_0001
-vO-3 -phenyl quinazolin- -one
Figure imgf000097_0002
Figure imgf000097_0003
[0354] To a solution of 2-((A)-l-aminoethyl)-5 -(3 -hydroxybut- l-yn-l-yl)-3 -phenyl quinazolin- 4(3i )-one (61 mg, 0.18 mmol) in l-butanol (1 mL) was added 6-chloro-5-(5-methyl-l,3,4- oxadiazol-2-yl)pyrimidin-4-amine (39 mg, 0.18 mmol) and DIPEA (0.1 mL, 0.6 mmol). After being stirred at 110 °C for 7 h, the reaction mixture was concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH/CH2Cl2 (v/v) = 1/20) to give the title compound as a yellow solid (74 mg, 80 %).
MS (ESI, pos. ion) m/z: 509.2 [M + H]+;
1H NMR (400 MHz, CDCI3) d (ppm): 8.52 (d, J= 7.1 Hz, 1H), 8.04 (s, 1H), 7.67 (d, J = 3.8 Hz, 2H), 7.64 - 7.52 (m, 3H), 7.46 (d, J = 7.3 Hz, 1H), 7.36 (d, J = 7.0 Hz, 1H), 6.40 (s, 2H), 5.20 - 5.10 (m, 1H), 4.79 (dd, j= 13.1, 6.3 Hz, 1H), 2.74 (s, 3H), 2.46 (s, 1H), 1.54 (d, J= 6.6 Hz, 3H), 1.47 (d, J= 6.6 Hz, 3H).
Example 8 2-((S)-l -(Y6-amino-5-(2-m ethyl -2H-tetrazol-5-vPpyrimidin-4-vDamino)ethvD-5-(3- hydroxybut- 1 -vn- 1 -vO-3 -phenyl quinazolin-4 -one
Figure imgf000097_0004
Figure imgf000098_0001
[0355] To a solution of 2-((X)-l-aminoethyl)-5 -(3 -hydroxybut-l-yn- l-yl)-3 -phenyl quinazolin- 4(3i )-one (61 mg, 0.18 mmol) in «-butanol (1 mL) was added 6-chloro-5-(2-methyl-2i7- tetrazol-5-yl)pyrimidin-4-amine (39 mg, 0.18 mmol) and DIPEA (0.1 mL, 0.6 mmol). After being stirred at 110 °C for 7 h, the reaction mixture was concentrated. The residue was purified by a silica gel column chromatography (MeOH/CH2Cl2 (v/v) = 1/20) to give the title compound as a yellow solid (65 mg, 70 %).
MS (ESI, pos. ion) m/z: 509.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.90 (d, J= 6.8 Hz, 1H), 8.04 (s, 1H), 7.69 - 7.63 (m, 2H), 7.56 (m, 3H), 7.50 (d, J= 6.7 Hz, 1H), 7.36 (d, J= 7.3 Hz, 1H), 5.21 - 5.10 (m, 1H), 4.79 (dd, J = 13.1, 6.5 Hz, 1H), 4.52 (s, 3H), 2.54 (s, 1H), 1.54 (d, J= 6.6 Hz, 3H), 1.50 (d, J= 6.7 Hz, 3H).
Example 9 (y)-2-(T-(Y6-amino-5-(3-methyl- oxadiazol-5-vOpyrimidin-4-vOamino)ethvO-3-
Figure imgf000098_0002
phenyl-5-(prop-l-vn-l-yl)quinazolin-4 one
Figure imgf000098_0003
Figure imgf000098_0004
Step 1) (X)-2-(T-aminoethvO-3-phenyl-5-(prop-l-yn-l-vOquinazolin-4 -one
Figure imgf000098_0005
[0356] To a solution of {S)-tert- butyl (l-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2- yl)ethyl)carbamate (1.5 g, 3.8 mmol) in DMAC (50 mL) was added prop-l-yne (50 mL, 3 mass% in heptane), 10% Pd/C (0.4 g), X-Phos (0.18 g, 0.38 mmol) and potassium carbonate (0.78 g, 5.6 mmol). The mixture was placed in a sealed tube and heated at 100 °C for 10 hours, then cooled down to room temperature. The reaction mixture was filtered, and washed with EtOAc (lOOmL). The filtrate was washed with water (100 mL c 3). The organic phase was concentrated in vacuo to give the crude product as a yellow solid. The crude product was redissolved in a mixture of HC1 in EtOAc (30 mL, 4.0 M) at room temperature, and stirred for 4 hours. The mixture was added water (30 mL), and the organic layer was separated. The aqueous layer was adjusted to pH= 10 by adding solid NaOH at ice-water cooling, filtered and the filter cake was dried in vacuo to give the title compound as a yellow solid (0.74g, 65%).
MS (ESI, pos. ion) m/z: 304.4[M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 7.69 - 7.60 (m, 2H), 7.60 - 7.45 (m, 4H), 7.30 (dd, J= 6.5, 3.3 Hz, 2H), 3.74 - 3.61 (m, 1H), 2.12 (s, 2H), 1.81 (s, 3H), 1.28 (d, J= 6.6 Hz, 3H).
Step 2) (S)-2-( \ -(Y6-amino-5-(3-methyl- l .2.4-oxadiazol-5-yl )pyrimidin-4-yl ) amino)ethvD-3- phenyl-5-(prop-l-vn-l-vQquinazolin- -one
Figure imgf000099_0001
[0357] To a mixture of (A)-2-(l-aminoethyl)-3-phenyl-5-(prop-l-yn-l-yl)quinazolin-4(3i )- one (82 mg, 0.27 mmol) and 6-chloro-5-(3-methyl-l,2,4-oxadiazol-5-yl)pyrimidin-4-amine (68 mg, 0.32 mmol) in propan-2-ol (2 mL) was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated to reflux and stirred for 4 hours and then cooled down to room temperature. To the mixture was added water (3 mL) and stirred for 30 min, filtered. The filter cake was dried in vacuo to give the title compound as a yellow solid (83 mg, 65%).
MS (ESI, pos. ion) m/z: 479.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.90 (d, J = 6.7 Hz, 1H), 8.05 (d, 7 = 5.1 Hz, 1H), 7.73 - 7.33 (m, 8H), 5.16 (dd, J= 13.4, 6.6 Hz, 1H), 2.54 (s, 3H), 2.13 (s, 3H), 1.65 (s, 2H), 1.48 (dd, J = 10.4, 5.7 Hz, 3H).
Example 10 (A)-2-(T-(Y6-amino-5-(5-methyl-E3.4-oxadiazol-2-v0pyrimidin-4-v0amino)ethv0- 3 -phenyl -5 -(prop- 1 -yn- 1 -vOquinazolin- -one
Figure imgf000099_0002
Figure imgf000099_0003
[0358] To a mixture of (A)-2-(l-aminoethyl)-3-phenyl-5-(prop-l-yn-l-yl)quinazolin-4(3i7)- one (82 mg, 0.27 mmol), 6-chloro-5-(5-methyl-l,3,4-oxadiazol-2-yl)pyrimidin-4-amine (68 mg, 0.32 mmol) in propan-2-ol (2 mL) was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated to reflux and stirred overnight and then cooled down to room temperature. To the mixture was added water (3 mL) and the resulted mixture was stirred for 30 min, filtered. The filter cake was dried in vacuo to give the title compound as a yellow solid (74 mg, 58%).
MS (ESI, pos. ion) m/z: 479.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.55 (t, J = 9.2 Hz, 1H), 8.04 (d, J = 4.4 Hz, 1H), 7.70 - 7.32 (m, 8H), 5.24 - 5.07 (m, 1H), 2.75 (s, 3H), 2.13 (s, 3H), 1.65 (s, 2H), 1.47 (d, j = 6.6 Hz, 3H). -(Y6-amino-5-(5-methyl-E2.4-oxadiazol-3-vOpyrimidin-4-vO amino)ethvP- n- 1 -vOquinazolin- -one
Figure imgf000100_0001
Figure imgf000100_0002
[0359] To a mixture of (S)-2-(l-aminoethyl)-3-phenyl-5-(prop-l-yn-l-yl)quinazolin-4(3//)- one (83 mg, 0.27 mmol), 6-chloro-5-(5-methyl-l,2,4-oxadiazol-3-yl)pyrimidin-4-amine (70 mg, 0.33 mmol) in propan-2-ol (2 mL) was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated to reflux and stirred overnight and then cooled down to room temperature. To the mixture was added water (3 mL) and stirred for 30 min, filtered. The filter cake was dried in vacuo to give the title compound as a yellow solid (89 mg, 68%)
MS (ESI, pos. ion) m/z: 479.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.81 (dd, J = 25.2, 7.0 Hz, 1H), 8.01 (d, J = 5.9 Hz, 1H),
7.68 - 7.43 (m, 7H), 7.36 (d, 7 = 6.3 Hz, 1H), 5.13 (p, 7= 6.8 Hz, 1H), 2.74 (s, 3H), 2.13 (s, 3H),
1.69 (s, 2H), 1.48 (d, J= 6.7 Hz, 3H).
Example 12 (S)-2-( \ -((6-amino-5-(2-methyl-2//-tetrazol-5-yl )pyrimidin-4-yl ) amino)ethvD-3- phenyl-5-(prop-l-vn-l-vQquinazolin- -one
Figure imgf000100_0003
Figure imgf000101_0001
[0360] To a mixture of (ri)-2-(l-aminoethyl)-3-phenyl-5-(prop-l-yn-l-yl)quinazolin-4(3i )- one (82 mg, 0.27 mmol), 6-chloro-5-(2-methyltetrazol-5-yl)pyrimidin-4-amine (68 mg, 0.32 mmol) in propan-2-ol (2 mL) was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated to reflux and stirred overnight and then cooled down to room temperature. To the mixture was added water (3 mL) and stirred for 30 min, filtered. The filter cake was dried in vacuo to give the title compound as a yellow solid (97 mg, 76%)
MS (ESI, pos. ion) m/z: 479.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.93 (dd, J= 14.8, 7.2 Hz, 1H), 8.04 (d, J= 5.7 Hz, 1H), 7.65-7.45 (m, 7H), 7.37 (d, J= 6.3 Hz, 1H), 5.22 - 5.11 (m, 1H), 4.52 (s, 3H), 2.13 (s, 3H), 1.50 (d, J= 6.7 Hz, 3H).
Example 13 (y)-2-(T-(Y6-amino-5-(T-methyl- E2.4-triazol-3-vOpyrimidin-4-vOamino)ethvO-
Figure imgf000101_0002
3-phenyl-5-(prop-l-vn-l-v0quinazolin-4 -one
Figure imgf000101_0003
Figure imgf000101_0004
[0361] To a mixture of (ri)-2-(l-aminoethyl)-3-phenyl-5-(prop-l-yn-l-yl)quinazolin-4(3i )- one (50 mg, 0.16 mmol), 6-chloro-5-(l-methyl-l,2,4-triazol-3-yl)pyrimidin-4-amine (40 mg, 0.19 mmol) (See the synthetic method of steps 1-7 of example 2 in WO2015042497) in propan- 2-ol (3 mL)was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated at 90 °C and stirred overnight, then cooled down to room temperature, diluted with water (3 mL), stirred for 30 min and filtered. The filter cake was dried in vacuo to give the title compound as a white solid (58 mg, 75%). MS (ESI, Pos. Ion) m/z: 478.2 [M + H]+;
1H NMR (400 MHz, DMSO-i¾) d (ppm): 9.64 (d, J = 6.6 Hz, 1H), 8.77 (s, 1H), 7.91 (s, 1H), 7.73 (t, J= 7.8 Hz, 1H), 7.67 - 7.46 (m, 7H), 4.96 - 4.77 (m, 1H), 4.03 (s, 3H), 2.04 (s, 3H), 1.38 (d, J= 6.6 Hz, 3H).
Example 1 -(l-((6-amino-5-(3-methyl-l.2.4-oxadiazol-5-yl)pyrimidin-4-yl)amino)propyl)-
Figure imgf000102_0001
3 -phenyl -5 -(prop- 1 -yn- 1 -vOauinazolin-4 -one
Figure imgf000102_0002
Figure imgf000102_0003
Step 1) (X)-fer/-butyl ( 1 -(4-oxo-3-phenyl-5-(prop- l -vn- 1 -yl )-3.4-dihydroquinazolin-2- vOpropyOcarbamate
[0362] To a suspension of {S)-tert- butyl (l-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin- 2-yl)propyl)carbamate (0.81 g, 2.0 mmol) (See the synthetic method of steps 1-3 of example 1 in W02015042077) in DMAC (4 mL) was added potassium carbonate(0.4l g, 2.9 mmol), X-Phos (95mg, 0.2mmol), 10% Pd/C (0.2lg) and a solution of prop-l-yne in heptane (13 g, 9.7mmol, 3%). The reaction was degassed with nitrogen. After being stirred at 110 °C overnight, the reaction mixture was diluted with CH2Cl2 (20 mL) and filtered. The filtrate was washed with H20 (8 mL x 5) and saturated NaCl (8 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtO Ac/PE (v/v) = 1/8) to give the title compound as yellow oil (0.43 g, 53 %).
MS (ESI, pos. ion) m/z: 418.1 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 7.64 - 7.51 (m, 6H), 7.40 - 7.32 (m, 1H), 7.32 - 7.27 (m, 1H), 5.49 (d, J= 8.2 Hz, 1H), 4.43 - 4.31 (m, 1H), 2.10 (s, 3H), 1.77 - 1.68 (m, 1H), 1.55 - 1.48 (m, 1H), 1.42 (s, 9H), 0.74 (t, j= 7.4 Hz, 3H).
Step 2) (X)-2-(T-aminopropyO-3 -phenyl-5 -(prop- l-vn-l-vQquinazolin-
Figure imgf000102_0004
[0363] To a suspension of {S)-tert- butyl (l-(3-cyclopropyl-4-oxo-5-(prop-l-yn-l-yl)-3,4- dihydroquinazolin-2-yl)propyl)carbamate (0.38 g, 0.91 mmol) in dioxane (5 mL) was added con. HC1 (0.5 mL). After being stirred at 35 °C for 3 h, the reaction mixture was concentrated in vacuo. The residue was diluted with CH2CI2 (20 mL) and neutralized with 5 M NaOH to rH=10. The water phase was extracted with CH2Cl2 (20 mL c 3). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo to give the title compound as yellow oil (0.29 g, 100 %).
Step 3) 0y)-2-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vDpyrimidin-4-vDamino)propyD-3- phenyl-5-(prop-l-vn-l-vQquinazolin- -one
Figure imgf000103_0001
[0364] To a suspension of (ri)-2-(l-aminopropyl)-3-phenyl-5-(prop-l-yn-l-yl)quinazolin- 4(3i )-one (0.11 g, 35 mmol) in «-butanol (2 mL) was added 6-chloro-5-(3 -methyl- 1,2,4- oxadiazol-5-yl)pyrimidin-4-amine (73 mg, 0.34 mmol) and DIPEA (0.2 mL, 1.1 mmol). After being stirred at 110 °C overnight, the reaction mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH/CH2Cl2 (v/v) = 1/400) to give the title compound as a yellow solid (39 mg, 23 %).
MS (ESI, pos. ion) m/z: 493.1 [M + H]+;
1H NMR (400 MHz, CDCI3) d (ppm): 8.76 (d, J= 7.2 Hz, 1H), 8.03 (s, 1H), 7.64 (d, J= 4.4 Hz, 2H), 7.60 - 7.53 (m, 4H), 7.45 (d, J= 6.9 Hz, 1H), 7.38 - 7.36 (m, 1H), 5.15 - 5.10 (m, 1H), 2.54 (s, 3H), 2.13 (s, 3H), 1.98 - 1.74 (m, 2H), 0.86 (t, j= 7.4 Hz, 3H).
Example 1 -(l-((6-amino-5-(5-methyl-L3.4-oxadiazol-2-yl)pyrimidin-4-yl)amino)propyl)-
Figure imgf000103_0002
3-phen yl-5-(prop-l-vn-l-vQquinazolin- -one
Figure imgf000103_0003
Figure imgf000103_0004
[0365] To a suspension of (ri)-2-(l-aminopropyl)-3-phenyl-5-(prop-l-yn-l-yl)quinazolin- 4(3i )-one (0.11 g, 0.35 mmol) in «-butanol (2 mL) was added 6-chloro-5-(5-methyl-l,3,4- oxadiazol-2-yl)pyrimidin-4-amine (73 mg, 0.34 mmol) and DIPEA (0.2 mL, 1.1 mmol). After being stirred at 110 °C overnight, the reaction mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica column chromatography (MeOH/CH2Cl2 (v/v) = 1/400) to give the title compound as a yellow solid (43 mg, 25 %).
MS (ESI, pos. ion) m/z: 493.2 [M + H]+; 1H NMR (400 MHz, CDCl3) d (ppm): 8.44 (d, J= 7.1 Hz, 1H), 8.02 (s, 1H), 7.65 - 7.57 (m, 6H), 7.45 (d, J= 7.1 Hz, 1H), 7.37 (d, J= 8.8 Hz, 1H), 6.35 (s, 2H), 5.14 - 5.09 (m, 1H), 2.74 (s, 3H), 2.13 (s, 3H), 1.97 - 1.76 (m, 2H), 0.86 (t, J= 7.4 Hz, 3H).
Example 16 (A)-3-(l-((6-amino-5-(3-methyl-L2.4-oxadiazol-5-vDpyrimidin-4-vDainino)ethvD- 2-phenyl -8-(prop- 1 -yn- 1 -yl)i soquinolin- 1 (2//)-one
Figure imgf000104_0001
Step 1) 0V)-3-( l -aminoethyl )-2-phenyl-8-(prop- 1 -vn- 1 -yl )isoquinolin- l -one
Figure imgf000104_0002
[0366] To a mixture of S)-3-(l-aminoethyl)-8-chloro-2-phenylisoquinolin-l(2i )-one (1.5 g, 5.0 mmol) (See the synthetic method of step 1-2 of example 8 in W02015042078) in DMAC (10 mL) was added Cs2C03 (2.5 g, 7.7 mmol), PdCl2(PCy3)2 (0.38 g, 0.51 mmol). The mixture was purged with N2, then propyne (21 mL, 15 mmol, 3-6% in «-heptane) was added, and the mixture was sealed and heated at H0°C for 5.5 h. Then the mixture was cooled down to room temperature, added EtOAc (150 mL) and water (30 mL). The organic layer was separated and washed with saturated brine (50 mL c 5), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (PE/EtO Ac/TEA (v/v/v) = 1/10/0.5) to give the title compound as a yellow solid (0.81 g, 53%).
MS (ESI, pos.ion)m/z: 303.2 [M + H]+;
1H NMR (600 MHz, CDCl3) d (ppm): 7.60 - 7.58 (m, 4 H), 7.48 (dd, J= 15.3, 7.9 Hz, 2 H), 7.42 (d, j = 7.7 Hz, 1 H), 7.34 (d, j = 7.4 Hz, 1 H), 6.76 (s, 1 H), 3.76 - 3.70 (m, 1 H), 2.13 (s, 3 H), 1.30 (d, 7= 6.5 Hz, 3 H).
13C NMR (151 MHz, CDCl3) d (ppm): 162.5, 138.0, 134.1, 131.6, 129.8, 129.7, 129.4, 129.0, 128.9, 125.6, 125.1, 124.7, 102.3, 92.8, 79.9, 46.9, 23.0, 5.4.
Step 2) (A)-3-(l-((6-amino-5-(3-methyl-L2.4-oxadiazol-5-vOpyrimidin-4-vOamino)ethvO-2- phenyl -8 -(prop- 1 -yn- 1 -vDisoquinolin- 1 (2H)-one
[0367] To a suspension of (ri)-3-(l-aminoethyl)-2-phenyl-8-(prop-l-yn-l-yl)isoquinolin- l(2//)-one (33 mg, 0.1 1 mmol) and 6-chloro-5-(3-methyl-l,2,4-oxadiazol-5-yl)pyrimidin-4- amine (25.5 mg, 0.12 mmol) in «-BuOH (1.5 mL) was added DIPEA (0.05 mL, 0.3 mmol). The mixture was heated to 100 °C and stirred for 3.5 h. Then the mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (DCM/MeOH/TEA (v/v/v) = 100/1/0.5) to give the title compound as an off- white solid (22 mg, 43%).
MS (ESI, pos.ion)m/z: 478.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.28 (d, J= 6.3 Hz, 1 H), 8.00 (s, 1 H), 7.58-7.48 (m, 3 H), 7.47 - 7.32 (m, 5 H), 6.54 (s, 1H), 5.04 - 4.95 (m, 1H), 2.49 (s, 3 H), 2.13 (s, 3 H), 1.47 (d, j = 6.8 Hz, 3 H).
Example 17 (y)-3-(T-(Y6-amino-5-(5-methyl-E3.4-oxadiazol-2-vDpyrimidin-4-vDamino)ethvD- 2-phenyl-8-(prop- 1 -yn- 1 -vPisoquinolin- 1 (2H)-one
Figure imgf000105_0001
[0368] To a mixture of (A)-3-(l-aminoethyl)-2-phenyl-8-(prop-l-yn-l-yl)isoquinolin-l(2i7)- one (50 mg, 0.16 mmol) and 6-chloro-5-(5-methyl-l,3,4-oxadiazol-2-yl)pyrimidin-4-amine (38.5 mg, 0.18 mmol) in «-BuOH (1.5 mL) was added DIPEA (0.06 mL, 0.3 mmol). The mixture was heated to l00°C and stirred for 4 h. Then the mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (DCM/MeOH/TEA (v/v/v) = 80/1/0.5)to give the title compound as a yellow solid (15.5 mg, 20%).
MS (ESI, pos.ion) m/z: 478.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.60 (d, J = 6.6 Hz, 1H), 8.01 (s, 1 H), 7.59 - 7.45 (m, 4 H), 7.44 - 7.39 (m, 2 H), 7.35 (d, J = 7.7 Hz, 2 H), 6.54 (s, 1 H), 6.05 (s, 2 H), 4.99 - 4.95 (m, 1 H), 2.69 (s, 3 H), 2.12 (s, 3 H), 1.47 (d, j= 6.8 Hz, 3 H).
Example 18 (y)-3-(T-(Y6-amino-5-(5-methyl-E2.4-oxadiazol-3-vDpyrimidin-4-vDamino)ethvD- 2-phenyl-8-(prop- 1 -yn- 1 -vPisoquinolin- 1 (2H)-one
Figure imgf000106_0001
[0369] To a suspension of (ri)-3-(l-aminoethyl)-2-phenyl-8-(prop-l-yn-l-yl)isoquinolin- l(2//)-one (50 mg, 0.16 mmol) and 6-chloro-5-(5-methyl-l,2,4-oxadiazol-3-yl)pyrimidin-4- amine (38.5 mg, 0.18 mmol) in «-BuOH (1.5 mL) was added DIPEA (0.06 mL, 0.3 mmol). The mixture was heated to 110 °C and stirred for 3.5 h. Then the mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (DCM/MeOH/TEA (v/v/v) = 80/1/0.5) to give the title compound as an off- white solid (15.3 mg, 19%).
MS (ESI, pos.ion) m/z: 478.3 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.22 (d, J= 6.4 Hz, 1 H), 7.99 (s, 1 H), 7.56 - 7.55 (d, J = 6.7 Hz, 1 H), 7.53 - 7.43 (m, 3 H), 7.41 - 7.32 (m, 4 H), 6.55 (s, 1 H), 5.01 - 4.93 (m, 1 H), 2.71 (s, 3 H), 2.12 (s, 3 H), 1.46 (d, j= 6.7 Hz, 3 H).
Example 19 (y)-3-(T-(Y6-amino-5-(T-methyl- E2.4-triazol-3-v0pyrimidin-4-v0amino)ethv0-
Figure imgf000106_0002
2-phenyl-8-(prop- 1 -yn- 1 -vPisoquinolin- 1 (2H)-one
Figure imgf000106_0003
[0370] To a suspension of (ri)-3-(l-aminoethyl)-2-phenyl-8-(prop-l-yn-l-yl)isoquinolin- l(2//)-one (50 mg, 0.16 mmol) and 6-chloro-5-(l-methyl-lH-l,2,4-triazol-3-yl)pyrimidin-4- amine (38.5 mg, 0.18 mmol) in «-BuOH (1.5 mL) was added DIPEA (0.15 mL, 0.86 mmol). The mixture was heated to 110 °C and stirred for 3.5 h. Then the mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (DCM/MeOH/TEA (v/v/v) = 80/1/0.5) to give the title compound as an off- white solid (12.3 mg, 16%).
MS (ESI, pos.ion) m/z: 477.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 9.08 (d, J= 6.6 Hz, 1 H), 8.08 (s, 1 H), 7.91 (s, 1 H), 7.53 (d, J= 7.0 Hz, 1 H), 7.50 - 7.43 (m, 2 H), 7.41 (d, J= 7.2 Hz, 1 H), 7.38 - 7.29 (m, 4 H), 6.56 (s, 1 H), 4.99 - 4.88 (m, 1 H), 3.99 (s, 3 H), 2.10 (s, 3 H), 1.44 (d, J= 6.7 Hz, 3 H).
Example 20 ( r)-3-n-((6-amino-5-(2-methyl-2 7-tetrazol-5-yl)pyrimidin-4-yl)amino)ethyl)-2- phenyl-8-(prop- 1 -yn- 1 -vOisoquinolin- 1 (2H)-one
Figure imgf000107_0001
[0371] To a suspension of (A)-3-(l-aminoethyl)-2-phenyl-8-(prop-l-yn-l-yl)isoquinolin- 1 (2//)-one (50 mg, 0.16 mmol) and 6-chloro-5-(2-methyltetrazol-5-yl)pyrimidin-4-amine (38.5 mg, 0.18 mmol) in «-BuOH (1.5 mL) was added DIPEA (0.15 mL, 0.86 mmol). The mixture was heated to 110 °C and stirred for 3.5 h. Then the mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (DCM/MeOH/TEA (v/v/v) = 80/1/0.5) to give the title compound as an off-white solid (7.0 mg, 9%).
MS (ESI, pos.ion) m/z: 478.2 [M + H]+;
1H NMR (400 MHz, CDCI3) d (ppm): 8.47 (d, J= 6.5 Hz, 1 H), 7.98 (s, 1 H), 7.53 (t, J= 6.8 Hz, 1 H), 7.47 (d, J = 8.0 Hz, 2 H), 7.45 - 7.40 (m, 1 H), 7.40 - 7.30 (m, 4 H), 6.54 (s, 1 H), 5.03 - 4.94 (m, 1 H), 4.46 (s, 3 H), 2.10 (s, 3 H), 1.46 (d, j= 6.7 Hz, 3 H).
Example 21 (y)-2-(T-(Y6-amino-5-(3-methyl-E2.4-oxadiazol-5-v0pyrimidin-4-v0amino)ethv0- 3-cvclopropyl-5 -(3 -hydroxyprop- 1 -yn- 1 -yl )quinazolin-4 -one
Figure imgf000107_0002
Figure imgf000108_0001
Step 1) (S)-tert- butyl ( 1 -(3-cvclopropyl -4-oxo-5-(prop- l -vn- 1 -yl )-3.4- dihvdroquinazolin-2- vOethyQcarbamate
[0372] To a mixture of {S)-tert- butyl (l-(5-chloro-3-cyclopropyl-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate (2.83 g, 7.78 mmol) (See the synthetic method of step 1- 3 of example 33 in W02015042077) and cesium carbonate (3.76 g, 11.5 mmol) in DMAC (18 mL) was added palladium diacetate (86.8 mg, 0.39 mmol), X-phos (367.0 mg, 0.77 mmol) under a N2 atmosphere, and then was added prop-l-yne (40.0 mL, 21 mmol) in heptanes. The reaction was stirred at 110 °C for 5 h in a sealed tube, then cooled down to room temperature, diluted with EtOAc (200 mL), filtered through a celite pad. The filtrate was washed with water (200 mL x 5), concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc / PE (v/v) = 1/3) to give the title compound as a light-yellow solid (970 mg, 34%).
MS (ESI, pos. ion) m/z: 368 [M + H]+ ;
Step 2) (S)-2-( 1 -aminoethvD-3 -cvclopropyl-5-(prop- 1 -yn- 1 -yl )quinazolin-4 -one
Figure imgf000108_0002
[0373] To a solution of (S)-tert- butyl (l-(3-cyclopropyl-4-oxo-5-(prop-l-yn-l-yl)-3,4- dihydroquinazolin-2-yl)ethyl)carbamate (970.0 mg, 2.64 mmol) in EtOAc (10 mL) was added concentrated hydrogen chloride (36%, 2.5 mL). The resulted solution was stirred at room temperature for 0.5 h, and then diluted with H20 (30 mL) and EtOAc (10 mL). The organic layer was separated and the aqueous phase was basified with NaHC03 powder to pH = 8.5, then extracted with CH2Cl2 (30 mL c 3). The combined organic phase was washed with saturated brine (20 mL), concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / CH2Cl2 (v/v) = 1/10) to give the title compound as a yellow solid (110 mg, 16%)
MS (ESI, pos. ion) m/z: 268.2 [M + H]+ ;
1H NMR (400 MHz, CDCl3) d (ppm): 7.57-7.48 (m, 3H), 4.75 (q, J= 6.8 Hz, 1H), 2.93-2.87 (m, 1H), 2.20 (s, 3H), 1.43 (d, J= 6.4 Hz, 3H), 1.39- 1.28 (m, 2H), 0.99-0.86 (m, 2H). Example 22 (y)-2-(T-(Y6-amino-5-(5-methyl-E3.4-oxadiazol-2-vDpyrimidin-4-vDamino)ethvD- 3-cvclopropyl-5-('3-hvdroxyprop- 1 -vn- 1 -yl )quinazolin-4 -one
Figure imgf000109_0001
Figure imgf000109_0002
[0374] A mixture of (A)-2-(l-aminoethyl)-3-cyclopropyl-5-(prop-l-yn-l-yl)quinazolin-4(3i )- one (31.0 mg, 0.116 mmol), 6-chloro-5-(5-methyl-l,3,4-oxadiazol-2-yl)pyrimidin-4-amine (25.6 mg, 0.121 mmol) and DIPEA (24.0 mg, 0.186 mmol) in «-butanol (1 mL) was heated to 90 °C overnight. The mixture was cooled down to room temperature, concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / CH2CI2 (v/v) = 1/100) to give the title compound as a yellow solid (25.0 mg, 49%).
MS (ESI, pos. ion) m/z: 443.2 [M + H]+;
1H NMR (600 MHz, CDCI3) d (ppm): 8.61 (d, J= 7.2 Hz, 1H), 8.15 (s, 1H), 7.56 - 7.55 (m, 1H), 7.50 - 7.49 (m, 2H), 6.32 - 6.27 (m, 1H), 3.05 - 3.02 (m, 1H), 2.72 (s, 3H), 2.19 (s, 3H), 1.61 (d, J= 6.6 Hz, 3H), 1.44 - 1.40 (m, 2H), 1.08 - 1.05 (m, 1H), 1.00 - 0.96 (m, 1H).
13C NMR (150 MHz, CDCI3) d (ppm): 162.9, 162.2, 160.8, 160.7, 160.3, 158.9, 158.1, 147.6, 133.3, 133.0, 126.4, 123.9, 121.0, 92.9, 81.3, 79.1, 47.7, 26.7, 21.1, 11.3, 10.7, 10.3, 5.3.
Example 23 (y)-3-(T-(Y6-amino-5-(3-methyl-E2.4-oxadiazol-5-vDpyrimidin-4-vDamino)ethvD- 2-cvclopropyl-8-(prop- 1 -yn- 1 -vPisoquinolin- 1 (2H)-one
Figure imgf000109_0003
Step 1 (A)-3-(Ί -aminoethyl )-2-cvclopropyl-8-(prop- l -vn- 1 -yl )isoquinolin- l -one
[0375] To a suspension of (A)-3-(l-aminoethyl)-8-chloro-2-cyclopropylisoquinolin-l(2i7)-one (610 mg, 2.32 mmol) (See the synthetic method of step 1-4 of example 4 in WO2015042078), cesium carbonate (915 mg, 2.80 mmol), dichlorobis(tricyclohexylphosphine)-palladium(II) (172 mg, 0.23 mmol) in DMSO (10 mL) was added a solution of propyne in heptane (24 mL, 13 mmol, 3 mass%) under N2 atmosphere. The resulted solution was place in a sealed tube (50 mL) and stirred at l20°C for 4 h. The mixture was then cooled down to room temperature and diluted with EtOAc (20 mL), filtered over a pad of Celite and washed with EtOAc (10 mL c 2). The filtrate was washed with H20 (15 mL c 3) and saturated NaCl (20 mL), dried over Na2S04 and concentrated in vacuo. The residue was purified by a silica gel column chromatography (DCM/MeOH (v/v) = 30/1) to give the title compound as a yellow solid (560 mg, 90%).
MS (ESI, pos. ion) m/z: 267.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm) 7.44 (d, J= 7.4 Hz, 1H), 7.38 (t, J= 7.6 Hz, 1H), 7.25 (d, J = 8.0 Hz, 1H), 6.50 (s, 1H), 4.73 (q, j= 6.5 Hz, 1H), 2.97 - 2.77 (m, 1H), 2.15 (s, 3H), 1.37 (d, J = 6.5 Hz, 3H), 1.28 - 1.19 (m, 2H), 0.88 - 0.76 (m, 2H).
Step 2 6y)-3-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vOpyrimidin-4-vOamino)ethvO-2- cvclopropyl-8-(prop- 1 -yn- 1 -vQisoquinolin- 1 -one
Figure imgf000110_0001
[0376] A suspension of (ri)-3-(l-aminoethyl)-2-cyclopropyl-8-(prop-l-yn-l-yl)isoquinolin- l(2//)-one (120 mg, 0.45 mmol), 6-chloro-5-(3-methyl-l,2,4-oxadiazol-5-yl)-pyrimidin-4-amine (114.5 mg, 0.54 mmol) and DIPEA (76 mg, 58.8 mmol) in «-butanol (4 mL) was heated at 120 °C for 2 h. The mixture was then cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 1/100) to give the title compound as a pale yellow solid (10 mg, 5%).
MS (ESI, Pos. ion) m/z: 442.3 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm) 8.44 (d, J= 6.7 Hz, 1H), 8.13 (s, 1H), 7.48 (d, J = 6.7 Hz, 1H), 7.40 (t, j = 7.7 Hz, 1H), 7.23 (d, j = 7.8 Hz, 1H), 6.37 (s, 1H), 6.14 (p, j = 6.8 Hz, 1H), 2.97 (ddd, 7 = 11.2, 6.9, 4.2 Hz, 1H), 2.48 (s, 3H), 2.20 (s, 3H), 1.62 (d, J= 6.8 Hz, 3H), 1.28 - 1.19 (m, 2H), 0.96 - 0.83 (m, 2H).
13C NMR (100 MHz, CDCl3) d (ppm): 173.3, 165.6, 163.7, 161.4, 159.8, 159.4, 148.2, 137.4, 133.5, 130.9, 125.1, 124.6, 102.2, 92.3, 81.9, 80.0, 46.7, 29.7, 27.1, 21.6, 11.5, 10.6, 5.3.
Example 24 (y)-3-(T-(Y6-amino-5-(5-methyl-L3.4-oxadiazol-2-vDpyrimidin-4-vDamino)ethvD- 2-cvclopropyl-8-(prop- 1 -yn- 1 -vPisoquinolin- 1 (2H)-one
Figure imgf000111_0001
[0377] A suspension of (ri)-3-(l-aminoethyl)-2-cyclopropyl-8-(prop-l-yn-l-yl)isoquinolin- l(2//)-one (80 mg, 0.30 mmol), 6-chloro-5-(5-methyl-l,3,4-oxadiazol-2-yl)pyrimidin-4-amine ( 83.9 mg, 0.40 mmol) and DIPEA (49.5 mg, 0.38 mmol) in butan-l-ol (2 mL) was heated at 120 °C for 2 h. The mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 100/1) to give the title compound as a pale yellow solid (9 mg, 7%).
MS (ESI, Pos. ion) m/z: 442.3 [M+H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.74 (d, J= 6.7 Hz, 1H), 8.11 (s, 1H), 7.49 (d, J= 7.4 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 7.23 (d, J = 7.7 Hz, 1H), 6.40 (s, 1H), 6.22 - 6.13 (m, 1H), 3.04 - 2.96 (m, 1H), 2.69 (s, 3H), 2.21 (s, 3H), 1.64 (d, J= 6.7 Hz, 3H), 1.46 - 1.41 (m, 2H), 0.86 - 0.81 (m, 2H).
13C NMR (100 MHz, CDCI3) d (ppm): 163.7, 162.8, 160.8, 159.8, 158.9, 158.4, 148.3, 137.5, 133.4, 130.9, 125.1, 124.5, 102.3, 92.2, 81.1, 80.1, 46.7, 29.7, 27.1, 21.7, 11.0, 10.6, 5.3.
Example 25 (y)-3-(T-(Y6-amino-5-(5-methyl-E2.4-oxadiazol-3-vDpyrimidin-4-vDamino)ethvD-
2-cvclopropyl-8-(prop- 1 -yn- 1 -vPisoquinolin- 1 (2H)-one
Figure imgf000111_0002
[0378] To a suspension of (ri)-3-(l-aminoethyl)-2-cyclopropyl-8-(prop-l-yn-l-yl)isoquinolin- l(2//)-one (30 mg, 0.11 mmol) in l,4-dioxane(2 mL) was added 6-chloro-5-(5-methyl-l,2,4- oxadiazol-3-yl)-pyrimidin-4-amine (27 mg, 0.13 mmol), cesium carbonate (45 mg, 0.14 mmol), palladium diacetate(4 mg, 0.018 mmol) and [l-(2-diphenylphosphanyl-l-naphthyl)-2-naphthyl]- diphenyl-phosphane (10 mg, 0.016 mmol). The mixture was heated at 100 °C for 2 h under a N2 atmosphere. The mixture was then cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 1/100) to give the title compound as a pale yellow solid (10 mg, 20%).
MS (ESI, Pos. ion) m/z: 442.2 [M+H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.38 (d, J= 6.8 Hz, 1H), 8.12 (s, 1H), 7.50 (d, J= 7.0 Hz, 1H), 7.41 (dd, J = 13.8, 6.2 Hz, 1H), 7.25 (d, j= 7.4 Hz, 1H), 6.41 (s, 1H), 6.21 - 6.09 (m, 1H), 3.08 - 2.88 (m, 1H), 2.72 (s, 3H), 2.21 (d, J = 9.8 Hz, 3H), 1.62 (t, J = 8.1 Hz, 3H), 1.28 - 1.19 (m, 2H), 0.96 - 0.83 (m, 2H).
13C NMR (100 MHz, CDCl3) d (ppm): 174.5, 165.9, 163.9, 161.3, 159.5, 158.3, 148.6, 137.5, 133.5, 131.0, 125.3, 125.0, 124.6, 102.3, 92.3, 82.4, 80.2, 46.7, 27.1, 22.7, 21.6, 14.1, 12.4, 5.4.
Example 2 -(l-((6-amino-5-(3-methyl-l.2.4-oxadiazol-5-yl)pyrimidin-4-yl)amino)propyl)-
Figure imgf000112_0001
3-cvclopropyl-5 -(prop- 1 -yn- 1 -yl )quinazolin-4 -one
Figure imgf000112_0002
Figure imgf000112_0003
Step 1) (M-fer/-butyl ri -G-cvclopropyl -4-oxo-5-(prop- l -vn- 1 -yl )-3.4-dihydroquinazolin-2- yl ipropyl icarbamate
[0379] To a suspension of {S)-tert- butyl (l-(5-chloro-3-cyclopropyl-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)carbamate (1.5 g, 4.0 mmol) (See the synthetic method of step 1- 4 of example 2 in W02015042077) in DMAC (8 mL) was added potassium carbonate(0.83 g, 5.9 mmol), X-Phos(0. l9 g, 0.4mmol), 10% Pd/C (0.42 g) and 3% prop-l-yne in heptane (27 g, 20.2 mmol). The reaction was degassed with nitrogen. After being stirred at 1 l0°C overnight, the reaction mixture was diluted with CH2Cl2 (30 mL) and filtered. The filtrate was washed with H20 (15 mL x 6) and brine (15 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc/PE (v/v) = 1/6) to give the title compound as a yellow solid (1.15 g, 76 %).
MS (ESI, pos. ion) m/z: 382.1 [M + H]+; Step 2) (S)-2-( 1 -aminopropyn-3 -cvclopropyl -5 -(prop- 1 -yn- 1 -yl )quinazolin- -one
Figure imgf000113_0001
[0380] To a suspension of {S)-tert- butyl (l-(3-cyclopropyl-4-oxo-5-(prop-l-yn-l-yl)-3,4- dihydroquinazolin-2-yl)propyl)carbamate (1.15 g, 3 mmol) in dioxane (20 mL) was added con. HC1 (2 mL). After being stirred at 35 °C for 3 h, the reaction mixture was concentrated in vacuo. The residue was diluted with 0T202 (50 mL) and neutralized with 5 M NaOH to rH=10. The water phase was extracted with CH2Cl2 (50 mL c 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo to give the title compound as a yellow solid (0.8 g, 94 %).
MS (ESI, pos. ion) m/z: 282.3 [M + H]+.
Step 3) (S)-2-( \ -(Y6-amino-5-(3-methyl- l .2.4-oxadiazol-5-yl )pyrimidin-4-yl )amino)propyl )-3- cvcl opropyl-5-(prop-l-vn-l-vPquinazolin-4 -one
Figure imgf000113_0002
[0381] To a suspension of (ri)-2-(l-aminopropyl)-3-cyclopropyl-5-(prop-l-yn-l- yl)quinazolin-4(3//)-one (133 mg, 0.47 mmol) in «-butanol (2 mL) was added 6-chloro-5-(3- methyl-l,2,4-oxadiazol-5-yl)pyrimidin-4-amine (100 mg, 0.47 mmol) and DIPEA (0.17 mL, 0.97 mmol). After being stirred at 110 °C overnight, the reaction mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH/CH2Cl2 (v/v) = 1/400) to give the title compound as a yellow solid (85 mg, 39%).
MS (ESI, pos. ion) m/z: 457.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 9.00 (d, J= 7.8 Hz, 1H), 8.15 (s, 1H), 7.60 - 7.46 (m, 3H), 6.37 - 6.27 (m, 1H), 3.09 - 3.00 (m, 1H), 2.52 (s, 3H), 2.20 (s, 3H), 2.15 - 2.02 (m, 1H), 2.03 - 1.90 (m, 1H), 1.16 - 1.08 (m, 1H), 1.03 - 0.92 (m, 4H), 0.91 - 0.81 (m, 2H).
Example 27 (y)-2-(T-(Y6-amino-5-(5-methyl-L3.4-oxadiazol-2-vDpyrimidin-4-vPamino)propyD- 3-cvclopropyl-5 -(prop- 1 -yn- 1 -yl )quinazolin-4 -one
Figure imgf000113_0003
Figure imgf000113_0004
[0382] To a suspension of (ri)-2-(l-aminopropyl)-3-cyclopropyl-5-(prop-l-yn-l- yl)quinazolin-4(3//)-one (114 mg, 0.41 mmol) in «-butanol (2 mL) was added 6-chloro-5-(5- methyl-l,3,4-oxadiazol-2-yl)pyrimidin-4-amine (86 mg, 0.41 mmol) and DIPEA (0.2 mL, 1.1 mmol). After being stirred at 110 °C for 6 h, the reaction mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH/CH2Cl2 (v/v) = 1/400) to give the title compound as a yellow solid (69 mg, 37 %).
MS (ESI, pos. ion) m/z: 457.1 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.51 (d, J= 7.8 Hz, 1H), 8.16 (s, 1H), 7.59 - 7.49 (m, 3H), 6.59 (s, 2H), 6.35 (dd, j= 13.1, 7.4 Hz, 1H), 3.10 - 3.05 (m, 1H), 2.74 (s, 3H), 2.22 (s, 3H), 2.13 - 1.95 (m, 2H), 1.32 - 1.25 (m, 1H), 1.17 - 1.13 (m, 1H), 1.02 (t, j= 7.4 Hz, 3H), 0.98 - 0.96 (m, 1H), 0.92 - 0.86 (m, 1H).
Example 28 (y)-2-(T-(Y6-amino-5-(5-methyl-E3.4-oxadiazol-2-vDpyrimidin-4-vPamino)propyD- 3-cvclopropyl-5-('3-hvdroxyprop- 1 -vn- 1 -yl )quinazolin-4 -one
Figure imgf000114_0001
Figure imgf000114_0002
Step _ 1) _ (S)-tert- butyl _ ( 1 -(3 -cvclopropyl-5 -(3 -hydroxyprop- 1 -yn- 1 -yl )-4-oxo-3.4- dihvdroquinazolin-2-vDpropyDcarbamate
[0383] To a solution of {S)-tert- butyl (l-(5-chloro-3-cyclopropyl-4-oxo-3,4- dihydroquinazolin-2-yl)propyl)carbamate (1.5 g, 4.0 mmol) in DMAC (8 mL) was added potassium carbonate (0.83 g, 5.9 mmol), X-Phos (0.19 g, 0.39 mmol), 10% Pd/C (0.42 g) and prop-2-yn-l-ol (1.2 mL, 20 mmol) under nitrogen atmosphere. After being stirred at 110 °C overnight, the reaction mixture was diluted with CH2Cl2 (30 mL) and filtered. The filtrate was washed with H20 (15 mL x 6) and brine (15 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc /PE (v/v) = 1/4) to give the title compound as yellow oil (1.66 g, 100 %).
MS (ESI, pos. ion) m/z: 398.2 [M + H]+. Step 2) (S)-2-( 1 -aminopropyn-3 -cvclopropyl -5 -(3 -hydroxyprop- 1 -yn- 1 -yl )quinazolin- -one
Figure imgf000115_0001
[0384] To a suspension of {S)-tert- butyl (l-(3-cyclopropyl-5-(3-hydroxyprop-l-yn-l-yl)-4- oxo-3,4-dihydroquinazolin-2-yl)propyl)carbamate (1.66 g, 4.2 mmol) in l,4-dioxane (20 mL) was added con. HC1 (2 mL). After being stirred at 30 °C for 2 h, the reaction mixture was concentrated in vacuo. The residue was diluted with CH2CI2 (50 mL) and neutralized with 5 M NaOH to rH=10. The water phase was extracted with CH2Cl2 (50 mL c 3). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo to give the title compound as yellow oil (0.94 g, 76 %).
MS (ESI, pos. ion) m/z: 298.1 [M + H]+.
Step 3) 6y)-2-(T-(Y6-amino-5-(5-methyl-L3.4-oxadiazol-2-vDpyrimidin-4-vDamino)propyD-3- cvclopropyl-5-(3-hvdroxyprop- l -yn- 1 -yl )quinazolin- -one
Figure imgf000115_0002
[0385] To a suspension of (ri)-2-(l-aminopropyl)-3-cyclopropyl-5-(3-hydroxyprop-l-yn-l- yl)quinazolin-4(3//)-one (200 mg, 0.67 mmol) in «-butanol (3 mL) was added 6-chloro-5-(5- methyl-l,3,4-oxadiazol-2-yl)pyrimidin-4-amine (114 mg, 0.54 mmol) and DIPEA (0.24 mL, 1.4 mmol). After being stirred at 110 °C overnight, the reaction mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH/CELCh (v/v) = 1/400) to give the title compound as a yellow solid. (58 mg, 18 %).
MS (ESI, pos. ion) m/z: 473.1 [M + H]+;
1H NMR (400 MHz, CDCI3) d (ppm): 8.58 (d, J= 7.6 Hz, 1H), 8.16 (s, 1H), 7.63 - 7.54 (m, 3H), 6.54 (s, 2H), 6.35 (dd, J = 12.9, 7.4 Hz, 1H), 4.62 (s, 2H), 3.75 (q, j = 7.0 Hz, 1H), 3.12 - 3.06 (m, 1H), 2.74 (s, 3H), 2.14 - 1.96 (m, 2H), 1.28 - 1.27 (m, 1H), 1.19 - 1.16 (m, 1H), 1.04 (t, j = 7.4 Hz, 3H), 0.98 - 0.94 (m, 1H), 0.92 - 0.88 (m, 1H).
Example 29 (y)-2-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vDpyrimidin-4-vPamino)propyD- 3-cvclopropyl-5 -(3 -hydroxyprop- 1 -yn- 1 -yl )quinazolin-4 -one
Figure imgf000115_0003
Figure imgf000115_0004
[0386] To a suspension of (ri)-2-(l-aminopropyl)-3-cyclopropyl-5-(3-hydroxyprop-l-yn-l- yl)quinazolin-4(3//)-one (0.20 g, 0.67 mmol) in «-butanol (3 mL) was added 6-chloro-5-(3- methyl-l,2,4-oxadiazol-5-yl)pyrimidin-4-amine (114 mg, 0.54 mmol) and DIPEA (0.24 mL, 1.4 mmol). After being stirred at 110 °C for 7 h, the reaction mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH/CH2Cl2 (v/v) = 1/200) to give the title compound as a yellow solid (123 mg, 39 %).
MS (ESI, pos. ion) m/z: 473.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.97 (d, J= 7.5 Hz, 1H), 8.17 (s, 1H), 7.62 - 7.61 (m, 2H), 7.56 (dd, J = 8.7, 4.5 Hz, 1H), 6.34 (dd, j = 12.7, 7.4 Hz, 1H), 5.84 (s, 2H), 4.63 (s, 2H), 3.11 - 3.06 (m, 1H), 2.54 (s, 3H), 2.17 - 1.94 (m, 2H), 1.31 - 1.28 (m, 1H), 1.19 - 1.16 (m, 1H), 1.03 (t, J= 7.4 Hz, 3H), 0.98 - 0.93 (m, 1H), 0.88 - 0.85 (m, 1H).
Example 30 (y)-2-(T-(Y6-amino-5-(3-methyl-E2.4-oxadiazol-5-vDpyrimidin-4-vDamino)ethvD- 3-cvcloDropyl-5-(3-hvdroxyprop- l -vn- 1 -yl )quinazolin-4 -one
Figure imgf000116_0001
Figure imgf000116_0002
Step _ 1) _ (S)-tert- butyl _ ( 1 -(3 -cvclopropyl-5 -(3 -hydroxyprop- 1 -yn- 1 -yl )-4-oxo-3.4- dihydroquinazolin-2-vDethvDcarbamate
[0387] To a solution of {S)-tert- butyl (l-(5-chloro-3-cyclopropyl-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate (2.45g g, 6.73 mmol) in DMAC (23 mL) was added 10% Pd/C (0.73 g), X-phos (0.65 g, 1.36 mmol) and potassium carbonate ( 1.91 g, 13.74 mmol) under a N2 atmosphere. Then to the mixture was added prop-2-yn-l-ol (2.4 mL, 41.0 mmol), the reaction was stirred at 1 10 °C for 20 h. The mixture was cooled down to room temperature, diluted with EtOAc (100 mL), filtered through a celite pad. The filtrate was washed with water (200 mL x 4), and saturated brine (200 mL), concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc / PE (v/v) = 3/2) to give the title compound as a yellow solid (250 mg, 10%). MS (ESI, pos. ion) m/z: 384.3 [M + H]+ ;
Step 2) (S)-2-( \ -aminoethyl )-3-cvclopropyl-5-(3-hvdroxyprop- l -vn- 1 -yl )quinazolin- -one
Figure imgf000117_0001
[0388] To a solution of {S)-tert- butyl (l-(3-cyclopropyl-5-(3-hydroxyprop-l-yn-l-yl)-4-oxo- 3,4-dihydroquinazolin-2-yl)ethyl)carbamate (0.25 g, 0.65 mmol) in EtOAc (5 mL)was added concentrated hydrogen chloride (36%, 0.55 mL). The resulted solution was stirred at rt. for 1 h, and then diluted with H20 (20 mL) and EtOAc (20 mL). The organic layer was separated and the aqueous phase was basified with NaHC03 powder to pH = 8.5, extracted with CH2Cl2 (30 mL c 3). The combined organic phase was washed with saturated NaCl (20 mL), concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / CH2Cl2 (v/v) = 3/100) to give the title compound as a yellow solid (98 mg, 53%).
MS (ESI, pos. ion) m/z: 284.2 [M + H]+ ;
1H NMR (400 MHz, CDCl3) d (ppm): 7.60 - 7.49 (m, 3H), 4.77 (q, J= 6.4 Hz, 1H), 4.58 (s, 2H), 2.88 - 2.85 (m, 1H), 1.45 - 1.44 (d, J= 6.4 Hz, 3H), 1.33 - 1.28 (m, 2H), 0.93 - 0.82 (m, 2H).
Step (T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vOpyrimidin-4-vOamino)ethvO-3-
Figure imgf000117_0002
cvclopropyl-5-(3-hvdroxyprop-l-vn-l-vQquinazolin-4 -one
Figure imgf000117_0003
[0389] A mixture of (ri)-2-(l-aminoethyl)-3-cyclopropyl-5-(3-hydroxyprop-l-yn-l- yl)quinazolin-4(3//)-one (34.0 mg, 0.12 mmol), 6-chloro-5-(3-methyl-l,2,4-oxadiazol-5- yl)pyrimidin-4-amine (30.3 mg, 0.143 mmol) and DIPEA (23.0 mg, 0.17 mmol) in «-butanol (1 mL) was heated to 120 °C for 2 h. The mixture was cooled down to room temperature, concentrated in vacuo. The residue was purified by prep-TLC (MeOH / CH2Cl2 (v/v) = 1/25) to give the title compound as a light-yellow solid (20.7mg, 38%).
MS (ESI, pos. ion) m/z: 459.2 [M + H]+ ;
1H NMR (600 MHz, CDCI3) d (ppm): 9.098 (d, J = 6.6 Hz, 1H), 8.15 (s, 1H), 7.60 - 7.58 (m, 2H), 7.53 (d, J= 6.0 Hz, 1H), 6.29 - 6.25 (m, 1H), 5.85 (bs, 1H), 4.60 (s, 2H), 3.05 (m, 1H), 2.52 (s, 3H), 1.64 (d, J= 6.6 Hz, 3H), 1.42 (m, 2H), 1.10 - 1.09 (m, 1H), 0.97 - 0.96 (m, 1H).
13C NMR (150 MHz, CDCl3) d (ppm): 173.3, 165.6, 162.1, 161.5, 160.1, 159.6, 158.8, 147.6, 133.1, 133.0, 127.5, 122.2, 120.8, 93.9, 84.8, 82.0, 51.8, 47.7, 26.6, 20.8, 11.6, 10.6, 10.2.
Example 31 (y)-2-(T-(Y6-amino-5-(5-methyl-E3.4-oxadiazol-2-vDpyrimidin-4-vDamino)ethvD- 3-cvclopropyl-5 -(3 -hydroxyprop- 1 -yn- 1 -yl )quinazolin-4 -one
Figure imgf000117_0004
Figure imgf000118_0001
[0390] A mixture of (ri)-2-(l-aminoethyl)-3-cyclopropyl-5-(3-hydroxyprop-l-yn-l- yl)quinazolin-4(3//)-one (34.0 mg, 0.12 mmol), 6-chloro-5-(5-methyl-l,3,4-oxadiazol-2-yl) pyrimidin-4-amine (32.6 mg, 0.15 mmol) and DIPEA (19.8 mg, 0.15 mmol) in «-butanol (1 mL) was heated to 120 °C for 2.5 h. The mixture was cooled down to room temperature, concentrated in vacuo. The residue was purified by a silica gel column chromatography (/MeOH CH2Cl2 (v/v) = 1/10) to give the title compound as a light-yellow solid (5.4 mg, 10%).
MS (ESI, pos. ion) m/z: 459.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.63 (d, J= 7.2 Hz, 1H), 8.16 (s, 1H), 7.57 - 7.52 (m, 3H), 6.34-6.28 (m, 1H), 4.60 (s, 2H), 3.09-3.03 (m, 1H), 2.73 (s, 3H), 2.51 (br.s, 1H), 1.63 (d, J= 6.8 Hz, 3H), 1.44 - 1.41 (m, 2H), 1.12 - 1.08 (m, 1H), 0.99 - 0.94 (m, 1H).
Example 32 fy)-2-(T-(Y6-arnino-5-(T-rnethyl- E2.4-triazol-3-vDpyrimidin-4-vDamino)ethvD-
Figure imgf000118_0002
3-cvclopropyl-5 -(3 -hydroxyprop- 1 -yn- 1 -yl )quinazolin-4 -one
Figure imgf000118_0003
Figure imgf000118_0004
[0391] A mixture of fV)-2-( l -aminoethyl)-3-cyclopropyl-5-(3-hydroxyprop- 1 -yn- 1 - yl)quinazolin-4(3//)-one (34.0 mg, 0.12 mmol), 6-chloro-5-(l-methyl-l,2,4-triazol-3-yl) pyrimidin-4-amine (30.2 mg, 0.14 mmol) and DIPEA (20.9 mg, 0.16 mmol) in «-butanol (1 mL) was heated to 120 °C for 10.5 h. The mixture was cooled down to room temperature, concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / CH2Cl2 (V/V) =1/20) to give the title compound as a light-yellow solid (17.2 mg, 31%). MS (ESI, pos. ion) m/z: 458.3 [M + H]+;
1H NMR (600 MHz, CDCl3) d (ppm): 9.45 (d, J= 7.2 Hz, 1H), 8.13 (s, 1H), 8.09 (s, 1H), 7.56 - 7.54 (m, 2H), 7.51 - 7.49 (m, 1H), 6.34 - 6.29 (m, 1H), 4.59 (s, 2H), 4.03 (s, 3H), 3.11 - 3.07 (m,lH), 1.65 (d, J= 6.6 Hz, 3H), 1.41 - 1.38 (m, 2H), 1.19 - 1.15 (m, 1H), 0.94 - 0.91 (m, 1H).
[0392] 13C NMR (150 MHz, CDCl3) d (ppm): 162.4, 161.4, 160.5, 160.3, 158.8, 156.6, 148.1,
141.9, 132.9, 132.8, 127.5, 122.3, 121.1, 93.8, 86.2, 85.2, 52.0, 47.7, 36.5, 26.9, 20.9, 10.5, 10.4.
Example 33 (A)-3-G1 -((6-amino-5-(3-methyl- l .2.4-oxadiazol-5-yl )-pyrimidin-4-yl )amino)ethyl )- 2-cvclopropyl-8-(3-hvdroxyprop- l -vn- 1 -yl )-isoquinolin- -one
Figure imgf000119_0001
Figure imgf000119_0002
Stepl) 0V)-3-( l -aminoethyl )-2-cvclopropyl-8-(3-hvdroxyprop- l -vn- 1 -yl )isoquinolin-U2//)-one
[0393] To a suspension of {S)-tert- butyl (l-(8-chloro-2-cyclopropyl-l-oxo-l,2- dihydroisoquinolin-3-yl)ethyl)carbamate (500 mg, 1.90 mmol), cesium carbonate (748 mg, 2.30 mmol) and dichlorobis(tricyclohexylphosphine)-palladium(II) (143 mg, 0.19 mmol) in DMSO (20 mL) was added the prop-2-yn-l-ol (0.4 mL, 7 mmol,) under a N2 atmosphere. The resulted mixture was stirred at 120 °C for 2 h in a 50 mL of sealed tube, then cooled to room temperature and diluted with EtOAc (40 mL), filtered through a pad of celite and washed with EtOAc (10 mL x 3). The filtrate was washed with H20 (20 mL c 3) and saturated brine (20 mL), dried over Na2S04 and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 1/30) to give the title compound as a yellow solid (81 mg, 15%).
MS (ESI, pos. ion) m/z: 283.2[M+H]+;
1H NMR (400 MHz, CDCI3) d (ppm): 7.46 (t, J= 6.4 Hz, 1H), 7.42 (d, J= 7.5 Hz, 1H), 7.33 (d, J= 7.5 Hz, 1H), 6.59 (s, 1H), 4.85 - 4.79 (m, 1H), 4.58 (s, 1H), 3.07 - 2.99 (m, 1H), 1.46 (d, J = 6.5 Hz, 2H), 1.35 - 1.26 (m, 2H), 0.86 - 0.78 (m, 2H).
Step 2) (y)-3-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vD-pyrimidin-4-vPamino)ethvD-2- cvclopropyl-8-(3-hvdroxyprop- l -vn- 1 -yl )-isoquinolin-U2//)-one [0394] A suspension of (ri)-3-(l-aminoethyl)-2-cyclopropyl-l-oxo-l,2-dihydroisoquinoline-8- carbonitrile (43 mg, 0.14 mmol), 6-chloro-5-(3-methyl-l,2,4-oxadiazol-5-yl)-pyrimidin-4-amine (37.0 mg, 0.17 mmol), DIPEA (30.0 mg, 0.21 mmol) in z-PrOH ( 4 mL) was heated at 100 °C for 2 h. The mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 1/100) to give the title compound as a pale yellow solid (20 mg, 29%).
MS (ESI, Pos. ion) m/z: 458.2 [M+H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 8.45 (d, J= 6.6 Hz, 1H), 8.12 (s, 1H), 7.51 (d, J= 7.2 Hz, 1H), 7.44 (t, J= 7.7 Hz, 1H), 7.30 (d, J= 7.7 Hz, 1H), 6.41 (s, 1H), 6.18 - 6.06 (m, 1H), 4.60 (s, 2H), 3.06 - 2.93 (m, 1H), 2.48 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H), 1.35 - 1.30 (m, 2H), 0.96 - 0.87 (m, 2H).
13C NMR (100 MHz, CDCI3) d (ppm): 173.3, 165.7, 163.7, 161.4, 159. 8, 159.4, 148.6, 137.5, 133.1, 131.1, 126.0, 125.0, 123.1, 102.3, 93.7, 86.2, 81.9, 52.0, 46.7, 29.7, 27.2, 21.6, 11.5, 10.6.
Example 34 (y)-2-(T-(Y6-amino-5-(3-methyl-E2.4-oxadiazol-5-vDpyrimidin-4-vDamino)ethvD-
5-(3 -hydroxyprop- 1 -yn- 1 -yl)-3 -phenyl quinazolin-4 -one
Figure imgf000120_0001
Figure imgf000120_0002
Step 1) (S)-tert- butyl n -(5-(3-hvdroxyprop- l -yn- 1 -yl )-4-oxo-3 -phenyl -3.4-dihydroqui nazolin-2- vPethvDcarbamate
[0395] To a mixture of tert- butyl (l-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2- yl)ethyl)carbamate (0.99 g, 2.5 mmol), 10% Pd/C (0.27 g), X-phos (0.21 g, 0.44 mmol), potassium carbonate (0.52 g, 32.54 mmol) in DMAC (8 mL) was added prop-2-yn-l-ol (0.3 mL, 5 mmol) under a N2 atmosphere. The reaction was stirred at 115 °C for 9 h and then cooled down to room temperature, diluted with EtOAc (100 mL), filtered through a celite pad. The filtrate was washed with water (100 mL x 4), and saturated brine (100 mL), concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc / PE (v/v) = 3/2) to give the title compound as a light-yellow solid (554 mg, 53%). MS (ESI, pos. ion) m/z: 420.2 [M + H]+ ;
1H NMR (400 MHz, CDCl3) d (ppm): 7.67 (d, J= 4.4 Hz, 2H), 7.60 - 7.49 (m, 4H), 7.38 (d, J = 6.4 Hz, 1H), 7.28 (d, J = 7.2 Hz, 1H), 5.61 (d, j = 7.2 Hz, 1H), 4.50 (d, J = 4.0 Hz, 2H), 4.50 - 4.49 (m, 1H), 2.11 (br.s, 1H), 1.41 (s, 9H), 1.25 (d, = 6.4 Hz, 3H).
Step 2 (S)-2-( 1 -aminoethyl)-5 -(3 -hydroxyprop- 1 -yn- 1 -vO-3 -phenyl quinazolin-4 one
Figure imgf000121_0001
[0396] To a solution of (S)-tert- butyl (l-(5-(3-hydroxyprop-l-yn-l-yl)-4-oxo-3-phenyl-3,4- dihydroquinazolin-2-yl)ethyl)carbamate (0.55 g, 1.31 mmol) in EtOAc (4 mL) and CH2Cl2 (4 mL) was added hydrogen chloride (36%, 1 mL). The resulted solution was stirred at room temperature for 1 h and then concentrated in vacuo. The residue was diluted with H20 (20 mL) and EtOAc (20 mL). The organic layer was separated and the aqueous layer was basified with NaHC03 powder to pH = 8.5, and then extracted with CH2Cl2 (20 mL c 3). The combined organic phase was washed with saturated brine (20 mL), concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / CH2Cl2 (v/v) = 3/200) to give the title compound as a light-yellow solid (237 mg, 56%).
MS (ESI, pos. ion) m/z: 320.4 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 7.66 - 7.65 (m, 2H), 7.57 - 7.49 (m, 4H), 7.27 - 7.24 (m, 2H), 4.48 (s, 2H), 3.65 (q, j= 6.4 Hz, 1H), 1.91 (br, s, 3H), 1.25 (d, j= 6.4 Hz, 3H).
Step 3) (M-2-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vDpyrimidin-4-vDamino)ethvD-5-(3- hydroxyprop- 1 -yn- 1 -vD-3 -phenyl quinazolin-4 -one
Figure imgf000121_0002
[0397] A mixture of fV)-2-( l -aminoethyl)-5-(3-hydroxyprop- 1 -yn- 1 -yl)-3-phenylquinazolin- 4(3i )-one (42.5 mg, 0.13 mmol), 6-chloro-5-(3-methyl-l,2,4-oxadiazol-5-yl) pyrimidin-4-amine (31.2 mg, 0.15 mmol) and DIPEA (34.6 mg, 0.27 mmol) in «-butanol (1 mL) was heated to 120 °C for 2 h. The mixture was then cooled down to room temperature, and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / CH2Cl2 (v/v) = 1/50) to give the title compound as a light-yellow solid (26.8mg, 47%).
MS (ESI, pos. ion) m/z: 495.2 [M + H]+;
1H NMR (400 MHz, DMSO-i¾) d (ppm): 9.21 (d, j= 6.4 Hz, 1H), 7.98 (s, 1H), 7.82 (dd, j= 8.0, 7.6 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.59 - 7.54 (m, 8H), 5.27 (t, J = 6.0 Hz, 1H), 4.96 - 4.89 (m, 1H), 4.29 (d, j= 6.0 Hz, 2H), 2.50 (s, 3H), 1.36 (d, j= 6.4 Hz, 3H).
13C NMR (100 MHz, DMSO-i¾) d (ppm): 172.8, 165.2, 161.1 , 159.7, 159.3, 158.3, 158.0, 147.7, 136.2, 133.9, 132.7, 129.5, 129.3, 129.2, 128.8, 127.1, 122.3, 120.4, 95.5, 82.7, 80.2, 49.7, 48.3, 20.1, 11.1. Example 35 (S)-2-( 1 -(Y6-amino-5-(5-methyl- 1.3.4-oxadiazol-2-vDpyrimidin-4-vDamino)ethvD- 5-(3 -hydroxyprop- 1 -yn- 1 -vD-3 -phenyl quinazolin-4('3//)-one
Figure imgf000122_0001
[0398] A mixture of fV)-2-( l -aminoethyl)-5-(3-hydroxyprop- 1 -yn- 1 -yl)-3-phenylquinazolin- 4(3i )-one (41.0 mg, 0.13 mmol), 6-chloro-5-(5-methyl-l,3,4-oxadiazol-2-yl) pyrimidin-4-amine (28.5 mg, 0.13 mmol) and DIPEA (36.1 mg, 0.28 mmol) in «-butanol (1 mL) was heated to 120 °C for 2.5 h. The mixture was then cooled down to room temperature, and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / CH2CI2 (v/v) = 1/50) to give the title compound as a light-yellow solid (14.9 mg, 24%).
MS (ESI, pos. ion) m/z: 495.3 [M + H]+;
1H NMR (400 MHz, CDCI3) d (ppm): 8.51 (d, J= 6.8 Hz, 1H), 8.00 (s, 1H), 7.65 - 7.64 (m, 2H), 7.59 - 7.51 (m, 4H), 7.44 - 7.43 (m, 1H), 7.34 - 7.32 (m, 1H), 6.39 (br.s, 2H), 5.15 - 5.08 (m, 1H), 4.49 (s, 2H), 4.49 (s, 15H), 2.71 (s, 3H), 2.71 (br.s, 1H),1.45 (d, j= 6.8 Hz, 3H).
13C NMR (150 MHz, CDCI3) d (ppm): 162.9, 161.4, 160.9, 160.4, 158.7, 158.6, 158.1, 148.4, 136.1, 133.6, 133.3, 130.1, 129.8, 129.8, 128.9, 127.9, 122.9, 121.0, 94.1, 84.8, 81.3, 51.9, 48.7, 20.5, 11.3.
Example 36 (y)-2-(T-(Y6-amino-5-(3-methyl-E2.4-oxadiazol-5-vDpyrimidin-4-vPamino)propyD- 5-(3 -h vdroxyprop- 1 -yn- 1 -vD-3 -phenyl quinazolin-4 -one
Figure imgf000122_0002
Figure imgf000122_0003
Step 1) (S)-tert- butyl n -(5-(3-hydroxyprop- l -vn- 1 -yl )-4-oxo-3 -phenyl -3.4-dihydroqui nazolin-2- vOpropyOcarbamate
[0399] To a suspension of {S)-tert- butyl (l-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin- 2-yl)propyl)carbamat (0.60 g, 1.4 mmol) in DMAC (3 mL) was added potassium carbonate (0.3 g, 2 mmol), X-Phos (71 mg, 0.15 mmol), 10% Pd/C (0.15 g) and prop-2-yn-l-ol (0.42 mL, 7.2 mmol). The reaction was degassed with nitrogen. After being stirred at 110 °C overnight, the reaction mixture was diluted with CH2Cl2 (20 mL) and then filtered. The filtrate was washed with H20 (6 mL x 6) and saturated brine (6mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtO Ac/PE (v/v) = 1/6) to give the title compound as a yellow solid (0.32 g, 51 %).
MS (ESI, pos. ion) m/z: 434.2 [M + H]+.
Step 2) (S)-2-( 1 -aminopropyD-5-(3 -hydroxyprop- 1 -yn- 1 -yl)-3 -phenyl quinazolin-4 -one
Figure imgf000123_0001
[0400] To a suspension of {S)-tert- butyl (l-(5-(3-hydroxyprop-l-yn-l-yl)-4-oxo-3-phenyl-3,4- dihydroquinazolin-2-yl)propyl)carbamate (0.32 g, 0.75 mmol) in dioxane (5 mL) was added con. HC1 (0.5 mL). After being stirred at 35 °C for 2 h, the reaction mixture was concentrated in vacuo. The residue was diluted with CH2Cl2 (20 mL) and neutralized with 5 M NaOH to pH = 10. The water phase was extracted with CH2Cl2 (20 ml c 3). The combined organic layer was washed with saturated brine (50 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo to give the title compound as a yellow solid (0.31 g, 100 %).
MS (ESI, pos. ion) m/z: 334.1 [M + H]+.
Step3) (X)-2-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vDpyrimidin-4-vDainino)propyD-5-(3- hydroxyprop- 1 -yn- 1 - yl)-3 -phenyl quinazolin-4 -one
Figure imgf000123_0002
[0401] To a suspension of (ri)-2-(l-aminopropyl)-5-(3-hydroxyprop-l-yn-l-yl)-3- phenylquinazolin-4(3//)-one (0.16 g, 0.46 mmol) in «-butanol (2.5 mL) was added 6-chloro-5- (3-methyl-l,2,4-oxadiazol-5-l)pyrimidin-4-amine (0.11 g, 0.51 mmol) and DIPEA (0.2 mL, 1.1 mmol). After being stirred at 110 °C overnight, the reaction mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH/CH2Cl2 (v/v) = 1/200) to give the title compound as a yellow solid (33 mg, 14 %).
MS (ESI, pos. ion) m/z: 509.1 [M + H]+; 1H NMR (400 MHz, CDCl3) d (ppm): 8.72 (d, J= 7.2 Hz, 1H), 8.03 (s, 1H), 7.70 - 7.65 (m, 2H), 7.61 - 7.54 (m, 4H), 7.47 (d, J = 6.2 Hz, 1H), 7.37 (d, J = 9.4 Hz, 1H), 5.73 (s, 2H), 5.14 - 5.09 (m, 1H), 4.53 (s, 2H), 2.54 (s, 3H), 2.19 (s, 1H), 1.98 - 1.77 (m, 2H), 0.87 (t, J= 7.4 Hz, 3H).
Example 37 (y)-2-(T-(Y6-amino-5-(5-methyl-E3.4-oxadiazol-2-vOpyrimidin-4-vOamino)propyO- 5-(3 -hydroxyprop- 1 -yn- 1 -vD-3 -phenyl quinazolin- -one
Figure imgf000124_0001
Figure imgf000124_0002
[0402] To a suspension of (A)-2-(l-aminopropyl)-5-(3-hydroxyprop-l-yn-l-yl)-3- phenylquinazolin-4(3//)-one (114 mg, 0.34 mmol) in «-butanol (2.5 mL) was added 6-chloro-5- (5-methyl-l,3,4-oxadiazol-2-yl)pyrimidin-4-amine (86 mg, 0.41 mmol) and DIPEA (0.14 mL, 0.8 mmol). After being stirred at 110 °C for 9 h, the reaction mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH/CH2Cl2 (v/v) = 1/200) to give the title compound as a yellow solid (53 mg, 30 %).
MS (ESI, pos. ion) m/z: 509.2 [M + H]+;
1H NMR (400 MHz, CDCI3) d (ppm): 8.45 (d, J= 7.6 Hz, 1H), 8.02 (s, 1H), 7.67 - 7.65 (m, 2H), 7.62 - 7.54 (m, 4H), 7.47 (d, J = 7.1 Hz, 1H), 7.35 (dd, J= 7.2, 2.0 Hz, 1H), 6.33 (s, 2H), 5.13 - 5.08 (m, 1H), 4.52 (s, 2H), 2.73 (s, 3H), 2.19 (s, 1H), 1.97 - 1.77 (m, 2H), 0.87 (t, j = 7.4 Hz, 3H).
Example 38 (y)-2-(T-(Y6-amino-5-(5-methyl-E2.4-oxadiazol-3-v0pyrimidin-4-v0amino)ethv0- 5-(3 -hydroxyprop- 1 -yn- 1 -vD-3 -phenyl quinazolin-4 -one
Figure imgf000124_0003
Figure imgf000125_0001
[0403] To a suspension of fV)-2-( l -aminoethyl)-5-(3-hydroxyprop- 1 -yn- 1 -yl)-3-phenyl- quinazolin-4(3//)-one (50 mg, 0.16 mmol), 6-chloro-5-(5-methyl-l,2,4-oxadiazol-3- yl)pyrimidin-4-amine (38.1 mg, 0.18 mmol) in «-BuOH (1.5 mL) was added DIPEA (0.06 mL, 0.31 mmol). The mixture was heated to 120 °C and stirred for 7 h. Then the mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 1/50) to give the title compound as a pale yellow solid (29 mg, 37%).
MS(ESI, pos.ion) m/z: 495.2 [M + H]+.
[0404] 1H NMR (400 MHz, DMSO-i¾) d (ppm): 8.95 (d, J= 6.6 Hz, 1H), 7.96 (s, 1H), 7.80 (t, J= 7.9 Hz, 1H), 7.65 (d, J= 8.0 Hz, 1H), 7.63 - 7.53 (m, 6H), 7.50 (s, 2 H), 5.28 - 5.26 (m, 1H), 4.95 - 4.85 (m, 1 H), 4.30 (d, J= 5.9 Hz, 2 H), 2.77 (s, 3 H), 1.37 (d, J= 6.6 Hz, 3 H).
Example 39 (A)-2-(T-(Y6-arnino-5-(2 -methyl -2iT-tetrazol-5-vPpyrimidin-4-vPamino)ethvD-5-(3- hydroxyprop- 1 -yn- 1 -vO-3 -phenyl quinazolin-4 -one
Figure imgf000125_0002
Figure imgf000125_0003
[0405] To a suspension of fV)-2-( l -ami noethyl )-5-(hydroxyethynyl)-3 -phenyl quinazolin- 4(3i )-one (50 mg, 0. l6mmol), 6-chloro-5-(2-methyltetrazol-5-yl)pyrimidin-4-amine (38.1 mg, 0.18 mmol) in «-BuOH (1.5 mL) was added DIPEA (43 mg, 0.33 mmol). The mixture was heated to 120 °C and stirred for 7 h. Then the mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 1/50) to give the title compound as a pale yellow solid (19 mg, 25%).
MS (ESI, pos.ion) m/z: 495.2 [M + H]+;
1H NMR (400 MHz, DMSO-i¾) d (ppm): 8.98 (d, J= 6.7 Hz, 1H), 7.97 (s, 1H), 7.80 (t, J = 7.9 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.63 - 7.53 (m, 6H), 7.48 (s, 2 H), 5.28 (t, j = 5.9 Hz, 1 H), 4.98 - 4.88 (m, 1H), 4.55 (s, 3H), 4.30 (d, J= 5.9 Hz, 2H), 1.39 (d, J= 6.6 Hz, 3H).
Example 4 -n-((6-amino-5-(3-methyl-l.2.4-oxadiazol-5-yl)pyrimidin-4-yl)amino)ethyl)-
Figure imgf000126_0001
8-(3 -hydroxyprop- 1 -yn- 1 -nP-2-phenylisoquinolin- 1 (2R)-one
Figure imgf000126_0002
Step 1) (M-fer/-butyl (4-(3-chloro-2-(phenylcarbamoyl)phenvn-3-oxobutan-2-yl)carbamate
[0406] At -30 °C, to a suspension of 2-chloro-6-methyl-/V-phenyl-benzamide (10.0 g, 40.70 mmol) in dry THF (81 mL) was added «-BuLi (50 mL, 120 mmol, 2.4 mol/L in hexane) dropwise over 30 min. After addition, the mixture was stirred at -30 °C for 1.5 h to give a red brown solution (i), which was directly used in the next step.
[0407] At -30 °C, to a suspension of /c/V-butyl (l-(methoxy(methyl)amino)-l-oxopropan-2- yl)carbamate (14.20 g, 61.13 mmol) in dry THF (120 mL) was added i-PrMgCl (67 mL, 67 mmol, 1.0 mol/L in THF) dropwise over 30 min. After addition, the mixture was stirred at -30 °C for 1.5 h to give pale yellow liquid (ii).
[0408] To the red brown solution (i) was added the pale yellow liquid (ii) dropwise at -30 °C. After addition, the mixture was stirred at -15 °C for 3.5h, then quenched by addition of saturated NH4Cl (150 mL), extracted with EtOAc (150 mL c 3). The combined organic phase was washed with saturated brine (200 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo to give the title compound as a pale yellow solid (17.0 g, 100%), which was directly used in the next step.
Step 2) fV)-3-( l -aminoethyl )-8-chloro-2-phenylisoquinolin- -one
Figure imgf000126_0003
[0409] To a suspension of /er/-butyl (L')-(4-(3 -chi oro-2-(phenyl carbarn oyl)phenyl)-3- oxobutan-2-yl)carbamate (17.0 g, 40.8 mmol) in methanol (112 mL) was added concentrated HC1 solution (112 mL, 36%). The mixture was heated to reflux and stirred overnight. Then the mixture was cooled down to room temperature and concentrated in vacuo. The residue was diluted with PE/EtOAc (200 mL/lOO mL) and water (200 mL). The aqueous layer was washed with PE/EA (100 mL/50 mL), and then adjusted to PH=l0 with Na2CO, powder, extracted with DCM (200 mL x 3). The combined organic layer was washed with saturated NaCl (300 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo to give the title compound as a yellow solid (9.2 g, 76%).
MS (ESI, pos.ion)m/z: 282.1 [M - NH3 + H]+;
1H NMR (400 MHz, DMSO-i¾) d (ppm): 7.67 - 7.60 (m, 2 H), 7.59 - 7.52 (m, 2 H), 7.52 - 7.43 (m, 2 H), 7.38 - 7.31 (m, 2 H), 6.92 (s, 1 H), 3.53 - 3.33 (m, 1 H), 1.08 (d, J= 6.5 Hz, 3 H).
Step 3) (S)- 3 -( 1 -aminoethvD-8-(3 -hydroxyprop- 1 -yn- 1 -vD-2-phenylisoquinolin- 1 (2H)-one
[0410] To a suspension of (ri)-3-(l-aminoethyl)-8-chloro-2-phenylisoquinolin-l(2f/)-one (1.5 g, 5.0 mmol) in DMAC (10 mL) was added Cs2C03 (2.5 g, 7.7 mmol), PdCl2(PCy3)2 (375 mg, 0.51 mmol). The mixture was purged with N2, then added prop-2-yn-l-ol (0.85 g, 15.0 mmol). The mixture was sealed and heated to 1 l0°C and stirred for 5.5 h. The mixture was cooled down to room temperature, added EtOAc (150 mL) and water (30 mL). The organic layer was separated and washed with saturated NaCl (50 mL c 5), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (PE/EtOAc/TEA (v/v/v) = 1/10/0.5) to give the title compound as a yellow solid (805 mg, 53%).
MS (ESI, pos.ion) m/z: 319.2 [M + H]+;
1H MR (600 MHz, CDCl3) d (ppm): 7.60 - 7.48 (m, 4 H), 7.50 - 7.46 (dd, J = 15.3, 7.9 Hz, 2 H), 7.42 - 7.41 (d, J= 7.7 Hz, 1 H), 7.34 - 7.33 (d, J= 7.4 Hz, 1 H), 6.76 (s, 1 H), 3.77 - 3.69 (m, 1 H), 2.13 (s, 3 H), 1.30 (d, = 6.5 Hz, 3 H).
13C NMR (151 MHz, CDCl3) d (ppm): 162.5, 138.0, 134.1, 131.6, 129.8, 129.7, 129.4, 129.0, 128.9, 125.6, 125.1, 124.7, 102.3, 92.8, 79.9, 46.9, 23.0, 5.4.
Step 4) (N)-3-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vDpyrimidin-4-vDamino)ethvD-8-(3- hydroxyprop- 1 -yn- 1 -nP-2-phenyli soquinolin- 1 (2H)-one
[0411] To a suspension of (A)-3-(l-aminoethyl)-8-(3 -hydroxyprop- l-yn-l-yl)-2- phenylisoquinolin-l(2f/)-one (40 mg, 0.13 mmol) and 6-chloro-5-(3-methyl-l,2,4-oxadiazol-5- yl)pyrimidin-4-amine (30 mg, 0.14 mmol) in «-BuOH (1.5 mL) was added DIPEA (0.05 mL). The mixture was stirred at 80 °C for 6 h, then cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (DCM/MeOH/TEA (v/v/v) = 100/1/0.5) to give the title compound as an off-white solid (12 mg, 23%).
MS (ESI, pos.ion) m/z: 494.3 [M + H]+;
1H NMR (600 MHz, DMSO-r¾) d (ppm): 8.38 (d, J= 6.4 Hz, 1 H), 7.98 (s, 1 H), 7.66 - 7.60 (m, 2 H), 7.56 - 7.50 (m, 2 H), 7.43 - 7.4l(m, 4 H), 6.73 (s, 1 H), 4.78- 4.72 (m, 1 H), 4.28 (d, J = 5.9 Hz, 2 H), 2.44 (s, 3 H), l .4l(d, j= 6.8 Hz, 3 H).
13C NMR (l5 l MHz, DMSO-r¾) d (ppm): 173.4, 165.7, 161.5, 161.3, 159.7, 159.0, 147.8, 138.6, 138.3, 133.5, 132.4, 130.0, 129.7, 129.6, 129.3, 128.8, 127.0 124.3, 123.4, 101.6, 95.6, 84.4, 81.0, 50.3, 47.6, 20.9, 11.6.
Example 41 0SV3 -( 1 -(Y6-amino-5-(5-methyl- 1.3.4-oxadiazol-2-vDpyrimidin-4-vDamino)ethvD- 8-(3 -hydroxyprop- 1 -yn- 1 -vD-2-phenylisoquinolin- 1 (2R)-one
Figure imgf000128_0001
[0412] To a suspension of (A)-3-(l-aminoethyl)-8-(3 -hydroxyprop- l-yn-l-yl)-2- phenylisoquinolin-l(2//)-one (30 mg, 0.09 mmol) and 6-chloro-5-(5-methyl-l,3,4-oxadiazol-2- yl)pyrimidin-4-amine (22 mg, 0.10 mmol) in «-BuOH (1.5 mL) was added DIPEA (0.03 mL). The mixture was stirred at 80 °C for 8 h, then cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (DCM/MeOH/TEA (v/v/v) = 40/1/0.5) to give the title compound as a pale yellow solid (4.5mg, 9%).
MS (ESI, pos.ion)m/z: 494.3 [M + H]+;
1H NMR (600 MHz, CD3OD) d (ppm): 8.70 (d, j = 5.7 Hz, 1 H), 7.92 (s, 1 H), 7.58 - 7.50 (m, 3H), 7.48 - 7.36 (m, 5 H), 6.67 (s, 1 H), 5.02 - 4.91 (m, 1 H), 4.40 (s, 2 H), 2.67 (s, 3 H), 1.46 (d, J= 5.5 Hz, 3 H). 13C NMR (l5 l MHz, CD3OD/CDCI3) d (ppm): 162.8, 162.7, 161.5, 159.6, 158.4, 158.1, 146.6, 138.3, 137.5, 133.6, 131.9, 129.3, 129.3, 129.2, 128.8, 128.8, 126.5, 124.3, 123.5, 103.3, 93.9, 84.8, 50.9, 47.3, 29.6, 20.7, 10.7.
Example 42 (y)-2-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-v0pyrimidin-4-v0amino)ethv0- 6-fluoro-5-(3 -hydroxyprop- 1 -yn- 1 -vD-3 -phenyl quinazolin- -one
Figure imgf000129_0001
Figure imgf000129_0002
Stepl ) 2-bro o-3-f1uoro-6-nitro-Af-phenylbenzamide
[0413] To a flask was added 2-bromo-3-fluoro-6-nitro-benzoic acid (2.0 g, 7.6 mmol) and SOCl2 (10 mL). The mixture was stirred at 80 °C for 5.0 h and then cooled down to room temperature, concentrated in vacuo to give yellow liquid. The liquid was dissolved in of DCM (15 mL) and then added into a stirred solution of TEA (2.5 mL, 18.0 mmol) and aniline (0.85 mL, 9.3 mmol) in of DCM (10 mL) at 0 °C. After addition, the mixture was continued to stir at 0 °C for 2 h. Then the mixture was concentrated in vacuo , and the residue was dissolved in water (50 mL) and DCM (100 mL). The water phase was extracted with DCM (50 mL). The combined organic phase was washed with 1.0 M HC1 (100 mL) and saturated aqueous NaHCCL (100 mL c 2), dried over anhydrous Na2S04 and concentrated in vacuo. The residue was purified by a silica gel column chromatography (PE/EtOAc (v/v) = 5/1) to give the title compound as a yellow solid (2.27 g, 88%).
MS (ESI, pos. ion) m/z: 340.1 [M+H]+ ;
1H NMR (400 MHz, DMSO-i¾) d (ppm): 10.76 (s, 1 H), 8.41 (dd, J= 9.2, 4.5 Hz, 1 H), 7.79 (dd, J= 9.0, 8.0 Hz, 1 H), 7.63 (d, J= 7.8 Hz, 2 H), 7.39 (t, J= 7.9 Hz, 2 H), 7.16 (t, J= 7.4 Hz, 1 H).
Step 2) 6-ami no-24) romo-3-fluoro-Af-phenylbenzamide
[0414] To a mixture of 2-bromo-3-fluoro-6-nitro-/V-phenylbenzamide (2.2 g, 6.7 mmol) in ethanol (20 mL) was added Fe dust (1.9 g, 76.3 mmol) and a solution of HCOONH4 (1.7 g, 27.0 mmol) in water (4.0 mL). The mixture was heated at 90 °C overnight. The mixture was cooled to 50 °C and filtered through celite and the filtrate was concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc /PE (v/v) = 1/5) to give the title compound as a light pink solid (1.13 g, 55%).
MS (ESI, pos. ion) m/z: 310.1 [M+H]+ ;
Step 3) (S)-tert- butyl (T-(Y3-bromo-4-fluoro-2-(phenylcarbamovDphenvDamino)-l-oxopropan-2- vPcarbamate
[0415] At 0 °C, to a suspension of 6-amino-2-bromo-3-fluoro-/V-phenylbenzamide (1.13 g, 3.66 mmol) and (2A)-2-(/er/-butoxycarbonylamino)propanoic acid (843 mg, 4.39 mmol) in DCM (10 mL) was added DIPEA (1.3 mL, 7.4 mmol) and ELATU (1.7 g, 4.38 mmol), and then the mixture was stirred at 45 °C overnight. The mixture was diluted with water (30 mL) and DCM (50 mL), and the aqueous layer was extracted with DCM (30 mL). The combined organic layer was dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc/PE (v/v) = 1/5) to get the title compound as a yellow solid (1.5 g, 85%).
MS (ESI, pos. ion) m/z: 502.0 [M + Na]+.
Step 4) (S)-tert- butyl (Ί -(5-bromo-6-fl uoro-4-oxo-3 -phenyl -3.4-dihydroqui nazolin-2- vPeth vPcarbamate
[0416] To a suspension of {S)-tert- butyl (l-((3-bromo-4-fluoro-2-
(phenylcarbamoyl)phenyl)amino)-l-oxopropan-2-yl)carbamate (860 mg, 1.79 mmol) in CEfCN (5 mL) was added DIPEA (0.70 mL, 4.0 mmol), DMAP (219 mg, 1.79 mmol) and BSA (1.5 mL, 6.0 mmol). The mixture was placed in a sealed tube and heated to 130 °C for 26 h. Then the mixture was cooled down to room temperature and diluted with EtOAc (100 mL), washed with saturated brine (50 mL c 2) and 1.0 M HC1 aqueous (50 mL). The organic phase was dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc / PE (v/v) = 1/5) to give the title compound as a yellow solid (630 mg, 76%).
MS (ESI, pos. ion) m/z: 461.8 [M+H]+ ;
1H NMR (600 MHz, CDCp) d (ppm): 7.71 (dd, J = 8.9, 4.9 Hz, 1 H), 7.63 (t, J = 7.1 Hz, 1 H), 7.60 - 7.52 (m, 3 H), 7.42 (d, J= 6.8 Hz, 1 H), 7.30 (d, J= 7.3 Hz, 1 H), 5.55 (d, J= 6.7 Hz, 1 H), 4.53 (m, 1 H), 1.44 (s, 9 H), 1.28 (d, j= 6.7 Hz, 3 H).
Step 5) (S)-tert- butyl (Ί -(6-f1uoro-5-(3-hvdroxyprop- l -yn- 1 -yl )-4-oxo-3-phenyl-3.4- dihvdroquinazolin-2-vDethvDcarbamate
[0417] To a suspension of {S)-tert- butyl (l-(5-bromo-6-fluoro-4-oxo-3-phenyl-3,4- dihydroquinazolin-2-yl)ethyl)carbamate (530 mg, 1.14 mmol) and Cs2C03 (561 mg, 1.72 mmol) in DMAC (5.0 mL) was added PdCl2(PCy3)2 (85.0 mg, 0.12 mmol) and prop-2-yn-l-ol (0.2 mL, 3.0 mmol). The mixture was purged with N2 and sealed, then stirred at 100 °C for 3.0 h. The mixture was cooled to room temperature and diluted with EtOAc (50 mL) and water (10 mL). The water phase was extracted with EtOAc (20 mL). The combined organic phase was washed with saturated brine (10 mL c 3) and dried over anhydrous Na2S04 filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc / PE (v/v) = 1/2) to give the title compound as yellow oil (93.0 mg, 19%).
MS (ESI, pos.ion) m/z: 438.1 [M + H]+ ;
Step 6) (S)-2-( \ -aminoethyl )-6-f1uoro-5-(3-hvdroxyprop- l -yn- 1 -yl )-3-phenylquinazolin-4 -
Figure imgf000131_0001
one
[0418] To a suspension of {S)-tert- butyl (l-(6-fluoro-5-(3-hydroxyprop-l-yn-l-yl)-4-oxo-3- phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (93.0 mg, 0.21 mmol) in EtOAc (1.0 mL) was added a solution of HC1 in EtOAc (2.0 mL, 6.0 mmol, 3.0 M). The mixture was stirred at room temperature for 1.0 h and then to the reaction mixture was added water (20 mL) and EtOAc (10 mL). The organic layer was separated and the aqueous layer was washed with EtOAc (10 mL), subjected to pH = 10 with Na2C03 powder, then extracted with EtOAc (20 mL c 2). The combined organic layer was dried over anhydrous Na2S04, filtered and concentrated in vacuo to give the title compound as yellow oil (53 mg, 74%), which was directly used in the next step without further purification.
MS (ESI, pos.ion) m/z: 338.1 [M + H]+.
Step 7) 6SV2-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vDpyrimidin-4-vOamino)ethvD-6- fluoro-5-(3 -hydroxyprop- 1 -yn- 1 -yl)-3 -phenyl quinazolin-4 -one
Figure imgf000131_0002
[0419] To a suspension of (ri)-2-(l-aminoethyl)-6-fluoro-5-(3-hydroxyprop-l-yn-l-yl)-3- phenylquinazolin-4(3//)-one (53.0 mg, 0.16 mmol) and 6-chloro-5-(3-methyl-l,2,4-oxadiazol-5- yl)pyrimidin-4-amine (37.0 mg, 0.18 mmol) in «-BuOH (1.5 mL) was added DIPEA (0.06 mL, 0.4mmol). The mixture was heated to 90 °C and stirred for 3.0 h, then concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH / DCM (v/v) = 1/40) to give the title compound as a pale yellow solid (22 mg, 27%).
MS (ESI, pos.ion) m/z: 513.2 [M + H]+;
1H NMR (400 MHz, DMSO-i¾) d (ppm): 9.19 (d, J= 6.5 Hz, 1 H), 7.99 (s, 1 H), 7.87 (t, j= 9.0 Hz, 1 H), 7.75 (dd, J = 8.9, 5.1 Hz, 1 H), 7.68 - 7.47 (m, 7 H), 4.99 - 4.86 (m, 1 H), 4.34 (d, J = 5.6 Hz, 2 H), 2.51 (s, 3 H), 1.37 (d, J= 6.5 Hz, 3 H). Example 43 (y)-2-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-v0pyrimidin-4-v0amino)ethv0- 3-cvclopropyl-5-ethvnylquinazolin- -one
Figure imgf000132_0001
Step _ 1) (S)-tert- butyl (T-(3-cvclopropyl-5-ethvnyl-4-oxo-3.4-dihvdroquinazolin-2- vOethvOcarbamate
[0420] To a mixture of {S)-tert- butyl (l-(5-chloro-3-cyclopropyl-4-oxo-3,4- dihydroquinazolin-2-yl)ethyl)carbamate (1.04 g, 2.86 mmol) in DMAC (10 mL) was added ethynyltrimethylsilane (4.0 mL, 28.3 mmol), 10% Pd/C (0.30 g), X-phos (0.14 g, 0.29 mmol) and potassium carbonate (0.60 g, 4.0 mmol). The mixture was degassed with nitrogen for several times and heated to 70 °C for 6.5 h. Then the mixture was cooled down to room temperature, diluted with EtOAc (50 mL) and water (10 mL). The organic layer was separated and washed with water (20 mL) and saturated brine (20 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc / PE (v/v) = 1/5) to give the title compound as a light-yellow solid (0.77 g, 76%).
MS (ESI, Pos. Ion) m/z: 354.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 7.68 - 7.53 (m, 3H), 5.72 - 5.54 (m, 2H), 3.54 (s, 1H), 3.00 - 2.89 (m, 1H), 1.48 - 1.44 (m, 12H), 1.42 - 1.37 (m, 2H), 1.12 - 1.03 (m, 1H), 1.00 - 0.90 (m, 1H).
Step 2) (S)-2-( \ -aminoethyl )-3-cvclopropyl-5-ethvnylquinazolin- -one
Figure imgf000132_0002
[0421] To a solid of {S)-tert- butyl (l-(3-cyclopropyl-5-ethynyl-4-oxo-3,4-dihydroquinazolin- 2-yl)ethyl)carbamate (0.77 g, 2.18 mmol) was added a solution of hydrogen chloride in EtOAc (10 mL, 40 mmol, 4.0 mol/L). The reaction was stirred at room temperature overnight, and then H20 (20 mL) was added and The mixture was stirred for another 10 min. The organic layer was separated and the aqueous phase was basified with NaOH powder to pH = 10, extracted with CH2Cl2 (15 mL x 3). The combined organic layer was dried over anhydrous Na2S04, filtered and concentrated in vacuo to give the title compound as a brown solid (0.49 g, 89%).
MS (ESI, Pos. Ion) m/z: 254.3 [M + H]+ ; 1H NMR (400 MHz, CDCl3) d (ppm): 7.66 - 7.51 (m, 3H), 4.83 - 4.67 (m, 1H), 3.53 (s, 1H), 2.97 - 2.83 (m, 1H), 1.43 (d, J= 6.6 Hz, 3H), 1.38 - 1.26 (m, 2H), 1.01 - 0.84 (m, 2H).
Step (T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vOpyrimidin-4-vOamino)ethvO-3-
Figure imgf000133_0001
cvclopropyl-5-ethvnylquinazolin- -one
Figure imgf000133_0002
[0422] A mixture of fV)-2-( l -ami noethyl )-3 -cyclopropyl -5-ethynylquinazolin-4(3//)-one (50 mg, 0.20 mmol), 6-chloro-5-(3 -methyl- 1, 2, 4-oxadiazol-5-yl)pyrimidin-4-amine (43 mg, 0.20 mmol) and DIPEA(0. l0 mL, 0.60 mmol) in propan-2-ol (3 mL) was heated to 85 °C for 12 h. The mixture was cooled down to room temperature, and then added water (5 mL) dropwise, stirred for 30 min and filtered. The filter cake was washed with water (1.0 mL) and dried in vacuo to give the title compound as an off-white solid (59 mg, 70%).
MS (ESI, Pos. Ion) m/z: 429.2 [M + H]+ ;
1H NMR (600 MHz, DMSO-i¾) d (ppm): 9.35 (d, J= 6.7 Hz, 1H), 8.13 (s, 1H), 7.76 (t, J = 7.8 Hz, 1H), 7.61 (d, J= 7.8 Hz, 2H), 6.17 - 6.06 (m, 1H), 4.46 (s, 1H), 3.16 - 3.08 (m, 1H), 2.50 (s, 3H), 1.59 (d, J= 6.5 Hz, 3H), 1.30 - 1.24 (m, 2H), 1.07 - 1.02 (m, 1H), 0.89 - 0.83 (m, 1H).
Example 44 (y)-2-(T-(Y6-amino-5-(3-methyl-L2.4-oxadiazol-5-vDpyrimidin-4-vDamino)ethvD- 5-ethvnyl-3-phenylquinazolin- -one
Figure imgf000133_0003
Figure imgf000133_0004
Step 1) (S)-tert- butyl n -(5-ethvnyl-4-oxo-3 -phenyl -3.4-dihydroquinazolin-2-yl iethyl icarbamate
[0423] To a mixture of (S)-tert- butyl (l-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2- yl)ethyl)carbamate (2.00 g, 5.00 mmol) in DMAC (20 mL) was added ethynyltrimethylsilane (7.0 mL, 50 mmol), 10% Pd/C (0.53 g), X-phos (0.24 g, 0.50 mmol) and potassium carbonate (1.00 g, 7.24 mmol). The mixture was degassed with nitrogen for several times and heated to 80 °C for 12 h. Then the mixture was cooled down to room temperature, diluted with EtOAc (150 mL) and filtered. The filtrate was washed with water (50 mL), dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by a silica gel column chromatography (EtOAc / PE (v/v) = 1/15) to give the title compound as a light-yellow solid (1.76 g, 76%). MS (ESI, Pos. Ion) m/z: 390.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 7.73 - 7.64 (m, 3H), 7.61 - 7.46 (m, 3H), 7.42 - 7.33 (m, 1H), 7.32 - 7.27 (m, 1H), 5.63 (d, J= 6.8 Hz, 1H), 4.61 - 4.45 (m, 1H), 3.46 (s, 1H), 1.39 (s, 9H), 1.26 (d, J= 6.7 Hz, 3H).
Step 2) (N)-2-(T-aminoethvO-5-ethvnyl-3-phenylquinazolin-4 -one
Figure imgf000134_0001
[0424] To a solid of {S)-tert- butyl (l-(5-ethynyl-4-oxo-3-phenyl-3,4-dihydroquinazolin-2- yl)ethyl)carbamate (0.74 g, 1.90 mmol) was added a solution of hydrogen chloride in EtOAc (30 mL, 120 mmol, 4.0 mol/L). The reaction was stirred at room temperature for 2 h., and then H20 (30 mL) was added and the mixture was stirred for another 10 min. The organic layer was separated and the aqueous phase was basified with NaOH powder to pH = 10, filtered and dried in vacuo to give the title compound as a brown solid (0.49 g, 89%).
MS (ESI, Pos. Ion) m/z: 290.2 [M + H]+ ;
1H NMR (400 MHz, CDCl3) d (ppm): 7.75 - 7.64 (m, 3H), 7.58 - 7.47 (m, 3H), 7.32 - 7.26 (m, 2H), 3.69 (q, J= 6.6 Hz, 1H), 3.46 (s, 1H), 1.28 (d, J= 6.6 Hz, 3H).
Step (T-(Y6-amino-5-(3-methyl-E2.4-oxadiazol-5-vOpyrimidin-4-vOamino)ethvO-5-
Figure imgf000134_0002
ethvnyl-3-phenylquinazolin- -one
Figure imgf000134_0003
[0425] A mixture of fV)-2-( l -ami noethyl )-5-ethynyl -3 -phenyl uinazolin-4(3//)-one 50 mg^
0.17 mmol), 6-chloro-5-(3-methyl-l,2,4- oxadiazol-5-yl)pyrimidin-4-amine (38 mg, 0.18 mmol) and DIPEA (0.10 mL, 0.60 mmol) in propan-2-ol (5 mL) was heated to 90 °C for 4 h. The mixture was cooled down to room temperature, and then water (5 mL) was added dropwise, the mixture was stirred for another 30 min and filtered. The filter cake was dried in vacuo to give the title compound as a white solid (57 mg, 71%).
MS (ESI, Pos. Ion) m/z: 465.3 [M + H]+ ;
1H NMR (400 MHz, DMSO-i¾) d (ppm): 9.23 (d, J= 6.6 Hz, 1H), 7.99 (s, 1H), 7.88 - 7.81 (m, 1H), 7.73 (d, J= 7.4 Hz, 1H), 7.67 (d, J= 7.4 Hz, 1H), 7.63 - 7.53 (m, 5H), 4.99 - 4.88 (m, 1H), 4.41 (s, 1H), 2.50 (s, 3H), 1.36 (d, j= 6.5 Hz, 3H).
Example 45 (y)-2-(T-(Y6-amino-5-(5-methyl-E3.4-oxadiazol-2-vDpyrimidin-4-vDamino)ethvD-
5-ethvnyl-3-phenylquinazolin- -one
Figure imgf000134_0004
Figure imgf000135_0001
[0426] A mixture of fV)-2-( l -ami noethyl )-5-ethynyl -3 -phenyl quinazolin-4(3//)-one
Figure imgf000135_0002
mg^
0.17 mmol), 6-chloro-5-(5-methyl-l,3,4-oxadiazol-2-yl)pyrimidin-4-amine (38 mg, 0.18 mmol), DIPEA (0.10 mL, 0.60 mmol) in propan-2-ol (3 mL) was heated to 90 °C for 12 h. The mixture was cooled down to room temperature, and then water (5 mL) was added dropwise. The mixture was stirred for another 10 min and filtered. The filter cake was dried in vacuo to give the title compound as a light-yellow solid (63 mg, 78%).
MS (ESI, Pos. Ion) m/z: 465.3 [M + H]+;
1H NMR (400 MHz, DMSO-r¾) d (ppm): 8.77 (d, J= 6.7 Hz, 1H), 7.96 (s, 1H), 7.84 - 7.77 (m, 1H), 7.72 - 7.47 (m, 7H), 7.26 (s, 2H), 4.93 - 4.82 (m, 1H), 4.40 (s, 1H), 2.60 (s, 3H), 1.37 (d, j = 6.6 Hz, 3H).
Example 46 fy)-2-(T-(Y6-arnino-5-(T-methyl-liT-E2.4-triazol-3-vPpyrimidin-4-vDamino)ethvD- 5-(3 -hydroxyprop- 1 -yn- 1 -vD-3 -phenyl quinazolin- -one
Figure imgf000135_0003
Figure imgf000135_0004
[0427] To a suspension of fV)-2-( l -ami noethyl )-5-(3-hydroxyprop- l -yn- 1 -yl )-3 - phenylquinazolin-4(3//)-one (65 mg, 0.20 mmol) in «-butanol (1 mL) was added 6-chloro-5-(l- m ethyl- 177-1, 2, 4-triazol-3-yl)pyrimidin-4-amine (43 mg, 0.20 mmol) and DIPEA (0.1 mL, 0.6 mmol). After being stirred at 110 °C overnight, the reaction mixture was cooled down to room temperature and concentrated in vacuo. The residue was purified by a silica gel column chromatography (MeOH/CH2Cl2 (v/v) = 1/20) to give the title compound as a yellow solid (38 mg, 38 %). MS (ESI, pos. ion) m/z: 494.2 [M + H]+;
1H NMR (400 MHz, DMSO-i¾) d (ppm): 9.58 (d, J = 6.6 Hz, 1H), 8.76 (s, 1H), 8.17 (s, 1H), 7.89 (s, 1H), 7.77 (t, j= 7.8 Hz, 1H), 7.66 (d, 7 = 8.1 Hz, 1H), 7.63 - 7.51 (m, 5H), 7.09 (s, 1H), 5.28 (t, J= 5.8 Hz, 1H), 4.90 - 4.83 (m, 1H), 4.308 (d, J= 4.2 Hz, 2H), 4.03 (s, 3H), 1.39 (d, J = 6.6 Hz, 3H).
Example 47 (y)-2-(T-(Y6-amino-5-(5-methyl-E2.4-oxadiazol-3-vOpyrimidin-4-vO amino)ethyl)- 5-ethvnyl-3-phenylquinazolin-4('3//)-one
Figure imgf000136_0001
[0428] To a suspension of (A)-2-(l-aminoethyl)-5-ethynyl-3-phenylquinazolin-4(3i )-one (50 mg, 0.17 mmol) and 6-chloro-5-(5-methyl-l,2,4-oxadiazol-3-yl)pyrimidin-4-amine (42 mg, 0.20 mmol) in propan-2-ol (5 mL) was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated to reflux and stirred for 8 h, then cooled down to room temperature, diluted with water (6 mL), stirred for another 30 min and filtered. The filter cake was dried in vacuo to give the title compound as a white solid (64 mg, 79%).
MS (ESI, pos. ion) m/z: 465.2 [M + H]+;
1H NMR (400 MHz, DMSO-76) d (ppm): 8.95 (d, J= 6.7 Hz, 1H), 7.96 (s, 1H), 7.81 (t, J = 7.8 Hz, 1H), 7.67 (dd, J = 13.8, 7.7 Hz, 2H), 7.59 (d, J= 8.7 Hz, 5H), 7.50 (s, 2H), 4.94 - 4.86 (m, 1H), 4.40 (s, 1H), 2.77 (s, 3H), 1.37 (d, J= 6.6 Hz, 3H).
Example 48 (M-2-(l-((6-amino-5-(2-m ethyl -2iT-tetrazol-5-vDpyrimidin-4-vDamino) ethvD-5- ethvnyl-3-phenylquinazolin- -one
Figure imgf000136_0002
Figure imgf000136_0003
[0429] To a suspension of (A)-2-(l-aminoethyl)-5-ethynyl-3-phenylquinazolin-4(3i )-one (52 mg, 0.18 mmol) and 6-chloro-5-(2-methyltetrazol-5-yl)pyrimidin-4-amine (40 mg, 0.19 mmol) in propan-2-ol (5 mL) was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated to reflux and stirred for 24 h, then cooled down to room temperature, diluted with water (6 mL), stirred for another 30 min and filtered. The filter cake was dried in vacuo to give the title compound as a white solid (51 mg, 61%).
MS (ESI, pos. ion) m/z: 465.1 [M + H]+;
1H NMR (400 MHz, DMSO-i¾) d (ppm): 8.98 (d, J = 6.8 Hz, 1H), 7.98 (s, 1H), 7.81 (s, 1H), 7.71 (s, 1H), 7.66 (s, 1H), 7.59 (d, j= 9.9 Hz, 5H), 7.48 (s, 2H), 4.99 - 4.87 (m, 1H), 4.55 (s, 3H), 4.40 (s, 1H), 1.39 (d, j= 6.6 Hz, 3H).
Example 49 (S)-2-( \ -t(6-amino-5-( l -methyl - 1 //- 1.2.4-triazol-3-yl )pyrimidin-4-yl ) aminoiethyl )- 5-ethvnyl-3-phenylquinazolin- -one
Figure imgf000137_0001
Figure imgf000137_0002
[0430] To a suspension of (A)-2-(l-aminoethyl)-5-ethynyl-3-phenylquinazolin-4(3i )-one (50 mg, 0.17 mmol), 6-chloro-5-(l-methyl-l,2,4-triazol-3-yl)pyrimidin-4-amine (40 mg, 0.19 mmol) in propan-2-ol (3 mL) was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated to reflux and stirred for 24 h, then cooled down to room temperature, diluted with water (6 mL), stirred for another 30 min and filtered. The filter cake was dried in vacuo to give the title compound as a white solid (62 mg, 77%).
MS (ESI, pos. ion) m/z: 464.3 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 9.41 (s, 1H), 8.14 (s, 1H), 7.95 (s, 1H), 7.76 - 7.60 (m, 3H), 7.60 - 7.43 (m, 4H), 7.34 (d, J= 7.5 Hz, 1H), 5.21 - 5.09 (m, 1H), 4.05 (s, 3H), 3.47 (s, 1H), 1.52 (d, J= 6.7 Hz, 3H).
Example 50 (y)-2-(T-(Y6-amino-5-(5-methyl-E3.4-oxadiazol-2-v0pyrimidin-4-v0amino)ethv0- 3-cvclopropyl-5-ethvnylquinazolin- -one
Figure imgf000138_0001
N -N Nhi
[0431] To a suspension of (A)-2-(l-aminoethyl)-3-cyclopropyl-5-ethynylquinazolin-4(3i )-one (50 mg, 0.20 mmol), 6-chloro-5-(5-methyl-l,3,4-oxadiazol-2-yl)pyrimidin-4-amine (43 mg, 0.20 mmol) in propan-2-ol (3 mL, 100 mass%) was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated to reflux and stirred for 24 h, then cooled down to room temperature, concentrated in vacuo. The residue was purified by prepared TLC (MeOH/DCM (v/v) = 1/25) to give the title compound as a white solid (71 mg, 84%).
MS (ESI, pos. ion) m/z: 429.2 [M + H]+;
1H NMR (400 MHz, CDCl3) d (ppm): 9.04 (d, J= 7.2 Hz, 1H), 8.15 (s, 1H), 7.66 - 7.49 (m, 3H), 6.44 - 6.23 (m, 1H), 3.56 (s, 1H), 3.11 - 2.99 (m, 1H), 2.74 (s, 3H), 1.66 (d, J= 6.6 Hz, 3H), 1.46 - 1.34 (m, 2H), 1.23 - 1.11 (m, 1H), 1.07 - 0.93 (m, 1H).
Example 51 (y)-2-(T-(Y6-amino-5-(5-methyl-E2.4-oxadiazol-3-vOpyrimidin-4-vO aminoiethyl )-
3-cvclopropyl-5-ethvnylquinazolin-4 -one
Figure imgf000138_0002
Figure imgf000138_0003
[0432] To a suspension of (A)-2-(l-aminoethyl)-3-cyclopropyl-5-ethynylquinazolin-4(3i )-one (50 mg, 0.20 mmol), 6-chloro-5-(5-methyl-l,2,4-oxadiazol-3-yl)pyrimidin-4-amine (43 mg, 0.20 mmol) in propan-2-ol (3 mL) was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated to reflux and stirred for 24 h, then cooled down to room temperature, concentrated in vacuo. The residue was purified by prepared TLC (MeOH/DCM (v/v) = 1/25) to give the title compound as a white solid (71 mg, 84%)
MS (ESI, pos. ion) m/z: 429.2 [M + H]+; 1H NMR (400 MHz, CDCl3) d (ppm): 9.01 (d, J= 7.2 Hz, 1H), 8.12 (s, 1H), 7.65 - 7.58 (m, 3H), 6.37 - 6.25 (m, 1H), 3.54 (s, 1H), 3.12 - 3.04 (m, 1H), 2.72 (s, 3H), 1.64 (d, J= 6.6 Hz, 3H), 1.46 - 1.39 (m, 2H), 1.24 - 1.15 (m, 1H), 1.01 - 0.94 (m, 1H).
Example 52 (S)-2-( \ -('('6-amino-5-('2-methyl- tetrazol-5-yl )pyrimidin-4-yl ) amino)ethvD-3-
Figure imgf000139_0001
cvclopropyl-5-ethvnylquinazolin-4 -one
Figure imgf000139_0002
Figure imgf000139_0003
[0433] To a suspension of (A)-2-(l-aminoethyl)-3-cyclopropyl-5-ethynylquinazolin-4(3i )-one (50 mg, 0.20 mmol), 6-chloro-5-(2-methyltetrazol-5-yl)pyrimidin-4-amine (45 mg, 0.21 mmol) in propan-2-ol (3 mL) was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated to reflux and stirred for 24 h, then cooled down to room temperature, concentrated in vacuo. The residue was purified by prepared TLC (MeOH/DCM (v/v) = 1/25) to give the title compound as a white solid (63 mg, 63%).
MS (ESI, pos. ion) m/z: 429.3 [M + H]+;
1H NMR (600 MHz, CDCI3) d (ppm): 9.14 (d, J= 7.3 Hz, 1H), 8.15 (s, 1H), 7.65 - 7.56 (m, 3H), 6.39 - 6.31 (m, 1H), 4.50 (s, 3H), 3.54 (s, 1H), 3.13 - 3.05 (m, 1H), 1.66 (d, J= 6.7 Hz, 3H), 1.47 - 1.38 (m, 2H), 1.20 - 1.13 (m, 1H), 1.01 - 0.93 (m, 1H).
Example 53 (S)-2-( \ -t(6-amino-5-( l -methyl - 1 //- 1.2.4-triazol-3-yl )pyrimidin-4-yl ) amino)ethvD- 3-cvclopropyl-5-ethvnylquinazolin- -one
Figure imgf000139_0004
Figure imgf000139_0005
[0434] To a suspension of (A)-2-(l-aminoethyl)-3-cyclopropyl-5-ethynylquinazolin-4(3i )-one (50 mg, 0.20 mmol), 6-chloro-5-(l-methyl-l,2,4-triazol-3-yl)pyrimidin-4-amine (45 mg, 0.21 mmol) in propan-2-ol (3 mL) was added DIPEA (0.1 mL, 0.6 mmol). The reaction mixture was heated to reflux and stirred for 24 h, then cooled down to room temperature, concentrated in vacuo. The residue was purified by prepared TLC (MeOH/DCM (v/v) = 1/25) to give the title compound as a white solid (68 mg, 81%).
MS (ESI, pos. ion) m/z: 428.2 [M + H]+;
1H NMR (600 MHz, CDCl3) d (ppm): 9.61 (d, J= 7.4 Hz, 1H), 8.15 (s, 1H), 8.10 (s, 1H), 7.67 - 7.52 (m, 3H), 6.38 - 6.31 (m, 1H), 4.04 (s, 3H), 3.56 (s, 1H), 3.27 (s, 2H), 3.15 - 3.08 (m, 1H)., 1.67 (d, J= 6.7 Hz, 3H), 1.48 - 1.37 (m, 2H), 1.24 - 1.13 (m, 1H), 1.03 - 0.92 (m, 1H).
BIOLOGICAL TESTING
[0435] The LC/MS/MS system used in the analysis consists of an Agilent 1200 Series vacuum degasser, binary pump, well-plate autosampler, thermostatted column compartment, the Agilent G6430 Triple Quadrupole Mass Spectrometer with an electrosprayionization (ESI) source. Quantitative analysis was carried out using MRM mode. The parameters for MRM transitions are in the Table A.
Table A
Figure imgf000140_0001
[0436] An Agilent XDB-C18, 2.1 x 30 mm, 3.5 mM column was used for the analysis. 5 pL of the samples were injected. Analysis condition: The mobile phase was 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B). The flow rate was 0.4 mL/min. And the gradient of Mobile phase was in the Table B.
Table B
Figure imgf000140_0002
Figure imgf000141_0001
[0437] Alternatively, an Agilent 6330 series LC/MS/MS spectrometer equipped with G1312A binary pumps, a G1367A autosampler and a G1314C UV detector were used in the analysis. An ESI source was used on the LC/MS/MS spectrometer. The analysis was done in positive ion mode as appropriate and the MRM transition for each analyte was optimized using standard solution. A Capcell MP-C18 100 x 4.6 mm I.D., 5 mM column (Phenomenex, Torrance, California, USA) was used during the analysis. The mobile phase was 5 mM ammonia acetate, 0.1% MeOH in water (A): 5 mM ammonia acetate, 0.1% MeOH in acetonitrile (B) (70:30, v/v). The flow rate was 0.6 mL/min. Column was maintained at ambient temperature. 20 pL of the samples were injected.
Example A: Compound Stability In Human and Rat Liver Microsomes
[0438] Human or rat liver microsomes incubations were conducted in duplicate in polypropylene tubes. The typical incubation mixtures consisted of human or rat liver microsomes (0.5 mg protein/mL), compounds of interest (5 mM) and NADPH (1.0 mM) in a total volume of 200 pL potassium phosphate buffer (PBS, 100 mM, pH 7.4). Compounds were dissolved in DMSO and diluted with PBS such that the final concentration of DMSO was 0.05%. The enzymatic reactions were commenced with the addition of protein after a 3-min preincubation and incubated in a water bath open to the air at 37 °C. Reactions were terminated at various time points (0, 5, 10, 15, 30, 60 min) by adding equal volume of ice-cold acetonitrile. The samples were stored at -80 °C until LC/MS/MS assays.
[0439] The concentrations of compounds in the incubation mixtures of human or rat liver microsomes were determined by a LC/MS/MS method. The ranges of the linearity in the concentration range were determined for each tested compounds.
[0440] A parallel incubation was performed using denatured microsomes as the negative control, and reactions were terminated at various time points (0, 15, 60 min) after incubation at 37 °C.
[0441] Dextromethorphan (70 pM) was selected as the positive control, and reactions were terminated at various time points (0, 5, 10, 15, 30, 60 min) after incubation at 37 °C. Both positive and negative control samples were included in each assay to ensure the integrity of the microsomal incubation system.
Data Analysis [0442] The concentrations of compounds in human or rat liver microsome incubations were plotted as a percentage of the relevant zero time point control for each reaction. The in vivo CLint were extrapolated (ref : Naritomi, Y.; Terashita, S.; Kimura, S.; Suzuki, A.; Kagayama, A.; and Sugiyama, Y.; Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Me tab. Dispos., 2001, 29: 1316-1324).
Table 2 Human and rat liver microsomes Stability
Figure imgf000142_0001
Figure imgf000143_0001
Example B: Evaluation of Pharmacokinetics After Intravenous and Oral Administration of The Compounds Disclosed Herein In Mice. Rats. Dogs And Monkeys
[0443] The compounds disclosed herein are assessed in pharmacokinetic studies in mice, rats, dogs or monkeys. The compounds are administered as a water solution, 2% HPMC + 1% TWEEN®80 in water solution, 5% DMSO + 5% solutol in saline, 4% MC suspension or capsule. For the intravenous administration, the animals are generally given at 1 or 2 mg/kg dose. For the oral (p.o.) dosing, mice and rats are generally given 5 or 10 mg/kg dose, and dogs and monkeys are generally given 10 mg/kg dose. The blood samples (0.3 mL) are drawn at 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 12 and 24 h time points or 0.083, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0, 8.0 and 24 h time points and centrifuged at 3,000 or 4000 rpm for 2 to 10 min. The plasma solutions are collected, stored at -20 °C or -70 °C until analyzed by LC/MS/MS as described above.
Table 3 Pharmacokinetic profiles in Rats
Figure imgf000143_0002
Figure imgf000144_0001
Example C: Kinase Activity Assay
[0444] The efficacy of the compounds disclosed herein as inhibitors of PI3 kinases and mTOR kinases can be evaluated as follows.
General Description for Kinase Assays
[0445] Kinase assays can be performed by measurement of incorporation of g-33R ATP into immobilized myelin basic protein (MBP). High binding white 384 well plates (Greiner) are coated with MBP (Sigma #M-l89l) by incubation of 60 pL/well of 20 pg/mL MBP in Tris- buffered saline (TBS; 50 mM Tris pH 8.0, 138 mM NaCl, 2.7 mM KC1) for 24 h at 4°C. Plates are washed 3 x with 100 pL TBS. Kinase reactions are carried out in a total volume of 34 pL in kinase buffer (5 mM Hepes pH 7.6, 15 mM NaCl, 0.01% bovine gamma globulin (Sigma #1- 5506), 10 mM MgCl2, 1 mM DTT, 0.02% TritonX-lOO). Compound dilutions are performed in DMSO and added to assay wells to a final DMSO concentration of 1%. Each data point is measured in duplicate, and at least two duplicate assays are performed for each individual compound determination. Enzyme is added to final concentrations of 10 nM or 20 nM, for example. A mixture of unlabeled ATP and g-33R ATP is added to start the reaction (2 x 106 cpm of g-33R ATP per well (3000 Ci/mmole) and 10 pM unlabeled ATP, typically. The reactions are carried out for 1 h at rt with shaking. Plates are washed 7x with TBS, followed by the addition of 50 pL/well scintillation fluid (Wallac). Plates are read using a Wallac Trilux counter. This is only one format of such assays; various other formats are possible, as known to one skilled in the art.
[0446] The above assay procedure can be used to determine the IC50 for inhibition and/or the inhibition constant, Ki. The IC50 is defined as the concentration of compound required to reduce the enzyme activity by 50% under the condition of the assay. The IC50 value is estimated by preparing a 10 point curve using a ½ log dilution series (for example, a typical curve may be prepared using the following compound concentrations: 10 mM, 3 pM, 1 pM, 0.3 pM, 0.1 pM, 0.03 pM, 0.01 pM, 0.003 pM, 0.001 pM and 0 pM).
PI3 KIANSE GENERAL ASSAY PROTOCOL
PI3K (r110a/r85a) (h) [Non-radioactive assay]
[0447] PI3K (r110a/r85a) (h) is incubated in assay buffer containing 10 pM phosphatidylinositol 4,5-bisphosphate and MgATP (concentration as required). The reaction is initiated by the addition of the ATP solution. After incubation for 30 minutes at room temperature, the reaction is stopped by the addition of stop solution containing EDTA and biotinylated phosphatidylinositol-3,4,5-trisphosphate. Finally, detection buffer is added, which contains europium-labelled anti-GST monoclonal antibody, GST-tagged GRP1 PH domain and streptavidin allophycocyanin. The plate is then read in timeresolved fluorescence mode and the homogenous time-resolved fluorescence (HTRF) signal is determined according to the formula HTRF = 10000 x (Em665nm/Em620nm).
PI3K (r110b/r85a) (h) [Non-radioactive assay]
[0448] PI3K (r110b/r85a) (h) is incubated in assay buffer containing 10 pM phosphatidylinositol-4, 5-bisphosphate and MgATP (concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 30 minutes at room temperature, the reaction is stopped by the addition of stop solution containing EDTA and biotinylated phosphatidylinositol-3,4,5-trisphosphate. Finally, detection buffer is added, which contains europium-labelled anti-GST monoclonal antibody, GST-tagged GRP1 PH domain and streptavidin-allophycocyanin. The plate is then read in timeresolved fluorescence mode and the homogenous time-resolved fluorescence (HTRF) signal is determined according to the formula HTRF = 10000 x (Em665nm/Em620nm).
PI3K (r110d/r85a) (h) [Non-radioactive assay]
[0449] PI3K (r110d/r85a) (h) is incubated in assay buffer containing 10 pM phosphatidylinositol-4, 5-bisphosphate and MgATP (concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 30 minutes at room temperature, the reaction is stopped by the addition of stop solution containing EDTA and biotinylated phosphatidylinositol-3,4,5-trisphosphate. Finally, detection buffer is added, which contains europium-labelled anti-GST monoclonal antibody, GST-tagged GRP1 PH domain and streptavidin-allophycocyanin. The plate is then read in timeresolved fluorescence mode and the homogenous time-resolved fluorescence (HTRF) signal is determined according to the formula HTRF = 10000 x (Em665nm/Em620nm).
PI3K (r120g) (h) [Non-radioactive assay]
[0450] PI3K (r120g) (h) is incubated in assay buffer containing 10 mM phosphatidylinositol-4, 5-bisphosphate and MgATP (concentration as required). The reaction is initiated by the addition of the MgATP mix. After incubation for 30 minutes at room temperature, the reaction is stopped by the addition of stop solution containing EDTA and biotinylated phosphatidylinositol-3,4,5- trisphosphate. Finally, detection buffer is added, which contains europium-labelled anti-GST monoclonal antibody, GST-tagged GRP1 PH domain and streptavidin-allophycocyanin. The plate is then read in timeresolved fluorescence mode and the homogenous time-resolved fluorescence (HTRF) signal is determined according to the formula HTRF = 10000 x (Em665nm/Em620nm).
mTOR (h]
[0451] mTOR (h) is incubated with 50 mM HEPES pH 7.5, 1 mM EDTA, 0.01% TWEEN®20, 2 mg/mL substrate, 3 mM Manganese Chloride and [g-33R-ATR] (specific activity approx. 500 cpm/pmol, concentration as required). The reaction is initiated by the addition of the MnATP mix. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 pL of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.
[0452] The kinase assays described herein were performed at Millipore ETC Ltd, Dundee Technology Park, Dundee DD2 1SW, UK.
[0453] The compounds disclosed herein exhibited potent activities in the PI3Ka (h) and mTOR (h) assays.
Table 4 Kinase inhibition data
Figure imgf000146_0001
Figure imgf000147_0001
NT : Not tested.
[0454] Alternatively, the kinase activities of the compounds can be measured using KINOME.scz///™, which is based on a competition binding assay that quantitatively measures the ability of a compound to compete with an immobilized, active-site directed ligand. The assay was performed by combining three components: DNA-tagged kinase; immobilized ligand; and a test compound. The ability of the test compound to compete with the immobilized ligand was measured via quantitative PCR of the DNA tag.
[0455] For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage and incubated with shaking at 32 °C until lysis. The lysates were centrifuged and filtered to remove cell debris. The remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for qPCR detection. Streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 minutes at room temperature to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and washed with blocking buffer (SEABLOCK™ (Pierce), 1% BSA, 0.05% TWEEN®20, 1 mM DTT) to remove unbound ligand and to reduce nonspecific binding. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in lx binding buffer (20% SEABLOCK™, 0. l7x PBS, 0.05% TWEEN®20, 6 mM DTT). All reactions were performed in polystyrene 96-well plates in a final volume of 0.135 mL. The assay plates were incubated at room temperature with shaking for 1 hour and the affinity beads were washed with wash buffer (lx PBS, 0.05% TWEEN®20). The beads were then re-suspended in elution buffer (lx PBS, 0.05% TWEEN®20, 0.5 mM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 minutes. The kinase concentration in the eluates was measured by qPCR.
[0456] The kinase assays described herein were performed using KINOMEvcc///™ Profiling Service at DiscoveRx Corporation, 42501 Albrae St. Fremont, CA 94538, ETSA.
Example D: p-AKT HTRF assay
[0457] The inhibitory activities of compounds against PI3K-a and PBK-b were assessed in SKOV3 and 786-0 cells, respectively while inhibition assay against PI3K-5 isoform was done in RAJI cell of receptor cell line of human B lymphoma cell which was cross-linked with an anti immunoglobulin M (anti-IgM) antibody. The inhibitory abilities of compounds against RI3K-g were assessed in the murine macrophage-like cell line RAW 264.7 which should be accumulated through a GPCR agonist of C5a before test.
[0458] The different cells were seeded into 96-well cell culture-grade plates at a density of 60,000 cells/50 pL/well for PI3K- , 30,000 cells/50 pL/well for PI3K- , 50,000 cells/30 pL/well for PI3K- , 60,000 cells/50 pL/well for PI3K- with Serum-free RPMI-1640 (Gibico).
[0459] Cells were incubated at 37° C in a 5% C02 atmosphere overnight. 50 ul solutions of compounds were added to the plates per well resulting with a final DMSO concentration of 0.2%, then incubated at 37 ° C in a 5% C02 atmosphere for another 60 minutes ( Cells were stimulated with 10 pg/mL anti -human IgM for 30 minutes in the presence of compounds for PI3K- test; Cells were stimulated with 25nM C5a for 5 minutes in the presence of compounds for PI3K- test) . Medium was then aspirated and 50 pL/well of lysis buffer was added. Plates were shaked for 45 minutes at room temperature and then 16 ul/well of lysate was tranfered to 384-well plate. 4 ul/well of premixed antibody was added to the wells. The plate was centrifuged at 1000 rpm at RT for 1 minute and then incubated for 4 hours at 22 °C, and Phospho-AKT (ser473) Kit was used for detection.
Table 5 p-AKT HTRF assay
Figure imgf000148_0001
[0460] The compounds disclosed herein exhibited good inhibitory activities against cells and good selectivities.
Example E: Cell proliferation assay 1. Harvest cells during the logarithmic growth period and count cell number using Count-star.
2. Adjust cell concentrations to 1.Ox 105 cells/mL with respective culture medium.
3. Add 90pL cell suspensions to 96-well plates with the final cell density of 1 x 104 cells/well (cell concentration will be adjusted according to the data base or density optimization assay.)
4. The next day, prepare lOxsolution (Top working concentration: 10 mM of test article in media with 3. l6-fold serial dilutions to achieve 9 dose levels).
5. Dispense 10 pL drug solution of both test article and reference control in each well (duplicate for each drug concentration) of the plate . (DMSO final concentration in culture medium: 0.1%
6. Incubate the test plates for 72 h in the humidified incubator at 37°C with 5% C02, and then measured by means of CTG assay.
7. Equilibrate the plate and its contents at RT forapproximately 30 min.
8. Add 50 pL CellTiter-Glo to each well.
9. The data is displayed graphically using GraphPad Prism 5.0.
Table 6 Cell proliferation assay
Figure imgf000149_0001
[0461] The compounds disclosed herein showed good inhibitory activities against different cells.
Example F : hERG assay
[0462] Voltage clamp protocol: Computer software was used to set voltage clamp protocols. In whole-cell model, cells were held at -80 mV, first depolarized to -50 mV for 80 ms, and then depolarized to +20 mV for 4800 ms to activate the hERG channels. After that the cells were repolarized to -50 mV for 5000 ms to elicit the characteristic tail currents. Finally the cells were held at -80 mV again. The peak values of tail currents were sampled for analysis.
[0463] Automated QPatch procedure: After achieving break-in (whole-cell) configuration, the cells were recorded for 120 sec to assess current stability. The voltage protocol described above was then applied to the cells every 15 sec throughout the whole procedure. Only stable cells with recording parameters above threshold were allowed to enter the drug application procedure. All experiments were conducted at room temperature (about 25°C). External solution containing 0.1 % DMSO (vehicle) was applied to the cells to establish the baseline. After allowing the current to stabilize for 3 minutes, compound was applied. Compound solution was added and the cells were kept in the test solution until the compound’s effect reached a steady state or for a maximum of 4 min. For dose response assay, compound was applied to the cells accumulatively from low to high concentrations. Washout with external solution was performed after compound testing. Positive control cisapride is used in the experiments to test the same batch of cells used for test compounds to ensure the normal response and the good quality of the cells.
[0464] Data were analyzed using Assay Software provided by Sophion, Microsoft Excel and Graphpad Prism.
[0465] Manual patch-clamp protocol: The manual patch-clamp system was used to record the hERG currents in human embryonic kidney (HEK-293) cells. The cells were harvested and transferred to the recording charmer on the stage of an inverted microscope and perfused consistently with extracellular solution. The volume of the recording chamber was about 1 mL. The extracellular solution in the chamber was completely exchanged within 1 min at a perfusion rate about 1 mL/min. Patch micropipettes were pulled with micropipette puller. Pipettes were moved to the cells by Micromanipulator and a slight positive pressure was used to clear the surface before seal formation. A high-resistance seal between the surface of the plasma membrane and the tip of pipettes were achieved by a gentle suck. Then, the membrane attached to the pipette was broken by a negative pressure to achieve whole cell recording model. All the experiments were performed at room temperature.
[0466] Data was presented as mean±S.E.M. The effects of test article were normalized with the peak currents recorded in vehicle control. Curve fitting and IC50 calculation were performed using Clampfit 10.3 and Graphpad Prism 5.00 Current density (pA/pF) = Peak current (pA) / Membrane capacity (pF).
Table 7 hERG assay results
Figure imgf000150_0001
* Data were obtained from Automated QPatch procedure, unless otherwise indicated. [0467] The compounds disclosed herein had weak interaction towards hERG. [0468] Finally, it should be noted that there are alternative ways of implementing the present invention. Accordingly, the present embodiments are to be considered as illustrative and not restrictive and the invention is not be limited to the details given herein, but may be modified within the scope and equivalents of the appended claims. All publications and patents cited herein are incorporated by reference.

Claims

WHAT IS CLAIMED IS:
1. A compound of Formula (I):
Figure imgf000152_0001
or a stereoisomer, a geometric isomer, a tautomer, an L'-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein:
each R1 and R2 is independently H, D, F, CN, N02, -C(=0)Ra, -C(=0)0Ra, -C(=0)NRaRb, - (Ci-C4)alkylene-C(=0)NRaRb, -(Ci-C4)alkylene-N(Rc)C(=0)NRaRb, -(Ci-C4)alkylene- N(Rc)C(=0)0Ra, -(Ci-C4)alkylene-OC(=0)NRaRb, -(Ci-C4)alkylene-S(=0)2NRaRb, -(C C4)alkylene-N(Rc)S(=0)2Rb, -(Ci-C4)alkylene-ORa, -(Ci-C4)alkylene-NRaRb, (Ci-C6)alkyl, (C2- C6)alkenyl, (C2-C6)alkynyl, (Ci-C8)cycloalkyl, -(Ci-C4)alkylene-(C3-C8)cycloalkyl, 3-8 membered heterocyclyl, -(Ci-C4)alkylene-(3-8 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C4)alkylene-(C6- C |o)aryl, 5-10 membered heteroaryl, or -(Ci-C4)alkylene-(5-l0 membered heteroaryl), wherein each of the (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, -(Ci-C4)alkylene-(C3- C8)cycloalkyl, 3-8 membered heterocyclyl, -(Ci-C4)alkylene-(3-8 membered heterocyclyl), (C6- C io)aryl, -(Ci-C4)alkylene-(C6-Cio)aryl, 5-10 membered heteroaryl and -(Ci-C4)alkylene-(5-l0 membered heteroaryl) is optionally substituted with 1 , 2, 3 or 4 substitutents independently selected from D, F, Cl, Br, oxo (=0), CN, Ra, ORa, NRaRb, (Ci-C6)alkyl, -(Ci-C4)alkylene-ORa and -(Ci- C4)alkylene-NRaRb; or R1 and R2, together with the carbon atom they are attached to, form an optionally substituted 3-8 membered carbocyclic or heterocyclic ring;
X is 3-8 membered heterocyclyl, (C6-Cio)aryl or 5-10 membered heteroaryl, wherein X is optionally substituted by 1, 2, 3, 4 or 5 R groups;
m is 1, 2 or 3;
W is N or CR5;
A is H, D, (Ci-C6)alkyl, (Ci-C6)haloalkyl, (Ci-C6)hydroxyalkyl, (Ci-C6)aminoalkyl, (C3- C8)cycloalkyl or 3-8 membered heterocyclyl, wherein each (Ci-C6)alkyl, (Ci-C6)haloalkyl, (Ci- C6)hydroxyalkyl, (Ci-C6)aminoalkyl, (C3-C8)cycloalkyl and 3-8 membered heterocyclyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH2, CN, N02, (Ci-C6)alkyl and (Ci-C6)alkoxy;
B is (C3-C8)cycloalkyl, 3-8 membered heterocyclyl, (C6-Cio)aryl or 5-10 membered heteroaryl, wherein each of the (Ci-C8)cycloalkyl, 3-8 membered heterocyclyl, (C6-Cio)aryl and 5-10 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo (=0), F, Cl, Br, CN, Ra, ORa, NRaRb, (Ci-C6)alkyl, -(Ci-C4)alkylene-ORa and -(Ci- C4)alkylene-NRaRb ;
each R3, R4 and R5 is independently H, D, F, Cl, Br, CN, N02, oxo (=0), -C(=0)Ra, - C(=0)0Ra, -C(=0)NRaRb, -0C(=0)NRaRb, -0C(=0)0Ra, -N(Rc)C(=0)NRaRb, -N(Rc)C(=0)0Ra, - N(Rc)C(=0)Ra, -S(=0)2NRaRb, -S(=0)2Ra, -N(Rc)S(=0)2Ra, -N(Rc)-(Ci-C4)alkylene-S(=0)2Ra, - (Ci-C4)alkylene-C(=0)NRaRb, -(Ci-C4)alkylene-N(Rc)C(=0)NRaRb, -(Ci-C4)alkylene- N(Rc)C(=0)0Ra, -(Ci-C4)alkylene-OC(=0)NRaRb, -(Ci-C4)alkylene-S(=0)2NRaRb, -(Ci- C4)alkylene-N(Rc)S(=0)2Ra, ORa, NRaRb, -(Ci-C4)alkylene-ORa, -(Ci-C4)alkylene-NRaRb, (Ci- C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, -(Ci-C4)alkylene-(C3-C8)cycloalkyl, 3- 8 membered heterocyclyl, -(Ci-C4)alkylene-(3-8 membered heterocyclyl), (C6-Cio)aryl, -(Ci- C4)alkylene-(C6-C!o)aryl, 5-10 membered heteroaryl, or -(Ci-C4)alkylene-(5-l0 membered heteroaryl), wherein each of the (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C8)cycloalkyl, - (Ci-C4)alkylene-(C3-C8)cycloalkyl, 3-8 membered heterocyclyl, -(Ci-C4)alkylene-(3-8 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C4)alkylene-(C6-Cio)aryl, 5-10 membered heteroaryl and -(Ci- C4)alkylene-(5-l0 membered heteroaryl) is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, oxo (=0), Ra, ORa, NRaRb, (Ci-C6)alkyl, -(Ci- C4)alkylene-ORa and -(Ci-C4)alkylene-NRaRb; and
each Ra, Rb and Rc is independently H, (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3- C6)cycloalkyl, -(Ci-C4)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C4)alkylene- (3-6 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C4)alkylene-(C6-Cio)aryl, 5-10 membered heteroaryl, or -(Ci-C4)alkylene-(5-l0 membered heteroaryl), wherein each of the (Ci-C6)alkyl, (C2- C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl, -(Ci-C4)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C4)alkylene-(3-6 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C4)alkylene-(C6- C |o)aryl, 5-10 membered heteroaryl and -(Ci-C4)alkylene-(5-l0 membered heteroaryl) is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, N02, N3, OH, NH2, (Ci-C6)alkyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy and (Ci-C6)alkylamino; or Ra and Rb, together with the nitrogen atom they are attached to, form an optionally substituted 3-8 membered heterocyclic ring.
2. The compound according to claim 1, a compound of Formula (II):
Figure imgf000154_0001
3. The compound according to claim 1 to 2, wherein X is 3-6 membered heterocyclyl or 5-6 membered heteroaryl, wherein X is optionally substituted by 1, 2, 3 or 4 R3 groups.
4. The compound according to any one of claims 1 to 3, wherein X is
Figure imgf000154_0002
Figure imgf000154_0003
Figure imgf000154_0004
wherein X is optionally substituted by 1, 2, or 3 R groups. H
d according to any one of claims 1 to 4, wherein X is ^i N¾/ H
5. The compoun
Figure imgf000154_0005
Figure imgf000155_0001
, 5 or vs ; and wherein X is optionally substituted by 1, 2, or 3 R3 groups.
6. The compound according to any one of claims 1 to 5, wherein A is H, D, (Ci-C4)alkyl, (Ci- C4)haloalkyl, (Ci-C4)hydroxyalkyl, (Ci-C4)aminoalkyl, (C3-C6)cycloalkyl or 3-6 membered heterocyclyl, wherein each (Ci-C4)alkyl, (Ci-C4)haloalkyl, (Ci-C4)hydroxyalkyl, (Ci-C4)aminoalkyl, (C3-C6)cycloalkyl and 3-6 membered heterocyclyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NH2, CN, N02, (Ci-C4)alkyl and (Ci-C4)alkoxy.
7. The compound according to any one of claims 1 to 6, wherein A is H, D, methyl, ethyl, «- propyl, isopropyl, / -butyl, trifluoromethyl, difluoromethyl, 1 ,2-difluoroethyl, 2,2-difluoroethyl, hydroxymethyl, 2-hydroxyethyl, 1 -hydroxy ethyl, 2-hydroxyprop-2-yl, aminomethyl, 2-aminoethyl, 1 -aminoethyl, 2-aminoprop-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiofen, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl, wherein each methyl, ethyl, «-propyl, isopropyl, /er/-butyl, trifluoromethyl, difluoromethyl, 1,2- difluoroethyl, 2,2-difluoroethyl, hydroxymethyl, 2-hydroxyethyl, 1 -hydroxyethyl, 2-hydroxyprop-2- yl, aminomethyl, 2-aminoethyl, 1 -aminoethyl, 2-aminoprop-2-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiofen, piperidyl, piperazinyl, morpholinyl and thiomorpholinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo, F, Cl, Br, OH, NFF, CN, N02, methyl, ethyl, «-propyl, isopropyl, tert- butyl, methoxyl and ethoxyl.
8. The compound according to any one of claims 1 to 7, wherein B is (C3-C6)cycloalkyl, 3-6 membered heterocyclyl, (C6-Cio)aryl or 5-6 membered heteroaryl, wherein each of the (C3- C6)cycloalkyl, 3-6 membered heterocyclyl, (C6-Cio)aryl and 5-6 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo (=0), F, Cl, Br, CN, Ra, ORa, NRaRb, (Ci-C4)alkyl, -(Ci-C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb
9. The compound according to any one of claims 1 to 8, wherein B is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, oxo (=0), F, Cl, Br, CN, Ra, ORa, NRaRb, methyl, ethyl, «-propyl, isopropyl, tert-butyl, -(Ci-C2)alkylene-ORa and - (Ci-C2)alkylene-NRaRb
10. The compound according to any one of claims 1 to 9, wherein each R1 and R2 is independently H, D, F, CN, N02, -C(=0)NRaRb, -(Ci-C2)alkylene-C(=0)NRaRb, -(Ci-C2)alkylene- N(Rc)C(=0)NRaRb, -(Ci-C2)alkylene-N(Rc)C(=0)ORa, -(Ci-C2)alkylene-OC(=0)NRaRb, -(Ci- C2)alkylene-S(=0)2NRaRb, -(Ci-C2)alkylene-N(Rc)S(=0)2Rb, -(Ci-C2)alkylene-ORa, -(C C2)alkylene-NRaRb, (Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C6)cycloalkyl, -(Ci- C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C2)alkylene-(C6-Cio)aryl, 5-6 membered heteroaryl, or -(Ci- C4)alkylene-(5-6 membered heteroaryl), wherein each of the (Ci-C4)alkyl, (C2-C4)alkenyl, (C2- C4)alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, - (Ci-C2)alkylene-(3-6 membered heterocyclyl), phenyl, -(Ci-C2)alkylene-phenyl, 5-6 membered heteroaryl and -(Ci-C2)alkylene-(5-6 membered heteroaryl) is optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, Br, oxo (=0), CN, Ra, ORa, NRaRb, (Ci-C4)alkyl, -(Ci-C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb; or R1 and R2, together with the carbon atom they are attached to, form an optionally substituted 3-6 membered carbocyclic or heterocyclic ring.
11. The compound according to any one of claims 1 to 10, wherein each R and R is independently H, D, F, CN, methyl, ethyl, «-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl or thiomorpholinyl, wherein each of methyl, ethyl, «-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl, morpholinyl and thiomorpholinyl is optionally substituted with 1, 2, 3 or 4 substitutents independently selected from D, F, Cl, Br, oxo (=0), CN, Ra, ORa, NRaRb, (Ci-C4)alkyl, -(Ci-C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb; or R1 and R2, together with the carbon atom they are attached to, form an optionally substituted 3-6 membered carbocyclic or heterocyclic ring.
12. The compound according to any one of claims 1 to 11, wherein each R3, R4 and R5 is independently H, D, F, Cl, Br, CN, N02, oxo (=0), -C(=0)NRaRb, -N(Rc)C(=0)NRaRb, - N(Rc)C(=0)0Ra, -N(Rc)C(=0)Ra, -S(=0)2NRaRb, -N(Rc)S(=0)2Ra, -N(Rc)-(Ci-C2)alkylene-
S(=0)2Ra, -(Ci-C2)alkylene-C(=0)NRaRb, -(Ci-C2)alkylene-N(Rc)C(=0)NRaRb, -(Ci-C2)alkylene- S(=0)2NRaRb, -(Ci-C2)alkylene-N(Rc)S(=0)2Ra, ORa, NRaRb, -(Ci-C2)alkylene-ORa, -(Ci- C2)alkylene-NRaRb, (Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C6)cycloalkyl, -(Ci- C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3-6 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C2)alkylene-(C6-Cio)aryl, 5-6 membered heteroaryl, or -(Cr C2)alkylene-(5-6 membered heteroaryl), wherein each of the (Ci-C4)alkyl, (C2-C4)alkenyl, (C2- C4)alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, - (Ci-C2)alkylene-(3-6 membered heterocyclyl), (C6-Cio)aryl, -(Ci-C2)alkylene-(C6-Cio)aryl, 5-6 membered heteroaryl and -(Ci-C2)alkylene-(5-6 membered heteroaryl) is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, oxo (=0), Ra, ORa, NRaRb, (Ci-C4)alkyl, -(Ci-C2)alkylene-ORa and -(Ci-C2)alkylene-NRaRb.
13. The compound according to any one of claims 1 to 12, wherein each R3, R4 and R5 is independently H, D, F, Cl, Br, CN, N02, oxo (=0), -C(=0)NRaRb, -N(Rc)C(=0)NRaRb, - N(Rc)C(=0)0Ra, -N(Rc)C(=0)Ra, -S(=0)2NRaRb, -N(Rc)S(=0)2Ra, ORa, NRaRb, methyl, ethyl, «- propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, Br, CN, oxo (=0), Ra, 0Ra, NRaRb, methyl, ethyl, «-propyl and isopropyl.
14. The compound according to any one of claims 1 to 13, wherein each Ra, Rb and Rc is independently H, (Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3-C6)cycloalkyl, -(Ci-C2)alkylene- (C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene-(3 -6 membered heterocyclyl) or 5- 6 membered heteroaryl, wherein each of the (Ci-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C3- C6)cycloalkyl, -(Ci-C2)alkylene-(C3-C6)cycloalkyl, 3-6 membered heterocyclyl, -(Ci-C2)alkylene- (3-6 membered heterocyclyl) and 5-6 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, CN, NCF, N3, OH, NH2, (Ci-C4)alkyl, (Ci- C4)haloalkyl, (Ci-C4)alkoxy and (Ci-C4)alkylamino.
15. The compound according to any one of claims 1 to 14, wherein each Ra, Rb and Rc is independently H, methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl, wherein each of the methyl, ethyl, «-propyl, isopropyl, vinyl, propenyl, allyl, ethynyl, propinyl, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, phenyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl is optionally substituted with 1, 2, 3, or 4 substitutents independently selected from D, F, Cl, CN, N02, N3, OH, NFL, methyl, ethyl, «-propyl, isopropyl, trifluoromethyl, difluoromethyl, methoxyl, ethoxyl, methylamino and dimethylamino.
16. A compound having one of the following structures:
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
, etric isomer, a tautomer, an L'-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof.
17. A pharmaceutical composition comprising the compound according to any one of claims 1 to 16, and one or more pharmaceutically acceptable carriers, excipients, diluents, adjuvants, vehicles or a combination thereof.
18. The pharmaceutical composition according to claim 17 further comprising one or more therapeutic agents.
19. The compound according to any one of claims 1 to 16 or the pharmaceutical composition according to any one of claims 17 to 18 for use in preventing, managing, treating or lessening the severity of a disorder mediated by inappropriate PI3 -kinase activity in a patient.
20. The compound or pharmaceutical composition according to claim 19, wherein the disorder is asthma, chronic obstructive pulmonary disease (COPD), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia, or central pain.
21. Use of the compound according to any one of claims 1 to 16, or the pharmaceutical composition according to any one of claims 17 to 18 in the manufacture of a medicament for the treatment of a disorder or a disease selected from asthma, chronic obstructive pulmonary disease (COPD), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or central pain.
22. A method of treating a disorder mediated by inappropriate PI3 -kinase activity comprising administering a therapeutically effective amount of the compound according to any one of claims 1 to 16 or a pharmaceutical composition according to any one of claims 17 to 18 to a patient in need thereof.
23. The method according to claim 22, wherein the disorder is a respiratory disease, a viral infection, a non-viral respiratory infection, an allergic disease, an autoimmune disease, an inflammatory disorder, a cardiovascular disease, a hematologic malignancy, a neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, or pain.
24. The method according to claim 22, wherein the disorder is asthma, chronic obstructive pulmonary disease (COPD), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or central pain.
25. A method of modulating the activity of the PI3 -kinase, in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 16 or a pharmaceutical composition according to any one of claims 17 to 18.
26. The method of claim 25, wherein the PI3 -kinase is PI3K5.
PCT/US2019/014101 2018-01-20 2019-01-18 Substituted aminopyrimidine compounds and methods of use WO2019143874A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2019209960A AU2019209960B2 (en) 2018-01-20 2019-01-18 Substituted aminopyrimidine compounds and methods of use
KR1020207023828A KR20200112900A (en) 2018-01-20 2019-01-18 Substituted aminopyrimidine compounds and methods of use thereof
EP19741784.3A EP3740468A4 (en) 2018-01-20 2019-01-18 Substituted aminopyrimidine compounds and methods of use
JP2020538684A JP7450541B2 (en) 2018-01-20 2019-01-18 Substituted aminopyrimidine compounds and methods of use
CA3083040A CA3083040A1 (en) 2018-01-20 2019-01-18 Substituted aminopyrimidine compounds and methods of use
JP2023176720A JP2023184559A (en) 2018-01-20 2023-10-12 Substituted aminopyrimidine compounds and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862619741P 2018-01-20 2018-01-20
US62/619,741 2018-01-20

Publications (1)

Publication Number Publication Date
WO2019143874A1 true WO2019143874A1 (en) 2019-07-25

Family

ID=67299630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/014101 WO2019143874A1 (en) 2018-01-20 2019-01-18 Substituted aminopyrimidine compounds and methods of use

Country Status (7)

Country Link
US (1) US10751339B2 (en)
EP (1) EP3740468A4 (en)
JP (2) JP7450541B2 (en)
KR (1) KR20200112900A (en)
AU (1) AU2019209960B2 (en)
CA (1) CA3083040A1 (en)
WO (1) WO2019143874A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023125275A1 (en) 2021-12-28 2023-07-06 广东东阳光药业有限公司 Salt of aminopyrimidine compound and use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023096850A1 (en) * 2021-11-24 2023-06-01 Geode Therapeutics Inc. Phosphoinositide 3 kinase gamma inhibitors and compositions and methods thereof

Citations (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100274A (en) 1976-05-11 1978-07-11 Imperial Chemical Industries Limited Polypeptide
US4636505A (en) 1982-07-23 1987-01-13 Imperial Chemical Industries Plc Amide derivatives
US4659516A (en) 1983-10-12 1987-04-21 Imperial Chemical Industries Plc Steroid derivatives
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
EP0520722A1 (en) 1991-06-28 1992-12-30 Zeneca Limited Therapeutic preparations containing quinazoline derivatives
WO1993013055A1 (en) 1991-12-24 1993-07-08 The Wellcome Foundation Limited Amidino derivatives and their use as nitric oxide synthase inhibitors
EP0564409A1 (en) 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidin derivatives and process for their preparation
EP0566226A1 (en) 1992-01-20 1993-10-20 Zeneca Limited Quinazoline derivatives
WO1995003283A1 (en) 1993-07-19 1995-02-02 Zeneca Limited Quinazoline derivatives and their use as anti-cancer agents
WO1995034534A1 (en) 1994-06-15 1995-12-21 The Wellcome Foundation Limited Enzyme inhibitors
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
WO1996032099A1 (en) 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
WO1996033980A1 (en) 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
WO1997002266A1 (en) 1995-07-06 1997-01-23 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
EP0787722A1 (en) 1996-02-05 1997-08-06 American Cyanamid Company Substituted quinazoline derivatives
WO1997030034A1 (en) 1996-02-14 1997-08-21 Zeneca Limited Quinazoline derivatives as antitumor agents
WO1997038983A1 (en) 1996-04-12 1997-10-23 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
WO1998008849A1 (en) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Method for producing epothilones, and intermediate products obtained during the production process
WO1998010121A1 (en) 1996-09-06 1998-03-12 Obducat Ab Method for anisotropic etching of structures in conducting materials
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1998022461A1 (en) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
WO1998025929A1 (en) 1996-12-13 1998-06-18 Novartis Ag Epothilone analogs
WO1998030537A1 (en) 1997-01-13 1998-07-16 Glaxo Group Limited Nitric oxide synthase inhibitors
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
WO1998054159A1 (en) 1997-05-30 1998-12-03 Schering Aktiengesellschaft Non-steroidal (hetero) cyclically substituted acylanilides with mixed gestagen and androgen activity
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO1999017804A1 (en) 1997-10-03 1999-04-15 Pharmacia & Upjohn S.P.A. Polymeric derivatives of camptothecins
WO1999043653A1 (en) 1998-02-25 1999-09-02 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
WO1999062875A1 (en) 1998-05-30 1999-12-09 Glaxo Group Limited Nitric oxide synthase inhibitors
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
WO2001004118A2 (en) 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Quinuclidine derivatives and their use as muscarinic m3 receptor ligands
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
WO2002002565A2 (en) 2000-07-05 2002-01-10 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
WO2002022577A2 (en) 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors
US6360739B1 (en) 1997-06-10 2002-03-26 Smithkline Beecham Corporation Dispenser with doses counter
WO2002026722A1 (en) 2000-09-29 2002-04-04 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
WO2002038561A1 (en) 2000-11-07 2002-05-16 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
WO2002050021A1 (en) 2000-12-21 2002-06-27 Glaxo Group Limited Nitric oxide synthase inhibitor phosphate salt
WO2002092599A1 (en) 2001-05-14 2002-11-21 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives
WO2003008277A2 (en) 2001-07-17 2003-01-30 Riverwood International Corporation Carton with improved dispenser and handle
WO2003013541A1 (en) 2001-08-07 2003-02-20 Novartis Ag 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003059899A1 (en) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
WO2003061651A1 (en) 2002-01-22 2003-07-31 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
WO2003082827A1 (en) 2002-04-02 2003-10-09 Schering Aktiengesellschaft Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents
WO2003082787A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003082280A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003082859A1 (en) 2002-04-03 2003-10-09 Novartis Ag Indolylmaleimide derivatives
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
WO2003101932A2 (en) 2002-05-29 2003-12-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003104195A1 (en) 2002-06-06 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
WO2004005229A1 (en) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulators of the glucocorticoid receptor
WO2004009017A2 (en) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004026248A2 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
WO2004035556A1 (en) 2002-10-16 2004-04-29 Glaxo Group Limited Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
WO2004052359A1 (en) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
WO2005044354A1 (en) 2003-11-03 2005-05-19 Glaxo Group Limited A fluid dispensing device
WO2005066156A1 (en) 2004-01-12 2005-07-21 Cytopia Research Pty Ltd Selective kinase inhibitors
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
WO2006015870A1 (en) 2004-08-12 2006-02-16 Glaxo Group Limited Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators
WO2006045416A1 (en) 2004-10-19 2006-05-04 F. Hoffmann-La Roche Ag Quinoline derivatives
WO2014100765A1 (en) * 2012-12-21 2014-06-26 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
WO2015042497A2 (en) 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016149160A1 (en) 2015-03-15 2016-09-22 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
US9834560B2 (en) * 2009-10-19 2017-12-05 Respivert Ltd. Compounds

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
GB2453058A (en) 2006-04-04 2009-03-25 Univ California Kinase antagonists
KR101897881B1 (en) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2593256T3 (en) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulations
SG194718A1 (en) 2011-05-04 2013-12-30 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
CN103930422A (en) 2011-07-19 2014-07-16 无限药品股份有限公司 Heterocyclic compounds and uses thereof
TWI565709B (en) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104768952B (en) 2012-08-08 2016-10-19 山东亨利医药科技有限责任公司 PI3K δ inhibitor
WO2014060432A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
BR112015014592A2 (en) 2012-12-21 2017-07-11 Gilead Calistoga Llc compound, pharmaceutical composition, and method for treating a human
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
US9216985B2 (en) 2013-03-28 2015-12-22 Scifluor Life Sciences, Inc. 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones
BR112015031475A2 (en) 2013-06-14 2017-07-25 Gilead Sciences Inc compound, pharmaceutical composition, method for treating a disease or condition, kit, and use of compound.
WO2015001491A1 (en) 2013-07-02 2015-01-08 Rhizen Pharmaceuticals Sa Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
CN104513235B (en) 2013-09-02 2017-12-05 广东东阳光药业有限公司 Substituted amino-metadiazine compound and its application method and purposes
ES2900806T3 (en) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015091532A1 (en) 2013-12-19 2015-06-25 Almirall, S.A. Pyrrolopyrimidine derivatives as pi3k inhibitors
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CN105130966B (en) 2014-05-07 2019-05-24 广东东阳光药业有限公司 Alkynyl compounds and its application method and purposes
WO2015175579A1 (en) 2014-05-15 2015-11-19 Calitor Sciences, Llc Alkynyl compounds and methods of use
CN106573922A (en) 2014-06-13 2017-04-19 吉利德科学公司 Phosphatidylinositol 3-kinase inhibitors
JP6383810B2 (en) 2014-06-13 2018-08-29 ギリアード サイエンシーズ， インコーポレイテッド Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
ES2833025T3 (en) 2014-06-13 2021-06-14 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
MX2016016530A (en) 2014-06-13 2017-03-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors.
WO2015191745A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
ES2900812T3 (en) 2014-06-24 2022-03-18 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
UA115296C2 (en) 2014-07-04 2017-10-10 Люпін Лімітед Quinolizinone derivatives as pi3k inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN105924434A (en) 2015-02-28 2016-09-07 广东东阳光药业有限公司 Substituted aminopyrimidine compound and usage method and application thereof
CN105924433B (en) 2015-02-28 2020-12-22 广东东阳光药业有限公司 Substituted aminopyrimidine compounds and use method and application thereof
CN105936635B (en) 2015-03-06 2019-06-21 南京圣和药业股份有限公司 Compound and its application as phosphatidyl-inositol 3-kinase delta inhibitor
CN106008479B (en) 2015-03-06 2020-01-10 南京圣和药业股份有限公司 Substituted pyrimidine compound as phosphatidylinositol 3-kinase delta inhibitor and application thereof
KR101845931B1 (en) 2015-06-18 2018-04-05 한국화학연구원 Heteroaryl derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases
CN106366085A (en) 2015-07-25 2017-02-01 复旦大学 Isoquinolone compound or salt thereof, and preparation method and use of isoquinolone compound
WO2017103825A1 (en) 2015-12-18 2017-06-22 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
CN106995438B (en) 2016-01-22 2019-09-20 中国科学院上海药物研究所 A kind of substituted quinazoline -4- ketone compounds and preparation method thereof and medical usage
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
TW201806953A (en) 2016-04-26 2018-03-01 印度商托仁特生技有限公司 Substituted fused pyrimidinone compounds
AU2017256488B2 (en) 2016-04-29 2020-12-17 Yuhan Corporation Quinazoline derivative or its salt and pharmaceutical composition comprising the same
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR101932146B1 (en) 2016-07-14 2018-12-24 주식회사 바이오웨이 Novel Quinazolinone derivatives as PI3K inhibitors, and pharmaceutical composition comprising the same
GB201615282D0 (en) 2016-09-08 2016-10-26 Univ Bath Tankyrase inhibitors
JP7273723B2 (en) 2016-12-20 2023-05-15 オリゴメリックス インコーポレイテッド Novel quinazolinones that inhibit the formation of tau oligomers and methods of use thereof
CN107286113A (en) 2017-06-16 2017-10-24 中国药科大学 A kind of isoquinolinone derivatives and its production and use
CN107417628A (en) 2017-06-28 2017-12-01 中国人民解放军军事医学科学院毒物药物研究所 Diaryl quianzolinones, its preparation method and its medical usage and the pharmaceutical composition comprising such compound

Patent Citations (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100274A (en) 1976-05-11 1978-07-11 Imperial Chemical Industries Limited Polypeptide
US4636505A (en) 1982-07-23 1987-01-13 Imperial Chemical Industries Plc Amide derivatives
US4659516A (en) 1983-10-12 1987-04-21 Imperial Chemical Industries Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
EP0520722A1 (en) 1991-06-28 1992-12-30 Zeneca Limited Therapeutic preparations containing quinazoline derivatives
WO1993013055A1 (en) 1991-12-24 1993-07-08 The Wellcome Foundation Limited Amidino derivatives and their use as nitric oxide synthase inhibitors
EP0566226A1 (en) 1992-01-20 1993-10-20 Zeneca Limited Quinazoline derivatives
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
EP0564409A1 (en) 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidin derivatives and process for their preparation
WO1995003283A1 (en) 1993-07-19 1995-02-02 Zeneca Limited Quinazoline derivatives and their use as anti-cancer agents
WO1995034534A1 (en) 1994-06-15 1995-12-21 The Wellcome Foundation Limited Enzyme inhibitors
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
WO1996032099A1 (en) 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
WO1996033980A1 (en) 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
WO1997002266A1 (en) 1995-07-06 1997-01-23 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
EP0787722A1 (en) 1996-02-05 1997-08-06 American Cyanamid Company Substituted quinazoline derivatives
WO1997030034A1 (en) 1996-02-14 1997-08-21 Zeneca Limited Quinazoline derivatives as antitumor agents
WO1997038983A1 (en) 1996-04-12 1997-10-23 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
WO1998008849A1 (en) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Method for producing epothilones, and intermediate products obtained during the production process
WO1998010121A1 (en) 1996-09-06 1998-03-12 Obducat Ab Method for anisotropic etching of structures in conducting materials
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
WO1998022461A1 (en) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
WO1998025929A1 (en) 1996-12-13 1998-06-18 Novartis Ag Epothilone analogs
WO1998030537A1 (en) 1997-01-13 1998-07-16 Glaxo Group Limited Nitric oxide synthase inhibitors
WO1998054159A1 (en) 1997-05-30 1998-12-03 Schering Aktiengesellschaft Non-steroidal (hetero) cyclically substituted acylanilides with mixed gestagen and androgen activity
US6431168B1 (en) 1997-06-10 2002-08-13 Smithkline Beecham Corporation Dispenser with doses′ counter
US6360739B1 (en) 1997-06-10 2002-03-26 Smithkline Beecham Corporation Dispenser with doses counter
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO1999017804A1 (en) 1997-10-03 1999-04-15 Pharmacia & Upjohn S.P.A. Polymeric derivatives of camptothecins
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
WO1999043653A1 (en) 1998-02-25 1999-09-02 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
WO1999062875A1 (en) 1998-05-30 1999-12-09 Glaxo Group Limited Nitric oxide synthase inhibitors
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6179118B1 (en) 1998-12-18 2001-01-30 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6679374B2 (en) 1998-12-18 2004-01-20 Smith Kline Beecham Corporation Package for storing a pressurized container containing a drug
WO2001004118A2 (en) 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Quinuclidine derivatives and their use as muscarinic m3 receptor ligands
WO2002002565A2 (en) 2000-07-05 2002-01-10 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
WO2002022577A2 (en) 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors
WO2002026722A1 (en) 2000-09-29 2002-04-04 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
WO2002038561A1 (en) 2000-11-07 2002-05-16 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
WO2002050021A1 (en) 2000-12-21 2002-06-27 Glaxo Group Limited Nitric oxide synthase inhibitor phosphate salt
WO2002092599A1 (en) 2001-05-14 2002-11-21 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives
WO2003008277A2 (en) 2001-07-17 2003-01-30 Riverwood International Corporation Carton with improved dispenser and handle
WO2003013541A1 (en) 2001-08-07 2003-02-20 Novartis Ag 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003059899A1 (en) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
WO2003061651A1 (en) 2002-01-22 2003-07-31 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
WO2003082787A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003082280A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003082827A1 (en) 2002-04-02 2003-10-09 Schering Aktiengesellschaft Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents
WO2003082859A1 (en) 2002-04-03 2003-10-09 Novartis Ag Indolylmaleimide derivatives
WO2003086294A2 (en) 2002-04-11 2003-10-23 Merck & Co., Inc. 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
WO2003101932A2 (en) 2002-05-29 2003-12-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003104195A1 (en) 2002-06-06 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. 4-(aryl or heteroaryl) -2-butylamine derivatives and their use as glucocorticoid ligans
WO2004005229A1 (en) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulators of the glucocorticoid receptor
WO2004009017A2 (en) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
WO2004018429A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004026248A2 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
WO2004035556A1 (en) 2002-10-16 2004-04-29 Glaxo Group Limited Substituted piperazines, (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
WO2004052359A1 (en) 2002-12-09 2004-06-24 The Board Of Regents Of The University Of Texas System Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)
WO2005044354A1 (en) 2003-11-03 2005-05-19 Glaxo Group Limited A fluid dispensing device
WO2005066156A1 (en) 2004-01-12 2005-07-21 Cytopia Research Pty Ltd Selective kinase inhibitors
WO2006000398A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
WO2006000401A1 (en) 2004-06-28 2006-01-05 Glaxo Group Limited Substituted oxazines as glucocorticoid receptor modulators
WO2006015870A1 (en) 2004-08-12 2006-02-16 Glaxo Group Limited Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators
WO2006045416A1 (en) 2004-10-19 2006-05-04 F. Hoffmann-La Roche Ag Quinoline derivatives
US9834560B2 (en) * 2009-10-19 2017-12-05 Respivert Ltd. Compounds
WO2014100765A1 (en) * 2012-12-21 2014-06-26 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
WO2015042497A2 (en) 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
WO2015042078A2 (en) 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
WO2015042077A1 (en) 2013-09-22 2015-03-26 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016149160A1 (en) 2015-03-15 2016-09-22 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use

Non-Patent Citations (61)

* Cited by examiner, † Cited by third party
Title
"Encyclopedia of Pharmaceutical Technology", 1988, MARCEL DEKKER
"McGraw-Hill Dictionary of Chemical Terms", 1984, MCGRAW-HILL BOOK COMPANY
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1289 - 1329
"Small-molecule inhibitors of the PI3K signaling network", FUTURE MED CHEM., vol. 3, no. 5, 2011, pages 549 - 565
AM. J. RESPIR. CRIT. CARE MED., vol. 179, no. 7, 2009, pages 542 - 548
ANNUAL REV. CELL DEV. BIOL., vol. 17, 2001, pages 615 - 675
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
BIOCHEM. BIOPHYS. RES. COMMUN, vol. 308, no. 4, 2003, pages 764 - 9
BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 32, 2004, pages 378
BLOOD, vol. 107, no. 2, 2006, pages 642 - 50
CAS , no. 124937-51- 5
CURR. OPINION CELL BIOL., vol. 14, no. 2, 2002, pages 203 - 13
CUSHING ET AL.: "PI3K-delta and P13K-gamma as Targets for Autoimmune and Inflammatory Diseases", J. MED. CHEM., vol. 55, 2012, pages 8559 - 8581, XP055110817, DOI: 10.1021/jm300847w *
DATABASE PubChem 13 February 2015 (2015-02-13), XP055625510, Database accession no. 90253701 *
DATABASE PubChem Compound 25 January 2017 (2017-01-25), XP055625517, Database accession no. 123891208 *
ELIEL ET AL.: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL
ELIEL, E.WILEN, S.: "Stereochemistry of Organic Compounds", 1994, JOHN WILEY & SONS, INC
FUTURE MED. CHEM., vol. 5, no. 4, 2013, pages 479 - 492
GAWLEY ET AL.: "Principles of Asymmetric Synthesis,", 2012, ELSEVIER
GREENE ET AL.: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS
HECKER ET AL.: "J. Med. Chem.", vol. 51, 2008, article "Prodrugs of Phosphates and Phosphonates", pages: 2328 - 2345
HIGUCHI ET AL.: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
IMMUNITY, vol. 16, no. 3, 2002, pages 441 - 51
INT. J. BIOCHEM. AND CELL BIOL., vol. 41, 2009, pages 1708 - 1718
J. BIOL. CHEM., vol. 273, no. 5, 1998, pages 2505 - 8
J. BIOL. CHEM., vol. 280, no. 44, 2005, pages 36952
J. CELL SCI., vol. 114, 2001, pages 2903 - 10
J. CELL SCIENCE, vol. 116, no. 15, 2003, pages 3037 - 3040
J. IMMUNOL., vol. 170, no. 5, 2003, pages 2647 - 54
J. IMMUNOL., vol. 178, no. 4, 2007, pages 2328 - 35
J. IMMUNOL., vol. 180, no. 2, 2008, pages 2538 - 880
J. IMMUNOL., vol. 183, no. 3, 2009, pages 1921 - 1933
J. MED. CHEM., vol. 55, no. 20, 2012, pages 8559 - 8581
JABLONOWSKI ET AL., J. MED. CHEM., vol. 46, 2003, pages 3957 - 3960
JACQUES ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE
KOCIENSKI ET AL.: "Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
LANCET, vol. 339, 1992, pages 324 - 8
MAIRA ET AL., EXPERT OPIN. THER. TARGETS, vol. 12, 2008, pages 223
MICHAEL B. SMITHJERRY MARCH: "Chiral Separation Techniques: A Practical Approach", 2007, WILEY-VCH VERLAG GMBH & CO. KGAA
MUCOSAL IMMUNOL., 2 March 2010 (2010-03-02), pages 193 - 205
NARITOMI, YTERASHITA, S.KIMURA, SSUZUKI, A.KAGAYAMA, ASUGIYAMA, Y: "Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans", DRUG METAB. DISPOS., vol. 29, 2001, pages 1316 - 1324
NAT. REV. MICROBIOL., 4 June 2008 (2008-06-04), pages 265 - 75
NATURE MEDICINE, vol. 11, 2005, pages 933 - 935
NATURE REVIEW DRUG DISCOVERY, vol. 13, 2014, pages 140 - 156
NATURE REVIEWS CANCER, vol. 2, no. 7, 2002, pages 489 - 501
NATURE REVIEWS CANCER, vol. 9, 2009, pages 551
NATURE REVIEWS MOLECULAR CELL BIOLOGY, vol. 11, 2010, pages 329
NATURE REVIEWS, vol. 5, 2006, pages 903 - 918
NATURE, vol. 431, 2004, pages 1007
NATURE, vol. 441, 2006, pages 366
OKKENHAUG ET AL., SCIENCE, vol. 297, 2002, pages 1031 - 4
ONCOGENE, vol. 25, no. 50, 2006, pages 6648 - 59
PROC. NATL. ACAD. SCI. USA, vol. 105, no. 22, 2008, pages 7797 - 7802
RAUTIO ET AL.: "Prodrugs: Design and Clinical Applications", NAT. REV. DRUG DISCOVERY, vol. 7, 2008, pages 255 - 270, XP055227338, DOI: 10.1038/nrd2468
ROCHE ET AL.: "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
SCIENCE, vol. 304, no. 5670, 2004, pages 554
STAHLWERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH
THOMAS SORRELL: "Organic Chemistry", 1999, UNIVERSITY SCIENCE BOOKS
VIROLOGY, vol. 344, no. 1, 2006, pages 131 - 8
WEI MANMAN ET AL., EJMC, vol. 125, 2017, pages 1156 - 1171
WILEN ET AL.: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023125275A1 (en) 2021-12-28 2023-07-06 广东东阳光药业有限公司 Salt of aminopyrimidine compound and use thereof

Also Published As

Publication number Publication date
AU2019209960A1 (en) 2020-05-28
EP3740468A4 (en) 2021-10-06
AU2019209960B2 (en) 2023-11-23
JP7450541B2 (en) 2024-03-15
KR20200112900A (en) 2020-10-05
US20190224197A1 (en) 2019-07-25
EP3740468A1 (en) 2020-11-25
JP2023184559A (en) 2023-12-28
CA3083040A1 (en) 2019-07-25
JP2021512052A (en) 2021-05-13
US10751339B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
US9657007B2 (en) Substituted aminopyrimidine compounds and methods of use
US9399637B2 (en) Substituted heteroaryl compounds and methods of use
EP3206691B1 (en) Substituted heteroaryl compounds and methods of use
CN104418849B (en) Substituted aminopyrimidine compounds and use method and application thereof
JP2023184559A (en) Substituted aminopyrimidine compounds and methods of use
WO2016149160A1 (en) Substituted aminopyrimidine compounds and methods of use
WO2015175579A1 (en) Alkynyl compounds and methods of use
WO2016134668A1 (en) Substituted aminopyrimidine compounds and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19741784

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3083040

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019209960

Country of ref document: AU

Date of ref document: 20190118

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020538684

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20207023828

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2019741784

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2019741784

Country of ref document: EP

Effective date: 20200820